PG-3 and biallelic markers thereof

ABSTRACT

The invention concerns the genomic sequence and cDNA sequences of the PG-3 gene. The invention also concerns biallelic markers of the PG-3 gene. The invention also concerns polypeptides encoded by the PG-3 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

FIELD OF THE INVENTION

[0001] The present invention is directed to polynucleotides encoding a PG-3 polypeptide as well as the regulatory regions located at the 5′- and 3′-ends of said coding region. The invention also relates to polypeptides encoded by the PG-3 gene. The invention also relates to antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the PG-3 gene useful in genetic analysis.

BACKGROUND OF THE INVENTION

[0002] Cancer is one of the leading causes of death in industrialized countries. This makes cancer a serious burden in terms of public health, especially in view of the aging of the population. Indeed, over the next 25 years there will be a dramatic increase in the number of people developing cancer. Globally, 10 million new cancer patients are diagnosed each year and there will be 20 million new cancer diagnoses by the year 2020.

[0003] In spite of a large number of available therapeutic techniques including but not limited to surgery, chemotherapy, radiotherapy, bone marow transplantation, and in spite of encouraging results obtained with experimental protocols in immunotherapy or gene therapy, the overall survival rate of cancer patients does not reach 50% after 5 years . Therefore, there is a strong need for both a reliable diagnostic procedure which would enable early-stage cancer prognosis, and for preventive and curative treatments of the disease.

[0004] A cancer is a clonal proliferation of cells produced as a consequence of cumulative genetic damage that finally results in unrestrained cell growth, tissue invasion and metastasis (cell transformation). Regardless of the type of cancer, transformed cells carry damaged DNA as gross chromosomal translocations or, more subtly, as DNA amplification, rearrangement or even point mutations.

[0005] Cancer is caused by the dysregulation of the expression of certain genes. The development of a tumor requires an important succession of steps. Each of these comprises the dysregulation of a gene either involved in cell cycle activity or in genomic stability and the emergence of an abnormal mutated clone which overwhelms the other normal cell types because of a proliferative advantage. Cancer indeed happens because of a combination of two mechanisms. Some mutations enhance cell proliferation, increasing the target population of cells for the next mutation. Other mutations affect the stability of the entire genome, increasing the overall mutation rate, as in the case of mismatch repair proteins (reviewed in Arnheim N & Shibata D, 1997).

[0006] Recent studies have identified three groups of genes which are frequently mutated in cancer. The first two groups are involved in cell cycle activity , which is a mechanism that drives normal cell proliferation and ensures the normal development and homeostasis of the organism. Conversely, many of the properties of cancer cells—uncontrolled proliferation, increased mutation rate, abnormal translocations and gene amplifications—can be attributed directly to perturbations of the normal regulation or progression of the cycle.

[0007] The first group of genes, called oncogenes, are genes whose products activate cell proliferation. The normal non-mutant versions are called protooncogenes. The mutated forms are excessively or inappropriately active in promoting cell proliferation and act in the cell in a dominant way such that a single mutant allele is enough to affect the cell phenotype. Activated oncogenes are rarely transmitted as germline mutations since they are probably be lethal when expressed in all the cells in the organism. Therefore oncogenes can only be investigated in tumor tissues. Oncogenes and protooncogenes can be classified into several different categories according to their function. This classification includes genes that code for proteins involved in signal transduction such as: growth factors (i.e., sis, int-2); receptor and non-receptor protein-tyrosine kinases (i.e., erbB, src, bcr-abl, met, trk); membrane-associated G proteins (i.e., ras); cytoplasmic protein kinases (i.e., mitogen-activated protein kinase—MAPK-family, raf mos, pak), or nuclear transcription factors (i.e., myc, myb, fos, jun, rel) (for review see Hunter T, 1991; Fanger G R et al., 1997 ; Weiss F U et al., 1997).

[0008] The second group of genes which are frequently mutated in cancer, called tumor suppressor genes, are genes whose products inhibit cell growth. Mutant versions in cancer cells have lost their normal function, and act in the cell in a recessive way such that both copies of the gene must be inactivated in order to change the cell phenotype. Most importantly, the tumor phenotype can be rescued by the wild type allele, as shown by cell fusion experiments first described by Harris and colleagues (Harris H et al. , 1969). Germline mutations of tumor suppressor genes are transmitted and thus studied in both constitutional and tumor DNA from familial or sporadic cases. The current family of tumor suppressors includes DNA-binding transcription factors (i.e., p53, WT1), transcription regulators (i.e., RB, APC, and BRCA1), and protein kinase inhibitors (i.e., p16), among others (for review, see Haber D & Harlow E, 1997).

[0009] The third group of genes which are frequently mutated in cancer, called mutator genes, are responsible for maintaining genome integrity and/or low mutation rates. Loss of function of both alleles increases cell mutation rates, and as a consequence, proto-oncogenes and tumor suppressor genes are mutated. Mutator genes can also be classified as tumor suppressor genes, except for the fact that tumorigenesis caused by this class of genes cannot be suppressed simply by restoration of a wild-type allele, as described above. Genes whose inactivation may lead to a mutator phenotype include mismatch repair genes (i.e., MLH1, MSH2), DNA helicases (i.e., BLM, WRN) or other genes involved in DNA repair and genomic stability (i.e., p53, possibly BRCA1 and BRCA2) (For review see Haber D & Harlow E, 1997; Fishel & Wilson. 1997 ; Ellis, 1997).

[0010] The recent development of sophisticated techniques for genetic mapping has resulted in an ever expanding list of genes associated with particular types of human cancers. The human haploid genome contains an estimated 80,000 to 100,000 genes scattered on a 3×10⁹ base-long double-stranded DNA. Each human being is diploid, i.e., possesses two haploid genomes, one from paternal origin, the other from maternal origin. The sequence of a given genetic locus may vary between individuals in a population or between the two copies of the locus on the chromosomes of a single individual. Genetic mapping techniques often exploit these differences, which are called polymorphisms, to map the location of genes associated with human phenotypes.

[0011] One mapping technique, called the loss of heterozygosity (LOH) technique, is often employed to detect genes in which a loss of function results in a cancer, such as the tumor suppressor genes described above. Tumor suppressor genes often produce cancer via a two hit mechanism in which a first mutation, such as a point mutation (or a small deletion or insertion) inactivates one allele of the tumor suppressor gene. Often, this first mutation is inherited from generation to generation. A second mutation, often a spontaneous somatic mutation such as a deletion which deletes all or part of the chromosome carrying the other copy of the tumor suppressor gene, results in a cell in which both copies of the tumor suppressor gene are inactive. As a consequence of the deletion in the tumor suppressor gene, one allele is lost for any genetic marker located close to the tumor suppressor gene. Thus, if the patient is heterozygous for a marker, the tumor tissue loses heterozygosity, becoming homozygous or hemizygous. This loss of heterozygosity generally provides strong evidence for the existence of a tumor suppressor gene in the lost region.

[0012] LOH has allowed the identification of several chromosomic regions associated with cancer. Indeed, substantial amounts of LOH data support the hypothesis that genes associated with distinct cancer types are located within 8p23 region of the human genome. Several regions of chromosome arm 8p were found to be frequently deleted in a variety of human malignacies including those of the prostate, head and neck, lung and colon. Emi et al. demonstrated the involvement of the 8p23.1-8p21.3 region in cases of hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer (Emi et al., 1992). Yaremko, et al., (1994) showed the existence of two major regions of LOH for chromosome 8 markers in a sample of 87 colorectal carcinomas. The most prominent loss was found for 8p23.1-pter, where 45% of informative cases demonstrated loss of alleles. Scholnick et al. (Scholnick et al, 1996 and Sunwoo et al., 1996) demonstrated the existence of three distinct regions of LOH for the markers of chromosome 8 in cases of squamous cell carcinoma of the supraglottic larynx. They showed that the allelic loss of 8p23 marker D8S264 serves as a statistically significant, independent predictor of poor prognosis for patients with supraglottic squamous cell carcinoma. The study of 51 squamous cell carcinomas of the head and neck and 29 oral squamous cell carcinoma cell lines showed a frequent allelic loss and homozygous deletion at 1 or more loci located in the 8p23 region (Ishwad C S et al., 1999). In addition, a high resolution deletion map of 150 squamous cell carninomas of the larynx and oral cavity showed two distinct classes of deletion for the 8p23 region within the D8S264 to D8S1788 interval (Sunwoo et al., 1999).

[0013] In other studies, Nagai et al. (1997) demonstrated the highest loss of heterozygosity in the specific region of 8p23 by genome wide scanning of LOH in 120 cases of hepatocellular carcinoma (HCC). Further studies using high-density polymorphic marker analysis identified three minimal deleted areas on chromosome 8p, one of them being a 5 cM area in 8p23, probably indicative of the presence of a tumor suppressor loci for HCC (Pineau P, et al, 1999). Gronwald et al. (1997) also demonstrated 8p23-pter loss in renal clear cell carcinomas.

[0014] The same region is involved in specific cases of prostate cancer. Matsuyama et al. (1994) showed the specific deletion of the 8p23 band in prostate cancer cases, as monitored by FISH with D8S7 probe. They were able to document a substantial number of cases with deletions of 8p23 but retention of the 8p22 marker LPL. Moreover, Ichikawa et al. (1996) deduced the existence of a prostate cancer metastasis suppressor gene and localized it to 8p23-q12 by studies of metastasis suppression in highly metastatic rat prostate cells after transfer of human chromosomes. Recently Washbum et al. (1997) were able to find substantial numbers of tumors with the allelic loss specific to 8p23 by LOH studies of 31 cases of human prostate cancer. In these samples they were able to define the minimal overlapping region with deletions covering genetic interval D8S262-D8S277. In addition, using PCR analysis of polymorphic microsatellite repeat markers, 29% of 60 prostate tumors showed LOH, at the locus D8S262 of the 8p23 region (Perinchery et al., 1999).

[0015] Recent studies have also implicated the 8p23 region in other types of cancers such as fibrous histiocytomas, ovarian adenocarcinomas and gastric cancers. Indeed, comparative genomic hybridization data showed the involvment of the 8p23.1 region in fibrous histiocytomas and detected a minimal amplified region between D8S1819 and D8S550 containing a gene MASL 1, the overexpression of which might be oncogenic (Sakabe et al., 1999). LOH was also observed for 27 ovarian adenocarcinomas on 8p. Detailed examination of nine tumours with partial deletions defined three regions of overlap including two in 8p23 (Wright et al., 1998). Comparative genomic hybridization of 58 primary gastric cancers detected gain of the 8p22-23 region in 24% of the tumors and even high-level amplification of the same region in 5% of the tumors. This amplified region was narrowed down to 8p23.1 by reverse-painting FISH to prophase chromosomes (Sakakura et al., 1999).

[0016] The present invention relates to PG-3 gene, a gene present in the 8p23 cancer candidate region, as well as diagnostic methods and reagents for detecting alleles of the PG-3 gene which may cause cancer, and therapies for treating cancer.

SUMMARY OF THE INVENTION

[0017] The present invention pertains to nucleic acid molecules comprising the genomic sequence and the cDNA sequence of a novel human gene which encodes a PG-3 protein. The PG-3 gene is localized in the 8p23 candidate region shown to be involved in several types of cancer by LOH studies.

[0018] The PG-3 genomic sequence comprises regulatory sequences located upstream (5′-end) and downstream (3′-end) of the transcribed portion of said gene, these regulatory sequences being also part of the invention.

[0019] The invention also relates to the cDNA sequence encoding the PG-3 protein, as well as to the corresponding translation product.

[0020] Oligonucleotide probes or primers hybridizing specifically with a PG-3 genomic or cDNA sequence are also part of the present invention, as well as DNA amplification and detection methods using said primers and probes.

[0021] A further object of the invention relates to recombinant vectors comprising any of the nucleic acid sequences described herein, and in particular to recombinant vectors comprising a PG-3 regulatory sequence or a sequence encoding a PG-3 protein. The present invention also relates to host cells and transgenic non-human animals comprising said nucleic acid sequences or recombinant vectors.

[0022] The invention further encompasses biallelic markers of the PG-3 gene useful in genetic analysis.

[0023] Finally, the invention is directed to methods for the screening of substances or molecules that inhibit the expression of PG-3, as well as to methods for the screening of substances or molecules that interact with a PG-3 polypeptide or that modulate the activity of a PG-3 polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024]FIG. 1 is a block diagram of an exemplary computer system.

[0025]FIG. 2 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.

[0026]FIG. 3 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous.

[0027]FIG. 4 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence.

BRIEF DESCRIPTION OF THE SEQUENCES PROVIDED IN THE SEQUENCE LISTING

[0028] SEQ ID No 1 is a genomic sequence of PG-3 comprising the 5′ regulatory region (upstream untranscribed region), the exons and introns, and the 3′ regulatory region (downstream untranscribed region).

[0029] SEQ ID No 2 is a cDNA sequence of PG-3.

[0030] SEQ ID No 3 is the amino acid sequence encoded by the cDNA of SEQ ID No 2.

[0031] SEQ ID No 4 is a primer containing the additional PU 5′ sequence further described in Example 2.

[0032] SEQ ID No 5 is a primer containing the additional RP 5′ sequence further described in Example 2.

[0033] In accordance with the regulations relating to Sequence Listings, the following codes have been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences and to identify each of the alleles present at the polymorphic base. The code “r” in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is an adenine. The code “y” in the sequences indicates that one allele of the polymorphic base is a thymine, while the other allele is a cytosine. The code “m” in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is a cytosine. The code “k” in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine. The code “s” in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a cytosine. The code “w” in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is a thymine. The nucleotide code of the original allele for each biallelic marker is the following: Biallelic marker Original allele  5-390-177 C  5-391-43 G  5-392-222 T  5-392-280 T  4-59-27 G  4-58-289 C  4-54-199 A  4-54-180 C  4-51-312 G 99-86-266 A  4-88-107 G  5-397-141 G  5-398-203 C 99-12738-248 A 99-109-358 C 99-12749-175 T  4-21-154 C  4-21-317 G  4-23-326 G 99-12753-34 A  5-364-252 G 99-12755-280 G 99-12755-329 C  4-87-212 A 99-12757-318 C 99-12758-102 G 99-12758-136 C  4-105-98 A  4-105-86 G  4-45-49 T  4-44-277 T  4-86-60 C  4-84-334 G 99-78-321 T 99-12767-36 G 99-12767-143 T 99-12767-189 T 99-12767-380 G  4-80-328 C  4-36-384 C  4-36-264 G  4-36-261 C  4-35-333 A  4-35-240 G  4-35-173 T  4-35-133 C 99-12771-59 T 99-12774-334 A 99-12776-358 G 99-12781-113 A  4-104-298 C  4-104-254 G  4-104-250 C  4-104-214 A 99-12818-289 T 99-24807-271 C 99-24807-84 G 99-12831-157 G 99-12831-241 C 99-12832-387 T 99-12836-30 G 99-12844-262 C  4-24-74 C  4-24-246 C  4-24-314 G  4-27-190 A  5-400-145 G  5-400-149 G  5-400-175 T  5-400-231 T  5-400-367 A 99-12852-110 T 99-12852-325 A  4-37-326 A  4-37-107 G  5-270-92 G 99-12860-47 G 99-12860-57 T  5-402-144 C

[0034] In some instances, the polymorphic bases of the biallelic markers alter the identity of an amino acid in the encoded polypeptide. This is indicated in the accompanying Sequence Listing by use of the feature VARIANT, placement of an Xaa at the position of the polymorphic amino acid, and definition of Xaa as the two alternative amino acids. For example if one allele of a biallelic marker is the codon CAC, which encodes histidine, while the other allele of the biallelic marker is CAA, which encodes glutamine, the Sequence Listing for the encoded polypeptide will contain an Xaa at the location of the polymorphic amino acid. In this instance, Xaa would be defined as being histidine or glutamine.

DETAILED DESCRIPTION

[0035] The present invention concerns polynucleotides and polypeptides related to the PG-3 gene. Oligonucleotide probes and primers hybridizing specifically with a genomic or a cDNA sequence of PG-3 are also part of the invention. A further object of the invention relates to recombinant vectors comprising any of the nucleic acid sequences described in the present invention, and in particular recombinant vectors comprising a regulatory region of PG-3 or a sequence encoding the PG-3 protein, as well as host cells comprising said nucleic acid sequences or recombinant vectors. The invention also encompasses methods of screening for molecules which regulates the expression of the PG-3 gene or which modulate the activity of the PG-3 protein. The invention also relates to antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

[0036] The invention also concerns PG-3-related biallelic markers which can be used in any method of genetic analysis including linkage studies in families, linkage disequilibrium studies in populations and association studies of case-control populations. An important aspect of the present invention is that biallelic markers allow association studies to be performed to identify genes involved in complex traits. These biallelic markers may lead to allelic variants of the PG-3 protein.

Definitions

[0037] Before describing the invention in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

[0038] The terms “PG-3 gene”, when used herein, encompasses genomic, mRNA and cDNA sequences encoding the PG-3 protein, including the untranscribed regulatory regions of the genomic DNA.

[0039] The term “PG-3 biological activity” is intended for polypeptides exhibiting an activity similar, but not necessarily identical, to an activity of the PG-3 polypeptide of the invention as described herein, especially in the section entitled “PG-3 polypeptide biological activities”. In contrast, the term “biological activity” refers to any activity that a polypeptide of the invention may have.

[0040] The term “heterologous protein”, when used herein, is intended to designate any protein or polypeptide other than the PG-3 protein. More particularly, the heterologous protein may be a compound which can be used as a marker in further experiments with a PG-3 regulatory region.

[0041] The term “isolated” requires that the material be removed from its original environment (e. g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such a polynucleotide could be part of a vector and/or such a polynucleotide or polypeptide could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.

[0042] The term “purified” does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. As an example, purification from 0.1% concentration to 10% concentration is two orders of magnitude. To illustrate, individual cDNA clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately 10⁴-10⁶ fold purification of the native message.

[0043] The term “purified” is further used herein to describe a polypeptide or polynucleotide of the invention which has been separated from other compounds including, but not limited to, polypeptides or polynucleotides, carbohydrates, lipids, etc. The term “purified” may be used to specify the separation of monomeric polypeptides of the invention from oligomeric forms such as homo- or hetero-dimers, trimers, etc. The term “purified” may also be used to specify the separation of covalently closed polynucleotides from linear polynucleotides. A polynucleotide is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polynucleotide sequence and conformation (linear versus covalently close). A substantially pure polypeptide or polynucleotide typically comprises about 50%, preferably 60 to 90% weight/weight of a polypeptide or polynucleotide sample, respectively, more usually about 95%, and preferably is over about 99% pure. Polypeptide and polynucleotide purity, or homogeneity, is indicated by a number of means well known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art. As an alternative embodiment, purification of the polypeptides and polynucleotides of the present invention may be expressed as “at least” a percent purity relative to heterologous polypeptides and polynucleotides (DNA, RNA or both). As a preferred embodiment, the polypeptides and polynucleotides of the present invention are at least; 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 96%, 98%, 99%, or 100% pure relative to heterologous polypeptides and polynucleotides, respectively. As a further preferred embodiment the polypeptides and polynucleotides have a purity ranging from any number, to the thousandth position, between 90% and 100% (e.g., a polypeptide or polynucleotide at least 99.995% pure) relative to either heterologous polypeptides or polynucleotides, respectively, or as a weight/weight ratio relative to all compounds and molecules other than those existing in the carrier. Each number representing a percent purity, to the thousandth position, may be claimed as individual species of purity. Each number representing a percent purity, to the thousandth position, may be claimed as individual species of purity.

[0044] The terms “polypeptide” and “protein”, used interchangeably herein, refer to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude chemical or post-expression modifications of the polypeptides of the invention, although chemical or post-expression modifications of these polypeptides may be included excluded as specific embodiments. Therefore, for example, modifications to polypeptides that include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide. Further, polypeptides with these modifications may be specified as individual species to be included or excluded from the present invention. The natural or other chemical modifications, such as those listed in examples above can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance Creighton (1993); Seifter et al., (1990); Rattan et al., (1992)). Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems, etc . . . ), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

[0045] As used herein, the terms “recombinant polynucleotide” and “polynucleotide construct” are used interchangeably to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment. In particular, this terms mean that the polynucleotide or cDNA is adjacent to “backbone” nucleic acid to which it is not adjacent in its natural environment. Additionally, to be “enriched” the cDNAs will represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. Backbone molecules according to the present invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic. acids used to maintain or manipulate a nucleic acid insert of interest. Preferably, the enriched cDNAs represent 15% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. More preferably, the enriched cDNAs represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In a highly preferred embodiment, the enriched cDNAs represent 90% or more (including any number between 90 and 100%, to the thousandth position, e.g., 99.5%) # of the number of nucleic acid inserts in the population of recombinant backbone molecules.

[0046] The term “recombinant polypeptide” is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

[0047] As used herein, the term “non-human animal” refers to any non-human vertebrate, birds and more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term “animal” is used to refer to any vertebrate, preferable a mammal. Both the terms “animal” and “mammal” expressly embrace human subjects unless preceded with the term “non-human”.

[0048] Throughout the present specification, the expression “nucleotide sequence” may be employed to designate indifferently a polynucleotide or a nucleic acid. More precisely, the expression “nucleotide sequence” encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule.

[0049] As used interchangeably herein, the terms “nucleic acid molecule(s)”, “oligonucleotide(s)”, and “polynucleotide(s)” include RNA or DNA (either single or double stranded, coding, complementary or antisense), or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form (although each of the above species may be particularly specified). The term “nucleotide” is used herein as an adjective to describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single-stranded or duplex form. More precisely, the expression “nucleotide sequence” encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule. The term “nucleotide” is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide. The term “nucleotide” is also used herein to encompass “modified nucleotides” which comprise at least one modifications such as (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar. For examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT publication No. WO 95/04064, which disclosure is hereby incorporated by reference in its entirety. Preferred modifications of the present invention include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v) ybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine. The polynucleotide sequences of the invention may be prepared by any known method, including synthetic, recombinant, ex vivo generation, or a combination thereof, as well as utilizing any purification methods known in the art. Methylenemethylimino linked oligonucleosides as well as mixed backbone compounds having, may be prepared as described in U.S. Pat. Nos. 5,378,825; 5,386,023; 5,489,677; 5,602,240; and 5,610,289, which disclosures are hereby incorporated by reference in their entireties. Formacetal and thioformacetal linked oligonucleosides may be prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564, which disclosures are hereby incorporated by reference in their entireties. Ethylene oxide linked oligonucleosides may be prepared as described in U.S. Pat. No. 5,223,618, which disclosure is hereby incorporated by reference in its entirety. Phosphinate oligonucleotides may be prepared as described in U.S. Pat. No. 5,508,270, which disclosure is hereby incorporated by reference in its entirety. Alkyl phosphonate oligonucleotides may be prepared as described in U.S. Pat. No. 4,469,863, which disclosure is hereby incorporated by reference in its entirety. 3′-Deoxy-3′-methylene phosphonate oligonucleotides may be prepared as described in U.S. Pat. Nos. 5,610,289 or 5,625,050 which disclosures are hereby incorporated by reference in their entireties. Phosphoramidite oligonucleotides may be prepared as described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878 which disclosures are hereby incorporated by reference in their entireties. Alkylphosphonothioate oligonucleotides may be prepared as described in published PCT applications WO 94/17093 and WO 94/02499 which disclosures are hereby incorporated by reference in their entireties. 3′-Deoxy-3′-amino phosphoramidate oligonucleotides may be prepared as described in U.S. Pat. No. 5,476,925, which disclosure is hereby incorporated by reference in its entirety. Phosphotriester oligonucleotides may be prepared as described in U.S. Pat. No. 5,023,243, which disclosure is hereby incorporated by reference in its entirety. Borano phosphate oligonucleotides may be prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198 which disclosures are hereby incorporated by reference in their entireties.

[0050] A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell required to initiate the specific transcription of a gene.

[0051] A sequence which is “operably linked” to a regulatory sequence such as a promoter means that said regulatory element is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the nucleic acid of interest. As used herein, the term “operably linked” refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. More precisely, two DNA molecules (such as a polynucleotide containing a promoter region and a polynucleotide encoding a desired polypeptide or polynucleotide) are said to be “operably linked” if the nature of the linkage between the two polynucleotides does not (1) result in the introduction of a frame-shift mutation or (2) interfere with the ability of the polynucleotide containing the promoter to direct the transcription of the coding polynucleotide.

[0052] The term “primer” denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves as an initiation point for nucleotide polymerization catalyzed by either DNA polymerase, RNA polymerase or reverse transcriptase.

[0053] The term “probe” denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., polynucleotide as defined herein) which can be used to identify a specific polynucleotide sequence present in samples, said nucleic acid segment comprising a nucleotide sequence complementary of the specific polynucleotide sequence to be identified.

[0054] The terms “trait” and “phenotype” are used interchangeably herein and refer to any visible, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to a disease for example. Typically the terms “trait” or “phenotype” are used herein to refer to symptoms of, or susceptibility to a disease, a beneficial response to or side effects related to a treatment or a vaccination. Said disease can be, without being limited to, cancer, developmental diseases, neurological diseases, disorders relating to abnormal cellular differentiation, proliferation, or degeneration, including but not limioted to hyperaldosteronism, hypocortisolism (Addison's disease), hyperthyroidism (Grave's disease), hypothyroidism, colorectal polyps, gastritis, gastric and duodenal ulcers, ulcerative colitis, and Crohn's disease; said disease is preferably cancer or a disorder relating to abnormal cellular differentiation, proliferation, or degeneration, and even more preferably said disease is cancer of the prostate, head, neck, lung, liver, kidney, ovary, stomach or colon. Preferably, the term “trait” or “phenotype”, when used herein, encompasses, but is not limited to, diseases, early onsets of diseases, a beneficial response to or side effects related to treatment or a vaccination against diseases, a susceptibility to diseases, the level of aggressiveness of diseases, a modified or forthcoming expression of the PG-3 gene, a modified or forthcoming production of the PG-3 protein, or the production of a modified PG-3 protein.

[0055] The term “allele” is used herein to refer to variants of a nucleotide sequence. A biallelic polymorphism has two forms. Typically the first identified allele is designated as the original allele whereas other alleles are designated as alternative alleles. Diploid organisms may be homozygous or heterozygous for an allelic form.

[0056] The term “heterozygosity rate” is used herein to refer to the incidence of individuals in a population which are heterozygous at a particular allele. In a biallelic system, the heterozygosity rate is on average equal to 2P_(a)(1−P_(a)), where P_(a) is the frequency of the least common allele. In order to be useful in genetic studies, a genetic marker should have an adequate level of heterozygosity to allow a reasonable probability that a randomly selected person will be heterozygous.

[0057] The term “genotype” as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention, a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term “genotyping” a sample or an individual for a biallelic marker consists of determining the specific allele or the specific nucleotide carried by an individual at a biallelic marker.

[0058] The term “mutation” as used herein refers to a difference in DNA sequence between or among different genomes or individuals which has a frequency below 1%.

[0059] The term “haplotype” refers to a combination of alleles present in an individual or a sample. In the context of the present invention, a haplotype preferably refers to a combination of biallelic marker alleles found in a given individual and which may be associated with a phenotype.

[0060] The term “polymorphism” as used herein refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals. “Polymorphic” refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A “polymorphic site” is the locus at which the variation occurs. A single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide also gives rise to single nucleotide polymorphisms. In the context of the present invention, “single nucleotide polymorphism” preferably refers to a single nucleotide substitution. Typically, between different individuals, the polymorphic site may be occupied by two different nucleotides.

[0061] The term “biallelic polymorphism” and “biallelic marker” are used interchangeably herein to refer to a single nucleotide polymorphism having two alleles at a fairly high frequency in the population. A “biallelic marker allele” refers to the nucleotide variants present at a biallelic marker site. Typically, the frequency of the less common allele of the biallelic markers of the present invention has been validated to be greater than 1%, preferably the frequency is greater than 10%, more preferably the frequency is at least 20% (i.e. heterozygosity rate of at least 0.32), even more preferably the frequency is at least 30% (i.e. heterozygosity rate of at least 0.42). A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a “high quality biallelic marker”.

[0062] The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3′ and 5′ ends of the polynucleotide is considered to be “at the center” of the polynucleotide, and any nucleotide immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be “within 1 nucleotide of the center.” With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the polynucleotide. Thus, either of the two central nucleotides would be considered to be “within 1 nucleotide of the center” and any of the four nucleotides in the middle of the polynucleotide would be considered to be “within 2 nucleotides of the center”, and so on. For polymorphisms which involve the substitution, insertion or deletion of 1 or more nucleotides, the polymorphism, allele or biallelic marker is “at the center” of a polynucleotide if the difference between the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 3′ end of the polynucleotide, and the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 5′ end of the polynucleotide is zero or one nucleotide. If this difference is 0 to 3, then the polymorphism is considered to be “within 1 nucleotide of the center.” If the difference is 0 to 5, the polymorphism is considered to be “within 2 nucleotides of the center.” If the difference is 0 to 7, the polymorphism is considered to be “within 3 nucleotides of the center,” and so on.

[0063] The term “upstream” is used herein to refer to a location which is toward the 5′ end of the polynucleotide from a specific reference point.

[0064] The terms “base paired” and “Watson & Crick base paired” are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one another be virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., 1995).

[0065] The terms “complementary” or “complement thereof” are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. For the purpose of the present invention, a first polynucleotide is deemed to be complementary to a second polynucleotide when each base in the first polynucleotide is paired with its complementary base. Complementary bases are, generally, A and T (or A and U), or C and G. “Complement” is used herein as a synonym of “complementary polynucleotide”, “complementary nucleic acid” and “complementary nucleotide sequence”. These terms are applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions under which the two polynucleotides would actually bind.

[0066] The terms “comprising”, “consisting of” and “consisting essentially of” may be interchanged for one another throughout the instant application”. The term “having” has the same meaning as “comprising” and may be replaced with either the term “consisting of” or “consisting essentially of”.

[0067] Unless otherwise specified in the application, nucleotides and amino acids of polynucleotides and polypeptides respectively of the present invention are contiguous and not interrupted by heterologous sequences.

[0068] Identity Between Nucleic Acids or Polypeptides

[0069] The terms “percentage of sequence identity” and “percentage homology” are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, CLUSTALW, FASTDB (Pearson and Lipman, 1988; Altschul et al., 1990; Thompson et al., 1994; Higgins et al., 1996; Altschul et al., 1990; Altschul et al., 1993; Brutlag et al, 1990), the disclosures of which are incorporated by reference in their entireties.

[0070] In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool (“BLAST”) which is well known in the art (see, e.g., Karlin and Altschul, 1990; Altschul et al., 1990, 1993, 1997), the disclosures of which are incorporated by reference in their entireties. In particular, five specific BLAST programs are used to perform the following task:

[0071] (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;

[0072] (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;

[0073] (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;

[0074] (4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and

[0075] (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

[0076] The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as “high-scoring segment pairs,” between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992; Henikoff and Henikoff, 1993), the disclosures of which are incorporated by reference in their entireties. Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978), the disclosure of which is incorporated by reference in its entirety. The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990), the disclosure of which is incorporated by reference in its entirety. The BLAST programs may be used with the default parameters or with modified parameters provided by the user.

[0077] Another preferred method for determining the best overall match between a query nucleotide sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (1990), the disclosure of which is incorporated by reference in its entirety. In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by first converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is 35 shorter. If the subject sequence is shorter than the query sequence because of 5′ or 3′ deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5′ and 3′ truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5′ or 3′ ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5′ and 3′ of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using 10, the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only nucleotides outside the 5′ and 3′ nucleotides of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score. For example, a 90 nucleotide subject sequence is aligned to a 100 nucleotide query sequence to determine percent identity. The deletions occur at the 5′ end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 nucleotides at 5′ end. The 10 unpaired nucleotides represent 10% of the sequence (number of nucleotides at the 5′ and 3′ ends not matched/total number of nucleotides in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 nucleotides were perfectly matched the final percent identity would be 90%. In another example, a 90 nucleotide subject sequence is compared with a 100 nucleotide query sequence. This time the deletions are internal deletions so that there are no nucleotides on the 5′ or 3′ of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only nucleotides 5′ and 3′ of the subject sequence which are not matched/aligned with the query sequence are manually corrected. No other manual corrections are made for the purposes of the present invention.

[0078] Another preferred method for determining the best overall match between a query amino acid sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (1990). In a sequence alignment the query and subject sequences are both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group25Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty-5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter. If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, the results, in percent identity, must be manually corrected. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query amino acid residues outside the farthest N- and C-terminal residues of the subject sequence. For example, a 90 amino acid residue subject sequence is aligned with a 100-residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not match/align with the first residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90-residue subject sequence is compared with a 100-residue query sequence. This time the deletions are internal so there are no residues at the N- or C-termini of the subject sequence, which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected. No other manual corrections are made for the purposes of the present invention.

[0079] The term “percentage of sequence similarity” refers to comparisons between polypeptide sequences and is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which an identical or equivalent amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence similarity. Similarity is evaluated using any of the variety of sequence comparison algorithms and programs known in the art, including those described above in this section. Equivalent amino acid residues are defined herein.

[0080] Hybridization Conditions

[0081] Stringent Hybridization Conditions

[0082] “Stringent hybridization conditions” are defined as conditions in which only nucleic acids having a high level of identity to the probe are able to hybridize to said probe. These conditions may be calculated as follows:

[0083] For probes between 14 and 70 nucleotides in length the melting temperature (Tm) is calculated using the formula: Tm=81.5+16.6(log (Na+))+0.41(fraction G+C)−(600/N) where N is the length of the probe.

[0084] If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation: Tm=81.5+16.6(log (Na+))+0.41(fraction G+C)−(0.63% formamide)−(600/N) where N is the length of the probe.

[0085] Prehybridization may be carried out in 6×SSC, 5× Denhardt's reagent, 0.5% SDS, 100 μg denatured fragmented salmon sperm DNA or 6×SSC, 5× Denhardt's reagent, 0.5% SDS, 100 μg denatured fragmented salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook et al., 1986.

[0086] Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to nucleic acids containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25° C. below the Tm. For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 15-25° C. below the Tm. Preferably, for hybridizations in 6×SSC, the hybridization is conducted at approximately 68° C. Preferably, for hybridizations in 50% formamide containing solutions, the hybridization is conducted at approximately 42° C.

[0087] Following hybridization, the filter is washed in 2×SSC, 0.1% SDS at room temperature for 15 minutes. The filter is then washed with 0.1×SSC, 0.5% SDS at room temperature for 30 minutes to 1 hour. Thereafter, the solution is washed at the hybridization temperature in 0.1×SSC, 0.5% SDS. A final wash is conducted in 0.1×SSC at room temperature.

[0088] Nucleic acids which have hybridized to the probe are identified by autoradiography or other conventional techniques.

[0089] Other conditions of high stringency which may be used are well known in the art and are cited in Sambrook et al., 1989; and Ausubel et al., 1989. By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65° C. in buffer composed of 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65° C., the preferred hybridization temperature, in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20×10⁶ cpm of ³²P-labeled probe. Alternatively, the hybridization step can be performed at 65° C. in the presence of SSC buffer, 1×SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37° C. for 1 h in a solution containing 2×SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1×SSC at 50° C. for 45 min. Alternatively, filter washes can be performed in a solution containing 2×SSC and 0.1% SDS, or 0.5×SSC and 0.1% SDS, or 0.1×SSC and 0.1% SDS at 68° C. for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. These hybridization conditions are suitable for a nucleic acid molecule of about 20 nucleotides in length. There is no need to say that the hybridization conditions described above are to be adapted according to the length of the desired nucleic acid, following techniques well known to the one skilled in the art. The suitable hybridization conditions may for example be adapted according to the teachings disclosed in Hames and Higgins (1985) or in Sambrook et al. (1989).

[0090] Low and Moderate Conditions

[0091] Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. The above procedure may thus be modified to identify nucleic acids having decreasing levels of identity to the probe sequence. For example, the hybridization temperature may be decreased in increments of 5° C. from 65° C. to 42° C. in a hybridization buffer having a sodium concentration of approximately 1M. Following hybridization, the filter may be washed with 2×SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be “moderate” conditions above 50° C. and “low” conditions below 50° C. Alternatively, the hybridization may be carried out in buffers, such as 6×SSC, containing formamide at a temperature of 42° C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of identity to the probe. Following hybridization, the filter may be washed with 6×SSC, 0.5% SDS at 50° C. These conditions are considered to be “moderate” conditions above 25% formamide and “low” conditions below 25% formamide. cDNAs or genomic DNAs which have hybridized to the probe are identified by autoradiography or other conventional techniques.

[0092] Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Polynucleotides of the Invention

[0093] 1) Genomic Sequences of the PG-3 Gene

[0094] The present invention concerns the genomic sequence of PG-3. The present invention encompasses compositions containing the PG-3 gene, or PG-3 genomic sequences consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 1, sequences complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

[0095] Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides in compositions comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-97921, 98517-103471, 103603-108222, 108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-240825. Additional preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides in compositions comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-10000, 10001-20000, 20001-30000, 30001-40000, 40001-50000, 50001-60000, 60001-70000, 70001-80000, 80001-90000, 90001-97921, 98517-103471, 103603-108222, 108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-159000, 159001-160000, 160001-170000, 170001-180000, 180001-190000, 190001-200000, 200001-210000, 210001-220000, 220001-230000, 230001-240825. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

[0096] The PG-3 genomic nucleic acid comprises 14 exons. The exon positions in SEQ ID No 1 are detailed below in Table A. TABLE A Position in SEQ ID No 1 Position in SEQ ID No 1 Exon Beginning End Intron Beginning End A 2001 2079 A-B 2080 4626 B 4627 4718 B-C 4719 10114 C 10115 10233 C-D 10234 26809 D 26810 26897 D-E 26898 31356 E 31357 31471 E-F 31472 34260 F 34261 34404 F-S 34405 37376 S 37377 37466 S-T 37467 39703 T 39704 40858 T-G 40859 50435 G 50436 50545 G-H 50546 72880 H 72881 72918 H-I 72919 75988 I 75989 76151 I-J 76152 95110 J 95111 95188 J-K 95189 216014 K 216015 216252 K-L 216253 237525 L 237526 238825

[0097] Thus, the invention embodies compositions containing purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 14 exons of the PG-3 gene, or a sequence complementary thereto. The invention also relates to compositions containing purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the PG-3 gene, wherein the polynucleotides are arranged within the nucleic acid, from the 5′-end to the 3′-end of said nucleic acid, in the same order as in SEQ ID No 1.

[0098] Intron A-B refers to the nucleotide sequence located between Exon A and Exon B, and so on. The position of the introns is detailed in Table A. The intron J-K is large. Indeed, it is 120 kb in length and comprises the whole angiopoietine gene.

[0099] Thus, the invention embodies compositions containing purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 13 introns of the PG-3 gene, or a sequence complementary thereto.

[0100] While this section is entitled “Genomic Sequences of PG-3,” it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of PG-3 on either side or between two or more such genomic sequences.

[0101] 2) PG-3 cDNA Sequences

[0102] The expression of the PG-3 gene has been shown to lead to the production of at least one mRNA species which nucleic acid sequence is set forth in SEQ ID No 2. Three cDNAs have been independently cloned. They all have the same size but exhibit strong polymorphism between each other and between each cDNA and the genomic seqeunce. These polymorphisms are indicated in the appended sequence listing by the use of the feature “variation” in SEQ ID No 2.

[0103] Another object of the invention is a composition comprising a purified, isolated, or recombinant nucleic acid comprising the nucleotide sequence of SEQ ID No 2, complementary sequences thereto, as well as allelic variants, and fragments thereof. Moreover, preferred polynucleotide compositions of the invention include purified, isolated, or recombinant PG-3 cDNAs consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 2.

[0104] Preferred embodiments of the invention include compositions containing isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 2 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 2: 1-500, 501-1000, 1001-1500, 1501-2000, 2001-2500, 2501-3000, 3001-3500, 3501-3809.

[0105] The cDNA of SEQ ID No 2 includes a 5′-UTR region starting from the nucleotide at position 1 and ending at the nucleotide in position 57 of SEQ ID No 2. The cDNA of SEQ ID No 2 includes a 3′-UTR region starting from the nucleotide at position 2566 and ending at the nucleotide at position 3809 of SEQ ID No 2. The polyadenylation signal starts from the nucleotide at position 3795 and ends at the nucleotide in position 3800 of SEQ ID No 2.

[0106] Consequently, the invention concerns a composition containing a purified, isolated, or recombinant nucleic acid comprising a nucleotide sequence of the 5′UTR of the PG-3 cDNA, a sequence complementary thereto, or an allelic variant thereof. The invention also concerns a composition containing a purified, isolated, or recombinant nucleic acid comprising a nucleotide sequence of the 3′UTR of the PG-3 cDNA, a sequence complementary thereto, or an allelic variant thereof.

[0107] While this section is entitled “PG-3 cDNA Sequences,” it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the PG-3 sequences on either side or between two or more such PG-3 sequences.

[0108] 3) Coding Regions

[0109] The PG-3 open reading frame is contained in the corresponding mRNA of SEQ ID No 2. More precisely, the effective PG-3 coding sequence (CDS) includes the region between nucleotide position 58 (first nucleotide of the ATG codon) and nucleotide position 2565 (end nucleotide of the TGA codon) of SEQ ID No 2.

[0110] The present invention also embodies compositions containing isolated, purified, and recombinant polynucleotides which encode a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3. Preferably, the present invention also embodies compositions containing isolated, purified, and recombinant polynucleotides which encode a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 3, wherein wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following amino acid positions of SEQ ID No 3: 1-100, 101-200, 201-300, 301-400, 401-500, 501-600, 601-700, 701-835.

[0111] The above disclosed polynucleotide that contains the coding sequence of the PG-3 gene may be expressed in a desired host cell or a desired host organism, when this polynucleotide is placed under the control of suitable expression signals. The expression signals may be either the expression signals contained in the regulatory regions in the PG-3 gene of the invention or in contrast the signals may be exogenous regulatory nucleic sequences. Such a polynucleotide, when placed under the suitable expression signals, may also be inserted in a vector for its expression and/or amplification.

[0112] 4) Regulatory Sequences of PG-3

[0113] As mentioned, the genomic sequence of the PG-3 gene contains regulatory sequences both in the non-transcribed 5′-flanking region and in the non-transcribed 3′-flanking region that border the PG-3 coding region containing the 14 exons of this gene.

[0114] The 5′ regulatory region of the PG-3 gene is localized between the nucleotide in position 1 and the nucleotide in position 2000 of the nucleotide sequence of SEQ ID No 1. The 3′ regulatory region of the PG-3 gene is localized between nucleotide position 238826 and nucleotide position 240825 of SEQ ID No 1.

[0115] Polynucleotides derived from the 5′ and 3′ regulatory regions are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID No 1 or a fragment thereof in a test sample.

[0116] The promoter activity of the 5′ regulatory regions contained in PG-3 can be assessed as described below.

[0117] In order to identify the relevant regulatory active polynucleotide fragments or variants of SEQ ID No 1, one of skill in the art will refer to the book of Sambrook et al. (1989) which describes the use of a recombinant vector carrying a marker gene (i.e. beta galactosidase, chloramphenicol acetyl transferase, etc.) the expression of which will be detected when placed under the control of a biologically active polynucleotide fragments or variants of SEQ ID No 1. Genomic sequences located upstream of the first exon of the PG-3 gene are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, pβgal-Basic, pβgal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech, or pGL2-basic or pGL3-basic promoterless luciferase reporter gene vector from Promega. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, luciferase, β galactosidase, or green fluorescent protein. The sequences upstream the PG-3 coding region are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for increasing transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

[0118] Promoter sequences within the upstream genomic DNA may be further defined by constructing nested 5′ and/or 3′ deletions in the upstream DNA using conventional techniques such as Exonuclease III or appropriate restriction endonuclease digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity, such as described, for example, by Coles et al. (1998). In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into cloning sites in promoter reporter vectors. This type of assay is well-known to those skilled in the art and is described in WO 97/17359, U.S. Pat. No. 5,374,544; EP 582 796; U.S. Pat. No. 5,698,389; U.S. Pat. No. 5,643,746; U.S. Pat. No. 5,502,176; and U.S. Pat. No. 5,266,488.

[0119] The strength and the specificity of the promoter of the PG-3 gene can be assessed through the expression levels of a detectable polynucleotide operably linked to the PG-3 promoter in different types of cells and tissues. The detectable polynucleotide may be either a polynucleotide that specifically hybridizes with a predefined oligonucleotide probe, or a polynucleotide encoding a detectable protein, including a PG-3 polypeptide or a fragment or a variant thereof. This type of assay is well-known to those skilled in the art and is described in U.S. Pat. No. 5,502,176; and U.S. Pat. No. 5,266,488. Some of the methods are discussed in more detail below.

[0120] Polynucleotides carrying the regulatory elements located at the 5′ end and at the 3′ end of the PG-3 coding region may be advantageously used to control the transcriptional and translational activity of an heterologous polynucleotide of interest.

[0121] Thus, the present invention also concerns a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the 5′ and 3′ regulatory regions, or a sequence complementary thereto or a regulatory active fragment or variant thereof.

[0122] Preferred fragments of the 5′ regulatory region have a length of about 1500 or 1000 nucleotides, preferably of about 500 nucleotides, more preferably about 400 nucleotides, even more preferably 300 nucleotides and most preferably about 200 nucleotides.

[0123] Preferred fragments of the 3′ regulatory region are at least 50, 100, 150, 200, 300 or 400 bases in length.

[0124] “Regulatory active” polynucleotide derivatives of SEQ ID No 1 are polynucleotides comprising or alternatively consisting essentially of or consisting of a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide in a recombinant cell host. It could act either as an enhancer or as a repressor.

[0125] For the purpose of the invention, a nucleic acid or polynucleotide is “functional” as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide if said regulatory polynucleotide contains nucleotide sequences which contain transcriptional and translational regulatory information, and such sequences are “operably linked” to nucleotide sequences which encode the desired polypeptide or the desired polynucleotide.

[0126] The regulatory polynucleotides of the invention may be prepared from the nucleotide sequence of SEQ ID No 1 by cleavage using suitable restriction enzymes, as described for example in the book of Sambrook et al. (1989). The regulatory polynucleotides may also be prepared by digestion of SEQ ID No 1 by an exonuclease enzyme, such as Bal31 (Wabiko et al., 1986). These regulatory polynucleotides can also be prepared by nucleic acid chemical synthesis, as described elsewhere in the specification.

[0127] The regulatory polynucleotides according to the invention may be part of a recombinant expression vector that may be used to express a coding sequence in a desired host cell or host organism. The recombinant expression vectors according to the invention are described elsewhere in the specification.

[0128] A preferred 5′-regulatory polynucleotide of the invention includes the 5′-untranslated region (5′-UTR) of the PG-3 cDNA, or a regulatory active fragment or variant thereof.

[0129] A preferred 3′-regulatory polynucleotide of the invention includes the 3′-untranslated region (3′-UTR) of the PG-3 cDNA, or a regulatory active fragment or variant thereof.

[0130] A further object of the invention relates to a purified or isolated nucleic acid comprising:

[0131] a) a nucleic acid comprising a regulatory nucleotide sequence selected from the group consisting of:

[0132] (i) a nucleotide sequence comprising a polynucleotide of the 5′ regulatory region or a complementary sequence thereto; or

[0133] (ii) a nucleotide sequence comprising a polynucleotide having at least 80, 85, 90, or 95% of nucleotide identity with the nucleotide sequence of the 5′ regulatory region or a complementary sequence thereto; or

[0134] (iii) a nucleotide sequence comprising a polynucleotide that hybridizes under stringent hybridization conditions with the nucleotide sequence of the 5′ regulatory region or a complementary sequence thereto; or

[0135] (iv) a regulatory active fragment or variant of the polynucleotides in (i), (ii) and (iii);

[0136] b) a polynucleotide encoding a desired polypeptide or a nucleic acid of interest, operably linked to the nucleic acid defined in (a) above;

[0137] c) Optionally, a nucleic acid comprising a 3′-regulatory polynucleotide, preferably a 3′-regulatory polynucleotide of the PG-3 gene.

[0138] In a specific embodiment of the nucleic acid defined above, said nucleic acid includes the 5′-untranslated region (5′-UTR) of the PG-3 cDNA, or a regulatory active fragment or variant thereof.

[0139] In a second specific embodiment of the nucleic acid defined above, said nucleic acid includes the 3′-untranslated region (3′-UTR) of the PG-3 cDNA, or a regulatory active fragment or variant thereof.

[0140] The regulatory polynucleotide of the 5′ regulatory region, or its regulatory active fragments or variants, is operably linked at the 5′-end of the polynucleotide encoding the desired polypeptide or polynucleotide.

[0141] The regulatory polynucleotide of the 3′ regulatory region, or its regulatory active fragments or variants, is advantageously operably linked at the 3′-end of the polynucleotide encoding the desired polypeptide or polynucleotide.

[0142] The desired polypeptide encoded by the above-described nucleic acid may be of various nature or origin, encompassing proteins of prokaryotic or eukaryotic origin. Among the polypeptides which may be expressed under the control of a PG-3 regulatory region are bacterial, fungal or viral antigens. Also encompassed are eukaryotic proteins such as intracellular proteins, like “house keeping” proteins, membrane-bound proteins, like receptors, and secreted proteins like endogenous mediators such as cytokines. The desired polypeptide may be the PG-3 protein, especially the protein of the amino acid sequence of SEQ ID No 3, or a fragment or a variant thereof.

[0143] The desired nucleic acids encoded by the above-described polynucleotide, usually an RNA molecule, may be complementary to a desired coding polynucleotide, for example to the PG-3 coding sequence, and thus useful as an antisense polynucleotide.

[0144] Such a polynucleotide may be included in a recombinant expression vector in order to express the desired polypeptide or the desired nucleic acid in host cell or in a host organism. Suitable recombinant vectors that contain a polynucleotide such as described herein are disclosed elsewhere in the specification.

[0145] 5) Polynucleotide Variants

[0146] The invention also relates to variants and fragments of the polynucleotides described herein, particularly of a PG-3 gene containing one or more biallelic markers according to the invention.

[0147] a) Allelic Variant

[0148] A variant of a polynucleotide may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. By an “allelic variant” is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism (see Lewin, 1990), the disclosure of which is incorporated by reference in its entirety. Diploid organisms may be homozygous or heterozygous for an allelic form. Non-naturally occurring variants of the polynucleotide may be made by art-known mutagenesis techniques, including those applied to polynucleotides, cells or organisms.

[0149] b) Degenerate Variant

[0150] In addition to the isolated polynucleotides of the present invention, and fragments thereof, the invention further includes polynucleotides which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode a PG-3 polypeptide of the present invention. These polynucleotide variants are referred to as “degenerate variants” throughout the instant application. That is, all possible polynucleotide sequences that encode the PG-3 polypeptides of the present invention are completed. This includes the genetic code and species-specific codon preferences known in the art. Thus, it would be routine for one skilled in the art to generate the degenerate variants described above, for instance, to optimize codon expression for a particular host (e.g., change codons in the human mRNA to those preferred by other mammalian or bacterial host cells).

[0151] Nucleotide changes present in a variant polynucleotide may be silent, which means that they do not alter the amino acids encoded by the polynucleotide. However, nucleotide changes may also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. In the context of the present invention, preferred embodiments are those in which the polynucleotide variants encode polypeptides which retain substantially the same biological properties or activities as the PG-3 protein. More preferred polynucleotide variants are those containing conservative substitutions.

[0152] c) Similar Polynucleotides

[0153] Other embodiments of the present invention is a purified, isolated or recombinant polynucleotide which is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a polynucleotide selected from the group consisting of sequences of SEQ ID NOS: 1 and 2, or a sequence complementary thereto, or a fragment thereof. The nucleotide differences with regard to the nucleotide sequence of SEQ ID No 1 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences are predominantly located outside the coding sequences contained in the exons of SEQ ID NO:1. The above polynucleotides are included regardless of whether they encode a polypeptide having a biological activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having a biological activity include, inter alia, isolating a PG-3 gene or allelic variants thereof from a DNA library, and detecting a copy of a PG-3 gene or PG-3 mRNA expression in biological samples, suspected of containing PG-3 mRNA or DNA by Northern Blot or PCR analysis.

[0154] The invention also pertains to a purified, isolated or recombinant nucleic acid molecules comprising a polynucleotide having at least 80, 85, 90, or 95% nucleotide identity with a polynucleotide selected from the group consisting of the 5′ and 3′ PG-3 regulatory regions, advantageously 99% nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group consisting of the 5′ and 3′ PG-3 regulatory regions, or a sequence complementary thereto or a variant thereof or a regulatory active fragment thereof.

[0155] The present invention is further directed to polynucleotides having sequences at least 50%. 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identity to a polynucleotide selected from the group consisting of sequences of SEQ ID NOS: 1 and 2, where said polynucleotide do, in fact, encode a polypeptide having a PG-3 biological activity. Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the polynucleotides at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a polynucleotide selected from the group consisting of sequences of SEQ ID NOS: 1 and 2 will encode a polypeptide having PG-3 biological activity. In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having a PG-3 biological activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid), as further described below. By a polynucleotide having a nucleotide sequence at least, for example, 95% “identical” to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the PG-3 polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted, inserted, or substituted with another nucleotide. The query sequence may be an entire sequence selected from the group consisting of sequences of SEQ ID NOS: 1 and 2, or the ORF (open reading frame) of a polynucleotide sequence selected from said group, or any fragment specified as described herein.

[0156] d) Hybridizing Polynucleotides

[0157] In another aspect, the invention provides an isolated or purified nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to any polynucleotide of the present invention using any methods known to those skilled in the art including those disclosed herein.

[0158] An object of the invention relates to purified, isolated or recombinant nucleic acid molecules comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of SEQ ID NOS: 1 and 2, or a sequence complementary thereto or a variant thereof or a fragment thereof. Another object of the invention relates to purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of the nucleotide sequences of the 5′- and 3′ regulatory regions, or a sequence complementary thereto or a variant thereof or a regulatory active fragment thereof.

[0159] Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions, preferably at moderate or low stringency conditions as defined herein. Such hybridizing polynucleotides may be of at least 15, 18, 20, 23, 25, 28, 30, 35, 40, 50, 75, 100, 200, 300, 500 or 1000 nucleotides in length.

[0160] Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3′ terminal polyA+ tract of a cDNA shown in the sequence listing), or to a 5′ complementary stretch of T (or U) residues, would not be included in the definition of “polynucleotide,” since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

[0161] Of particular interest, are the polynucleotides hybridizing to any polynucleotide of the invention encoding PG-3 polypeptides, particularly PG-3 polypeptides exhibiting a PG-3 biological activity.

[0162] 6) Polynucleotides Fragments

[0163] The present invention is further directed to polynucleotides encoding portions or fragments of the nucleotide sequences described herein. A polynucleotide fragment is a polynucleotide having a sequence that is entirely the same as part but not all of a given nucleotide sequence, preferably the nucleotide sequence of a PG-3 gene, and variants thereof. The fragment can be a portion of an intron or an exon of a PG-3 gene. It can be the open reading frame of a PG-3 gene. It can also be a portion of the regulatory regions of PG-3.

[0164] Preferably, such fragments comprise at least one of the PG-3-related biallelic markers, wherein said said PG-3-related biallelic marker is selected from the group consisting of A1 to A80 or the complements thereto or a biallelic marker in linkage disequilibrium with one or more of the biallelic markers A1 to A80; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith. A set of preferred fragments contain at least one of the biallelic markers A1 to A80 of the PG-3 gene which are described herein or the complements thereto.

[0165] Uses for the polynucleotide fragments of the present invention include probes, primers, molecular weight markers and for expressing the polypeptide fragments of the present invention. Fragments include portions of polynucleotides selected from the group consisting of a) the sequences of SEQ ID NOS: 1 and 2, b) the polynucleotides encoding a polypeptide of SEQ ID NO: 3, c) and variants of polynucleotides described in a) or b). Particularly included in the present invention is a purified or isolated polynucleotide comprising at least 8 consecutive bases of a polynucleotide of the present invention. In one aspect of this embodiment, the polynucleotide comprises at least 10, 12, 15, 18, 20, 25, 28, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, 500, 800, 1000, 1500, or 2000 consecutive nucleotides of a polynucleotide of the present invention.

[0166] In addition to the above preferred polynucleotide sizes, further preferred sub-genuses of polynucleotides comprise at least 8 nucleotides, wherein “at least 8” is defined as any integer between 8 and the integer representing the 3′ most nucleotide position as set forth in the sequence listing or elsewhere herein. Further included as preferred polynucleotides of the present invention are polynucleotide fragments at least 8 nucleotides in length, as described above, that are further specified in terms of their 5′ and 3′ position. The 5′ and 3′ positions are represented by the position numbers set forth in the appended sequence listing. For allelic, degenerate and other variants, position 1 is defined as the 5′ most nucleotide of the ORF, i.e., the nucleotide “A” of the start codon with the remaining nucleotides numbered consecutively. Therefore, every combination of a 5′ and 3′ nucleotide position that a polynucleotide fragment of the present invention, at least 8 contiguous nucleotides in length, could occupy on a polynucleotide of the invention is included in the invention as an individual species. The polynucleotide fragments specified by 5′ and 3′ positions can be immediately envisaged and are therefore not individually listed solely for the purpose of not unnecessarily lengthening the specifications.

[0167] It is noted that the above species of polynucleotide fragments of the present invention may alternatively be described by the formula “a to b”; where “a” equals the 5′ most nucleotide position and “b” equals the 3′ most nucleotide position of the polynucleotide; and further where “a” equals an integer between 1 and the number of nucleotides of the polynucleotide sequence of the present invention minus 8, and where “b” equals an integer between 9 and the number of nucleotides of the polynucleotide sequence of the present invention; and where “a” is an integer smaller then “b” by at least 8.

[0168] The present invention also provides for the exclusion of any species of polynucleotide fragments of the present invention specified by 5′ and 3′ positions or sub-genuses of polynucleotides specified by size in nucleotides as described above. Any number of fragments specified by 5′ and 3′ positions or by size in nucleotides, as described above, may be excluded.

[0169] Preferred fragments of the invention are polynucleotides comprising polynucleotides encoding domains of polypeptides. Such fragments may be used to obtain other polynucleotides encoding polypeptides having similar domains using hybridization or RT-PCR techniques. Alternatively, these fragments may be used to express a polypeptide domain which may present a specific biological property. Preferred domains for the PG-3 polypeptides of the invention, herein named “described PG-3 domains”, are those that comprise amino acids from positions 3 to 87, from position 642 to 730, and from position 753 to 833 of SEQ ID NO:3. Thus, another object of the invention is an isolated, purified or recombinant polynucleotide encoding a polypeptide consisting of, consisting essentially of, or comprising a contiguous span of at least 5, 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 75, 100, 150 or 200 consecutive amino acids of SEQ ID NOS: 3, where said contiguous span comprises at least 1, 2, 3, 5, or 10 of the amino acid positions of a PG-3 described domain. The present invention also encompasses isolated, purified or recombinant polynucleotides encoding a polypeptide comprising a contiguous span of at least 5, 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 75, 100, 150 or 200 consecutive amino acids of SEQ ID NO:3, where said contiguous span is a PG-3 described domain. The present invention also encompasses isolated, purified or recombinant polynucleotides encoding a polypeptide comprising a PG-3 described domain of SEQ ID Nos: 3.

[0170] The present invention further encompasses any combination of the polynucleotide fragments listed in this section.

[0171] Such fragments may be “free-standing”, i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region. Indeed, several of these fragments may be present within a single larger polynucleotide.

[0172] 7) Polynucleotide Constructs

[0173] The terms “polynucleotide construct” and “recombinant polynucleotide” are used interchangeably herein to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment.

[0174] DNA Construct that Enables Temporal and Spatial PG-3 Gene Expression in Recombinant Cell Hosts and in Transgenic Animals.

[0175] In order to study the physiological and phenotypic consequences of a lack of synthesis of the PG-3 protein, both at the cell level and at the multi cellular organism level, the invention also encompasses DNA constructs and recombinant vectors enabling a conditional expression of a specific allele of the PG-3 genomic sequence or cDNA and also of a copy of this genomic sequence or cDNA harboring substitutions, deletions, or additions of one or more bases as regards to the PG-3 nucleotide sequence of SEQ ID Nos 1 and 2, or a fragment thereof, these base substitutions, deletions or additions being located either in an exon, an intron or a regulatory sequence, but preferably in the 5′-regulatory sequence or in an exon of the PG-3 genomic sequence or within the PG-3 cDNA of SEQ ID No 2. In a preferred embodiment, the PG-3 sequence comprises a biallelic marker of the present invention. In a preferred embodiment, the PG-3 sequence comprises at least one of the biallelic markers A1 to A80.

[0176] The present invention embodies recombinant vectors comprising any one of the polynucleotides described in the present invention. More particularly, the polynucleotide constructs according to the present invention can comprise any of the polynucleotides described in the “Genomic Sequences Of The PG3 Gene” section, the “PG-3 cDNA Sequences” section, the “Coding Regions” section, and the “Oligonucleotide Probes And Primers” section.

[0177] A first preferred DNA construct is based on the tetracycline resistance operon tet from E. coli transposon Tn10 for controlling the PG-3 gene expression, such as described by Gossen et al. (1992, 1995) and Furth et al. (1994). Such a DNA construct contains seven tet operator sequences from Tn10 (tetop) that are fused to either a minimal promoter or a 5′-regulatory sequence of the PG-3 gene, said minimal promoter or said PG-3 regulatory sequence being operably linked to a polynucleotide of interest that codes either for a sense or an antisense oligonucleotide or for a polypeptide, including a PG-3 polypeptide or a peptide fragment thereof. This DNA construct is functional as a conditional expression system for the nucleotide sequence of interest when the same cell also comprises a nucleotide sequence coding for either the wild type (tTA) or the mutant (rTA) repressor fused to the activating domain of viral protein VP16 of herpes simplex virus, placed under the control of a promoter, such as the HCMVIE1 enhancer/promoter or the MMTV-LTR. Indeed, a preferred DNA construct of the invention comprises both the polynucleotide containing the tet operator sequences and the polynucleotide containing a sequence coding for the tTA or the rTA repressor.

[0178] In a specific embodiment, the conditional expression DNA construct contains the sequence encoding the mutant tetracycline repressor rTA, the expression of the polynucleotide of interest is silent in the absence of tetracycline and induced in its presence.

[0179] DNA Constructs Allowing Homologous Recombination: Replacement Vectors

[0180] A second preferred DNA construct comprises, from 5′-end to 3′-end: (a) a first nucleotide sequence that is included within the PG-3 genomic sequence; (b) a nucleotide sequence comprising a positive selection marker, such as the marker for neomycine resistance (neo); and (c) a second nucleotide sequence that is included within the PG-3 genomic sequence, and is located on the genome downstream the first PG-3 nucleotide sequence (a).

[0181] In a preferred embodiment, this DNA construct also comprises a negative selection marker located upstream of the nucleotide sequence (a) or downstream from the nucleotide sequence (c). Preferably, the negative selection marker comprises of the thymidine kinase (tk) gene (Thomas et al., 1986), the hygromycine beta gene (Te Riele et al., 1990), the hprt gene (Van der Lugt et al., 1991; Reid et al., 1990) or the Diphteria toxin A fragment (Dt-A) gene (Nada et al., 1993; Yagi et al. 1990). Preferably, the positive selection marker is located within a PG-3 exon sequence so as to interrupt the sequence encoding a PG-3 protein. These replacement vectors are described, for example, by Thomas et al. (1986; 1987), Mansour et al. (1988) and Koller et al. (1992).

[0182] The first and second nucleotide sequences (a) and (c) may be indifferently located within a PG-3 regulatory sequence, an intronic sequence, an exon sequence or a sequence containing both regulatory and/or intronic and/or exon sequences. The size of the nucleotide sequences (a) and (c) ranges from 1 to 50 kb, preferably from 1 to 10 kb, more preferably from 2 to 6 kb and most preferably from 2 to 4 kb.

[0183] DNA Constructs Allowing Homologous Recombination: Cre-LoxP System

[0184] These new DNA constructs make use of the site specific recombination system of the P1 phage. The P1 phage possesses a recombinase called Cre which interacts specifically with a 34 base pairs loxP site. The loxP site is composed of two palindromic sequences of 13 bp separated by a 8 bp conserved sequence (Hoess et al., 1986). The recombination by the Cre enzyme between two loxP sites having an identical orientation leads to the deletion of the DNA fragment.

[0185] The Cre-loxP system used in combination with a homologous recombination technique has been first described by Gu et al. (1993, 1994). Briefly, a nucleotide sequence of interest to be inserted in a targeted location of the genome harbors at least two loxP sites in the same orientation and located at the respective ends of a nucleotide sequence to be excised from the recombinant genome. The excision event requires the presence of the recombinase (Cre) enzyme within the nucleus of the recombinant cell host. The recombinase enzyme may be provided at the desired time either by (a) incubating the recombinant cell hosts in a culture medium containing this enzyme, by injecting the Cre enzyme directly into the desired cell, such as described by Araki et al. (1995), or by lipofection of the enzyme into the cells, such as described by Baubonis et al. (1993); (b) transfecting the cell host with a vector comprising the Cre coding sequence operably linked to a promoter functional in the recombinant host cell, said promoter being optionally inducible, said vector being introduced in the recombinant cell host, such as described by Gu et al. (1993) and Sauer et al. (1988); (c) introducing in the genome of the cell host a polynucleotide comprising the Cre coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter is optionally inducible, and said polynucleotide being inserted in the genome of the cell host either by a random insertion event or an homologous recombination event, such as described by Gu et al. (1994).

[0186] In a specific embodiment, the vector containing the sequence to be inserted in the PG-3 gene by homologous recombination is constructed in such a way that selectable markers are flanked by loxP sites of the same orientation, it is possible, by treatment by the Cre enzyme, to eliminate the selectable markers while leaving the PG-3 sequences of interest that have been inserted by an homologous recombination event. Again, two selectable markers are needed: a positive selection marker to select for the recombination event and a negative selection marker to select for the homologous recombination event. Vectors and methods using the Cre-loxP system are described by Zou et al. (1994).

[0187] Thus, a third preferred DNA construct of the invention comprises, from 5′-end to 3′-end: (a) a first nucleotide sequence that is included in the PG-3 genomic sequence; (b) a nucleotide sequence comprising a polynucleotide encoding a positive selection marker, said nucleotide sequence comprising additionally two sequences defining a site recognized by a recombinase, such as a loxP site, the two sites being placed in the same orientation; and (c) a second nucleotide sequence that is included in the PG-3 genomic sequence, and is located on the genome downstream of the first PG-3 nucleotide sequence (a).

[0188] The sequences defining a site recognized by a recombinase, such as a loxP site, are preferably located within the nucleotide sequence (b) at suitable locations bordering the nucleotide sequence for which the conditional excision is sought. In one specific embodiment, two loxP sites are located at each side of the positive selection marker sequence, in order to allow its excision at a desired time after the occurrence of the homologous recombination event.

[0189] In a preferred embodiment of a method using the third DNA construct described above, the excision of the polynucleotide fragment bordered by the two sites recognized by a recombinase, preferably two loxP sites, is performed at a desired time, due to the presence within the genome of the recombinant host cell of a sequence encoding the Cre enzyme operably linked to a promoter sequence, preferably an inducible promoter, more preferably a tissue-specific promoter sequence and most preferably a promoter sequence which is both inducible and tissue-specific, such as described by Gu et al. (1994).

[0190] The presence of the Cre enzyme within the genome of the recombinant cell host may result from the breeding of two transgenic animals, the first transgenic animal bearing the PG-3-derived sequence of interest containing the loxP sites as described above and the second transgenic animal bearing the Cre coding sequence operably linked to a suitable promoter sequence, such as described by Gu et al (994).

[0191] Spatio-temporal control of the Cre enzyme expression may also be achieved with an adenovirus based vector that contains the Cre gene thus allowing infection of cells, or in vivo infection of organs, for delivery of the Cre enzyme, such as described by Anton et al. (1995) and Kanegae et al. (995).

[0192] The DNA constructs described above may be used to introduce a desired nucleotide sequence of the invention, preferably a PG-3 genomic sequence or a PG-3 cDNA sequence, and most preferably an altered copy of a PG-3 genomic or cDNA sequence, within a predetermined location of the targeted genome, leading either to the generation of an altered copy of a targeted gene (knock-out homologous recombination) or to the replacement of a copy of the targeted gene by another copy sufficiently homologous to allow an homologous recombination event to occur (knock-in homologous recombination). In a specific embodiment, the DNA constructs described above may be used to introduce a PG-3 genomic sequence or a PG-3 cDNA sequence comprising at least one biallelic marker of the present invention, preferably at least one biallelic marker selected from the group consisting of A1 to A80.

[0193] Nuclear Antisense DNA Constructs

[0194] Other compositions comprise a vector of the invention comprising an oligonucleotide fragment of the nucleic acid sequence of SEQ ID No 2, preferably a fragment including the start codon of the PG-3 gene, as an antisense tool that inhibits the expression of the corresponding PG-3 gene. Preferred methods using antisense polynucleotide according to the present invention are described in the section entitled “Antisense Approach”.

[0195] 8) Oligonucleotide Probes and Primers

[0196] Polynucleotides derived from the PG-3 gene are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID No 1, or a fragment, complement, or variant thereof in a test sample.

[0197] a) Structural Definitions

[0198] Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-97921, 98517-103471, 103603-108222, 108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-240825. Additional preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-10000, 10001-20000, 20001-30000, 30001-40000,40001-50000, 50001-60000, 60001-70000, 70001-80000, 80001-90000, 90001-97921, 98517-103471, 103603-108222,108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-159000, 159001-160000, 160001-170000, 170001-180000, 180001-190000, 190001-200000, 200001-210000, 210001-220000, 220001-230000, 230001-240825.

[0199] Another object of the invention is a purified, isolated, or recombinant nucleic acid comprising the nucleotide sequence of SEQ ID No 2, complementary sequences thereto, as well as allelic variants, and fragments thereof. Moreover, preferred probes and primers of the invention include purified, isolated, or recombinant PG-3 cDNAs consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 2. Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 2 or the complements thereof. Additional preferred embodiments of the invention include probes and primers comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 2 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 2: 1-500, 501-1000, 1001-1500, 1501-2000, 2001-2500,2501-3000, 3001-3500, 3501-3809.

[0200] Thus, the invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid selected from the group consisting of the nucleotide sequences 1-97921, 98517-103471, 103603-108222, 108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-240825 of SEQ ID No 1 or a variant thereof or a sequence complementary thereto. The invention relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid of SEQ ID No 2 or a variant or a fragment thereof or a sequence complementary thereto.

[0201] In one embodiment the invention encompasses isolated, purified, and recombinant polynucleotides consisting of, or consisting essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 30, 35, 40, or 50 nucleotides in length of any one of SEQ ID Nos 1 and 2 and the complement thereof, wherein said span includes a PG-3-related biallelic marker in said sequence; optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; optionally, said polynucleotide comprises, consists essentially of, or consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide; optionally, the 3′ end of said contiguous span is present at the 3′ end of said polynucleotide; and optionally, the 3′ end of said contiguous span is located at the 3′ end of said polynucleotide and said biallelic marker is present at the 3′ end of said polynucleotide. In a preferred embodiment, said probes comprises, consists of, or consists essentially of a sequence selected from the following sequences: P1 to P4 and P6 to P80 and the complementary sequences thereto.

[0202] In another embodiment the invention encompasses isolated, purified or recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 30, 35, 40, or 50 nucleotides in length of SEQ ID Nos 1 and 2, or the complements thereof, wherein the 3′ end of said contiguous span is located at the 3′ end of said polynucleotide, and wherein the 3′ end of said polynucleotide is located within 20 nucleotides upstream of a PG-3-related biallelic marker in said sequence; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein the 3′ end of said polynucleotide is located 1 nucleotide upstream of said PG-3-related biallelic marker in said sequence; and optionally, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D4, D6 to D80, E1 to E4 and E6 to E80.

[0203] In a further embodiment, the invention encompasses isolated, purified, or recombinant polynucleotides comprising, consisting of, or consisting essentially of a sequence selected from the following sequences: B1 to B52 and C1 to C52.

[0204] In an additional embodiment, the invention encompasses polynucleotides for use in hybridization assays, sequencing assays, and enzyme-based mismatch detection assays for determining the identity of the nucleotide at a PG-3-related biallelic marker in SEQ ID Nos 1 and 2, as well as polynucleotides for use in amplifying segments of nucleotides comprising a PG-3-related biallelic marker in SEQ ID Nos 1 and 2; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith.

[0205] The invention concerns the use of the polynucleotides according to the invention for determining the identity of the nucleotide at a PG-3-related biallelic marker, preferably in hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay and in amplifying segments of nucleotides comprising a PG-3-related biallelic marker.

[0206] b) Design of Primers and Probes

[0207] A probe or a primer according to the invention has between 8 and 1000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 nucleotides in length. More particularly, the length of these probes and primers can range from 8, 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30 nucleotides. Shorter probes and primers tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes and primers are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of assay conditions may be empirically determined by one of skill in the art. The formation of stable hybrids depends on the melting temperature (TM) of the DNA. The TM depends on the length of the primer or probe, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in the probes of the invention usually ranges between 10 and 75%, preferably between 35 and 60%, and more preferably between 40 and 55%.

[0208] For amplification purposes, pairs of primers with approximately the same Tm are preferable. Primers may be designed using the OSP software (Hillier and Green, 1991), the disclosure of which is incorporated by reference in its entirety, based on GC content and melting temperatures of oligonucleotides, or using PC-Rare (http://bioinformatics.weizrnann.ac.il/software/PC-Rare/doc/manuel.html) based on the octamer frequency disparity method (Griffais et al., 1991), the disclosure of which is incorporated by reference in its entirety. DNA amplification techniques are well known to those skilled in the art. Amplification techniques that can be used in the context of the present invention include, but are not limited to, the ligase chain reaction (LCR) described in EP-A-320 308, WO 9320227 and EP-A-439 182, the polymerase chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA) described in Guatelli et al. (1990) and in Compton (1991), Q-beta amplification as described in European Patent Application No 4544610, strand displacement amplification as described in Walker et al. (1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461, the disclosures of which are incorporated by reference in their entireties.

[0209] A preferred probe or primer consists of a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P4 and P6 to P80 and the complementary sequence thereto, B1 to B52, C1 to C52, D1 to D4, D6 to D80, E1 to E4 and E6 to E80, for which the respective locations in the sequence listing are provided in Tables 1, 2, and 3.

[0210] c) Preparation of Primers and Probes

[0211] The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al. (1979), the phosphodiester method of Brown et al. (1979), the diethylphosphoramidite method of Beaucage et al. (1981) and the solid support method described in EP 0 707 592, which disclosures are hereby incorporated by reference in their entireties.

[0212] Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Pat. Nos. 5,185,444; 5,034,506 and 5,142,047, which disclosures are hereby incorporated by reference in their entireties. The probe may have to be rendered “non-extendable” in that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3′ end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3′ end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3′ hydroxyl group simply can be cleaved, replaced or modified, U.S. patent application Ser. No. 07/049,061 filed Apr. 19, 1993, which disclosure is hereby incorporated by reference in its entirety, describes modifications, which can be used to render a probe non-extendable.

[0213] d) Labeling of Probes

[0214] Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating any label known in the art to be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances (including, ³²P, ³⁵S, ³H, ¹²⁵I), fluorescent dyes (including, 5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3′ and 5′ ends. Examples of non-radioactive labeling of nucleic acid fragments are described in the French patent No. FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988), which disclosures are hereby incorporated by reference in their entireties. In addition, the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807 (Chiron), which disclosures are hereby incorporated by reference in their entireties.

[0215] The detectable probe may be single stranded or double stranded and may be made using techniques known in the art, including in vitro transcription, nick translation, or kinase reactions. A nucleic acid sample containing a sequence capable of hybridizing to the labeled probe is contacted with the labeled probe. If the nucleic acid in the sample is double stranded, it may be denatured prior to contacting the probe. In some applications, the nucleic acid sample may be immobilized on a surface such as a nitrocellulose or nylon membrane. The nucleic acid sample may comprise nucleic acids obtained from a variety of sources, including genomic DNA, cDNA libraries, RNA, or tissue samples.

[0216] Procedures used to detect the presence of nucleic acids capable of hybridizing to the detectable probe include well known techniques such as Southern blotting, Northern blotting, dot blotting, colony hybridization, and plaque hybridization. In some applications, the nucleic acid capable of hybridizing to the labeled probe may be cloned into vectors such as expression vectors, sequencing vectors, or in vitro transcription vectors to facilitate the characterization and expression of the hybridizing nucleic acids in the sample. For example, such techniques may be used to isolate and clone sequences in a genomic library or cDNA library which are capable of hybridizing to the detectable probe as described herein.

[0217] e) Immobilization of Probes

[0218] A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or “tail” that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

[0219] The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in the PG-3 gene or mRNA using other techniques.

[0220] Any of the polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic beads, non-magnetic beads (including polystyrene beads), membranes (including nitrocellulose strips), plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes® and other configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

[0221] Consequently, the invention also relates to a method for detecting the presence of a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 1 and 2, fragments thereof, variants thereof and complementary sequences thereto in a sample, said method comprising the following steps of:

[0222] a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with said nucleotide sequence included in said nucleic acid molecule in said sample to be assayed; and

[0223] b) detecting the hybrid complex formed between said probe(s) and said nucleic acid molecule in said sample.

[0224] The invention further concerns a kit for detecting the presence of a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 1 and 2, fragments thereof, variants thereof and complementary sequences thereto in a sample, said kit comprising:

[0225] a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with said nucleotide sequence included in said nucleic acid molecule in said sample to be assayed; and

[0226] b) optionally, the reagents necessary for performing the hybridization reaction.

[0227] In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group consisting of the nucleotide sequences of P1 to P4 and P6 to P80 and the complementary sequence thereto, B1 to B52, C1 to C52, D1 to D4, D6 to D80, E1 to E4 and E6 to E80 or a biallelic marker selected from the group consisting of A1 to A80 and the complements thereto.

[0228] f) Oligonucleotide Arrays

[0229] A substrate comprising a plurality of oligonucleotide primers or probes of the invention may be used either for detecting or amplifying targeted sequences in the PG-3 gene and may also be used for detecting mutations in the coding or in the non-coding sequences of the PG-3 gene.

[0230] As used herein, the term “array” means a one dimensional, two dimensional, or multidimensional arrangement of nucleic acids of sufficient length to permit specific detection of gene expression. For example, the array may contain a plurality of nucleic acids derived from genes whose expression levels are to be assessed. The array may include a PG-3 genomic DNA, a PG-3 cDNA, sequences complementary thereto or fragments thereof. Preferably, the fragments are at least 12, 15, 18, 20, 25, 30, 35, 40 or 50 nucleotides in length. More preferably, the fragments are at least 100 nucleotides in length. Even more preferably, the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

[0231] Any polynucleotide provided herein may be attached in overlapping areas or at random locations on the solid support. Alternatively, the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be “addressable” where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotide makes these “addressable” arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips™, and has been generally described in U.S. Pat. No. 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as “Very Large Scale Immobilized Polymer Synthesis” (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in U.S. Pat. Nos. 5,143,854; and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

[0232] In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in the PG-3 gene and preferably in its regulatory region. For this particular purpose, probes are specifically designed to have a nucleotide sequence allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations, it is meant, mutations on the PG-3 gene that have been identified according, for example to the technique used by Huang et al. (1996) or Samson et al. (1996).

[0233] Another technique that may be used to detect mutations in the PG-3 gene is the use of a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of the PG-3 genomic DNA or cDNA. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is used to determine the identity of the target sequence within a sample, measure its amount, and detect differences between the target sequence and the sequence of the PG-3 gene in the sample. In one such design, termed 4L tiled array, a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers, is used. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes. Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a “footprint” for the probes flanking a mutation position. This technique was described by Chee et al. in 1996.

[0234] Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide of the invention, particularly a probe or primer as described herein. Preferably, the invention concerns an array of nucleic acid comprising at least two polynucleotides of the invention, particularly probes or primers as described herein. Preferably, the invention concerns an array of nucleic acid comprising at least five polynucleotides of the invention, particularly probes or primers as described herein.

[0235] A preferred embodiment of the present invention is an array of polynucleotides of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 100 or 500 nucleotides in length which includes at least 1, 2, 5, 10, 15, 20, 35, 50 or 100 sequences selected from the group consisting of the polynucleotides of SEQ ID NOS: 1 and 2, the polynucleotides encoding the polypeptide of SEQ ID NO:3, sequences fully complementary thereto, and fragments thereof.

[0236] A further object of the invention consists of an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P4 and P6 to P80, B 1 to B52, C1 to C52, D1 to D4, D6 to D80, E1 to E4 and E6 to E80, the sequences complementary thereto, a fragment thereof of at least 8, 10, 12, 15, 18, or 20 consecutive nucleotides thereof, or at least one sequence comprising a biallelic marker selected from the group consisting of A1 to A80 and the complements thereto.

[0237] The invention also pertains to an array of nucleic acid sequences comprising either at least two of the sequences selected from the group consisting of P1 to P4, P6 to P80, B1 to B52, C1 to C52, D1 to D4, D6 to D80, E1 to E4 and E6 to E80, the sequences complementary thereto, a fragment thereof of at least 8 consecutive nucleotides thereof, or at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A80 and the complements thereof.

PG3 Proteins and Polypeptide Fragments

[0238] The term “PG-3 polypeptides” is used herein to embrace all of the proteins and polypeptides of the present invention. Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies PG-3 proteins from humans, including isolated or purified PG-3 proteins consisting, consisting essentially, or comprising the sequence of SEQ ID No 3. More particularly, the present invention concerns allelic variants of the PG-3 protein comprising at least one amino acid selected from the group consisting of an arginine or an isoleucine residue at the amino acid position 304 of the SEQ ID No 3, a histidine or an aspartic acid residue at the amino acid position 314 of the SEQ ID No 3, a threonine or an asparagine residue at the amino acid position 682 of the SEQ ID No 3, an alanine or a valine residue at the amino acid position 761 of the SEQ ID No 3, and a proline or a serine residue at the amino acid position 828 of the SEQ ID No 3. In adddition, the invention also encompasses polypeptide variants of PG-3 comprising at least one amino acid selected from the group consisting of a methionine or an isoleucine residue at the position 91 of SEQ ID No 3, a valine or an alanine residue at the position 306 of SEQ ID No 3, a proline or a serine residue at the position 413 of SEQ ID No 3, a glycine or an aspartate residue at the position 528 of SEQ ID No 3, a valine or an alanine residue at the position 614 of SEQ ID No 3, a threonine or an asparagine residue at the position 677 of SEQ ID No 3, a valine or an alanine residue at the position 756 of SEQ ID No 3, a valine or an alanine residue at the position 758 of SEQ ID No 3, a lysine or a glutamate residue at the position 809 of SEQ ID No 3, and a cysteine or an arginine residue at the position 821 of SEQ ID No 3.

[0239] Variant Polypeptides

[0240] The present invention further provides for PG-3 polypeptides encoded by allelic and splice variants, orthologs, species homologues, and derivatives of the polypeptides described herein, including mutated PG-3 proteins. Procedures known in the art can be used to obtain, allelic variants, splice variants, orthologs, and/or species homologues of polynucleotides encoding polypeptide of SEQ ID NO:3, using information from the sequences disclosed herein.

[0241] The invention also encompasses purified, isolated, or recombinant polypeptides comprising a sequence at least 50% identical, more preferably at least 60% identical, and still more preferably 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID No:3 or a fragment thereof.

[0242] By a polypeptide having an amino acid sequence at least, for example, 95% “identical” to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% (5 of 100) of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.

[0243] Further polypeptides of the present invention include polypeptides which have at least 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above. By a polypeptide having an amino acid sequence at least, for example, 95% “similar” to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is similar (i.e. contain identical or equivalent amino acid residues) to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% similar to a query amino acid sequence, up to 5% (5 of 100) of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another non-equivalent amino acid.

[0244] These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. The query sequence may be an entire amino acid sequence of SEQ ID NO:3 or any fragment specified as described herein.

[0245] The variant polypeptides described herein are included in the present invention regardless of whether they have their normal biological activity. This is because even where a particular polypeptide molecule does not have a biological activity, one of skill in the art would still know how to use the polypeptide, for instance, as a vaccine or to generate antibodies. Other uses of the polypeptides of the present invention that do not have a biological activity include, inter alia, as epitope tags, in epitope mapping, and as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods known to those of skill in the art. As described below, the polypeptides of the present invention can also be used to raise polyclonal and monoclonal antibodies, which are useful in assays for detecting PG-3 protein expression or as agonists and antagonists capable of enhancing or inhibiting PG-3 protein function. Further, such polypeptides can be used in the yeast two-hybrid system to “capture” PG-3 protein binding proteins, which are also candidate agonists and antagonists according to the present invention (See, e.g., Fields et al. 1989), which disclosure is hereby incorporated by reference in its entirety.

[0246] Preparation of the Polypeptides of the Invention

[0247] The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. The polypeptides of the present invention are preferably provided in an isolated form, and may be partially or preferably substantially purified.

[0248] Consequently, the present invention also comprises methods of making the polypeptides of the invention, particularly polypeptides encoded by the sequences of SEQ ID NOS: 1 and 2, or fragments thereof and methods of making the polypeptide of SEQ ID NO:3 or fragments thereof. The methods comprise sequentially linking together amino acids to produce the nucleic polypeptides having the preceding sequences. In some embodiments, the polypeptides made by these methods are 150 amino acids or less in length. In other embodiments, the polypeptides made by these methods are 120 amino acids or less in length.

[0249] Isolation

[0250] From Natural Sources

[0251] The PG-3 proteins of the invention may be isolated from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured cells, of humans or non-human animals. Methods for extracting and purifying natural proteins are known in the art, and include the use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion exchange chromatography, affinity chromatography, sedimentation according to density, and gel electrophoresis. See, for example, “Methods in Enzymology, Academic Press, 1993” for a variety of methods for purifying proteins, which disclosure is hereby incorporated by reference in its entirety. Polypeptides of the invention also can be purified from natural sources using antibodies directed against the polypeptides of the invention, such as those described herein, in methods which are well known in the art of protein purification.

[0252] From Recombinant Sources

[0253] Preferably, the PG-3 polypeptides of the invention are recombinantly produced using routine expression methods known in the art. The polynucleotide encoding the desired polypeptide is operably linked to a promoter into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems are used in forming recombinant polypeptides. The polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use.

[0254] Any PG-3 polynucleotide, including the cDNA described in SEQ ID NO: 2, and allelic variants thereof may be used to express PG-3 polypeptides. The nucleic acid encoding the PG-3 polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The PG-3 insert in the expression vector may comprise the full coding sequence for the PG-3 protein or a portion thereof. For example, the PG-3 derived insert may encode a polypeptide comprising at least 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 75, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 consecutive amino acids of the PG-3 protein of SEQ ID No:3.

[0255] Consequently, a further embodiment of the present invention is a method of making comprising a PG-3 polypeptide, preferably a protein of SEQ ID NO:3, said method comprising the steps of

[0256] a) obtaining a nucleic acid molecule encoding said PG-3 polypeptide, preferably said nucleic acid molecule is selected from the group consisting of the sequence of SEQ ID NO:2 and sequences encoding the polypeptide of SEQ ID NO:3;

[0257] b) inserting said nucleic acid molecule in an expression vector such said nucleic acid molecule is operably linked to a promoter; and

[0258] c) introducing said expression vector into a host cell whereby said host cell produces said PG-3 polypeptide.

[0259] In one aspect of this embodiment, the method further comprises the step of isolating the polypeptide. Another embodiment of the present invention is a polypeptide obtainable by the method described in the preceding paragraph.

[0260] The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, Mass.), Stratagene (La Jolla, Calif.), Promega (Madison, Wis.), and Invitrogen (San Diego, Calif.). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence is optimized for the particular expression organism in which the expression vector is introduced, as explained in U.S. Pat. No. 5,082,767, which disclosure is hereby incorporated by reference in its entirety.

[0261] In one embodiment, the entire coding sequence of a PG-3 cDNA and the 3′ UTR through the poly A signal of the cDNA is operably linked to a promoter in the expression vector. Alternatively, if the nucleic acid encoding a portion of the PG-3 protein lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the PG-3 cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXTl (Stratagene). pXTl contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The nucleic acid encoding the PG-3 protein or a portion thereof is obtained by PCR from a vector containing the PG-3 cDNA of SEQ ID NO: 2 using oligonucleotide primers complementary to the PG-3 cDNA or portion thereof and containing restriction endonuclease sequences for Pst I incorporated into the 5′ primer and BglII at the 5′ end of the corresponding cDNA 3′ primer, taking care to ensure that the sequence encoding the PG-3 protein or a portion thereof is positioned properly with respect to the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXTl, now containing a poly A signal and digested with BglII.

[0262] In another embodiment, it is often advantageous to add to the recombinant polynucleotide additional nucleotide sequence which codes for secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[0263] As a control, the expression vector lacking a cDNA insert is introduced into host cells or organisms.

[0264] Transfection of a PG-3 expressing vector into mouse NTH 3T3 cells is but one embodiment of introducing polynucleotides into host cells. Introduction of a polynucleotide encoding a polypeptide into a host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al. (1986), which disclosure is hereby incorporated by reference in its entirety. For example, the expression vector is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, N.Y.) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600 ug/ml G418 (Sigma, St. Louis, Mo.). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

[0265] Recombinant cell extracts, or proteins from the culture medium if the expressed polypeptide is secreted, are then prepared and proteins separated by gel electrophoresis. If desired, the proteins may be ammonium sulfate precipitated or separated based on size or charge prior to electrophoresis. The proteins present are detected using techniques such as Coomassie or silver staining or using antibodies against the PG3 protein of interest. Coomassie and silver staining techniques are familiar to those skilled in the art.

[0266] To confirm expression of the PG-3 protein or a portion thereof, the proteins expressed from the host cells or organisms containing an expression vector comprising an insert which encodes the PG-3 polypeptide or a portion thereof are compared to the proteins expressed from the control cells or organisms containing the expression vector without an insert. The presence of a band from the cells containing the expression vector which is absent in control cells indicates that the PG-3 cDNA is expressed. Generally, the band corresponding to the protein encoded by the PG-3 cDNA will have a mobility near that expected based on the number of amino acids in the open reading frame of the cDNA. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

[0267] Alternatively, the PG-3 polypeptide to be expressed may also be a product of transgenic animals, i.e., as a component of the milk of transgenic cows, goats, pigs or sheeps which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein of interest.

[0268] A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including differential extraction, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. See, for example, “Methods in Enzymology”, supra for a variety of methods for purifying proteins. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification. A recombinantly produced version of a PG-3 polypeptide can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson (1988), which disclosure is hereby incorporated by reference in its entirety. Polypeptides of the invention also can be purified from recombinant sources using antibodies directed against the polypeptides of the invention, such as those described herein, in methods which are well known in the art of protein purification.

[0269] Preferably, the recombinantly expressed PG-3 polypeptide is purified using standard immunochromatography techniques. In such procedures, a solution containing the protein of interest, such as the culture medium or a cell extract, is applied to a column having antibodies against the protein attached to the chromatography matrix. The recombinant protein is allowed to bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically bound secreted protein is then released from the column and recovered using standard techniques.

[0270] If antibody production is not possible, the PG-3 cDNA sequence or fragment thereof may be incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the coding sequence of the PG-3 cDNA or fragment thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera may be beta-globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to beta-globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites may be engineered between the beta-globin gene or the nickel binding polypeptide and the PG-3 cDNA or fragment thereof. Thus, the two polypeptides of the chimera may be separated from one another by protease digestion. Antibodies capable of specifically recognizing the expressed PG-3 protein or a portion thereof are described below.

[0271] One useful expression vector for generating beta-globin chimerics is pSG5 (Stratagene), which encodes rabbit beta-globin. Intron II of the rabbit beta-globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques as described are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al., (1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro Express™ Translation Kit (Stratagene).

[0272] Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

[0273] The above procedures may also be used to express a mutant PG-3 protein responsible for a detectable phenotype or a portion thereof.

[0274] From Chemical Synthesis

[0275] In addition, polypeptides of the invention, especially short protein fragments, can be chemically synthesized using techniques known in the art (See, e.g., Creighton, 1983; and Hunkapiller et al., 1984), which disclosures are hereby incorporated by reference in their entireties. For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. A variety of methods of making polypeptides are known to those skilled in the art, including methods in which the carboxyl terminal amino acid is bound to polyvinyl benzene or another suitable resin. The amino acid to be added possesses blocking groups on its amino moiety and any side chain reactive groups so that only its carboxyl moiety can react. The carboxyl group is activated with carbodiimide or another activating agent and allowed to couple to the immobilized amino acid. After removal of the blocking group, the cycle is repeated to generate a polypeptide having the desired sequence. Alternatively, the methods described in U.S. Pat. No. 5,049,656, which disclosure is hereby incorporated by reference in its entirety, may be used.

[0276] Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amnino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoroamino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0277] Modifications

[0278] The invention encompasses polypeptides which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

[0279] Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

[0280] Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity. See U.S. Pat. No. 4,179,337. The chemical moieties for derivatization may be selected See U.S. Pat. No. 4,179,337, which disclosure is hereby incorporated by reference in its entirety. The chemical moieties for derivatization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0281] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term “about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on a biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

[0282] The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, (coupling PEG to G-CSF), and Malik et al. (1992) (reporting pegylation of GM-CSF using tresyl chloride), which disclosures are hereby incorporated by reference in their entireties. For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

[0283] One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

[0284] Multimerization

[0285] The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

[0286] Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term “homomer”, refers to a multimer containing only polypeptides corresponding to the amino acid sequences of SEQ ID NO:3 (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomenc multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

[0287] As used herein, the term “heteromer” refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

[0288] Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences, which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

[0289] In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., U.S. Pat. No. 5,478,925, which disclosure is hereby incorporated by reference in its entirety). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, oseteoprotegerin (see, e.g., International Publication No: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

[0290] Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins, and have since been found in a variety of different proteins (Landschulz et al., 1988). Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supematant using techniques known in the art.

[0291] Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (1994) and in U.S. patent application Ser. No. 08/446,922, which disclosure is hereby incorporated by reference in its entirety. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention. In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti Flag® antibody.

[0292] The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). Additionally, 30 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety).

[0293] Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety).

[0294] Mutated Polypeptides

[0295] To improve or alter the characteristics of PG-3 polypeptides of the present invention, protein engineering may be employed. Recombinant DNA technology known to those skilled in the art can be used to create novel mutant proteins or muteins including single or multiple amino acid substitutions, deletions, additions, or fusion proteins. Such modified polypeptides can show, e.g., increased/decreased biological activity or increased/decreased stability. In addition, they may be purified in higher yields and show better solubility than the corresponding natural polypeptide, at least under certain purification and storage conditions. Further, the polypeptides of the present invention may be produced as multimers including dimers, trimers and tetramers. Multimerization may be facilitated by linkers or recombinantly though heterologous polypeptides such as Fc regions.

[0296] N- and C-terminal Deletions

[0297] It is known in the art that one or more amino acids may be deleted from the N-terminus or C-terminus without substantial loss of biological function. For instance, Ron et al. (1993), reported modified KGF proteins that had heparin binding activity even if 3, 8, or 27 N-terminal amino acid residues were missing. Accordingly, the present invention provides polypeptides having one or more residues deleted from the amino terminus of the polypeptide of SEQ ID NO:3. Similarly, many examples of biologically functional C-terminal deletion mutants are known. For instance, Interferon gamma shows up to ten times higher activities by deleting 810 amino acid residues from the C-terminus of the protein (See, e.g., Dobeli, et al. 1988), which disclosure is hereby incorporated by reference in its entirety. Accordingly, the present invention provides polypeptides having one or more residues deleted from the carboxy terminus of the polypeptide of SEQ ID NO:3. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini as described below.

[0298] Other Mutations

[0299] Other mutants in addition to N- and C-terminal deletion forms of the protein discussed above are included in the present invention. It also will be recognized by one of ordinary skill in the art that some amino acid sequences of the PG-3 polypeptides of the present invention can be varied without significant effect of the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity. Thus, the invention further includes variations of the PG-3 polypeptides which show substantial PG-3 polypeptide activity. Such mutants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided.

[0300] There are two main approaches for studying the tolerance of an amino acid sequence to change (See, Bowie et al. 1994), which disclosure is hereby incorporated by reference in its entirety. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection.

[0301] The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality. These studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The studies indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described by Bowie et al. (supra) and the references cited therein.

[0302] Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Phe; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr. Thus, the fragment, derivative, analog, or homologue of the polypeptide of the present invention may be, for example: (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code: or (ii) one in which one or more of the amino acid residues includes a substituent group: or (iii) one in which the PG-3 polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol): or (iv) one in which the additional amino acids are fused to the above form of the polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the above form of the polypeptide or a pro-protein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

[0303] Thus, the PG-3 polypeptides of the present invention may include one or more amino acid substitutions, deletions, or additions, either from natural mutations or human manipulation. As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein. The following groups of amino acids generally represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.

[0304] A specific embodiment of a modified PG-3 peptide molecule of interest according to the present invention, includes, but is not limited to, a peptide molecule which is resistant to proteolysis, is a peptide in which the —CONH— peptide bond is modified and replaced by a (CH2NH) reduced bond, a (NHCO) retro inverso bond, a (CH2—O) methylene-oxy bond, a (CH2—S) thiomethylene bond, a (CH2CH2) carba bond, a (CO—CH2) cetomethylene bond, a (CHOH—CH2) hydroxyethylene bond), a (N—N) bound, a E-alcene bond or also a —CH═CH—bond. The invention also encompasses a human PG-3 polypeptide or a fragment or a variant thereof in which at least one peptide bond has been modified as described above.

[0305] Amino acids in the PG-3 proteins of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (See, e.g., Cunningham et al. 1989), which disclosure is hereby incorporated by reference in its entirety. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for a biological activity, preferably a PG-3 biological activity, using assays appropriate for measuring the function of the particular protein. Of special interest are substitutions of charged amino acids with other charged or neutral amino acids which may produce proteins with highly desirable improved characteristics, such as less aggregation. Aggregation may not only reduce activity but also be problematic when preparing pharmaceutical formulations, because aggregates can be immunogenic, (See, e.g., Pinckard et al., 1967; Robbins, et al., 1987; and Cleland, et al., 1993).

[0306] A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of a PG-3 polypeptide having an amino acid sequence which contains at least one conservative amino acid substitution, but not more than 50 conservative amino acid substitutions, not more than 40 conservative amino acid substitutions, not more than 30 conservative amino acid substitutions, and not more than 20 conservative amino acid substitutions. Also provided are polypeptides which comprise the amino acid sequence of a PG-3 polypeptide, having at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative amino acid substitutions.

[0307] Polypeptide Fragments

[0308] a) Structural Definition

[0309] The present invention is further directed to fragments of the amino acid sequences described herein such as the polypeptide of SEQ ID NO: 3. More specifically, the present invention embodies purified, isolated, and recombinant polypeptides comprising at least 5, 6, preferably at least 8 to 10, more preferably 12, 15, 20, 25, 30, 35, 40, 50, 60, 75, 100, 125, 150, 175, 200, 250, 300, 400, 500, 600, 700 or 800 consecutive amino acids of SEQ ID NO:3, and other polypeptides of the present invention. The present invention also embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 3, wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid positions of SEQ ID No 3: 1-100, 101-200, 201-300, 301-400, 401-500, 501-600, 601-700, 701-835. In other preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids.

[0310] In addition to the above polypeptide fragments, further preferred sub-genuses of polypeptides comprise at least 6 amino acids, wherein “at least 6” is defined as any integer between 6 and the integer representing the C-terminal amino acid of the polypeptide of the present invention including the polypeptide sequences of the sequence listing below. Further included are species of polypeptide fragments at least 6 amino acids in length, as described above, that are further specified in terms of their N-terminal and C-terminal positions. However, included in the present invention as individual species are all polypeptide fragments, at least 6 amino acids in length, as described above, and may be particularly specified by a N-terminal and C-terminal position. That is, every combination of a N-terminal and C-terninal position that a fragment at least 6 contiguous amino acid residues in length could occupy, on any given amino acid sequence of the sequence listing or of the present invention is included in the present invention

[0311] The present invention also provides for the exclusion of any fragment species specified by N-terminal and C-terminal positions or of any fragment sub-genus specified by size in amino acid residues as described above. Any number of fragments specified by N-terminal and C-terminal positions or by size in amino acid residues as described above may be excluded as individual species.

[0312] The above polypeptide fragments of the present invention can be immediately envisaged using the above description and are therefore not individually listed solely for the purpose of not unnecessarily lengthening the specification. Moreover, the above fragments need not have a biological activity, although polypeptides having these activities are preferred embodiments of the invention, since they would be useful, for example, in immunoassays, in epitope mapping, epitope tagging, as vaccines, and as molecular weight markers. The above fragments may also be used to generate antibodies to a particular portion of the polypeptide. These antibodies can then be used in immunoassays well known in the art to distinguish between human and non-human cells and tissues or to determine whether cells or tissues in a biological sample are or are not of the same type which express the polypeptides of the present invention.

[0313] It is noted that the above species of polypeptide fragments of the present invention may alternatively be described by the formula “a to b”; where “a” equals the N-terminal most amino acid position and “b” equals the C-terminal most amino acid position of the polynucleotide; and further where “a” equals an integer between 1 and the number of amino acids of the polypeptide sequence of the present invention minus 6, and where “b” equals an integer between 7 and the number of amino acids of the polypeptide sequence of the present invention; and where “a” is an integer smaller then “b” by at least 6.

[0314] b) Domains

[0315] Preferred polynucleotide fragments of the invention are domains of polypeptides of the invention. Such domains may eventually comprise linear or structural motifs and signatures including, but not limited to, leucine zippers, helix-turn-helix motifs, post-translational modification sites such as glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites. Such domains may present a particular biological activity such as DNA or RNA-binding, secretion of proteins, transcription regulation, enzymatic activity, substrate binding activity, etc . . .

[0316] A domain has a size generally comprised between 3 and 1000 amino acids. In preferred embodiment, domains comprise a number of amino acids that is any integer between 6 and 200. Domains may be synthesized using any methods known to those skilled in the art, including those disclosed herein, particularly in the section entitled “Preparation of the polypeptides of the invention”. Methods for determining the amino acids which make up a domain with a particular biological activity include mutagenesis studies and assays to determine the biological activity to be tested.

[0317] Alternatively, the polypeptides of the invention may be scanned for motifs, domains and/or signatures in databases using any computer method known to those skilled in the art. Searchable databases include Prosite (Hofmann et al., 1999; Bucher and Bairoch 1994), Pfam (Sonnhammer et al., 1997; Henikoff et al., 2000; Bateman et al., 2000), Blocks (Henikoffet et al., 2000), Print (Attwood et al., 1996), Prodom (Sonnhammer and Kahn, 1994; Corpet et al. 2000), Sbase (Pongor et al., 1993; Murvai et al., 2000), Smart (Schultz et al., 1998), Dali/FSSP (Holm and Sander, 1996, 1997 and 1999), HSSP (Sander and Schneider 1991), CATH (Orengo et al., 1997; Pearl et al., 2000), SCOP (Murzin et al., 1995; Lo Conte et al., 2000), COG (Tatusov et al., 1997 and 2000), specific family databases and derivatives thereof (Nevill-Manning et al., 1998; Yona et a., 1999; Attwood et al., 2000), each of which disclosures are hereby incorporated by reference in their entireties. For a review on available databases, see issue 1 of volume 28 of Nucleic Acid Research (2000), which disclosure is hereby incorporated by reference in its entirety.

[0318] Consequently, preferred polynucleotide fragments of the invention are domains of the polypeptide of SEQ ID NO:3. Preferred domains for the PG-3 polypeptides of the invention, herein named “described PG-3 domains”, are those that comprise amino acids from positions 3 to 87, from position 642 to 730, and from position 753 to 833 of SEQ ID NO:3.

[0319] Therefore, the present invention encompasses isolated, purified, or recombinant polypeptides which consist of, consist essentially of, or comprise a contiguous span of at least 6, preferably at least 8 to 10, more preferably 12, 15, 20, 25, 30, 35, 40, 50, 60, 75, 100, 125, 150, 175, 200, 225, 250, 275, or 300 amino acids of the polypeptide of SEQ ID NO:3, where said contiguous span comprises at least 1, 2, 3, 5, or 10 amino acids positions of a PG-3 described domain. The present invention also encompasses isolated, purified, or recombinant polypeptides comprising, consisting essentially of, or consisting of a contiguous span of at least 6, preferably at least 8 to 10, more preferably 12, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80 or 90 amino acids of the polypeptide of SEQ ID NO:3, where said contiguous span is a PG-3 described domain. The present invention also encompasses isolated, purified, or recombinant polypeptides which comprise, consist of or consist essentially PG-3 described domain of the polypeptide of SEQ ID NO:3.

[0320] Polypeptides of the present invention that are not specifically described in this table are not considered as not belonging to a domain. This is because they may still be not recognized as such by the particular algorithms used or not be included in the particular database searched. In fact, all fragments of the polypeptides of the present invention, at least 6 amino acids residues in length, are included in the present invention as being a domain. The domains of the present invention preferably comprises 6 to 200 amino acids (i.e. any integer between 6 and 200, inclusive) of a polypeptide of the present invention. Also, included in the present invention are domain fragments between the integers of 6 and the full length PG-3 sequence of the sequence listing. All combinations of sequences between the integers of 6 and the full-length sequence of a PG-3 polypeptide are included. The domain fragments may be specified by either the number of contiguous amino acid residues (as a sub-genus) or by specific N-terminal and C-terminal positions (as species) as described above for the polypeptide fragments of the present invention. Any number of domain fragments of the present invention may also be excluded in the same manner.

[0321] c) Epitones and Antibody Fusions:

[0322] A preferred embodiment of the present invention is directed to epitope-bearing polypeptides and epitope-bearing polypeptide fragments. These epitopes may be “antigenic epitopes” or both an “antigenic epitope” and an “immunogenic epitope”. An “immunogenic epitope” is defined as a part of a protein that elicits an antibody response in vivo when the polypeptide is the immunogen. On the other hand, a region of polypeptide to which an antibody binds is defined as an “antigenic determinant” or “antigenic epitope.” The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes (See, e.g., Geysen, et al., 1984), which disclosure is hereby incorporated by reference in its entirety. It is particularly noted that although a particular epitope may not be immunogenic, it is nonetheless useful since antibodies can be made to both immunogenic and antigenic epitopes.

[0323] An epitope can comprise as few as 3 amino acids in a spatial conformation, which is unique to the epitope. Generally an epitope consists of at least 6 such amino acids, and more often at least 8-10 such amino acids. In preferred embodiment, antigenic epitopes comprise a number of amino acids that is any integer between 3 and 50. Fragments which function as epitopes may be produced by any conventional means (See, e.g., Houghten, 1985), also further described in U.S. Pat. No. 4,631,21, which disclosures are hereby incorporated by reference in their entireties. Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping, e.g., the Pepscan method described by Geysen et al. (1984); PCT Publication No. WO 84/03564; and PCT Publication No. WO 84/03506, which disclosures are hereby incorporated by reference in their entireties. Another example is the algorithm of Jameson and Wolf, (1988) (said reference incorporated by reference in its entirety). The Jameson-Wolf antigenic analysis, for example, may be performed using the computer program PROTEAN, using default parameters (Version 4.0 Windows, DNASTAR, Inc., 1228 South Park Street Madison, Wis.

[0324] Antigenic epitopes predicted by the Jameson-Wolf algorithm for the PG-3 polypeptide of SEQ ID NO:3 are the fragments comprising the amino acids from position 17 to 29, 52 to 68, 104 to 127, 138 to 148, 188 to 195, 198 to 210, 238 to 254, 280 to 292, 336 to 341,346 to 383, 386 to 395, 406 to 420, 419 to 438, 465 to 470, 480 to 497, 511 to 526, 532 to 544, 559 to 570, 568 to 580, 599 to 609, 610 to 618, 619 to 628, 636 to 647, 655 to 661, 747 to 754, or 799 to 808. As used herein, the term “epitope described for PG-3” refers to all preferred polynucleotide fragments described in the above list. It is pointed out that the immunogenic epitopes listed above describe only amino acid residues comprising epitopes predicted to have the highest degree of immunogenicity by a particular algorithm. Polypeptides of the present invention that are not specifically described as immunogenic are not considered non-antigenic. This is because they may still be antigenic in vivo but merely not recognized as such by the particular algorithm used. Alternatively, the polypeptides are most likely antigenic in vitro using methods such a phage display. Thus, listed above are the amino acid residues comprising only preferred epitopes, not a complete list. In fact, all fragments of the PG-3 polypeptides of the present invention, at least 6 amino acids residues in length, are included in the present invention as being useful as antigenic epitope. Amino acid residues comprising other immunogenic epitopes may be determined by algorithms similar to the Jameson-Wolf analysis or by in vivo testing for an antigenic response using the methods described herein or those known in the art.

[0325] Therefore, the present invention encompasses isolated, purified, or recombinant polypeptides which consist of, consist essentially of, or comprise a contiguous span of at least 6, preferably at least 8 to 10, more preferably 12, 15, 20, 25, 30,35, 40, 50, 60, 75, 100, 125, 150, 175, 200, 225, 250, 275, or 300 amino acids of SEQ ID NO:3, where said contiguous span comprises at least 1, 2, 3, 5, or 10 amino acids positions of an epitope described for PG-3. The present invention also encompasses isolated, purified, or recombinant polypeptides comprising, consisting essentially of, or consisting of a contiguous span of at least 6, preferably at least 7, or 8 , more preferably 10, 12, 15, 18 or 20 amino acids of SEQ ID NO:3, where said contiguous span is an epitope described for PG-3. The present invention also encompasses isolated, purified, or recombinant polypeptides which comprise, consist of or consist essentially of an epitope described for PG-3 of the sequence of SEQ ID NO:3.

[0326] The epitope-bearing fragments of the present invention preferably comprises 6 to 50 amino acids (i.e. any integer between 6 and 50, inclusive) of a polypeptide of the present invention. Also, included in the present invention are antigenic fragments between the integers of 6 and the full length PG-3 sequence of the sequence listing. All combinations of sequences between the integers of 6 and the full-length sequence of a PG-3 polypeptide are included. The epitope-bearing fragments may be specified by either the number of contiguous amino acid residues (as a sub-genus) or by specific N-terminal and C-terminal positions (as species) as described above for the polypeptide fragments of the present invention. Any number of epitope-bearing fragments of the present invention may also be excluded in the same manner.

[0327] Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies that specifically bind the epitope (See, Wilson et al., 1984; and Sutcliffe, et al., 1983), which disclosures are hereby incorporated by reference in their entireties. The antibodies are then used in various techniques such as diagnostic and tissue/cell identification techniques, as described herein, and in purification methods such as immunoaffinity chromatography.

[0328] Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art (See, Sutcliffe et al., supra; Wilson et al., supra; Chow et al.;(1985) and Bittle, et al., (1985), which disclosures are hereby incorporated by reference in their entireties). A preferred immunogenic epitope includes the natural PG-3 protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.).

[0329] Epitope-bearing polypeptides of the present invention are used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods (See, e.g., Sutcliffe, et al., supra; Wilson, et al., supra, and Bittle, et al., supra). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as -maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 μgs of peptide or carrier protein and Freund's adjuvant. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody, which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

[0330] As one of skill in the art will appreciate, and discussed above, the PG-3 polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to heterologous polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, any combination thereof including both entire domains and portions thereof) resulting in chimeric polypeptides. These fusion proteins facilitate purification, and show an increased half-life in vivo. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (See, e.g., EPA 0,394,827; and Traunecker et al., 1988), which disclosures are hereby incorporated by reference in their entireties. Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion can also be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone (See, e.g., Fountoulakis et al., 1995), which disclosure is hereby incorporated by reference in its entirety. Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag to aid in detection and purification of the expressed polypeptide.

[0331] Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, or codon-shuffling (collectively referred to as “DNA shuffling”). DNA shuffling may be employed to modulate the activities of polypeptides of the present invention thereby effectively generating agonists and antagonists of the polypeptides. See, for example, U.S. Pat. Nos. 5,605,793; 5,811,238; 5,834,252; 5,837,458; and Patten, et al., (1997); Harayama, (1998); Hansson, et al (1999); and Lorenzo and Blasco, (1998). (Each of these documents are hereby incorporated by reference). In one embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of coding polynucleotides of the invention, or the polypeptides encoded thereby may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

[0332] The present invention further encompasses any combination of the polypeptide fragments listed in this section.

[0333] PG-3 Polypeptide Biological Activities

[0334] It is believed that the PG3 polypeptide of the invention is involved in DNA repair, recombination and cell cycle control. Preferred polypeptides of the invention are those that comprise amino acids from positions 3 to 87, from position 642 to 730, and from position 753 to 833 of SEQ ID NO:3. Other preferred polypeptides of the invention are any fragment of SEQ ID NO:3 having any of the biological activities described herein.

[0335] Multimerization

[0336] The invention relates to compositions and methods using the PG-3 protein of the invention or fragments thereof, preferably PG-3 multimerizationd domains, more preferably PG-3 fragments that comprise amino acids from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, to mediate multimerization of proteins of interest.

[0337] Multimerization domains have been shown to be useful tools in several areas of biotechnology, especially in protein engineering, where their ability to mediate homo-dimerization or hetero-dimerization has found several applications. For example, Bosslet et al have described the use of a pair of leucine zipper for in vitro diagnosis, in particular for the immunochemical detection and determination of an analyte in a biological liquid (U.S. Pat. No. 5,643,731)/Tso et al have used leucine zippers for producing bispecific antibody heterodimers (U.S. Pat. No. 5,932,448)/Methods of preparing soluble oligomeric proteins using leucine zippers have been described by Conrad et al (U.S. Pat. No. 5,965,712), Ciardelli et al (U.S. Pat. No. 5,837,816), Spriggs et al (WO9410308)/Leucine zipper forming sequences have been used by Pelletier et al in protein fragment complementation assays to detect biomolecular interactions (WO9834120). Because of their usefulness in biotechnology, it is thus highly interesting to isolate new multimerization domains.

[0338] The multimerization activity of PG-3 or any proteins containing a PG-3 fragment, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3 may be assayed using any of the assays known to those skilled in the art including those disclosed in the references cited herein.

[0339] In a preferred embodiment, the invention relates to compositions and methods of using PG-3 or part thereof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, for preparing soluble multimeric proteins, which consist in multimers of fusion proteins containing PG-3 or part thereof fused to a protein of interest, using any technique known to those skilled in the art including those teached in international patent WO9410308, which disclosure is hereby incorporated by reference in its entirety. In another preferred embodiment, PG-3 or part thereof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, is used to produce bispecific antibody heterodimers using the teaching of U.S. Pat. No. 5,932,448, which disclosure is hereby incorporated by reference in its entirety. Briefly, PG-3 or part thereof is linked to an epitope binding component whereas a second multimerization domain is linked to a second epitope binding component with a different specificity. The second multimerization domain can either be the same or another PG-3 fragment, or an heterologous multimerization domain. Bispecific antibodies are formed by pairwise association of the multimerization domains, forming an heterodimer which links two distinct epitope binding components. In still another preferred embodiment, PG-3 or part thereof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, is used for detection and determination of an analyte in a biological liquid as described in U.S. Pat. No. 5,643,731, which disclosure is hereby incorporated by reference in its entirety. Briefly, a first PG-3 multimerization domain is immobilized on a solid support and the second multimerization domain is coupled to a specific binding partner for an analyte in a biological fluid. The two peptides are then brought into contact thereby immobilizing the binding partner on the solid phase. The biological sample is then contacted with the immobilized binding partner and the amount of analyte in the sample bound to the binding partner determined. The second multimerization domain can either be the same or another PG-3 fragment, or an heterologous multimerization domain. In still another preferred embodiment, PG-3 or part thereof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, may be used to synthesize novel nucleic acid binding proteins which are able to multimerize with proteins of interest, for example to inhibit and/or control cellular growth using any genetic engineering technique known to those skilled in the art including the ones described in the U.S. Pat. No. 5,942,433, which disclosure is hereby incorporated by reference in its entirety .

[0340] In another embodiment, the invention relates to compositions and methods using PG-3 or part thereof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, in protein fragment complementation assays to detect biomolecular interactions in vivo and in vitro as described in international patent WO9834120, which disclosures is hereby incorporated by reference in its entirety. Such assays may be used to study the equilibrium and kinetic aspects of molecular interactions including protein-protein, protein-nucleic acid, protein-carbohydrate and protein-small molecule interactions, for screening cDNA libraries for binding to a target protein with unknown proteins or libraries of small organic molecules for biological activity.

[0341] Still, another object of the present invention relates to the use of PG-3 or part thereof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3 for identifying new multimerization domains using any techniques for detecting protein-protein interaction known to those skilled in the art. Among the traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of cell lysates. Once isolated as a protein interacting with PG-3, or part thereof, such an intracellular protein can be identified (e.g. its amino acid sequence determined) and can, in turn, be used, in conjunction with standard techniques, to identify other proteins with which it interacts. The amino acid sequence thus obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such intracellular proteins. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (See, e.g., Ausubel et al., eds., Current Protocols in Molecular Biology, J. Wiley and Sons (New York, N.Y. 1993) and PR Protocols: A Guide to Methods and Applications, 1990, Innis, M. et al., eds. Academic Press, Inc., New York).

[0342] Alternatively, PG-3 or fragments therof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, could be used by those skilled in art as a “bait protein” in a well established yeast double hybridization system to identify its interacting protein partners in vivo from cDNA library derived from different tissues or cell types of a given organism. Alternatively, PG-3 or fragments therof, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, could be used by those skilled in art in mammalian cell transfection experiments. When fused to a suitable peptide tag such as [His]₆ tag in a protein expression vector and introduced into culture cells, this expressed fusion protein can be immunoprecipitated with its potential interacting proteins by using anti-tag peptide antibody. This method could be chosen either to identify the associated partner or to confirm the results obtained by other methods such as those just mentioned.

[0343] Alternatively, methods may be employed which result in the simultaneous identification of genes which encode the intracellular proteins that can dimerize with the PG-3 or fragments therof, using any technique known to those skilled in the art. These methods include, for example, probing cDNA expression libraries, in a manner similar to the well known technique of antibody probing of lambda.gt11 libraries, using as a probe a labeled version of PG-3 protein or part thereof, or fusion protein, e.g., PG-3 or part thereof fused to a marker (e.g., an enzyme, fluor, luminescent protein, or dye), or an Ig-Fc domain (for technical details on screening of cDNA expression libraries, see Ausubel et al, supra). Alternatively, another method for the detection of protein interaction in vivo, the two-hybrid system, may be used.

[0344] Regulation of Ranscription

[0345] The invention relates to compositions and methods using PG3 polypeptides or part thereof, preferably fragments comprising a transcription regulation domain, more preferably PG-3 fragments that comprise amino acids from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, to regulate gene transcription.

[0346] The transcription regulation activity of PG-3 or any proteins containing a PG-3 fragment, preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3 may be assayed using any of the assays known to those skilled in the art including those disclosed in the references cited herein. Such assays include the yeast transcription assay described in Hayes et al., Cancer Res. 60:2411-2418 (2000) and in Miyake et al., J. Biol. Chem. 275:40169-40173 (2000).

[0347] One of the remarkable features of such domains of transcriptional factors in general is that “fusing” them to heterologous protein domains seldom affects their ability to regulate transcription when recruited to a wide variety of promoters. The high degree of functional independence exhibited by these regulation domains makes them valuable tools in various biological assays for analyzing gene expression and protein-protein or protein-RNA or protein-small molecule drug interactions. Several strategies to improve the potency of such transcription regulation domains and thereby the expression of genes under their control have been reported. These approaches generally involve increasing the number of copies of regulation domains fused to the DNA binding domain or generating transcriptional regulators containing synergizing combinations of regulation domains.

[0348] Therefore, in an additional embodiment, this invention provides compositions and methods containing new transcription factors comprising PG3 or part thereof, preferably fragments comprising a transcription regulation domain, more preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3. Such transcription factors may be designed to regulate the expression of target genes of interest. Aspects of the invention are applicable to systems involving either covalent or non-covalent linking of the transcription regulation domain to a DNA binding domain. In practice, cells can be engineered by the introduction of recombinant nucleic acids encoding the fusion proteins containing at least two mutually heterologous domains, one of them being the regulation domain of the invention, and in some cases additional nucleic acid constructs, to render them capable of ligand-dependent regulation of transcription of a target gene. Administration of the ligand to the cells then regulates positively or negatively target gene transcription (all laboratory methods related to this embodiment are completely described in U.S. Pat. No. 6,015,709, which disclosure is hereby incorporated by reference in its entirety). Illustrative (non-limiting) examples of heterologous domains which can be included along with the regulation domain of the invention in various fusion proteins of this invention include another transcription regulatory domain (i.e., transcription activation domains such as a p65, VP16 or AP domain; transcription potentiating or synergizing domains; or transcription repression domains such as an ssn-6TUP-1 domain or Kruppel family suppressor domain); a DNA binding domain such as a GAL4, lex A or a composite DNA binding domain such as a composite zinc finger domain or a ZFHD1 domain; or a ligand-binding domain comprising or derived from (a) an immunophilin, cyclophilin or FRB domain; (b) an antibiotic binding domain such as tetR: or (c) a hormone receptor such as a progesterone receptor or ecdysone receptor. A wide variety of ligand binding domains may be used in this invention, although ligand binding domains which bind to a cell permeant ligand are preferred. It is also preferred that the ligand have a molecular weight under about 5 kD, more preferably below 2.5 kD and optimally below about 1500 D. Non-proteinaceous ligands are also preferred. Examples of ligand binding domain/ligand pairs that may be used in the practice of this invention include, but are not limited to: FKBP:FK1012, FKBP:synthetic divalent FKBP ligands (see WO 96/0609 and WO 97/31898), FRB:rapamycin/FKBP (see e.g., WO 96/41865 and Rivera et al, “A humanized system for pharmacologic control of gene expression”, Nature Medicine 2(9):1028-1032 (1997)), cyclophilin:cyclosporin (see e.g. WO 94/18317), DHFR:methotrexate (see e.g. Licitra et al, 1996, Proc. Natl. Acad. Sci. U.S.A. 93:12817-12821), TetR:tetracycline or doxycycline or other analogs or mimics thereof (Gossen and Bujard, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:5547; Gossen et al, 1995, Science 268:1766-1769; Kistner et al, 1996, Proc. Natl. Acad. Sci. U.S.A. 93:10933-10938), a progesterone receptor:RU486 (Wang et al, 1994, Proc. Natl. Acad. Sci. U.S.A. 91:8180-8184), ecodysone receptor:ecdysone or muristerone A or other analogs or mimics thereof (No et al, 1996, Proc. Natl. Acad. Sci. U.S.A. 93:3346-3351) and DNA gyrase:counermycin (see e.g. Farrar et al, 1996, Nature 383:178-181). In many applications it is preferable to use a DNA binding domain which is heterologous to the cells to be engineered. In the case of composite DNA binding domains, component peptide portions which are endogenous to the cells or organism to be engineered are generally preferred.

[0349] In another aspect of this embodiment, polynucleotides encoding transcription regulation domains as well as any other functional fragments of PG3 may be introduced into polynucleotides encoding fusion proteins for a variety of regulated gene expression systems, including both allostery-based systems such as those regulated by tetracycline, RU486 or ecdysone, or analogs or mimics thereof, and dimerization-based systems such as those regulated by divalent compounds like FK1012, FKCsA, rapamycin, AP1510 or coumermycin, or analogs or mimics thereof, all as described below (See also, Clackson, Controlling mammalian gene expression with small molecules, Current Opinion in Chem. Biol. 1:210-218 (1997)). The fusion proteins may comprise any combination of relevant components, including bundling domains, DNA binding domains, transcription activation (or repression) domains and ligand binding domains. Other heterologous domains may also be included.

[0350] Another embodiment of this invention relates to expression systems, preferably vectors and vector-containing cells, using PG3 or part thereof, preferably fragments comprising a transcription regulation domain, more preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3. In this regard, recombinant nucleic acids are provided which encode fusion proteins containing the transcription regulation domain of the invention and at least one additional domain that is heterologous thereto, where the peptide sequence of said activation domain is itself eventually modified relative to the naturally occurring sequence from which it was derived to increase or decrease its potency as a transcriptional regulator relative to the counterpart comprising the native peptide sequence. Each of the recombinant nucleic acids of this invention may further comprise an expression control sequence operably linked to the coding sequence and may be provided within a DNA vector, e.g., for use in transducing prokaryotic or eukaryotic cells. Some of the recombinant nucleic acids of a given composition as described above, including any optional recombinant nucleic acids, may be present within a single vector or may be apportioned between two or more vectors. The recombinant nucleic acids may be provided as inserts within one or more recombinant viruses which may be used, for example, to transduce cells in vitro or cells present within an organism, including a human or non-human mammalian subject. It should be appreciated that non-viral approaches (naked DNA, liposomes or other lipid compositions, etc.) may be used to deliver recombinant nucleic acids of this invention to cells in a recipient organism. The resultant engineered cells and their progeny containing one or more of these recombinant nucleic acids or nucleic acid compositions of this invention may be used in a variety of important applications, including human gene therapy, analogous veterinary applications, the creation of cellular or animal models (including transgenic applications) and assay applications. Such cells are useful, for example, in methods involving the addition of a ligand, preferably a cell permeant ligand, to the cells (or administration of the ligand to an organism containing the cells) to regulate expression of a target gene.

[0351] In another embodiment, the present invention relates to compositions and methods using PG3 or part thereof, preferably fragments comprising a transcription regulation domain, more preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, to alter the expression of genes of interest in a target cells. Such genes of interest may be disease related genes, such as oncogenes or exogenous genes from pathogens, such as bacteria or viruses using any techniques known to those skilled in the art including those described in U.S. Pat. Nos. 5,861,495; 5,866,325 and 6,013,453.

[0352] In still another embodiment, PG3 or part thereof, preferably fragments comprising a transcription regulation domain, more preferably PG-3 fragments from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3, may be used to diagnose, treat and/or prevent disorders linked to dysregulation of gene transcription such as cancer and other disorders relating to abnormal cellular differentiation, proliferation, or degeneration, including hyperaldosteronism, hypocortisolism (Addison's disease), hyperthyroidism (Grave's disease), hypothyroidism, colorectal polyps, gastritis, gastric and duodenal ulcers, ulcerative colitis, and Crohn's disease.

[0353] DNA Repair Activity

[0354] The invention relates to compositions and methods using the PG-3 protein of the invention or fragments thereof, preferably preferably PG-3 fragments that comprise amino acids from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3 to repair DNA breaks.

[0355] In one embodiment, cell lines may be genetically engineered in order to overexpress PG-3 or part thereof, preferably PG-3 fragments that comprise amino acids from positions 3 to 87, from position 642 to 730, or from position 753 to 833 of SEQ ID NO:3 using genetic engineering techniques well known to those skilled in the art. Optionally, such cell lines may be engineered to overexpress fusion proteins comprising PG-3 or part thereof fused to a protein able to repair DNA damage. Exemplary DNA repair proteins for use in the present invention include those from the base excision repair (BER) pathway, e.g., AP endonucleases such as human APE (HAPE, Genbank Accession No. M80261) and related bacterial or yeast proteins such as APN-1 (e.g., Genbank Accession No. U33625 and M33667), exonuclease III (ExoIII, xth gene, Genbank Accession No. M22592,) bacterial endonuclease m (EndoIII, nth gene, Genbank Accession No. J02857), huEndoIII (Genbank Accession No. U79718), and endonuclease IV (EndoIV nfo gene Genbank Accession No. M22591). Additional BER proteins suitable for use in the invention include, for example, DNA glycosylases such as, formamidopyrimidine-DNA glycosylase (FPG, Genbank Accession No. X06036), human 3-alkyladenine DNA glycosylase (HAAG, also known as human methylpurine-DNA glycosylase (hMPG, Genbank Accession No. M74905), NTG-1 (Genbank Accession No. P31378 or 171860), SCR-1 (YAL015C), SCR-2 (Genbank Accession No. YOL043C), DNA ligase I (Genbank Accession No. M36067), .beta.-polymerase (Genbank Accession No. M13140 (human)) and 8-oxoguanine DNA glycosylase (OGG1 Genbank Accession No. U44855 (yeast); Y13479 (mouse); Y11731 (human)). Proteins for use in the invention from the direct reversal pathway include human MGMT (Genbank Accession No. M2997 1) and other similar proteins.

[0356] Such cell lines will exhibit a high level of DNA repair activity and will be more resistant to carcinogens inducing single stranded or double stranded DNA breaks. Such cell lines would thus provide an interesting model for carcinogen and drug testing.

Antibodies that Bind PG-3 Polypeptides of the Invention

[0357] Definitions

[0358] The present invention further relates to antibodies and T-cell antigen receptors (TCR), which specifically bind the polypeptides, and more specifically, the epitopes of the polypeptides of the present invention. The antibodies of the present invention include IgG (including IgG1, IgG2, IgG3, and IgG4), IgA (including IgA1 and IgA2), IgD, IgE, or IgM, and IgY. The term “antibody” (Ab) refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where a binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen, which allows an immunological reaction with the antigen. As used herein, the term “antibody” is meant to include whole antibodies, including single-chain whole antibodies, and antigen binding fragments thereof. In a preferred embodiment the antibodies are human antigen binding antibody fragments of the present invention include, but are not limited to, Fab, Fab′F(ab)2 and F(ab′)2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a V_(L) or V_(H) domain. The antibodies may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine, rabbit, goat, guinea pig, camel, horse, or chicken.

[0359] Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entire or partial of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are any combinations of variable region(s) and hinge region, CH1, CH2, and CH3 domains. The present invention further includes chimeric, humanized, and human monoclonal and polyclonal antibodies, which specifically bind the polypeptides of the present invention. The present invention further includes antibodies that are anti-idiotypic to the antibodies of the present invention.

[0360] The antibodies of the present invention may be monospecific, bispecific, and trispecific or have greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for heterologous compositions, such as a heterologous polypeptide or solid support material. See, e.g., WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al. (1991); U.S. Pat. Nos. 5,573,920, 4,474,893, 5,601,819, 4,714,681, 4,925,648; Kostelny et al. (1992), which disclosures are hereby incorporated by reference in their entireties.

[0361] Antibodies of the present invention may be described or specified in terms of the epitope(s) or epitope-bearing portion(s) of a polypeptide of the present invention, which are recognized or specifically bound by the antibody. The antibodies may specifically bind a complete protein encoded by a nucleic acid of the present invention, or a fragment thereof. Therefore, the epitope(s) or epitope bearing polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or otherwise described herein (including the sequence listing). Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded as individual species. Therefore, the present invention includes antibodies that specifically bind specified polypeptides of the present invention, and allows for the exclusion of the same.

[0362] Thus, another embodiment of the present invention is a purified or isolated antibody capable of specifically binding to a polypeptide comprising a sequence of SEQ ID NO:3. In one aspect of this embodiment, the antibody is capable of binding to an epitope-containing polypeptide comprising at least 6 consecutive amino acids, preferably at least 8 to 10 consecutive amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 consecutive amino acids of SEQ ID NO:3.

[0363] Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not specifically bind any other analog, ortholog, or homologue of the polypeptides of the present invention are included. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein, e.g., using FASTDB and the parameters set forth herein) to a polypeptide of the present invention are also included in the present invention. Further included in the present invention are antibodies, which only bind polypeptides encoded by polynucleotides, which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity. Preferred binding affinities include those with a dissociation constant or Kd less than 5×10⁻⁶M, 10⁻⁶M, 5×10⁻⁷M, 10⁻⁷M, 5×10⁻⁸M, 10⁻⁸M, 5×10⁻⁹M, 10⁻⁹M, 5×10⁻¹⁰M, 10⁻¹⁰M, 5×10⁻¹¹ M, 10⁻¹¹M, 5×10⁻¹²M, 10⁻¹²M, 5×10⁻¹³M, 10⁻¹³M, 5×10⁻¹⁴M, 10⁻¹⁴M, 5×10¹⁵M, and 10⁻⁵M.

[0364] Any PG-3 polypeptide or whole protein may be used to generate antibodies capable of specifically binding to an expressed PG-3 protein or fragments thereof as described.

[0365] One antibody composition of the invention is capable of specifically binding to the PG-3 protein of SEQ ID No 3. For an antibody composition to specifically bind to the PG-3 protein, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for PG-3 protein than for another protein in an ELISA, RIA, or other antibody-based binding assay.

[0366] The invention also concerns antibody compositions which are specific for variants of the PG-3 protein, more particuarly variants comprising at least one amino acid selected from the group consisting of a methionine or an isoleucine residue at the position 91 of SEQ ID No 3, a valine or an alanine residue at the position 306 of SEQ ID No 3, a proline or a serine residue at the position 413 of SEQ ID No 3, a glycine or an aspartate residue at the position 528 of SEQ ID No 3, a valine or an alanine residue at the position 614 of SEQ ID No 3, a threonine or an asparagine residue at the position 677 of SEQ ID No 3, a valine or an alanine residue at the position 756 of SEQ ID No 3, a valine or an alanine residue at the position 758 of SEQ ID No 3, a lysine or a glutamate residue at the position 809 of SEQ ID No 3, and a cysteine or an arginine residue at the position 821 of SEQ ID No 3. More preferably, the invention encompasses antibody compositions which are specific for an allelic variant of the PG-3 protein, more particuarly a variant comprising at least one amino acid selected from the group consisting of an arginine or an isoleucine residue at the amino acid position 304 of SEQ ID No 3, a histidine or an aspartic acid residue at the amino acid position 314 of SEQ ID No 3, a threonine or an asparagine residue at the amino acid position 682 of SEQ ID No 3, an alanine or a valine residue at the amino acid position 761 of SEQ ID No 3, and a proline or a serine residue at the amino acid position 828 of SEQ ID No 3.

[0367] In a preferred embodiment, the invention concerns antibody compositions, either polyclonal or monoclonal, capable of selectively binding, or selectively bind to an epitope-containing a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 3; preferably, said epitope comprises at least 1, 2, 3, 5 or 10 of the following amino acid positions of SEQ ID No 3: 1-100, 101-200, 201-300, 301-400, 401-500, 501-600, 601-700, 701-835.

[0368] The invention also concerns a purified or isolated antibody capable of specifically binding to a mutated PG-3 protein or to a fragment or variant thereof comprising an epitope of the mutated PG-3 protein. In another preferred embodiment, the present invention concerns an antibody capable of binding to a polypeptide comprising at least 10 consecutive amino acids of a PG-3 protein and including at least one of the amino acids which can be encoded by the trait causing mutations.

[0369] In a preferred embodiment, the invention concerns the use in the manufacture of antibodies of a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 3; preferably, said contiguous span comprises at least 1, 2, 3, 5 or 10 of the following amino acid positions of SEQ ID No 3: 1-100, 101-200, 201-300, 301-400, 401-500, 501-600, 601-700, 701-835.

[0370] The antibodies of the invention may be labeled using any one of the radioactive, fluorescent or enzymatic labels known in the art.

[0371] Consequently, the invention is also directed to a method for specifically detecting the presence of a PG-3 polypeptide according to the invention in a biological sample, said method comprising the following steps:

[0372] a) bringing said biological sample into contact with a polyclonal or monoclonal antibody that specifically binds to a PG-3 polypeptide comprising an amino acid sequence of SEQ ID No 3, or to a peptide fragment or to a variant thereof; and

[0373] b) detecting the antigen-antibody complex formed.

[0374] The invention also concerns a diagnostic kit for detecting the presence of a PG-3 polypeptide according to the present invention in a biological sample in vitro , wherein said kit comprises:

[0375] a) a polyclonal or monoclonal antibody that specifically binds to a PG-3 polypeptide comprising the amino acid sequence of SEQ ID No 3, or to a peptide fragment or to a variant thereof; optionally the antibody may be labeled; and

[0376] b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent optionally carrying a label, or being able to be recognized itself by a labeled reagent (particularly in the case when the above-mentioned monoclonal or polyclonal antibody itself is not labeled).

[0377] Preparation of Antibodies

[0378] The antibodies of the present invention may be prepared by any suitable method known in the art. Some of these methods are described in more detail in the example entitled “PREPARATION OF ANTIBODY COMPOSITIONS TO THE PG-3 PROTEIN”. For example, a polypeptide of the present invention or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing “polyclonal antibodies”. As used herein, the term “monoclonal antibody” is not limited to antibodies produced through hybridoma technology but it rather refers to an antibody that is derived from a single clone, including eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technology.

[0379] Hybridoma techniques include those known in the art (See, e.g., Harlow et al. 1988; Hammerling, et al, 1981). (Said references incorporated by reference in their entireties). Fab and F(ab′)2 fragments may be produced, for example, from hybridoma-produced antibodies by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′)2 fragments).

[0380] Alternatively, antibodies of the present invention can be produced through the application of recombinant DNA technology or through synthetic chemistry using methods known in the art. For example, the antibodies of the present invention can be prepared using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of a phage particle, which carries polynucleotide sequences encoding them. Phage with a desired binding property are selected from a repertoire or combinatorial antibody library (e.g. human or murine) by selecting directly with antigen, typically antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al. (1995); Ames, et al. (1995); Kettleborough, et al. (1994); Persic, et al. (1997); Burton et al. (1994); PCT/GB91/01134; WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727 and 5,733,743 (said references incorporated by reference in their entireties).

[0381] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host including mammalian cells, insect cells, plant cells, yeast, and bacteria. For example, techniques to recombinantly produce Fab, Fab′ F(ab′)2 and F(ab′)2 fragments can also be employed using methods known in the art such as those disclosed in WO 92/22324; Mullinax et al. (1992); and Sawai et al. (1 995); and Better et al. (1988) (said references incorporated by reference in their entireties).

[0382] Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Pat. Nos. 4,946,778 and 5,258,498; Huston et al. (1991); Shu et al. (1993); and Skerra et al. (1988), which disclosures are hereby incorporated by reference in their entireties. For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, (1985); Oi et al., (1986); Gillies et al. (1989); and U.S. Pat. No. 5,807,715, which disclosures are hereby incorporated by reference in their entireties. Antibodies can be humanized using a variety of techniques including CDR-grafting (EP 0 239 400; WO 91/09967; U.S. Pat. Nos. 5,530,101; and 5,585,089), veneering or resurfacing, (EP 0 592 106; EP 0 519 596; Padlan, 1991; Studnicka et al., 1994; Roguska et al., 1994), and chain shuffling (U.S. Pat. No. 5,565,332), which disclosures are hereby incorporated by reference in their entireties. Human antibodies can be made by a variety of methods known in the art including phage display methods described above. See also, U.S. Pat. Nos. 4,444,887, 4,716,111, 5,545,806, and 5,814,318; WO 98/46645; WO 98/50433; WO 98/24893; WO 96/34096; WO 96/33735; and WO 91/10741 (said references incorporated by reference in their entireties).

[0383] Further included in the present invention are antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide of the present invention. The antibodies may be specific for antigens other than polypeptides of the present invention. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, or toxins. See, e.g., WO 92/08495; WO 91/14438; WO 89/12624; U.S. Pat. No. 5,314,995; and EP 0 396 387, which disclosures are hereby incorporated by reference in their entireties. Fused antibodies may also be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in vitro immunoassays and purification methods using methods known in the art (See e.g., Harbor et al. supra; WO 93/21232; EP 0 439 095; Naramura, M. et al. 1994; U.S. Pat. No. 5,474,981; Gillies et al., 1992; Fell et al., 1991) (said references incorporated by reference in their entireties).

[0384] The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides of the present invention may be fused or conjugated to the above antibody portions to increase the in vivo half-life of the polypeptides or for use in immunoassays using methods known in the art. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See e.g., U.S. Pat. Nos. 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, 5,112,946; EP 0 307 434, EP 0 367 166; WO 96/04388, WO 91/06570; Ashkenazi et al. (1991); Zheng et al. (1995); and Vil et al. (1992) (said references incorporated by reference in their entireties).

[0385] Non-human animals or mammals, whether wild-type or transgenic, which express a different species of PG-3 than the one to which antibody binding is desired, and animals which do not express PG-3 (i.e. a PG-3 knock out animal as described herein) are particularly useful for preparing antibodies. PG-3 knock out animals will recognize all or most of the exposed regions of a PG-3 protein as foreign antigens, and therefore produce antibodies with a wider array of PG-3 epitopes. Moreover, smaller polypeptides with only 10 to 30 amino acids may be useful in obtaining specific binding to any one of the PG-3 proteins. In addition, the humoral immune system of animals which produce a species of PG-3 that resembles the antigenic sequence will preferentially recognize the differences between the animal's native PG-3 species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence. Such a technique will be particularly useful in obtaining antibodies that specifically bind to any one of the PG-3 proteins.

[0386] Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

[0387] The antibodies of the invention may be labeled by any one of the radioactive, fluorescent or enzymatic labels known in the art.

PG-3-Related Biallelic Markers

[0388] Advantages of the Biallelic Markers of the Present Invention

[0389] The PG-3-related biallelic markers of the present invention offer a number of important advantages over other genetic markers such as RFLP (Restriction fragment length polymorphism) and VNTR (Variable Number of Tandem Repeats) markers.

[0390] The first generation of markers were RFLPs, which are variations that modify the length of a restriction fragment. But methods used to identify and to type RFLPs are relatively wasteful of materials, effort, and time. The second generation of genetic markers were VNTRs, which can be categorized as either minisatellites or microsatellites. Minisatellites are tandemly repeated DNA sequences present in units of 5-50 repeats which are distributed along regions of the human chromosomes ranging from 0.1 to 20 kilobases in length. Since they present many possible alleles, their informative content is very high. Minisatellites are scored by performing Southern blots to identify the number of tandem repeats present in a nucleic acid sample from the individual being tested. However, there are only 10⁴ potential VNTRs that can be typed by Southern blotting. Moreover, both RFLP and VNTR markers are costly and time-consuming to develop and assay in large numbers.

[0391] Single nucleotide polymorphisms (SNPs) or biallelic markers can be used in the same manner as RFLPs and VNTRs but offer several advantages. SNPs are densely spaced in the human genome and represent the most frequent type of variation. An estimated number of more than 10⁷ sites are scattered along the 3×10⁹ base pairs of the human genome. Therefore, SNPs occur at a greater frequency and with greater uniformity than RFLP or VNTR markers which means that there is a greater probability that such a marker will be found in close proximity to a genetic locus of interest. SNPs are less variable than VNTR markers but are mutationally more stable.

[0392] Also, the different forms of a characterized single nucleotide polymorphism, such as the biallelic markers of the present invention, are often easier to distinguish and can therefore be typed easily on a routine basis. Biallelic markers have single nucleotide based alleles and they have only two common alleles, which allows highly parallel detection and automated scoring. The biallelic markers of the present invention offer the possibility of rapid, high throughput genotyping of a large number of individuals.

[0393] Biallelic markers are densely spaced in the genome, sufficiently informative and can be assayed in large numbers. The combined effects of these advantages make biallelic markers extremely valuable in genetic studies. Biallelic markers can be used in linkage studies in families, in allele sharing methods, in linkage disequilibrium studies in populations, in association studies of case-control populations or of trait positive and trait negative populations. An important aspect of the present invention is that biallelic markers allow association studies to be performed to identify genes involved in complex traits. Association studies examine the frequency of marker alleles in unrelated case- and control-populations and are generally employed in the detection of polygenic or sporadic traits. Association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families linkage studies). Biallelic markers in different genes can be screened in parallel for direct association with disease or response to a treatment. This multiple gene approach is a powerful tool for a variety of human genetic studies as it provides the necessary statistical power to examine the synergistic effect of multiple genetic factors on a particular phenotype, drug response, sporadic trait, or disease state with a complex genetic etiology.

[0394] Candidate Gene of the Present Invention

[0395] Different approaches can be employed to perform association studies: genome-wide association studies, candidate region association studies and candidate gene association studies. Genome-wide association studies rely on the screening of genetic markers evenly spaced and covering the entire genome. The candidate gene approach is based on the study of genetic markers specifically located in genes potentially involved in a biological pathway related to the trait of interest. In the present invention, PG-3 is a good candidate gene for cancer or a disorder relating to abnormal cellular differentiation. The candidate gene analysis clearly provides a short-cut approach to the identification of genes and gene polymorphisms related to a particular trait when some information concerning the biology of the trait is available. However, it should be noted that all of the biallelic markers disclosed in the instant application can be employed as part of genome-wide association studies or as part of candidate region association studies and such uses are specifically contemplated in the present invention and claims.

[0396] PG-3-Related Biallelic Markers and Polynucleotides Related Thereto

[0397] The invention also concerns PG-3-related biallelic markers. As used herein the term “PG-3-related biallelic marker” relates to a set of biallelic markers in linkage disequilibrium with the PG-3 gene. The term PG-3-related biallelic marker includes the biallelic markers designated A1 to A80.

[0398] A portion of the biallelic markers of the present invention are disclosed in Table 2. Their locations in the PG-3 gene are indicated in Table 2 and also as a single base polymorphism in the features of SEQ ID Nos 1 and 2 listed in the accompanying Sequence Listing. The pairs of primers allowing the amplification of a nucleic acid containing the polymorphic base of one PG-3 biallelic marker are listed in Table 1 of Example 2.

[0399] Eight PG-3-related biallelic markers A3, A6, A7, A14, A70, A71, A72 and A80, are located in the exonic regions of the genomic sequence of PG-3 at the following positions: 10228, 39944, 39973, 76060, 216026, 216082, 216218 and 237555 of the SEQ ID No 1. They are located in exons C, T, I, K and L of the PG-3 gene. Their respective positions in the cDNA and protein sequences are given in Table 2.

[0400] The invention also relates to a purified and/or isolated nucleotide sequence comprising a polymorphic base of a PG-3-related biallelic marker, preferably of a biallelic marker selected from the group consisting of A1 to A80, and the complements thereof. The sequence is between 8 and 1000 nucleotides in length, and preferably comprises at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 1 and 2 or a variant thereof or a complementary sequence thereto. These nucleotide sequences comprise the polymorphic base of either allele I or allele 2 of the considered biallelic marker. Optionally, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of said polynucleotide or at the center of said polynucleotide. Optionally, the 3′ end of said contiguous span may be present at the 3′ end of said polynucleotide. Optionally, biallelic marker may be present at the 3′ end of said polynucleotide. Optionally, said polynucleotide may further comprise a label. Optionally, said polynucleotide can be attached to solid support. In a further embodiment, the polynucleotides defined above can be used alone or in any combination.

[0401] The invention also relates to a purified and/or isolated nucleotide sequence comprising a sequence between 8 and 1000 nucleotides in length, and preferably at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ D) Nos 1 and 2 or a variant thereof or a complementary sequence thereto. Optionally, the 3′ end of said polynucleotide may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a PG-3-related biallelic marker in said sequence. Optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A80; Optionally, the 3′ end of said polynucleotide may be located 1 nucleotide upstream of a PG-3-related biallelic marker in said sequence. Optionally, said polynucleotide may further comprise a label. Optionally, said polynucleotide can be attached to solid support. In a further embodiment, the polynucleotides defined above can be used alone or in any combination.

[0402] In a preferred embodiment, the sequences comprising a polymorphic base of one of the biallelic markers listed in Table 2 are selected from the group consisting of the nucleotide sequences comprising, consisting essentially of, or consisting of the amplicons listed in Table 1 or a variant thereof or a complementary sequence thereto.

[0403] The invention further concerns a nucleic acid encoding the PG-3 protein, wherein said nucleic acid comprises a polymorphic base of a biallelic marker selected from the group consisting of A1 to A80 and the complements thereof.

[0404] The invention also encompasses the use of any polynucleotide for, or any polynucleotide for use in, determining the identity of one or more nucleotides at a PG-3-related biallelic marker. In addition, the polynucleotides of the invention for use in determining the identity of one or more nucleotides at a PG-3-related biallelic marker encompass polynucleotides with any further limitation described in this disclosure, or those following, specified alone or in any combination. Optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said PG-3-related biallelic marker is selected from the group consisting of Al to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said PG-3-related biallelic marker is selected from the group consisting A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, said polynucleotide may comprise a sequence disclosed in the present specification; Optionally, said polynucleotide may comprise, consist of, or consist essentially of any polynucleotide described in the present specification; Optionally, said determining may involve a hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay; Optionally, said polynucleotide may be attached to a solid support, array, or addressable array; Optionally, said polynucleotide may be labeled. A preferred polynucleotide may be used in a hybridization assay for determining the identity of the nucleotide at a PG-3-related biallelic marker. Another preferred polynucleotide may be used in a sequencing or microsequencing assay for determining the identity of the nucleotide at a PG-3-related biallelic marker. A third preferred polynucleotide may be used in an enzyme-based mismatch detection assay for determining the identity of the nucleotide at a PG-3-related biallelic marker. A fourth preferred polynucleotide may be used in amplifying a segment of polynucleotides comprising a PG-3-related biallelic marker. Optionally, any of the polynucleotides described above may be attached to a solid support, array, or addressable array; Optionally, said polynucleotide may be labeled.

[0405] Additionally, the invention encompasses the use of any polynucleotide for, or any polynucleotide for use in amplifying a segment of nucleotides comprising a PG-3-related biallelic marker. In addition, the polynucleotides of the invention for use in amplifying a segment of nucleotides comprising a PG-3-related biallelic marker encompass polynucleotides with any further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said PG-3-related biallelic marker is selected from the group consisting A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, said polynucleotide may comprise a sequence disclosed in the present specification; Optionally, said polynucleotide may comprise, consist of, or consist essentially of any polynucleotide described in the present specification; Optionally, said amplifying may involve PCR or LCR. Optionally, said polynucleotide may be attached to a solid support, array, or addressable array. Optionally, said polynucleotide may be labeled.

[0406] The primers for amplification or sequencing reaction of a polynucleotide comprising a biallelic marker of the invention may be designed from the disclosed sequences for any method known in the art. A preferred set of primers are fashioned such that the 3′ end of the contiguous span of identity with a sequence selected from the group consisting of SEQ ID Nos 1 and 2 or a sequence complementary thereto or a variant thereof is present at the 3′ end of the primer. Such a configuration allows the 3′ end of the primer to hybridize to a selected nucleic acid sequence and dramatically increases the efficiency of the primer for amplification or sequencing reactions. Allele specific primers may be designed such that a polymorphic base of a biallelic marker is at the 3′ end of the contiguous span and the contiguous span is present at the 3′ end of the primer. Such allele specific primers tend to selectively prime an amplification or sequencing reaction so long as they are used with a nucleic acid sample that contains one of the two alleles present at a biallelic marker. The 3′ end of the primer of the invention may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a PG-3-related biallelic marker in said sequence or at any other location which is appropriate for their intended use in sequencing, amplification or the location of novel sequences or markers. Thus, another set of preferred amplification primers comprise an isolated polynucleotide consisting essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 30, 35, 40, or 50 nucleotides in length of a sequence selected from the group consisting of SEQ ID Nos 1 and 2 or a sequence complementary thereto or a variant thereof, wherein the 3′ end of said contiguous span is located at the 3′ end of said polynucleotide, and wherein the 3′end of said polynucleotide is located upstream of a PG-3-related biallelic marker in said sequence. Preferably, those amplification primers comprise a sequence selected from the group consisting of the sequences B1 to B52 and C1 to C52. Primers with their 3′ ends located 1 nucleotide upstream of a biallelic marker of PG-3 have a special utility as microsequencing assays. Preferred microsequencing primers are described in Table 4. Optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said PG-3-related biallelic marker is selected from the group consisting A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, microsequencing primers are selected from the group consisting of the nucleotide sequences of D1 to D4, D6 to D80, E1 to E4 and E6 to E80. More preferred microsequencing primers are selected from the group consisting of the nucleotides sequences of D14, D46, D68, D70, D71, E3, E6, E7, E11, E13, E42, E44, E72 and E75.

[0407] The probes of the present invention may be designed from the disclosed sequences for use in any method known in the art, particularly methods for testing if a marker disclosed herein is present in a sample. A preferred set of probes may be designed for use in the hybridization assays of the invention in any manner known in the art such that they selectively bind to one allele of a biallelic marker, but not the other under any particular set of assay conditions. Preferred hybridization probes comprise the polymorphic base of either allele 1 or allele 2 of the relevant biallelic marker. Optionally, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of the hybridization probe or at the center of said probe. In a preferred embodiment, the robes are selected from the group consisting of the sequences P1 to P4 and P6 to P80 and the complementary sequence thereto.

[0408] It should be noted that the polynucleotides of the present invention are not limited to having the exact flanking sequences surrounding the polymorphic bases which are enumerated in Sequence Listing. Rather, it will be appreciated that the flanking sequences surrounding the biallelic markers may be lengthened or shortened to any extent compatible with their intended use and the present invention specifically contemplates such sequences. The flanking regions outside of the contiguous span need not be homologous to native flanking sequences which actually occur in human subjects. The addition of any nucleotide sequence which is compatible with the polynucleotide's intended use is specifically contemplated.

[0409] Primers and probes may be labeled or immobilized on a solid support as described in the section entitled “Oligonucleotide probes and primers”.

[0410] The polynucleotides of the invention which are attached to a solid support encompass polynucleotides with any further limitation described in this disclosure, or those following, alone or in any combination: Optionally, said polynucleotides may be attached individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. Optionally, polynucleotides other than those of the invention may attached to the same solid support as polynucleotides of the invention. Optionally, when multiple polynucleotides are attached to a solid support they may be attached at random locations, or in an ordered array. Optionally, said ordered array may be addressable.

[0411] The present invention also encompasses diagnostic kits comprising one or more polynucleotides of the invention with a portion or all of the necessary reagents and instructions for genotyping a test subject by determining the identity of a nucleotide at a PG-3-related biallelic marker. The polynucleotides of a kit may optionally be attached to a solid support, or be part of an array or addressable array of polynucleotides. The kit may provide for the determination of the identity of the nucleotide at a marker position by any method known in the art including, but not limited to, a sequencing assay method, a microsequencing assay method, a hybridization assay method, or an enzyme-based mismatch detection assay method.

Methods for De Novo Identification of Biallelic Markers

[0412] Any of a variety of methods can be used to screen a genomic fragment for single nucleotide polymorphisms, including methods such as differential hybridization with oligonucleotide probes, detection of changes in the mobility measured by gel electrophoresis or direct sequencing of the amplified nucleic acid. A preferred method for identifying biallelic markers involves comparative sequencing of genomic DNA fragments from an appropriate number of unrelated individuals.

[0413] In a first embodiment, DNA samples from unrelated individuals are pooled together, following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms. One of the major advantages of this method resides in the fact that the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing reactions, which must be carried out. Moreover, this method is sufficiently sensitive so that a biallelic marker obtained thereby usually demonstrates a sufficient frequency of its less common allele to be useful in conducting association studies.

[0414] In a second embodiment, the DNA samples are not pooled and are therefore amplified and sequenced individually. This method is usually preferred when biallelic markers need to be identified in order to perform association studies within candidate genes. Preferably, highly relevant gene regions such as promoter regions or exon regions may be screened for biallelic markers. A biallelic marker obtained using this method may show a lower degree of informativeness for conducting association studies, e.g. if the frequency of its less frequent allele is less than about 10%. Such a biallelic marker will, however, be sufficiently informative to conduct association studies and it will further be appreciated that including less informative biallelic markers in the genetic analysis studies of the present invention, may, in some cases, allow the direct identification of causal mutations, which may, depending on their penetrance, be rare mutations.

[0415] The following is a description of the various parameters of a preferred method used by the inventors for the identification of the biallelic markers of the present invention.

[0416] Genomic DNA Samples

[0417] The genomic DNA samples from which the biallelic markers of the present invention are generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background. The number of individuals from whom DNA samples are obtained can vary substantially, but is preferably from about 10 to about 1000, or preferably from about 50 to about 200 individuals. It is usually preferred to collect DNA samples from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to identify as many markers as possible and to generate statistically significant results.

[0418] As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor. Techniques to prepare genomic DNA from biological samples are well known to the skilled technician. Details of a preferred embodiment are provided in Example 1. The person skilled in the art can choose to amplify pooled or unpooled DNA samples.

[0419] DNA Amplification

[0420] The identification of biallelic markers in a sample of genomic DNA may be facilitated through the use of DNA amplification methods. DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well known to those skilled in the art.

[0421] Amplification techniques that can be used in the context of the present invention include, but are not limited to, the ligase chain reaction (LCR) described in EP-A-320 308, WO 9320227 and EP-A439 182, the polymerase chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA) described in Guatelli J. C., et al. (1990) and in Compton J. (1991), Q-beta amplification as described in European Patent Application No 4544610, strand displacement amplification as described in Walker et al. (1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

[0422] LCR and Gap LCR are exponential amplification techniques, both of which utilize DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5′ phosphate-3′hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes, which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

[0423] For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Pat. No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall et al. (1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

[0424] The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see White (1992) and the publication entitled “PCR Methods and Applications” (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including U.S. Pat. Nos. 4,683,195; 4,683,202; and 4,965,188.

[0425] The PCR technology is the preferred amplification technique used to identify new biallelic markers. A typical example of a PCR reaction suitable for the purposes of the present invention is provided in Example 2.

[0426] One of the aspects of the present invention is a method for the amplification of the human PG-3 gene, particularly of a fragment of the genomic sequence of SEQ ID No 1 or of the cDNA sequence of SEQ ID No 2, or a fragment or a variant thereof in a test sample, preferably using the PCR technology. This method comprises the steps of:

[0427] a) contacting a test sample with amplification reaction reagents comprising a pair of amplification primers as described above which are located on either side of the polynucleotide region to be amplified, and

[0428] b) optionally, detecting the amplification products.

[0429] The invention also concerns a kit for the amplification of a PG-3 gene sequence, particularly of a portion of the genomic sequence of SEQ ID No 1 or of the cDNA sequence of SEQ ID No 2, or a variant thereof in a test sample, wherein said kit comprises:

[0430] a) a pair of oligonucleotide primers located on either side of the PG-3 region to be amplified;

[0431] b) optionally, the reagents necessary for performing the amplification reaction.

[0432] In one embodiment of the above amplification method and kit, the amplification product is detected by hybridization with a labeled probe having a sequence which is complementary to the amplified region. In another embodiment of the above amplification method and kit, primers comprise a sequence which is selected from the group consisting of the nucleotide sequences of B1 to B52, C1 to C52, D1 to D4, D6 to D80, E1 to E4, and E6 to E80.

[0433] In a first embodiment of the present invention, biallelic markers are identified using genomic sequence information generated by the inventors. Sequenced genomic DNA fragments are used to design primers for the amplification of 500 bp fragments. These 500 bp fragments are amplified from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

[0434] Preferred primers, useful for the amplification of genomic sequences encoding the candidate genes, focus on promoters, exons and splice sites of the genes. A biallelic marker presents a higher probability to be a causal mutation if it is located in these functional regions of the gene. Preferred amplification primers of the invention include the nucleotide sequences B1 to B52 and C1 to C52, detailed further in Example 2, Table 1.

[0435] Sequencing of Amplified Genomic DNA and Identification of Single Nucleotide Polymorphisms

[0436] The amplification products generated as described above, are then sequenced using any method known and available to the skilled technician. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to those of ordinary skill in the art. Such methods are disclosed in Sambrook et al. (1989) for example. Alternative approaches include hybridization to high-density DNA probe arrays as described in Chee et al. (1996).

[0437] Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. The products of the sequencing reactions are run on sequencing gels and the sequences are determined using gel image analysis. The polymorphism search is based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position. Because each dideoxy terminator is labeled with a different fluorescent molecule, the two peaks corresponding to a biallelic site present distinct colors corresponding to two different nucleotides at the same position on the sequence. However, the presence of two peaks can be an artifact due to background noise. To exclude such an artifact, the two DNA strands are sequenced and a comparison between the peaks is carried out. In order to confirm that a sequence is polymorphic, the polymorphism is be detected on both strands.

[0438] The above procedure permits those amplification products which contain biallelic markers to be identified. The detection limit for the frequency of biallelic polymorphisms detected by sequencing pools of 100 individuals is approximately 0.1 for the minor allele, as verified by sequencing pools of known allelic frequencies. However, more than 90% of the biallelic polymorphisms detected by the pooling method have a frequency for the minor allele higher than 0.25. Therefore, the biallelic markers selected by this method have a frequency of at least 0.1 for the minor allele and less than 0.9 for the major allele. Preferably, the biallelic markers selected by this method have a frequency of at least 0.2 for the minor allele and less than 0.8 for the major allele, more preferably at least 0.3 for the minor allele and less than 0.7 for the major allele. Thus, the biallelic markers preferably have a heterozygosity rate higher than 0.18, more preferably higher than 0.32, still more preferably higher than 0.42.

[0439] In another embodiment, biallelic markers are detected by sequencing individual DNA samples. In some embodiments, the frequency of the minor allele of such a biallelic marker may be less than 0.1.

[0440] Validation of the Biallelic Markers of the Present Invention

[0441] The polymorphisms are evaluated for their usefulness as genetic markers by validating that both alleles are present in a population. Validation of the biallelic markers is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. Microsequencing is a preferred method of genotyping alleles. The validation by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group can be as small as one individual if that individual is heterozygous for the allele in question. Preferably the group contains at least three individuals, more preferably the group contains five or six individuals, so that a single validation test will be more likely to result in the validation of more of the biallelic markers that are being tested. It should be noted, however, that when the validation test is performed on a small group it may result in a false negative result if as a result of sampling error none of the individuals tested carries one of the two alleles. Thus, the validation process is less useful in demonstrating that a particular initial result is an artifact, than it is at demonstrating that there is a bona fide biallelic marker at a particular position in a sequence. All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with validated biallelic markers.

[0442] Evaluation of the Frequency of the Biallelic Markers of the Present Invention

[0443] The validated biallelic markers are further evaluated for their usefulness as genetic markers by determining the frequency of the least common allele at the biallelic marker site. The higher the frequency of the less common allele the greater the usefulness of the biallelic marker in association and interaction studies. The identification of the least common allele is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. The determination of marker frequency by genotyping may be performed using individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group must be large enough to be representative of the population as a whole. Preferably the group contains at least 20 individuals, more preferably the group contains at least 50 individuals, most preferably the group contains at least 100 individuals. Of course the larger the group the greater the accuracy of the frequency determination because of reduced sampling error. A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a “high quality biallelic marker.” All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with high quality biallelic markers.

[0444] Methods for Genotyping an Individual for Biallelic Markers

[0445] Methods are provided to genotype a biological sample for one or more biallelic markers of the present invention, all of which may be performed in vitro. Such methods of genotyping comprise determining the identity of a nucleotide at a PG-3 biallelic marker site by any method known in the art. These methods find use in genotyping case-control populations in association studies as well as individuals in the context of detection of alleles of biallelic markers which are known to be associated with a given trait, in which case both copies of the biallelic marker present in individual's genome are determined so that an individual may be classified as homozygous or heterozygous for a particular allele.

[0446] These genotyping methods can be performed on nucleic acid samples derived from a single individual or pooled DNA samples.

[0447] Genotyping can be performed using methods similar to those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and association study applications.

[0448] In one embodiment, the invention encompasses methods of genotyping comprising determining the identity of a nucleotide at a PG-3-related biallelic marker or the complement thereof in a biological sample; optionally, the PG-3-related biallelic marker is selected from the group consisting of A1 to A80; and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, the biological sample is derived from a single subject; optionally, the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; optionally, said biological sample is derived from multiple subjects; Optionally, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following, alone or in any combination; Optionally, said method is performed in vitro; optionally, the method further comprises amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; Optionally, the amplifyication is performed by PCR, LCR, or replication of a recombinant vector comprising an origin of replication and said fragment in a host cell; optionally, the determination involves a hybridization assay, a sequencing assay, a microsequencing assay, or an enzyme-based mismatch detection assay.

[0449] Source of Nucleic Acids for Genotyping

[0450] Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA may be extracted from cells, tissues, body fluids and the like as described above. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

[0451] Amplification of DNA Fragments Comprising Biallelic Markers

[0452] Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present invention. Amplification of DNA may be achieved by any method known in the art. Amplification techniques are described above in the section entitled, “DNA amplification.”

[0453] Some of these amplification methods are particularly suited for the detection of single nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as further described below.

[0454] The identification of biallelic markers as described above allows the design of appropriate oligonucleotides, which can be used as primers to amplify DNA fragments comprising the biallelic markers of the present invention. Amplification can be performed using the primers initially used to discover new biallelic markers which are described herein or any set of primers allowing the amplification of a DNA fragment comprising a biallelic marker of the present invention.

[0455] In some embodiments, the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention. Preferred amplification primers are listed in Example 2. It will be appreciated that the primers listed are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present invention are also of use.

[0456] The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention, amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence which allow the specific amplification of any DNA fragment carrying the markers. Amplification primers may be labeled or immobilized on a solid support as described in the section “Oligonucleotide probes and primers”.

[0457] Methods of Genotyping DNA Samples for Biallelic Markers

[0458] Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the DNA region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al. (1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield et al. (1991), White et al. (1992), Grompe et al. (1989 and 1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in U.S. Pat. No. 4,656,127.

[0459] Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique. The term “sequencing” is generally used herein to refer to polymerase extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

[0460] 1) Sequencing Assays

[0461] The nucleotide present at a polymorphic site can be determined by sequencing methods. In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as described above. DNA sequencing methods are described in the section entitled “Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms”.

[0462] Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

[0463] 2) Microsequencing Assays

[0464] In microsequencing methods, the nucleotide at a polymorphic site in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which hybridize just upstream of the polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3′ end of the primer with one single ddNTP (chain terminator) complementary to the nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

[0465] Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as described in EP 412 883. Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in Example 4.

[0466] Different approaches can be used for the labeling and detection of ddNTPs. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al. (1997). In this method, amplified genomic DNA fragments containing polymorphic sites are incubated with a 5′-fluorescein-labeled primer in the presence of allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time. Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff and Smirnov, 1997).

[0467] Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase microsequencing techniques. The basic microsequencing protocol is the same as described previously, except that the method is conducted as a heterogeneous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase extension. The 5′ ends and internal nucleotides of synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator regent. This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if more than one affinity group is used. This permits the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner, oligonucleotides or templates may be attached to a solid support in a high-density format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of antifluorescein antibody conjugated with alkaline phosphatase, followed by incubation with a chromogenic substrate (such as p-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated streptavidin with o-phenylenediamine as a substrate (WO 92/15712). As yet another alternative solid-phase microsequencing procedure, Nyren et al. (1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

[0468] Pastinen et al. (1997) describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are further described below.

[0469] In one aspect the present invention provides polynucleotides and methods to genotype one or more biallelic markers of the present invention by performing a microsequencing assay. Preferred microsequencing primers include the nucleotide sequences D1 to D4 and D6 to D80 and E1 to E4 and E6 to E80. It will be appreciated that the microsequencing primers listed in Example 4 are merely exemplary and that any primer having a 3′ end immediately adjacent to the polymorphic nucleotide may be used. Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic marker or any combination of biallelic markers of the present invention. One aspect of the present invention is a solid support which includes one or more microsequencing primers listed in Example 4, or fragments comprising at least 8, 12, 15, 20, 25, 30, 40, or 50 consecutive nucleotides thereof, to the extent that such lengths are consistent with the primer described, and having a 3′ terminus immediately upstream of the corresponding biallelic marker, for determining the identity of a nucleotide at a biallelic marker site.

[0470] 3) Mismatch Detection Assays Based on Polymerases and Ligases

[0471] In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of polymerases and ligases. Polymerization reactions place particularly stringent requirements on correct base pairing of the 3′ end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3′ end. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described above in the section entitled “Amplification Of DNA Fragments Comprising Biallelic Markers”.

[0472] Allele Specific Amplification Primers

[0473] Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy whereby one of the alleles is amplified without amplification of the other allele. For allele specific amplification, at least one member of the pair of primers is sufficiently complementary with a region of a PG-3 gene comprising the polymorphic base of a biallelic marker of the present invention to hybridize therewith and to initiate the amplification. Such primers are able to discriminate between the two alleles of a biallelic marker.

[0474] This is accomplished by placing the polymorphic base at the 3′ end of one of the amplification primers. Because the extension progresses from the 3′end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Determining the precise location of the mismatch and the corresponding assay conditions are well within the ordinary skill in the art.

[0475] Ligation/Amplification Based Methods

[0476] The “Oligonucleotide Ligation Assay” (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable of detecting single nucleotide polymorphisms and may be advantageously combined with PCR as described by Nickerson et al. (1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

[0477] Other amplification methods which are particularly suited for the detection of single nucleotide polymorphism include LCR (ligase chain reaction), Gap LCR (GLCR) which are described above in the section entitled “DNA Amplification”. LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides are selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when they hybridize to the target molecule, a “gap” is created as described in WO 90/01069. This gap is then “filled” with complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

[0478] Ligase/Polymerase-mediated Genetic Bit Analysis™ is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

[0479] 4) Hybridization Assay Methods

[0480] A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., 1989).

[0481] Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are often used in pairs, one member of a pair showing perfect match to a target sequence containing the original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions, under which a probe will hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Although such hybridization can be performed in solution, it is preferred to employ a solid-phase hybridization assay. The target DNA comprising a biallelic marker of the present invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of methods. Various detection assay formats are well known which utilize detectable labels bound to either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

[0482] Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan assay takes advantage of the 5′ nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al., 1995). In an alternative homogeneous hybridization based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., 1998).

[0483] The polynucleotides provided herein can be used to produce probes which can be used in hybridization assays for the detection of biallelic marker alleles in biological samples. These probes preferably comprise between 8 and 50 nucleotides and are sufficiently complementary to a sequence comprising a biallelic marker of the present invention to hybridize thereto and preferably sufficiently specific to be able to discriminate the targeted sequence for only one nucleotide variation. A particularly preferred probe is 25 nucleotides in length. Preferably the biallelic marker is within 4 nucleotides of the center of the polynucleotide probe. In particularly preferred probes, the biallelic marker is at the center of said polynucleotide. Preferred probes comprise a nucleotide sequence selected from the group consisting of amplicons listed in Table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. Preferred probes comprise a nucleotide sequence selected from the group consisting of P1 to P4 and P6 to P80 and the sequences complementary thereto. In preferred embodiments the polymorphic base(s) are within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide.

[0484] Preferably the probes of the present invention are labeled or immobilized on a solid support. Labels and solid supports are further described in the section entitled “Oligonucleotide Probes and Primers”. The probes can be non-extendable as described in the section entitled “Oligonucleotide Probes and Primers”.

[0485] By assaying the hybridization to an allele specific probe, one can detect the presence or absence of a biallelic marker allele in a given sample. High-Throughput parallel hybridization in array format is specifically encompassed within “hybridization assays” and is described below.

[0486] 5) Hybridization to Addressable Arrays of Oligonucleotides

[0487] Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants. Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (e.g., the chip) at selected positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

[0488] The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in S. cerevisiae mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (Hychip and HyGnostics), and Protogene Laboratories.

[0489] In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP 785280, describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be “tiled” for a large number of specific polymorphisms. By “tiling” is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular, the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To obtain probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block. These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No. WO 92/10092 and WO 95/11995 and U.S. Pat. No. 5,424,186.

[0490] Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one of the sequences selected from the group consisting of amplicons listed in Table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. In preferred embodiments the polymorphic base is within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide. In some embodiments, the chip may comprise an array of at least 2, 3, 4, 5, 6, 7, 8 or more of these polynucleotides of the invention. Solid supports and polynucleotides of the present invention attached to solid supports are further described in the section entitled “Oligonucleotide Probes And Primers”.

[0491] 6) Integrated Systems

[0492] Another technique, which may be used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in U.S. Pat. No. 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips.

[0493] Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts.

[0494] For genotyping biallelic markers, the microfluidic system may integrate nucleic acid amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

Methods of Genetic Analysis Using the Biallelic Markers of the Present Invention

[0495] Different methods are available for the genetic analysis of complex traits (see Lander and Schork, 1994). The search for disease-susceptibility genes is conducted using two main methods: the linkage approach in which evidence is sought for cosegregation between a locus and a putative trait locus using family studies, and the association approach in which evidence is sought for a statistically significant association between an allele and a trait or a trait causing allele (Khoury et al., 1993). In general, the biallelic markers of the present invention find use in any method known in the art to demonstrate a statistically significant correlation between a genotype and a phenotype. The biallelic markers may be used in parametric and non-parametric linkage analysis methods. Preferably, the biallelic markers of the present invention are used to identify genes associated with detectable traits using association studies, an approach which does not require the use of affected families and which permits the identification of genes associated with complex and sporadic traits.

[0496] The genetic analysis using the biallelic markers of the present invention may be conducted on any scale. The whole set of biallelic markers of the present invention or any subset of biallelic markers of the present invention corresponding to the candidate gene may be used. Further, any set of genetic markers including a biallelic marker of the present invention may be used. A set of biallelic polymorphisms that could be used as genetic markers in combination with the biallelic markers of the present invention has been described in WO 98/20165. As mentioned above, it should be noted that the biallelic markers of the present invention may be included in any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

[0497] Linkage Analysis

[0498] Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. Thus, the aim of linkage analysis is to detect marker loci that show cosegregation with a trait of interest in pedigrees.

[0499] Parametric Methods

[0500] When data are available from successive generations there is the opportunity to study the degree of linkage between pairs of loci. Estimates of the recombination fraction enable loci to be ordered and placed onto a genetic map. With loci that are genetic markers, a genetic map can be established, and then the strength of linkage between markers and traits can be calculated and used to indicate the relative positions of markers and genes affecting those traits (Weir, 1996). The classical method for linkage analysis is the logarithm of odds (lod) score method (see Morton, 1955; Ott, 1991). Calculation of lod scores requires specification of the mode of inheritance for the disease (parametric method). Generally, the length of the candidate region identified using linkage analysis is between 2 and 20 Mb. Once a candidate region is identified as described above, analysis of recombinant individuals using additional markers allows further delineation of the candidate region. Linkage analysis studies have generally relied on the use of a maximum of 5,000 microsatellite markers, thus limiting the maximum theoretical attainable resolution of linkage analysis to about 600 kb on average.

[0501] Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance (i.e., the ratio between the number of trait positive carriers of allele a and the total number of a carriers in the population). However, parametric linkage analysis suffers from a variety of drawbacks. First, it is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, as already mentioned, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 2 Mb to 20 Mb regions initially identified through linkage analysis. In addition, parametric linkage analysis approaches have proven difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. It is very difficult to model these factors adequately in a lod score analysis. In such cases, too large an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations, as recently discussed by Risch, N. and Merikangas, K. (1996).

[0502] Non-Parametric Methods

[0503] The advantage of the so-called non-parametric methods for linkage analysis is that they do not require specification of the mode of inheritance for the disease, they tend to be more useful for the analysis of complex traits. In non-parametric methods, one tries to prove that the inheritance pattern of a chromosomal region is not consistent with random Mendelian segregation by showing that affected relatives inherit identical copies of the region more often than expected by chance. Affected relatives should show excess “allele sharing” even in the presence of incomplete penetrance and polygenic inheritance. In non-parametric linkage analysis the degree of agreement at a marker locus in two individuals can be measured either by the number of alleles identical by state (IBS) or by the number of alleles identical by descent (IBD). Affected sib pair analysis is a well-known special case and is the simplest form of these methods.

[0504] The biallelic markers of the present invention may be used in both parametric and non-parametric linkage analysis. Preferably biallelic markers may be used in non-parametric methods which allow the mapping of genes involved in complex traits. The bialielic markers of the present invention may be used in both IBD- and IBS-methods to map genes affecting a complex trait. In such studies, taking advantage of the high density of biallelic markers, several adjacent biallelic marker loci may be pooled to achieve the efficiency attained by multi-allelic markers (Zhao et al., 1998).

[0505] Population Association Studies

[0506] The present invention comprises methods for detecting an association between the PG-3 gene and a detectable trait using the biallelic markers of the present invention. In one embodiment the present invention comprises methods to detect an association between a biallelic marker allele or a biallelic marker haplotype and a trait. Further, the invention comprises methods to identify a trait causing allele in linkage disequilibrium with any biallelic marker allele of the present invention.

[0507] As described above, alternative approaches can be employed to perform association studies: genome-wide association studies, candidate region association studies and candidate gene association studies. In a preferred embodiment, the biallelic markers of the present invention are used to perform candidate gene association studies. The candidate gene analysis clearly provides a short-cut approach to the identification of genes and gene polymorphisms related to a particular trait when some information concerning the biology of the trait is available. Further, the biallelic markers of the present invention may be incorporated in any map of genetic markers of the human genome in order to perform genome-wide association studies. Methods to generate a high-density map of biallelic markers has been described in U.S. Provisional Patent application serial No. 60/082,614. The biallelic markers of the present invention may further be incorporated in any map of a specific candidate region of the genome (a specific chromosome or a specific chromosomal segment for example).

[0508] As mentioned above, association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families. Association studies are extremely valuable as they permit the analysis of sporadic or multifactor traits. Moreover, association studies represent a powerful method for fine-scale mapping enabling much finer mapping of trait causing alleles than linkage studies. Studies based on pedigrees often only narrow the location of the trait causing allele. Association studies using the biallelic markers of the present invention can therefore be used to refine the location of a trait causing allele in a candidate region identified by Linkage Analysis methods. Moreover, once a chromosome segment of interest has been identified, the presence of a candidate gene such as a candidate gene of the present invention, in the region of interest can provide a shortcut to the identification of the trait causing allele. Biallelic markers of the present invention can be used to demonstrate that a candidate gene is associated with a trait. Such uses are specifically contemplated in the present invention.

[0509] Determining the Frequency of a Biallelic Marker Allele or of a Biallelic Marker Haplotype in a Population

[0510] Association studies explore the relationships among frequencies for sets of alleles between loci.

[0511] Determining the Frequency of an Allele in a Population

[0512] Allelic frequencies of the biallelic markers in a populations can be determined using one of the methods described above under the heading “Methods for genotyping an individual for biallelic markers”, or any genotyping procedure suitable for this intended purpose. Genotyping pooled samples or individual samples can determine the frequency of a biallelic marker allele in a population. One way to reduce the number of genotypings required is to use pooled samples. A drawback in using pooled samples is in terms of accuracy and reproducibility for determining accurate DNA concentrations in setting up the pools. Genotyping individual samples provides higher sensitivity, reproducibility and accuracy and; is the preferred method used in the present invention. Preferably, each individual is genotyped separately and simple gene counting is applied to determine the frequency of an allele of a biallelic marker or of a genotype in a given population.

[0513] The invention also relates to methods of estimating the frequency of an allele in a population comprising: a) genotyping individuals from said population for said biallelic marker according to the method of the present invention; b) determining the proportional representation of said biallelic marker in said population. In addition, the methods of estimating the frequency of an allele in a population of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination; optionally, the PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic marker is one of the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, the determination of the frequency of a biallelic marker allele in a population may be accomplished by determining the identity of the nucleotides for both copies of said biallelic marker present in the genome of each individual in said population and calculating the proportional representation of said nucleotide at said PG-3-related biallelic marker for the population; Optionally, the determination of the proportional representation may be accomplished by performing a genotyping method of the invention on a pooled biological sample derived from a representative number of individuals, or each individual, in said population, and calculating the proportional amount of said nucleotide compared with the total.

[0514] Determining the Frequency of a Haplotype in a Population

[0515] The gametic phase of haplotypes is unknown when diploid individuals are heterozygous at more than one locus. Using genealogical information in families gametic phase can sometimes be inferred (Perlin et al., 1994). When no genealogical information is available different strategies may be used. One possibility is that the multiple-site heterozygous diploids can be eliminated from the analysis, keeping only the homozygotes and the single-site heterozygote individuals, but this approach might lead to a possible bias in the sample composition and the underestimation of low-frequency haplotypes. Another possibility is that single chromosomes can be studied independently, for example, by asymmetric PCR amplification (see Newton et al, 1989; Wu et al., 1989) or by isolation of single chromosome by limit dilution followed by PCR amplification (see Ruano et al., 1990). Further, a sample may be haplotyped for sufficiently close biallelic markers by double PCR amplification of specific alleles (Sarkar, G. and Sommer S. S., 1991). These approaches are not entirely satisfying either because of their technical complexity, the additional cost they entail, their lack of generalization at a large scale, or the possible biases they introduce. To overcome these difficulties, an algorithm to infer the phase of PCR-amplified DNA genotypes introduced by Clark, A. G. (1990) may be used. Briefly, the principle is to start filling a preliminary list of haplotypes present in the sample by examining unambiguous individuals, that is, the complete homozygotes and the single-site heterozygotes. Then other individuals in the same sample are screened for the possible occurrence of previously recognized haplotypes. For each positive identification, the complementary haplotype is added to the list of recognized haplotypes, until the phase information for all individuals is either resolved or identified as unresolved. This method assigns a single haplotype to each multiheterozygous individual, whereas several haplotypes are possible when there are more than one heterozygous site. Alternatively, one can use methods estimating haplotype frequencies in a population without assigning haplotypes to each individual. Preferably, a method based on an expectation-maximization (EM) algorithm (Dempster et al., 1977) leading to maximum-likelihood estimates of haplotype frequencies under the assumption of Hardy-Weinberg proportions (random mating) is used (see Excoffier L. and Slatkin M., 1995). The EM algorithm is a generalized iterative maximum-likelihood approach to estimation that is useful when data are ambiguous and/or incomplete. The EM algorithm is used to resolve heterozygotes into haplotypes. Haplotype estimations are further described below under the heading “Statistical Methods.” Any other method known in the art to determine or to estimate the frequency of a haplotype in a population may be used.

[0516] The invention also encompasses methods of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising the steps of: a) genotyping at least one PG-3-related biallelic marker according to a method of the invention for each individual in said population; b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency. In addition, the methods of estimating the frequency of a haplotype of the invention encompass methods with any further limitation described in this disclosure, or those following, alone or in any combination: optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, said haplotype determination method is performed by asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark algorithm, or an expectation-maximization algorithm.

[0517] Linkage Disequilibrium Analysis

[0518] Linkage disequilibrium is the non-random association of alleles at two or more loci and represents a powerful tool for mapping genes involved in disease traits (see Ajioka R. S. et al., 1997). Biallelic markers, because they are densely spaced in the human genome and can be genotyped in greater numbers than other types of genetic markers (such as RFLP or VNTR markers), are particularly useful in genetic analysis based on linkage disequilibrium.

[0519] When a disease mutation is first introduced into a population (by a new mutation or the immigration of a mutation carrier), it necessarily resides on a single chromosome and thus on a single “background” or “ancestral” haplotype of linked markers. Consequently, there is complete disequilibrium between these markers and the disease mutation: one finds the disease mutation only in the presence of a specific set of marker alleles. Through subsequent generations recombination events occur between the disease mutation and these marker polymorphisms, and the disequilibrium gradually dissipates. The pace of this dissipation is a function of the recombination frequency, so the markers closest to the disease gene will manifest higher levels of disequilibrium than those that are further away. When not broken up by recombination, “ancestral” haplotypes and linkage disequilibrium between marker alleles at different loci can be tracked not only through pedigrees but also through populations. Linkage disequilibrium is usually seen as an association between one specific allele at one locus and another specific allele at a second locus.

[0520] The pattern or curve of disequilibrium between disease and marker loci is expected to exhibit a maximum that occurs at the disease locus. Consequently, the amount of linkage disequilibrium between a disease allele and closely linked genetic markers may yield valuable information regarding the location of the disease gene. For fine-scale mapping of a disease locus, it is useful to have some knowledge of the patterns of linkage disequilibrium that exist between markers in the studied region. As mentioned above the mapping resolution achieved through the analysis of linkage disequilibrium is much higher than that of linkage studies. The high density of biallelic markers combined with linkage disequilibrium analysis provides powerful tools for fine-scale mapping. Different methods to calculate linkage disequilibrium are described below under the heading “Statistical Methods”.

[0521] Population-Based Case-Control Studies of Trait-Marker Associations

[0522] As mentioned above, the occurrence of pairs of specific alleles at different loci on the same chromosome is not random and the deviation from random is called linkage disequilibrium. Association studies focus on population frequencies and rely on the phenomenon of linkage disequilibrium. If a specific allele in a given gene is directly involved in causing a particular trait, its frequency will be statistically increased in an affected (trait positive) population, when compared to the frequency in a trait negative population or in a random control population. As a consequence of the existence of linkage disequilibrium, the frequency of all other alleles present in the haplotype carrying the trait-causing allele will also be increased in trait positive individuals compared to trait negative individuals or random controls. Therefore, association between the trait and any allele (specifically a biallelic marker allele) in linkage disequilibrium with the trait-causing allele will suffice to suggest the presence of a trait-related gene in that particular region. Case-control populations can be genotyped for biallelic markers to identify associations that narrowly locate a trait causing allele. As any marker in linkage disequilibrium with one given marker associated with a trait will be associated with the trait. Linkage disequilibrium allows the relative frequencies in case-control populations of a limited number of genetic polymorphisms (specifically biallelic markers) to be analyzed as an alternative to screening all possible functional polymorphisms in order to find trait-causing alleles. Association studies compare the frequency of marker alleles in unrelated case-control populations, and represent powerful tools for the dissection of complex traits.

[0523] Case-Control Populations (Inclusion Criteria)

[0524] Population-based association studies do not concern familial inheritance but compare the prevalence of a particular genetic marker, or a set of markers, in case-control populations. They are case-control studies based on comparison of unrelated case (affected or trait positive) individuals and unrelated control (unaffected, trait negative or random) individuals. Preferably the control group is composed of unaffected or trait negative individuals. Further, the control group is ethnically matched to the case population. Moreover, the control group is preferably matched to the case-population for the main known confusion factor for the trait under study (for example age-matched for an age-dependent trait). Ideally, individuals in the two samples are paired in such a way that they are expected to differ only in their disease status. The terms “trait positive population”, “case population” and “affected population” are used interchangeably herein.

[0525] An important step in the dissection of complex traits using association studies is the choice of case-control populations (see Lander and Schork, 1994). A major step in the choice of case-control populations is the clinical definition of a given trait or phenotype. Any genetic trait may be analyzed by the association method proposed here by carefully selecting the individuals to be included in the trait positive and trait negative phenotypic groups. Four criteria are often useful: clinical phenotype, age at onset, family history and severity. The selection procedure for continuous or quantitative traits (such as blood pressure for example) involves selecting individuals at opposite ends of the phenotype distribution of the trait under study, so as to include in these trait positive and trait negative populations individuals with non-overlapping phenotypes. Preferably, case-control populations consist of phenotypically homogeneous populations. Trait positive and trait negative populations consist of phenotypically uniform populations of individuals representing each between 1 and 98%, preferably between 1 and 80%, more preferably between 1 and 50%, and more preferably between 1 and 30%, most preferably between 1 and 20% of the total population under study, and preferably selected among individuals exhibiting non-overlapping phenotypes. The clearer the difference between the two trait phenotypes, the greater the probability of detecting an association with biallelic markers. The selection of those drastically different but relatively uniform phenotypes enables efficient comparisons in association studies and the possible detection of marked differences at the genetic level, provided that the sample sizes of the populations under study are significant enough.

[0526] In preferred embodiments, a first group of between 50 and 300 trait positive individuals, preferably about 100 individuals, are recruited according to their phenotypes. A similar number of control individuals are included in such studies.

[0527] Association Analysis

[0528] The invention also comprises methods of detecting an association between a genotype and a phenotype, comprising the steps of: a) determining the frequency of at least one PG-3-related biallelic marker in a trait positive population according to a genotyping method of the invention; b) determining the frequency of said PG-3-related biallelic marker in a control population according to a genotyping method of the invention; and c) determining whether a statistically significant association exists between said genotype and said phenotype. In addition, the methods of detecting an association between a genotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, said control population may be a trait negative population, or a random population; Optionally, each of said genotyping steps a) and b) may be performed on a pooled biological sample derived from each of said populations; Optionally, each of said genotyping of steps a) and b) is performed separately on biological samples derived from each individual in said population or a subsample thereof; Optionally, said trait is susceptibility to cancer or a disorder relating to abnormal cellular differentiation.

[0529] The general strategy to perform association studies using biallelic markers derived from a region carrying a candidate gene is to scan two groups of individuals (case-control populations) in order to measure and statistically compare the allele frequencies of the biallelic markers of the present invention in both groups.

[0530] If a statistically significant association with a trait is identified for at least one or more of the analyzed biallelic markers, one can assume that: either the associated allele is directly responsible for causing the trait (i.e. the associated allele is the trait causing allele), or more likely the associated allele is in linkage disequilibrium with the trait causing allele. The specific characteristics of the associated allele with respect to the candidate gene function usually give further insight into the relationship between the associated allele and the trait (causal or in linkage disequilibrium). If the evidence indicates that the associated allele within the candidate gene is most probably not the trait causing allele but is in linkage disequilibrium with the real trait causing allele, then the trait causing allele can be found by sequencing the vicinity of the associated marker, and performing further association studies with the polymorphisms that are revealed in an iterative manner.

[0531] Association studies are usually run in two successive steps. In a first phase, the frequencies of a reduced number of biallelic markers from the candidate gene are determined in the trait positive and control populations. In a second phase of the analysis, the position of the genetic loci responsible for the given trait is further refined using a higher density of markers from the relevant region. However, if the candidate gene under study is relatively small in length, as is the case for PG-3, a single phase may be sufficient to establish significant associations.

[0532] Haplotype Analysis

[0533] As described above, when a chromosome carrying a disease allele first appears in a population as a result of either mutation or migration, the mutant allele necessarily resides on a chromosome having a set of linked markers: the ancestral haplotype. This haplotype can be tracked through populations and its statistical association with a given trait can be analyzed. Complementing single point (allelic) association studies with multi-point association studies also called haplotype studies increases the statistical power of association studies. Thus, a haplotype association study allows one to define the frequency and the type of the ancestral carrier haplotype. A haplotype analysis is important in that it increases the statistical power of an analysis involving individual markers.

[0534] In a first stage of a haplotype frequency analysis, the frequency of the possible haplotypes based on various combinations of the identified biallelic markers of the invention is determined. The haplotype frequency is then compared for distinct populations of trait positive and control individuals. The number of trait positive individuals, which should be, subjected to this analysis to obtain statistically significant results usually ranges between 30 and 300, with a preferred number of individuals ranging between 50 and 150. The same considerations apply to the number of unaffected individuals (or random control) used in the study. The results of this first analysis provide haplotype frequencies in case-control populations, for each evaluated haplotype frequency a p-value and an odd ratio are calculated. If a statistically significant association is found the relative risk for an individual carrying the given haplotype of being affected with the trait under study can be approximated.

[0535] An additional embodiment of the present invention encompasses methods of detecting an association between a haplotype and a phenotype, comprising the steps of: a) estimating the frequency of at least one haplotype in a trait positive population, according to a method of the invention for estimating the frequency of a haplotype; b) estimating the frequency of said haplotype in a control population, according to a method of the invention for estimating the frequency of a haplotype; and c) determining whether a statistically significant association exists between said haplotype and said phenotype. In addition, the methods of detecting an association between a haplotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following: optionally, said PG-3-related biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said PG-3-related biallelic marker is selected from the group consisting of A6 and A7, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, said control population is a trait negative population, or a random population. Optionally, said method comprises the additional steps of determining the phenotype in said trait positive and said control populations prior to step c); optionally, said trait is susceptibility to cancer or a disorder relating to abnormal cellular differentiation.

[0536] Interaction Analysis

[0537] The biallelic markers of the present invention may also be used to identify patterns of biallelic markers associated with detectable traits resulting from polygenic interactions. The analysis of genetic interaction between alleles at unlinked loci requires individual genotyping using the techniques described herein. The analysis of allelic interaction among a selected set of biallelic markers with an appropriate level of statistical significance can be considered as a haplotype analysis. Interaction analysis consists in stratifying the case-control populations with respect to a given haplotype for the first loci and performing a haplotype analysis with the second loci with each subpopulation.

[0538] Statistical methods used in association studies are further described below.

[0539] Testing for Linkage in the Presence of Association

[0540] The biallelic markers of the present invention may further be used in TDT (transmission/disequilibrium test). TDT tests for both linkage and association and is not affected by population stratification. TDT requires data for affected individuals and their parents or data from unaffected sibs instead of from parents (see Spielmann S. et al., 1993; Schaid D. J. et al., 1996, Spielmann S. and Ewens W. J., 1998). Such combined tests generally reduce the false-positive errors produced by separate analyses.

Statistical Methods

[0541] In general, any method known in the art to test whether a trait and a genotype show a statistically significant correlation may be used.

[0542] 1) Methods in Linkage Analysis

[0543] Statistical methods and computer programs useful for linkage analysis are well-known to those skilled in the art (see Terwilliger J. D. and Ott J., 1994; Ott J., 1991).

[0544] 2) Methods to Estimate Haplotype Frequencies in a Population

[0545] As described above, when genotypes are scored, it is often not possible to distinguish heterozygotes so that haplotype frequencies cannot be easily inferred. When the gametic phase is not known, haplotype frequencies can be estimated from the multilocus genotypic data. Any method known to person skilled in the art can be used to estimate haplotype frequencies (see Lange K., 1997; Weir, B. S., 1996) Preferably, maximum-likelihood haplotype frequencies are computed using an Expectation-Maximization (EM) algorithm (see Dempster et al, 1977; Excoffier L. and Slatkin M., 1995). This procedure is an iterative process aiming at obtaining maximum-likelihood estimates of haplotype frequencies from multi-locus genotype data when the gametic phase is unknown. Haplotype estimations are usually performed by applying the EM algorithm using for example the EM-HAPLO program (Hawley M. E. et al., 1994) or the Arlequin program (Schneider et al., 1997). The EM algorithm is a generalized iterative maximum likelihood approach to estimation and is briefly described below.

[0546] Please note that in the present section, “Methods To Estimate Haplotype Frequencies In A Population, ”, phenotypes will refer to multi-locus genotypes with unknown haplotypic phase. Genotypes will refer to mutli-locus genotypes with known haplotypic phase.

[0547] Suppose one has a sample of N unrelated individuals typed for K markers. The data observed are the unknown-phase K-locus phenotypes that can be categorized with F different phenotypes. Further, suppose that we have H possible haplotypes (in the case of K biallelic markers, we have for the maximum number of possible haplotypes H=2^(K)).

[0548] For phenotype j with cj possible genotypes, we have: $\begin{matrix} {P_{j} = {{\sum\limits_{i = 1}^{c_{j}}{P\left( {{genotype}(i)} \right)}} = {\sum\limits_{i = 1}^{c_{j}}{{P\left( {h_{k},h_{l}} \right)}.}}}} & {{Equation}\quad 1} \end{matrix}$

[0549] Here, P_(j) is the probability of the j^(th) phenotype, and P(h_(k),h_(l)) is the probability of the i^(th) genotype composed of haplotypes h_(k) and h_(l). Under random mating (i.e. Hardy-Weinberg Equilibrium), P(h_(k)h_(l)) is expressed as:

P(h _(k) ,h _(l))=P(h _(k))² for h _(k) =h _(l), and

P(h _(k) ,h _(l))=2 P(h _(k))P(h _(l)) for h _(k) ≢h _(l)  Equation 2

[0550] The E-M algorithm is composed of the following steps: First, the genotype frequencies are estimated from a set of initial values of haplotype frequencies. These haplotype frequencies are denoted P₁ ⁽⁰⁾, P₂ ⁽⁰⁾, P₃ ⁽⁰⁾, . . . , P_(H) ⁽⁰⁾. The initial values for the haplotype frequencies may be obtained from a random number generator or in some other way well known in the art. This step is referred to the Expectation step. The next step in the method, called the Maximization step, consists of using the estimates for the genotype frequencies to re-calculate the haplotype frequencies. The first iteration haplotype frequency estimates are denoted by P₁ ⁽¹⁾, P₂ ⁽¹⁾, P₃ ⁽¹⁾, . . . , P_(H) ⁽¹⁾. In general, the Expectation step at the s^(th) iteration consists of calculating the probability of placing each phenotype into the different possible genotypes based on the haplotype frequencies of the previous iteration: $\begin{matrix} {{{P\left( {h_{k},h_{l}} \right)}^{(s)} = {\frac{n_{j}}{N}\left\lbrack \frac{{P_{j}\left( {h_{k},h_{l}} \right)}^{(s)}}{P_{j}} \right\rbrack}},} & {{Equation}\quad 3} \end{matrix}$

[0551] where n_(j) is the number of individuals with the j^(th) phenotype and P_(j)(h_(k),h_(l))^((s)) is the probability of genotype h_(k),h_(l) in phenotype j. In the Maximization step, which is equivalent to the gene-counting method (Smith, 1957), the haplotype frequencies are re-estimated based on the genotype estimates: $\begin{matrix} {P_{t}^{({s + 1})} = {\frac{1}{2}{\sum\limits_{j = 1}^{F}{\sum\limits_{i = 1}^{c_{j}}{\delta_{it}{{P_{j}\left( {h_{k},h_{l}} \right)}^{(s)}.}}}}}} & {{Equation}\quad 4} \end{matrix}$

[0552] Here, δ_(it) is an indicator variable which counts the number of occurrences that haplotype t is present in i^(th) genotype; it takes on values 0, 1, and 2.

[0553] The E-M iterations cease when the following criterion has been reached. Using Maximum Likelihood Estimation (MLE) theory, one assumes that the phenotypes j are distributed multinomially. At each iteration s, one can compute the likelihood function L. Convergence is achieved when the difference of the log-likehood between two consecutive iterations is less than some small number, preferably 10⁻⁷.

[0554] 3) Methods to Calculate Linkage Disequilibrium Between Markers

[0555] A number of methods can be used to calculate linkage disequilibrium between any two genetic positions, in practice linkage disequilibrium is measured by applying a statistical association test to haplotype data taken from a population.

[0556] Linkage disequilibrium between any pair of biallelic markers comprising at least one of the biallelic markers of the present invention (M_(i), M_(j)) having alleles (a_(i)/b_(i)) at marker M_(i) and alleles (a_(j)/b_(j)) at marker M_(j) can be calculated for every allele combination (a_(i),a_(j);a_(i),b_(j); b_(i),a_(j) and b_(i),b_(j)), according to the Piazza formula:

Δ_(aiaj)={square root}θ4−{square root}(θ4+θ3) (θ4+θ2), where:

[0557] θ4=−−=frequency of genotypes not having allele a_(i); at M_(i) and not having allele a_(j) at M_(j)

[0558] θ3=−+=frequency of genotypes not having allele a_(i) at M_(i) and having allele a_(j) at M_(j)

[0559] θ2=+−=frequency of genotypes having allele a_(i) at M_(i) and not having allele a_(j) at M_(j)

[0560] Linkage disequilibrium (LD) between pairs of biallelic markers (M_(i), M_(j)) can also be calculated for every allele combination (ai,aj; ai,bj; b_(i),a_(j) and b_(i),b_(j)), according to the maximum-likelihood estimate (MLE) for delta (the composite genotypic disequilibrium coefficient), as described by Weir (Weir B. S., 1996). The MLE for the composite linkage disequilibrium is:

D _(aiaj)=(2n ₁ +n ₂ +n ₃ +n ₄/2)/N−2(pr(a _(i))·pr(a _(j)))

[0561] Where n₁=Σ phenotype (a_(i)/a_(i), a_(j)/a_(j)), n₂=Σ phenotype (a_(i)/a_(i), a_(j)/b_(j)), n₃=Σ phenotype (a_(i)/b_(i), a_(j)/a_(j)), n4=Σ phenotype (a_(i)/b_(i), a_(j)/b_(j)) and N is the number of individuals in the sample.

[0562] This formula allows linkage disequilibrium between alleles to be estimated when only genotype, and not haplotype, data are available.

[0563] Another means of calculating the linkage disequilibrium between markers is as follows. For a couple of biallelic markers, M_(i) (a_(i)/b_(i)) and M_(j) (a_(j)/b_(j)), fitting the Hardy-Weinberg equilibrium, one can estimate the four possible haplotype frequencies in a given population according to the approach described above.

[0564] The estimation of gametic disequilibrium between ai and aj is simply:

D _(aiaj) =pr(haplotype(a _(i) ,a _(j)))−pr(a _(i))·pr(a _(j)).

[0565] Where pr(a_(i)) is the probability of allele a_(i) and pr(a_(j)) is the probability of allele a_(j) and where pr(haplotype (a_(i), a_(j))) is estimated as in Equation 3 above.

[0566] For a couple of biallelic marker only one measure of disequilibrium is necessary to describe the association between M_(i) and M_(j).

[0567] Then a normalized value of the above is calculated as follows:

D′ _(aiaj) =D _(aiaj)/max(−pr(a _(i))·pr(a _(j)), −pr(b _(i))·pr(b _(j))) with D _(aiaj)<0

D′ _(aiaj) =D _(aiaj)/max(pr(b _(i))·pr(a _(j)), pr(a _(i))·pr(b _(j))) with D _(aiaj)>0

[0568] The skilled person will readily appreciate that other linkage disequilibrium calculation methods can be used.

[0569] Linkage disequilibrium among a set of biallelic markers having an adequate heterozygosity rate can be determined by genotyping between 50 and 1000 unrelated individuals, preferably between 75 and 200, more preferably around 100.

[0570] 4) Testing for Association

[0571] Methods for determining the statistical significance of a correlation between a phenotype and a genotype, in this case an allele at a biallelic marker or a haplotype made up of such alleles, may be determined by any statistical test known in the art and with any accepted threshold of statistical significance being required. The application of particular methods and thresholds of significance are well with in the skill of the ordinary practitioner of the art.

[0572] Testing for association is performed by determining the frequency of a biallelic marker allele in case and control populations and comparing these frequencies with a statistical test to determine if their is a statistically significant difference in frequency which would indicate a correlation between the trait and the biallelic marker allele under study. Similarly, a haplotype analysis is performed by estimating the frequencies of all possible haplotypes for a given set of biallelic markers in case and control populations, and comparing these frequencies with a statistical test to determine if their is a statistically significant correlation between the haplotype and the phenotype (trait) under study. Any statistical tool useful to test for a statistically significant association between a genotype and a phenotype may be used. Preferably the statistical test employed is a chi-square test with one degree of freedom. A P-value is calculated (the P-value is the probability that a statistic as large or larger than the observed one would occur by chance).

[0573] Statistical Significance

[0574] In preferred embodiments, significance for diagnosis purposes, either as a positive basis for further diagnostic tests or as a preliminary starting point for early preventive therapy, the p value related to a biallelic marker association is preferably about 1×10⁻² or less, more preferably about 1×10⁻⁴ or less, for a single biallelic marker analysis and about 1×10⁻³ or less, still more preferably 1×10⁻⁶ or less and most preferably of about 1×10⁻⁸ or less, for a haplotype analysis involving two or more markers. These values are believed to be applicable to any association studies involving single or multiple marker combinations.

[0575] The skilled person can use the range of values set forth above as a starting point in order to carry out association studies with biallelic markers of the present invention. In doing so, significant associations between the biallelic markers of the present invention and a trait can be revealed and used for diagnosis and drug screening purposes.

[0576] Phenotypic Permutation

[0577] In order to confirm the statistical significance of the first stage haplotype analysis described above, it might be suitable to perform further analyses in which genotyping data from case-control individuals are pooled and randomized with respect to the trait phenotype. Each individual genotyping data is randomly allocated to two groups, which contain the same number of individuals as the case-control populations used to compile the data obtained in the first stage. A second stage haplotype analysis is preferably run on these artificial groups, preferably for the markers included in the haplotype of the first stage analysis showing the highest relative risk coefficient. This experiment is reiterated preferably at least between 100 and 10000 times. The repeated iterations allow the determination of the probability to obtain the tested haplotype by chance.

[0578] Assessment of Statistical Association

[0579] To address the problem of false positives similar analysis may be performed with the same case-control populations in random genomic regions. Results in random regions and the candidate region are compared as described in a co-pending U.S. Provisional Patent Application entitled “Methods, Software And Apparati For Identifying Genomic Regions Harboring A Gene Associated With A Detectable Trait,” U.S. Ser. No. 60/107,986, filed Nov. 10, 1998, and a second U.S. Provisional Patent Application also entitled “Methods, Software And Apparati For Identifying Genomic Regions Harboring A Gene Associated With A Detectable Trait,” U.S. Ser. No. 60/140,785, filed Jun. 23, 1999.

[0580] 5) Evaluation of Risk Factors

[0581] The association between a risk factor (in genetic epidemiology the risk factor is the presence or the absence of a certain allele or haplotype at marker loci) and a disease is measured by the odds ratio (OR) and by the relative risk (RR). If P(R⁺) is the probability of developing the disease for individuals with R and P(R⁻) is the probability for individuals without the risk factor, then the relative risk is simply the ratio of the two probabilities, that is:

RR=P(R ⁺)/P(R ⁻)

[0582] In case-control studies, direct measures of the relative risk cannot be obtained because of the sampling design. However, the odds ratio allows a good approximation of the relative risk for low-incidence diseases and can be calculated: ${OR} = {\left\lbrack \frac{F^{+}}{1 - F^{+}} \right\rbrack/\left\lbrack \frac{F^{-}}{\left( {1 - F^{-}} \right)} \right\rbrack}$

OR=(F ⁺/(1−F ⁺))/(F ⁻/(1−F ⁻))

[0583] F⁺ is the frequency of the exposure to the risk factor in cases and F⁻ is the frequency of the exposure to the risk factor in controls. F⁺ and F⁻ are calculated using the allelic or haplotype frequencies of the study and further depend on the underlying genetic model (dominant, recessive, additive . . . ).

[0584] One can further estimate the attributable risk (AR) which describes the proportion of individuals in a population exhibiting a trait due to a given risk factor. This measure is important in quantifying the role of a specific factor in disease etiology and in terms of the public health impact of a risk factor. The public health relevance of this measure lies in estimating the proportion of cases of disease in the population that could be prevented if the exposure of interest were absent. AR is determined as follows:

AR=P _(E)(RR−1)/(P _(E)(RR−1)+1)

[0585] AR is the risk attributable to a biallelic marker allele or a biallelic marker haplotype. P_(E) is the frequency of exposure to an allele or a haplotype within the population at large; and RR is the relative risk which, is approximated with the odds ratio when the trait under study has a relatively low incidence in the general population.

[0586] Identification of Biallelic Markers in Linkage Disequilibrium with the Biallelic Markers of the Invention

[0587] Once a first biallelic marker has been identified in a genomic region of interest, the practitioner of ordinary skill in the art, using the teachings of the present invention, can easily identify additional biallelic markers in linkage disequilibrium with this first marker. As mentioned before, any marker in linkage disequilibrium with a first marker associated with a trait will be associated with the trait. Therefore, once an association has been demonstrated between a given biallelic marker and a trait, the discovery of additional biallelic markers associated with this trait is of great interest in order to increase the density of biallelic markers in this particular region. The causal gene or mutation will be found in the vicinity of the marker or set of markers showing the highest correlation with the trait.

[0588] Identification of additional markers in linkage disequilibrium with a given marker involves: (a) amplifying a genomic fragment comprising a first biallelic marker from a plurality of individuals; (b) identifying of second biallelic markers in the genomic region harboring said first biallelic marker; (c) conducting a linkage disequilibrium analysis between said first biallelic marker and second biallelic markers; and (d) selecting said second biallelic markers as being in linkage disequilibrium with said first marker. Subcombinations comprising steps (b) and (c) are also contemplated.

[0589] Methods to identify biallelic markers and to conduct linkage disequilibrium analysis are described herein and can be carried out by the skilled person without undue experimentation. The present invention then also concerns biallelic markers which are in linkage disequilibrium with the biallelic markers A1 to A80 and which are expected to present similar characteristics in terms of their respective association with a given trait.

Identification of Functional Mutations

[0590] Mutations in the PG-3 gene which are responsible for a detectable phenotype or trait may be identified by comparing the sequences of the PG-3 gene from trait positive and control individuals. Once a positive association is confirmed with a biallelic marker of the present invention, the identified locus can be scanned for mutations. In a preferred embodiment, functional regions such as exons and splice sites, promoters and other regulatory regions of the PG-3 gene are scanned for mutations. In a preferred embodiment the sequence of the PG-3 gene is compared in trait positive and control individuals. Preferably, trait positive individuals carry the haplotype shown to be associated with the trait and trait negative individuals do not carry the haplotype or allele associated with the trait. The detectable trait or phenotype may comprise a variety of manifestations of altered PG-3 function.

[0591] The mutation detection procedure is essentially similar to that used for biallelic marker identification. The method used to detect such mutations generally comprises the following steps:

[0592] amplification of a region of the PG-3 gene comprising a biallelic marker or a group of biallelic markers associated with the trait from DNA samples of trait positive patients and trait-negative controls using any of the methods disclosed herein;

[0593] sequencing of the amplified region;

[0594] comparison of DNA sequences from trait positive and control individuals;

[0595] determination of mutations specific to trait-positive patients.

[0596] In one embodiment, said biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof. It is preferred that candidate polymorphisms be then verified by screening a larger population of cases and controls by means of any genotyping procedure such as those described herein, preferably using a microsequencing technique in an individual test format. Polymorphisms are considered as candidate mutations when present in cases and controls at frequencies compatible with the expected association results. Polymorphisms are considered as candidate “trait-causing” mutations when they exhibit a statistically significant correlation with the detectable phenotype.

[0597] Biallelic Markers of the Invention in Methods of Genetic Diagnostics

[0598] The biallelic markers of the present invention can also be used to develop diagnostics tests capable of identifying individuals who express a detectable trait as the result of a specific genotype or individuals whose genotype places them at risk of developing a detectable trait at a subsequent time. The trait analyzed using the present diagnostics may be any detectable trait, including diseases such as cancer or a disorder relating to abnormal cellular differentiation. Such a diagnosis can be useful in the staging, monitoring, prognosis and/or prophylactic or curative therapy of diseases.

[0599] The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a biallelic marker pattern associated with an increased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids.

[0600] The present invention provides diagnostic methods to determine whether an individual is at risk of developing a disease or suffers from a disease resulting from a mutation or a polymorphism in the PG-3 gene. The present invention also provides methods to determine whether an individual has a susceptibility to diseases such as cancer or a disorder relating to abnormal cellular differentiation.

[0601] These methods involve obtaining a nucleic acid sample from the individual and, determining, whether the nucleic acid sample contains at least one allele or at least one biallelic marker haplotype, indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular PG-3 polymorphism or mutation (trait-causing allele).

[0602] Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the individual and this sample is genotyped using methods described above in “Methods Of Genotyping DNA Samples For Biallelic markers. The diagnostics may be based on a single biallelic marker or a on group of biallelic markers.

[0603] In each of these methods, a nucleic acid sample is obtained from the test subject and the biallelic marker pattern of one or more of the biallelic markers A1 to A80 is determined.

[0604] In one embodiment, a PCR amplification is conducted on the nucleic acid sample to amplify regions in which polymorphisms associated with a detectable phenotype have been identified. The amplification products are sequenced to determine whether the individual possesses one or more PG-3 polymorphisms associated with a detectable phenotype. The primers used to generate amplification products may comprise the primers listed in Table 1. Alternatively, the nucleic acid sample is subjected to microsequencing reactions as described above to determine whether the individual possesses one or more PG-3 polymorphisms associated with a detectable phenotype resulting from a mutation or a polymorphism in the PG-3 gene. The primers used in the microsequencing reactions may include the primers listed in Table 4. In another embodiment, the nucleic acid sample is contacted with one or more allele specific oligonucleotide probes which, specifically hybridize to one or more PG-3 alleles associated with a detectable phenotype. The probes used in the hybridization assay may include the probes listed in Table 3. In another embodiment, the nucleic acid sample is contacted with a second PG-3 oligonucleotide capable of producing an amplification product when used with the allele specific oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that the individual possesses one or more PG-3 alleles associated with a detectable phenotype.

[0605] In a preferred embodiment the identity of the nucleotide present at, at least one, biallelic marker selected from the group consisting of A1 to An and the complements thereof, is determined and the detectable trait is diseases such as cancer or a disorder relating to abnormal cellular differentiation. Diagnostic kits comprise any of the polynucleotides of the present invention.

[0606] These diagnostic methods are extremely valuable as they can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms.

[0607] Diagnostics, which analyze and predict response to a drug or side effects to a drug, may be used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects.

[0608] Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of either response to an agent acting against a disease, preferably cancer or a disorder relating to abnormal cellular differentiation, or to side effects to an agent acting against a disease, preferably cancer or a disorder relating to abnormal cellular differentiation, may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

Recombinant Vectors

[0609] The term “vector” is used herein to designate either a circular or a linear DNA or RNA molecule, which is either double-stranded or single-stranded, and which comprise at least one polynucleotide of interest that is sought to be transferred in a cell host or in a unicellular or multicellular host organism.

[0610] The present invention encompasses a family of recombinant vectors that comprise a regulatory polynucleotide derived from the PG-3 genomic sequence, and/or a coding polynucleotide from either the PG-3 genomic sequence or the cDNA sequence.

[0611] Generally, a recombinant vector of the invention may comprise any of the polynucleotides described herein, including regulatory sequences, coding sequences and polynucleotide constructs, as well as any PG-3 primer or probe as defined above. More particularly, the recombinant vectors of the present invention can comprise any of the polynucleotides described in the “Genomic Sequences Of The PG3 Gene” section, the “PG-3 cDNA Sequences” section, the “Coding Regions” section, the “Polynucleotide constructs” section, and the “Oligonucleotide Probes And Primers” section.

[0612] In a first preferred embodiment, a recombinant vector of the invention is used to amplify the inserted polynucleotide derived from a PG-3 genomic sequence of SEQ ID No 1 or a PG-3 cDNA, for example the cDNA of SEQ ID No 2 in a suitable cell host, this polynucleotide being amplified at every time that the recombinant vector replicates.

[0613] A second preferred embodiment of the recombinant vectors according to the invention comprises expression vectors comprising either a regulatory polynucleotide or a coding nucleic acid of the invention, or both. Within certain embodiments, expression vectors are employed to express the PG-3 polypeptide, which can then be purified and, for example be used in ligand screening assays or as an immunogen in order to raise specific antibodies directed against the PG-3 protein. In other embodiments, the expression vectors are used for constructing transgenic animals and also for gene therapy. Expression requires that appropriate signals are provided in the vectors, said signals including various regulatory elements, such as enhancers/promoters from both viral and mammalian sources that drive expression of the genes of interest in host cells. Dominant drug selection markers for establishing permanent, stable cell clones expressing the products are generally included in the expression vectors of the invention, as they are elements that link expression of the drug selection markers to expression of the polypeptide.

[0614] More particularly, the present invention relates to expression vectors which include nucleic acids encoding a PG-3 protein, preferably the PG-3 protein of the amino acid sequence of SEQ ID No 3 or variants or fragments thereof.

[0615] The invention also pertains to a recombinant expression vector useful for the expression of the PG-3 coding sequence, wherein said vector comprises a nucleic acid of SEQ ID No 2.

[0616] Recombinant vectors comprising a nucleic acid containing a PG-3-related biallelic marker are also part of the invention. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1 to A80, and the complements thereof.

[0617] Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

[0618] The present invention also encompasses primary, secondary, and immortalized homologously recombinant host cells of vertebrate origin, preferably mammalian origin and particularly human origin, that have been engineered to: a) insert exogenous (heterologous) polynucleotides into the endogenous chromosomal DNA of a targeted gene, b) delete endogenous chromosomal DNA, and/or c) replace endogenous chromosomal DNA with exogenous polynucleotides. Insertions, deletions, and/or replacements of polynucleotide sequences may be to the coding sequences of the targeted gene and/or to regulatory regions, such as promoter and enhancer sequences, operably associated with the targeted gene.

[0619] The present invention further relates to a method of making a homologously recombinant host cell in vitro or in vivo, wherein the expression of a targeted gene not normally expressed in the cell is altered. Preferably the alteration causes expression of the targeted gene under normal growth conditions or under conditions suitable for producing the polypeptide encoded by the targeted gene. The method comprises the steps of: (a) transfecting the cell in vitro or in vivo with a polynucleotide construct, the polynucleotide construct comprising; (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; and (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination.

[0620] The present invention further relates to a method of altering the expression of a targeted gene in a cell in vitro or in vivo wherein the gene is not normally expressed in the cell, comprising the steps of: (a) transfecting the cell in vitro or in vivo with a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; and (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell; and (c) maintaining the homologously recombinant cell in vitro or in vivo under conditions appropriate for expression of the gene.

[0621] The present invention further relates to a method of making a polypeptide of the present invention by altering the expression of a targeted endogenous gene in a cell in vitro or in vivo wherein the gene is not normally expressed in the cell, comprising the steps of: a) transfecting the cell in vitro with a a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell; and c) maintaining the homologously recombinant cell in vitro or in vivo under conditions appropriate for expression of the gene thereby making the polypeptide.

[0622] The present invention further relates to a polynucleotide construct which alters the expression of a targeted gene in a cell type in which the gene is not normally expressed. This occurs when the a polynucleotide construct is inserted into the chromosomal DNA of the target cell, wherein the a polynucleotide construct comprises: a) a targeting sequence; b) a regulatory sequence and/or coding sequence; and c) an unpaired splice-donor site, if necessary. Further included are a polynucleotide constructs, as described above, wherein the construct further comprises a polynucleotide which encodes a polypeptide and is in-frame with the targeted endogenous gene after homologous recombination with chromosomal DNA.

[0623] The compositions may be produced, and methods performed, by techniques known in the art, such as those described in U.S. Pat. Nos. 6,054,288; 6,048,729; 6,048,724; 6,048,524; 5,994,127; 5,968,502; 5,965,125; 5,869,239; 5,817,789; 5,783,385; 5,733,761; 5,641,670; 5,580,734; International Publication Nos:WO96/29411, WO 94/12650; and scientific articles including Koller et al.,1989.

[0624] 1. General Features of the Expression Vectors of the Invention

[0625] A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may consist of a chromosomal, non-chromosomal, semi-synthetic and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit comprising an assembly of:

[0626] (1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp in length that act on the promoter to increase the transcription.

[0627] (2) a structural or coding sequence which is transcribed into mRNA and eventually translated into a polypeptide, said structural or coding sequence being operably linked to the regulatory elements described in (1); and

[0628] (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, when a recombinant protein is expressed without a leader or transport sequence, it may include a N-terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

[0629] Generally, recombinant expression vectors will include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of the translated protein into the periplasmic space or the extracellular medium. In a specific embodiment wherein the vector is adapted for transfecting and expressing desired sequences in mammalian host cells, preferred vectors will comprise an origin of replication in the desired host, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation signal, splice donor and acceptor sites, transcriptional termination sequences, and 5′-flanking non-transcribed sequences. DNA sequences derived from the SV40 viral genome, for example SV40 origin, early promoter, enhancer, splice and polyadenylation signals may be used to provide the required non-transcribed genetic elements.

[0630] The in vivo expression of a PG-3 polypeptide of SEQ ID No 3 or fragments or variants thereof may be useful in order to correct a genetic defect related to the expression of the native gene in a host organism or to the production of a biologically inactive PG-3 protein.

[0631] Consequently, the present invention also deals with recombinant expression vectors mainly designed for the in vivo production of the PG-3 polypeptide of SEQ ID No 3 or fragments or variants thereof by the introduction of the appropriate genetic material in the organism of the patient to be treated. This genetic material may be introduced in vitro in a cell that has been previously extracted from the organism, the modified cell being subsequently reintroduced in the said organism, directly in vivo into the appropriate tissue.

[0632] 2. Regulatory Elements

[0633] Promoters

[0634] The suitable promoter regions used in the expression vectors according to the present invention are chosen taking into account the cell host in which the heterologous gene has to be expressed. The particular promoter employed to control the expression of a nucleic acid sequence of interest is not believed to be important, so long as it is capable of directing the expression of the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell, such as, for example, a human or a viral promoter.

[0635] A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

[0636] Promoter regions can be selected from any desired gene using, for example, CAT (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors.

[0637] Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the gpt, lambda PR, PL and trp promoters (EP 0036776), the polyhedrin promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983; O'Reilly et al., 1992), the lambda PR promoter or also the trc promoter.

[0638] Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

[0639] The choice of a promoter is well within the ability of a person skilled in the field of genetic egineering. For example, one may refer to the book of Sambrook et al. (1989) or also to the procedures described by Fuller et al. (1996).

[0640] Other Regulatory Elements

[0641] Where a cDNA insert is employed, one will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

[0642] 3. Selectable Markers

[0643] Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression construct. The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for S. cerevisiae or tetracycline, rifampicin or ampicillin resistance in E. coli, or levan saccharase for mycobacteria, this latter marker being a negative selection marker.

[0644] 4. Preferred Vectors.

[0645] Bacterial Vectors

[0646] As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and a bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, Wis., USA).

[0647] Large numbers of other suitable vectors are known to those of skill in the art, and commercially available, such as the following bacterial vectors: pQE70, pQE60, pQE-9 (Qiagen), . pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); pQE-30 (QIAexpress).

[0648] Bacteriophage Vectors

[0649] The P1 bacteriophage vector may contain large inserts ranging from about 80 to about 100 kb.

[0650] The construction of P1 bacteriophage vectors such as p158 or p158/neo8 are notably described by Sternberg (1992, 1994). Recombinant P1 clones comprising PG-3 nucleotide sequences may be designed for inserting large polynucleotides of more than 40 kb (Linton et al., 1993). To generate P1 DNA for transgenic experiments, a preferred protocol is the protocol described by McCormick et al. (1994). Briefly, E. coli (preferably strain NS3529) harboring the P1 plasmid are grown overnight in a suitable broth medium containing 25 μg/ml of kanamycin. The P1 DNA is prepared from the E. coli by alkaline lysis using the Qiagen Plasmid Maxi kit (Qiagen, Chatsworth, Calif., USA), according to the manufacturer's instructions. The P1 DNA is purified from the bacterial lysate on two Qiagen-tip 500 columns, using the washing and elution buffers contained in the kit. A phenol/chloroform extraction is then performed before precipitating the DNA with 70% ethanol. After solubilizing the DNA in TE (10 mM Tris-HCl, pH 7.4, 1 mM EDTA), the concentration of the DNA is assessed by spectrophotometry.

[0651] When the goal is to express a P1 clone comprising PG-3 nucleotide sequences in a transgenic animal, typically in transgenic mice, it is desirable to remove vector sequences from the P1 DNA fragment, for example by cleaving the P1 DNA at rare-cutting sites within the P1 polylinker (SfiI, NotI or SalI). The P1 insert is then purified from vector sequences on a pulsed-field agarose gel, using methods similar using methods similar to those originally reported for the isolation of DNA from YACs (Schedl et al., 1993a; Peterson et al., 1993). At this stage, the resulting purified insert DNA can be concentrated, if necessary, on a Millipore Ultrafree-MC Filter Unit (Millipore, Bedford, Mass., USA—30,000 molecular weight limit) and then dialyzed against microinjection buffer (10 mM Tris-HCl, pH 7.4; 250 μM EDTA) containing 100 mM NaCl, 30 μM spermine, 70 μM spermidine on a microdyalisis membrane (type VS, 0.025 μM from Millipore). The intactness of the purified P1 DNA insert is assessed by electrophoresis on 1% agarose (Sea Kem GTG; FMC Bio-products) pulse-field gel and staining with ethidium bromide.

[0652] Baculovirus Vectors

[0653] A suitable vector for the expression of the PG-3 polypeptide of SEQ ID No 3 or fragments or variants thereof is a baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharmingen) that is used to transfect the SF9 cell line (ATCC N^(o)CRL 1711) which is derived from Spodoptera frugiperda.

[0654] Other suitable vectors for the expression of the PG-3 polypeptide of SEQ ID No 3 or fragments or variants thereof in a baculovirus expression system include those described by Chai et al. (1993), Vlasak et al. (1983) and Lenhard et al. (1996).

[0655] Viral Vectors

[0656] In one specific embodiment, the vector is derived from an adenovirus. Preferred adenovirus vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al. (1994). Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the human adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin (French patent application N^(o) FR-93.05954).

[0657] Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery systems of choice for the transfer of exogenous polynucleotides in vivo, particularly to mammals, including humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.

[0658] Particularly preferred retroviruses for the preparation or construction of retroviral in vitro or in vitro gene delivery vehicles of the present invention include retroviruses selected from the group consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include the 4070A and the 1504A viruses, Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190; PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include Bryan high titer (ATCC Nos VR-334, VR-657, VR-726, VR-659 and VR-728). Other preferred retroviral vectors are those described in Roth et al. (1996), PCT Application No WO 93/25234, PCT Application No WO 94/06920, Roux et al., 1989, Julan et al., 1992 and Neda et al., 1991.

[0659] Yet another viral vector system that is contemplated by the invention consists in the adeno-associated virus (AAV). The adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

[0660] BAC Vectors

[0661] The bacterial artificial chromosome (BAC) cloning system (Shizuya et al., 1992) has been developed to stably maintain large fragments of genomic DNA (100-300 kb) in E. coli. A preferred BAC vector consists of pBeloBAC11 vector that has been described by Kim et al. (1996). BAC libraries are prepared with this vector using size-selected genomic DNA that has been partially digested using enzymes that permit ligation into either the Bam HI or HindIII sites in the vector. Flanking these cloning sites are T7 and SP6 RNA polymerase transcription initiation sites that can be used to generate end probes by either RNA transcription or PCR methods. After the construction of a BAC library in E. coli, BAC DNA is purified from the host cell as a supercoiled circle. Converting these circular molecules into a linear form precedes both size determination and introduction of the BACs into recipient cells. The cloning site is flanked by two Not I sites, permitting cloned segments to be excised from the vector by Not I digestion. Alternatively, the DNA insert contained in the pBeloBAC11 vector may be linearized by treatment of the BAC vector with the commercially available enzyme lambda terminase that leads to the cleavage at the unique cosN site, but this cleavage method results in a full length BAC clone containing both the insert DNA and the BAC sequences.

[0662] 5. Delivery of the Recombinant Vectors

[0663] In order to effect expression of the polynucleotides and polynucleotide constructs of the invention, these constructs must be delivered into a cell. This delivery may be accomplished in vitro, as in laboratory procedures for transforming cell lines, or in vivo or ex vivo, as in the treatment of certain diseases states.

[0664] One mechanism is viral infection where the expression construct is encapsulated in an infectious viral particle.

[0665] Several non-viral methods for the transfer of polynucleotides into cultured mammalian cells are also contemplated by the present invention, and include, without being limited to, calcium phosphate precipitation (Graham et al., 1973; Chen et al., 1987;), DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al., 1986; Potter et al., 1984), direct microinjection (Harland et al., 1985), DNA-loaded liposomes (Nicolau et al., 1982; Fraley et al., 1979), and receptor-mediated transfection (Wu and Wu, 1987; 1988). Some of these techniques may be successfully adapted for in vivo or ex vivo use.

[0666] Once the expression polynucleotide has been delivered into the cell, it may be stably integrated into the genome of the recipient cell. This integration may be in the cognate location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non specific location (gene augmentation). In yet further embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or “episomes” encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle.

[0667] One specific embodiment for a method for delivering a protein or peptide to the interior of a cell of a vertebrate in vivo comprises the step of introducing a preparation comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for the polypeptide of interest into the interstitial space of a tissue comprising the cell, whereby the naked polynucleotide is taken up into the interior of the cell and has a physiological effect. This is particularly applicable for transfer in vitro but it may be applied to in vivo as well.

[0668] Compositions for use in vitro and in vivo comprising a “naked” polynucleotide are described in PCT application N^(o) WO 90/11092 (Vical Inc.), and also in PCT application No. WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa), as well as in the articles of Tacson et al. (1996) and of Huygen et al. (1996).

[0669] In still another embodiment of the invention, the transfer of a naked polynucleotide of the invention, including a polynucleotide construct of the invention, into cells may be proceeded with a particle bombardment (biolistic), said particles being DNA-coated microprojectiles accelerated to a high velocity allowing them to pierce cell membranes and enter cells without killing them, such as described by Klein et al. (1987).

[0670] In a further embodiment, the polynucleotide of the invention may be entrapped in a liposome (Ghosh and Bacchawat, 1991; Wong et al., 1980; Nicolau et al., 1987)

[0671] In a specific embodiment, the invention provides a composition for the in vivo production of the PG-3 protein or polypeptide described herein. It comprises a naked polynucleotide operatively coding for this polypeptide, in solution in a physiologically acceptable carrier, and suitable for introduction into a tissue to cause cells of the tissue to express the said protein or polypeptide.

[0672] The amount of vector to be injected to the desired host organism varies according to the site of injection. As an indicative dose, it will be injected between 0.1 and 100 μg of the vector in an animal body, preferably a mammal body, for example a mouse body.

[0673] In another embodiment of the vector according to the invention, it may be introduced in vitro in a host cell, preferably in a host cell previously harvested from the animal to be treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has been transformed with the vector coding for the desired PG-3 polypeptide or the desired fragment thereof is reintroduced into the animal body in order to deliver the recombinant protein within the body either locally or systemically.

Cell Hosts

[0674] Another object of the invention consists of a host cell that has been transformed or transfected with one of the polynucleotides described herein, and in particular a polynucleotide either comprising a PG-3 regulatory polynucleotide or the coding sequence for the PG-3 polypeptide in a polynucleotide selected from the group consisting of SEQ ID Nos 1 and 2 or a fragment or a variant thereof. Also included are host cells that are transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a recombinant vector such as one of those described above. More particularly, the cell hosts of the present invention can comprise any of the polynucleotides described in the “Genomic Sequences Of The PG3 Gene” section, the “PG-3 cDNA Sequences” section, the “Coding Regions” section, the “Polynucleotide constructs” section, and the “Oligonucleotide Probes And Primers” section.

[0675] A further recombinant cell host according to the invention comprises a polynucleotide containing a biallelic marker selected from the group consisting of A1 to A80, and the complements thereof.

[0676] An additional recombinant cell host according to the invention comprises any of the vectors described herein, more particularly any of the vectors described in the “Recombinant Vectors” section.

[0677] Preferred host cells used as recipients for the expression vectors of the invention are the following:

[0678] a) Prokaryotic host cells: Escherichia coli strains (I.E. DH5-α strain), Bacillus subtilis, Salmonella typhimurium, and strains from species like Pseudomonas, Streptomyces and Staphylococcus.

[0679] b) Eukaryotic host cells: HeLa cells (ATCC N^(o)CCL2; N^(o)CCL2.1; N^(o)CCL2.2), Cv 1 cells (ATCC N^(o)CCL70), COS cells (ATCC N^(o)CRL1650; N^(o)CRL1651), Sf-9 cells (ATCC N^(o)CRL1711), C127 cells (ATCC N^(o)CRL-1804), 3T3 (ATCC N^(o)CRL-6361), CHO (ATCC N^(o)CCL-61), human kidney 293. (ATCC N^(o)45504; N^(o)CRL-1573) and BHK (ECACC N^(o)84100501; N^(o)84111301).

[0680] c) Other mammalian host cells.

[0681] The PG-3 gene expression in mammalian, and typically human, cells may be rendered defective, or alternatively expression may be provided by the insertion of a PG-3 genomic or cDNA sequence with the replacement of the PG-3 gene counterpart in the genome of an animal cell by a PG-3 polynucleotide according to the invention. These genetic alterations may be generated by homologous recombination events using specific DNA constructs that have been previously described.

[0682] One kind of cell hosts that may be used are mammalian zygotes, such as murine zygotes. For example, murine zygotes may undergo microinjection with a purified DNA molecule of interest, for example a purified DNA molecule that has previously been adjusted to a concentration range from 1 ng/ml—for BAC inserts—3 ng/μl—for P1 bacteriophage inserts—in 10 mM Tris-HCl, pH 7.4, 250 μM EDTA containing 100 mM NaCl, 30 μM spermine, and70 μM spermidine. When the DNA to be microinjected has a large size, polyamines and high salt concentrations can be used in order to avoid mechanical breakage of this DNA, as described by Schedl et al (1993b).

[0683] Anyone of the polynucleotides of the invention, including the DNA constructs described herein, may be introduced in an embryonic stem (ES) cell line, preferably a mouse ES cell line. ES cell lines are derived from pluripotent, uncommitted cells of the inner cell mass of pre-implantation blastocysts. Preferred ES cell lines are the following: ES-E14TG2a (ATCC n^(o)CRL-1821), ES-D3 (ATCC n^(o)CRL1934 and n^(o)CRL-11632), YS001 (ATCC n^(o)CRL-11776), 36.5 (ATCC n^(o)CRL-11116). To maintain ES cells in an uncommitted state, they are cultured in the presence of growth inhibited feeder cells which provide the appropriate signals to preserve this embryonic phenotype and serve as a matrix for ES cell adherence. Preferred feeder cells consist of primary embryonic fibroblasts that are established from tissue of day 13-day 14 embryos of virtually any mouse strain, that are maintained in culture, such as described by Abbondanzo et al. (1993) and are inhibited in growth by irradiation, such as described by Robertson (1987), or by the presence of an inhibitory concentration of LIF, such as described by Pease and Williams (1990).

[0684] The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

[0685] Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

[0686] Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

[0687] Microbial cells employed in the expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

Transgenic Animals

[0688] The terms “transgenic animals” or “host animals” are used herein designate animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from Mus (e.g. mice), Rattus (e.g. rats) and Oryctogalus (e.g. rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention. In one embodiment, the invention encompasses non-human host mammals and animals comprising a recombinant vector of the invention or a PG-3 gene disrupted by homologous recombination with a knock out vector.

[0689] The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising a PG-3 coding sequence, a PG-3 regulatory polynucleotide, a polynucleotide construct, or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

[0690] Generally, a transgenic animal according the present invention comprises any one of the polynucleotides, the recombinant vectors and the cell hosts described in the present invention. More particularly, the transgenic animals of the present invention can comprise any of the polynucleotides described in the “Genomic Sequences Of The PG3 Gene” section, the “PG-3 cDNA Sequences” section, the “Coding Regions” section, the “Polynucleotide constructs” section, the “Oligonucleotide Probes And Primers” section, the “Recombinant Vectors” section and the “Cell Hosts” section.

[0691] A further transgenic animals according to the invention contains in their somatic cells and/or in their germ line cells a polynucleotide comprising a biallelic marker selected from the group consisting of A1 to A80, and the complements thereof.

[0692] In a first preferred embodiment, these transgenic animals may be good experimental models in order to study the diverse pathologies related to cell differentiation, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native PG-3 protein, or alternatively a mutant PG-3 protein.

[0693] In a second preferred embodiment, these transgenic animals may express a desired polypeptide of interest under the control of the regulatory polynucleotides of the PG-3 gene, leading to good yields in the synthesis of this protein of interest, and eventually a tissue specific expression of this protein of interest.

[0694] The design of the transgenic animals of the invention may be made according to the conventional techniques well known from the one skilled in the art. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to U.S. Pat. No. 4,873,191, issued Oct. 10, 1989; U.S. Pat. No. 5,464,764 issued Nov 7, 1995; and U.S. Pat. No. 5,789,215, issued Aug 4, 1998; these documents disclosing methods producing transgenic mice.

[0695] Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that has incorporated exogenous genetic material. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either a PG-3 coding sequence, a PG-3 regulatory polynucleotide or a DNA sequence encoding a PG-3 antisense polynucleotide such as described in the present specification.

[0696] A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is preferably made using electroporation, such as described by Thomas et al. (1987). The cells subjected to electroporation are screened (e.g. by selection via selectable markers, by PCR or by Southern blot analysis) to find positive cells which have integrated the exogenous recombinant polynucleotide into their genome, preferably via an homologous recombination event. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al. (1988).

[0697] Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice, such as described by Bradley (1987). The blastocysts are then inserted into a female host animal and allowed to grow to term.

[0698] Alternatively, the positive ES cells are brought into contact with embryos at the 2.5 days old 8-16 cell stage (morulae) such as described by Wood et al. (1993) or by Nagy et al. (1993), the ES cells being internalized to colonize extensively the blastocyst including the cells which will give rise to the germ line.

[0699] The offspring of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

[0700] Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a recombinant expression vector or a recombinant host cell according to the invention.

[0701] Recombinant Cell Lines Derived from the Transgenic Animals of the Invention.

[0702] A further object of the invention consists of recombinant host cells obtained from a transgenic animal described herein. In one embodiment the invention encompasses cells derived from non-human host mammals and animals comprising a recombinant vector of the invention or a PG-3 gene disrupted by homologous recombination with a knock out vector.

[0703] Recombinant cell lines may be established in vitro from cells obtained from any tissue of a transgenic animal according to the invention, for example by transfection of primary cell cultures with vectors expressing onc-genes such as SV40 large T antigen, as described by Chou (1989) and Shay et al. (1991).

[0704] Methods for Screening Substances Interacting with a PG-3 Polypeptide

[0705] For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding to the PG-3 protein or one of its fragments or variants or to modulate the expression of the polynucleotide coding for PG-3 or a fragment or variant thereof. These molecules may be used in therapeutic compositions, preferably therapeutic compositions acting against cancer or a disorder relating to abnormal cellular differentiation.

[0706] In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the PG-3 protein is brought into contact with the corresponding purified PG-3 protein, for example the corresponding purified recombinant PG-3 protein produced by a recombinant cell host as described hereinbefore, in order to form a complex between this protein and the putative ligand molecule to be tested.

[0707] As an illustrative example, to study the interaction of the PG-3 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3, with drugs or small molecules, such as molecules generated through combinatorial chemistry approaches, the microdialysis coupled to HPLC method described by Wang et al. (1997) or the affinity capillary electrophoresis method described by Bush et al. (1997).

[0708] In further methods, peptides, drugs, fatty acids, lipoproteins, or small molecules which interact with the PG-3 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3 may be identified using assays such as the following. The molecule to be tested for binding is labeled with a detectable label, such as a fluorescent .radioactive, or enzymatic tag and placed in contact with immobilized PG-3 protein, or a fragment thereof under conditions which permit specific binding to occur. After removal of non-specifically bound molecules, bound molecules are detected using appropriate means.

[0709] Another object of the present invention consists of methods and kits for the screening of candidate substances that interact with PG-3 polypeptide.

[0710] The present invention pertains to methods for screening substances of interest that interact with a PG-3 protein or one fragment or variant thereof. By their capacity to bind covalently or non-covalently to a PG-3 protein or to a fragment or variant thereof, these substances or molecules may be advantageously used both in vitro and in vivo.

[0711] In vitro, said interacting molecules may be used as detection means in order to identify the presence of a PG-3 protein in a sample, preferably a biological sample.

[0712] A method for the screening of a candidate substance comprises the following steps

[0713] a) providing a polypeptide consisting of a PG-3 protein or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3;

[0714] b) obtaining a candidate substance;

[0715] c) bringing into contact said polypeptide with said candidate substance;

[0716] d) detecting the complexes formed between said polypeptide and said candidate substance.

[0717] The invention further concerns a kit for the screening of a candidate substance interacting with the PG-3 polypeptide, wherein said kit comprises:

[0718] a) a PG-3 protein having an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID No 3 or a peptide fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3;

[0719] b) optionally means useful to detect the complex formed between the PG-3 protein or a peptide fragment or a variant thereof and the candidate substance.

[0720] In a preferred embodiment of the kit described above, the detection means consist in monoclonal or polyclonal antibodies directed against the PG-3 protein or a peptide fragment or a variant thereof.

[0721] Various candidate substances or molecules can be assayed for interaction with a PG-3 polypeptide. These substances or molecules include, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides. When the candidate substance or molecule consists of a polypeptide, this polypeptide may be the resulting expression product of a phage clone belonging to a phage-based random peptide library, or alternatively the polypeptide may be the resulting expression product of a cDNA library cloned in a vector suitable for performing a two-hybrid screening assay.

[0722] The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a PG-3 polypeptide or a fragment or a variant thereof, and optionally means useful to detect the complex formed between the PG-3 polypeptide or its fragment or variant and the candidate substance. In a preferred embodiment the detection means consist in monoclonal or polyclonal antibodies directed against the corresponding PG-3 polypeptide or a fragment or a variant thereof.

[0723] A. Candidate Ligands Obtained from Random Peptide Libraries

[0724] In a particular embodiment of the screening method, the putative ligand is the expression product of a DNA insert contained in a phage vector (Parmley and Smith, 1988). Specifically, random peptide phages libraries are used. The random DNA inserts encode for peptides of 8 to 20 amino acids in length (Oldenburg K. R. et al., 1992; Valadon P., et al., 1996; Lucas A. H., 1994; Westerink M. A. J., 1995; Felici F. et al., 1991). According to this particular embodiment, the recombinant phages expressing a protein that binds to the immobilized PG-3 protein is retained and the complex formed between the PG-3 protein and the recombinant phage may be subsequently immunoprecipitated by a polyclonal or a monoclonal antibody directed against the PG-3 protein.

[0725] Once the ligand library in recombinant phages has been constructed, the phage population is brought into contact with the immobilized PG-3 protein. Then the preparation of complexes is washed in order to remove the non-specifically bound recombinant phages. The phages that bind specifically to the PG-3 protein are then eluted by a buffer (acid pH) or immunoprecipitated by the monoclonal antibody produced by the hybridoma anti-PG-3, and this phage population is subsequently amplified by an over-infection of bacteria (for example E. coli). The selection step may be repeated several times, preferably 2-4 times, in order to select the more specific recombinant phage clones. The last step consists in characterizing the peptide produced by the selected recombinant phage clones either by expression in infected bacteria and isolation, expressing the phage insert in another host-vector system, or sequencing the insert contained in the selected recombinant phages.

[0726] B. Candidate Ligands Obtained by Competition Experiments.

[0727] Alternatively, peptides, drugs or small molecules which bind to the PG-3 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3, may be identified in competition experiments. In such assays, the PG-3 protein, or a fragment thereof, is immobilized to a surface, such as a plastic plate. Increasing amounts of the peptides, drugs or small molecules are placed in contact with the immobilized PG-3 protein, or a fragment thereof, in the presence of a detectable labeled known PG-3 protein ligand. For example, the PG-3 ligand may be detectably labeled with a fluorescent, radioactive, or enzymatic tag. The ability of the test molecule to bind the PG-3 protein, or a fragment thereof, is determined by measuring the amount of detectably labeled known ligand bound in the presence of the test molecule. A decrease in the amount of known ligand bound to the PG-3 protein, or a fragment thereof, when the test molecule is present indicated that the test molecule is able to bind to the PG-3 protein, or a fragment thereof.

[0728] C. Candidate Ligands Obtained by Affinity Chromatography.

[0729] Proteins or other molecules interacting with the PG-3 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3, can also be found using affinity columns which contain the PG-3 protein, or a fragment thereof. The PG-3 protein, or a fragment thereof, may be attached to the column using conventional techniques including chemical coupling to a suitable column matrix such as agarose, Affi Gel®, or other matrices familiar to those of skill in art. In some embodiments of this method, the affinity column contains chimeric proteins in which the PG-3 protein, or a fragment thereof, is fused to glutathion S transferase (GST). A mixture of cellular proteins or pool of expressed proteins as described above is applied to the affinity column. Proteins or other molecules interacting with the PG-3 protein, or a fragment thereof, attached to the column can then be isolated and analyzed on 2-D electrophoresis gel as described in Ramunsen et al. (1997). Alternatively, the proteins retained on the affinity column can be purified by electrophoresis based methods and sequenced. The same method can be used to isolate antibodies, to screen phage display products, or to screen phage display human antibodies.

[0730] D. Candidate Ligands Obtained by Optical Biosensor Methods

[0731] Proteins interacting with the PG-3 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3, can also be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow (1997) and also in Szabo et al. (1995). This technique permits the detection of interactions between molecules in real time, without the need of labeled molecules. This technique is based on the surface plasmon resonance (SPR) phenomenon. Briefly, the candidate ligand molecule to be tested is attached to a surface (such as a carboxymethyl dextran matrix). A light beam is directed towards the side of the surface that does not contain the sample to be tested and is reflected by said surface. The SPR phenomenon causes a decrease in the intensity of the reflected light with a specific association of angle and wavelength. The binding of candidate ligand molecules cause a change in the refraction index on the surface, which change is detected as a change in the SPR signal. For screening of candidate ligand molecules or substances that are able to interact with the PG-3 protein, or a fragment thereof, the PG-3 protein, or a fragment thereof, is immobilized onto a surface. This surface consists of one side of a cell through which flows the candidate molecule to be assayed. The binding of the candidate molecule on the PG-3 protein, or a fragment thereof, is detected as a change of the SPR signal. The candidate molecules tested may be proteins, peptides, carbohydrates, lipids, or small molecules generated by combinatorial chemistry. This technique may also be performed by immobilizing eukaryotic or prokaryotic cells or lipid vesicles exhibiting an endogenous or a recombinantly expressed PG-3 protein at their surface.

[0732] The main advantage of the method is that it allows the determination of the association rate between the PG-3 protein and molecules interacting with the PG-3 protein. It is thus possible to select specifically ligand molecules interacting with the PG-3 protein, or a fragment thereof, through strong or conversely weak association constants.

[0733] E. Candidate Ligands Obtained Through a Two-Hybrid Screening Assay.

[0734] The yeast two-hybrid system is designed to study protein-protein interactions in vivo (Fields and Song, 1989), and relies upon the fusion of a bait protein to the DNA binding domain of the yeast Gal4 protein. This technique is also described in the U.S. Pat. No. 5,667,973 and the U.S. Pat. No. 5,283,173.

[0735] The general procedure of library screening by the two-hybrid assay may be performed as described by Harper et al. (1993) or as described by Cho et al. (1998) or also Fromont-Racine et al. (1997).

[0736] The bait protein or polypeptide consists of a PG-3 polypeptide or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700 or 800 amino acids of SEQ ID No 3.

[0737] More precisely, the nucleotide sequence encoding the PG-3 polypeptide or a fragment or variant thereof is fused to a polynucleotide encoding the DNA binding domain of the GAL4 protein, the fused nucleotide sequence being inserted in a suitable expression vector, for example pAS2 or pM3.

[0738] Then, a human cDNA library is constructed in a specially designed vector, such that the human cDNA insert is fused to a nucleotide sequence in the vector that encodes the transcriptional domain of the GAL4 protein. Preferably, the vector used is the pACT vector. The polypeptides encoded by the nucleotide inserts of the human cDNA library are termed “pray” polypeptides.

[0739] A third vector contains a detectable marker gene, such as beta galactosidase gene or CAT gene that is placed under the control of a regulation sequence that is responsive to the binding of a complete Gal4 protein containing both the transcriptional activation domain and the DNA binding domain. For example, the vector pG5EC may be used.

[0740] Two different yeast strains are also used. As an illustrative but non limiting example the two different yeast strains may be the followings:

[0741] Y190, the phenotype of which is (MATa, Leu2-3, 112 ura3-12, trp1-901, his3-D200, ade2-101, gal4Dgal180D URA3 GAL-LacZ, LYS GAL-HIS3, cyh′);

[0742] Y187, the phenotype of which is (MATa gal4 gal80his3 trp1-901 ade2-101 ura3-52 leu2-3, -112 URA3 GAL-lacZmet⁻), which is the opposite mating type of Y190.

[0743] Briefly, 20 μg of pAS2/PG-3 and 20 μg of pACT-cDNA library are co-transformed into yeast strain Y190. The transformants are selected for growth on minimal media lacking histidine, leucine and tryptophan, but containing the histidine synthesis inhibitor 3-AT (50 mM). Positive colonies are screened for beta galactosidase by filter lift assay. The double positive colonies (His⁺, beta-gal⁺) are then grown on plates lacking histidine, leucine, but containing tryptophan and cycloheximide (10 mg/ml) to select for loss of pAS2/PG-3 plasmids bu retention of pACT-cDNA library plasmids. The resulting Y190 strains are mated with Y187 strains expressing PG-3 or non-related control proteins; such as cyclophilin B, lamin, or SNF1, as Gal4 fusions as described by Harper et al. (1993) and by Bram et al. (1993), and screened for beta galactosidase by filter lift assay. Yeast clones that are beta gal- after mating with the control Gal4 fusions are considered false positives.

[0744] In another embodiment of the two-hybrid method according to the invention, interaction between the PG-3 or a fragment or variant thereof with cellular proteins may be assessed using the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), nucleic acids encoding the PG-3 protein or a portion thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. A desired cDNA, preferably human cDNA, is inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain interaction between PG-3 and the protein or peptide encoded by the initially selected cDNA insert.

[0745] Method for Screening Substances Interacting with the Regulatory Sequences of the PG-3 Gene.

[0746] The present invention also concerns a method for screening substances or molecules that are able to interact with the regulatory sequences of the PG-3 gene, such as for example promoter or enhancer sequences.

[0747] Nucleic acids encoding proteins which are able to interact with the regulatory sequences of the PG-3 gene, more particularly a nucleotide sequence selected from the group consisting of the polynucleotides of the 5′ and 3′ regulatory region or a fragment or variant thereof, and preferably a variant comprising one of the biallelic markers of the invention; may be identified by using a one-hybrid system, such as that described in the booklet enclosed in the Matchmaker One-Hybrid System kit from Clontech (Catalog Ref. n^(o)K1603-1). Briefly, the target nucleotide sequence is cloned upstream of a selectable reporter sequence and the resulting DNA construct is integrated in the yeast genome (Saccharomyces cerevisiae). The yeast cells containing the reporter sequence in their genome are then transformed with a library consisting of fusion molecules between cDNAs encoding candidate proteins for binding onto the regulatory sequences of the PG-3 gene and sequences encoding the activator domain of a yeast transcription factor such as GAL4. The recombinant yeast cells are plated in a culture broth for selecting cells expressing the reporter sequence. The recombinant yeast cells thus selected contain a fusion protein that is able to bind onto the target regulatory sequence of the PG-3 gene. Then, the cDNAs encoding the fusion proteins are sequenced and may be cloned into expression or transcription vectors in vitro. The binding of the encoded polypeptides to the target regulatory sequences of the PG-3 gene may be confirmed by techniques familiar to the one skilled in the art, such as gel retardation assays or DNAse protection assays.

[0748] Gel retardation assays may also be performed independently in order to screen candidate molecules that are able to interact with the regulatory sequences of the PG-3 gene, such as described by Fried and Crothers (1981), Garner and Revzin (1981) and Dent and Latchman (1993). These techniques are based on the principle according to which a DNA fragment which is bound to a protein migrates slower than the same unbound DNA fragment. Briefly, the target nucleotide sequence is labeled. Then the labeled target nucleotide sequence is brought into contact with either a total nuclear extract from cells containing transcription factors, or with different candidate molecules to be tested. The interaction between the target regulatory sequence of the PG-3 gene and the candidate molecule or the transcription factor is detected after gel or capillary electrophoresis through a retardation in the migration.

[0749] Method for Screening Ligands that Modulate the Expression of the PG-3 Gene.

[0750] Another subject of the present invention is a method for screening molecules that modulate the expression of the PG-3 protein. Such a screening method comprises the steps of:

[0751] a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding the PG-3 protein or a variant or a fragment thereof, placed under the control of its own promoter;

[0752] b) bringing into contact the cultivated cell with a molecule to be tested;

[0753] c) quantifying the expression of the PG-3 protein or a variant or a fragment thereof.

[0754] In an embodiment, the nucleotide sequence encoding the PG-3 protein or a variant or a fragment thereof comprises an allele of at least one of the biallelic markers A1 to A80, and the complements thereof.

[0755] Using DNA recombination techniques well known by the one skill in the art, the PG-3 protein encoding DNA sequence is inserted into an expression vector, downstream from its promoter sequence. As an illustrative example, the promoter sequence of the PG-3 gene is contained in the nucleic acid of the 5′ regulatory region.

[0756] The quantification of the expression of the PG-3 protein may be realized either at the mRNA level or at the protein level. In the latter case, polyclonal or monoclonal antibodies may be used to quantify the amounts of the PG-3 protein that have been produced, for example in an ELISA or a RIA assay.

[0757] In a preferred embodiment, the quantification of the PG-3 mRNA is realized by a quantitative PCR amplification of the cDNA obtained by a reverse transcription of the total mRNA of the cultivated PG-3-transfected host cell, using a pair of primers specific for PG-3.

[0758] The present invention also concerns a method for screening substances or molecules that are able to increase, or in contrast to decrease, the level of expression of the PG-3 gene. Such a method may allow the one skilled in the art to select substances exerting a regulating effect on the expression level of the PG-3 gene and which may be useful as active ingredients included in pharmaceutical compositions for treating patients suffering from cancer or a disorder relating to abnormal cellular differentiation.

[0759] Thus, another aspect of the present invention is a method for screening a candidate substance or molecule for the ability to modulate the expression of the PG-3 gene, comprising the following steps:

[0760] a) providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a nucleotide sequence of the 5′ regulatory region or a regulatory active fragment or variant thereof located upstream of a polynucleotide encoding a detectable protein;

[0761] b) obtaining a candidate substance; and

[0762] c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

[0763] In a further embodiment, the nucleic acid comprising the nucleotide sequence of the 5′ regulatory region or a regulatory active fragment or variant thereof also includes a 5′UTR region of the PG-3 cDNA of SEQ ID No 2, or one of its regulatory active fragments or variants thereof.

[0764] Among the preferred polynucleotides encoding a detectable protein, there may be cited polynucleotides encoding beta galactosidase, green fluorescent protein (GFP) and chloramphenicol acetyl transferase (CAT).

[0765] The invention also pertains to kits useful for performing the herein described screening method. Preferably, such kits comprise a recombinant vector that allows the expression of a nucleotide sequence of the 5′ regulatory region or a regulatory active fragment or variant thereof located upstream and operably linked to a polynucleotide encoding a detectable protein or the PG-3 protein or a fragment or a variant thereof.

[0766] In another embodiment of a method for the screening of a candidate substance or molecule for the ability to modulate the expression of the PG-3 gene, the method comprises the following steps:

[0767] a) providing a recombinant host cell containing a nucleic acid, wherein said nucleic acid comprises a 5′UTR sequence of the PG-3 cDNA of SEQ ID No 2, or one of its regulatory active fragments or variants, the 5′UTR sequence or its regulatory active fragment or variant being operably linked to a polynucleotide encoding a detectable protein;

[0768] b) obtaining a candidate substance; and

[0769] c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

[0770] In a specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5′UTR sequence of the PG-3 cDNA of SEQ ID No 2 or one of its regulatory active fragments or variants, includes a promoter sequence which is endogenous with respect to the PG-3 5′UTR sequence.

[0771] In another specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5′UTR sequence of the PG-3 cDNA of SEQ ID No 2 or one of its regulatory active fragments or variants, includes a promoter sequence which is exogenous with respect to the PG-3 5′UTR sequence defined therein.

[0772] In a further preferred embodiment, the nucleic acid comprising the 5′-UTR sequence of the PG-3 cDNA or SEQ ID No 2 or the regulatory active fragments thereof includes a biallelic marker selected from the group consisting of A1 to A80 or the complements thereof.

[0773] The invention further encompasses a kit for the screening of a candidate substance for the ability to modulate the expression of the PG-3 gene, wherein said kit comprises a recombinant vector that comprises a nucleic acid including a 5′UTR sequence of the PG-3 cDNA of SEQ ID No 2, or one of their regulatory active fragments or variants, the 5′UTR sequence or its regulatory active fragment or variant being operably linked to a polynucleotide encoding a detectable protein.

[0774] For the design of suitable recombinant vectors useful for performing the screening methods described above, the section of the present specification wherein the preferred recombinant vectors of the invention are detailed is pertinent.

[0775] Expression levels and patterns of PG-3 may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277. Briefly, the PG-3 cDNA or the PG-3 genomic DNA described above, or fragments thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the PG-3 insert comprises at least 100 or more consecutive nucleotides of the genomic DNA sequence or the cDNA sequences. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridization is performed under standard stringent conditions (40-50° C. for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

[0776] Quantitative analysis of PG-3 gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of a plurality of nucleic acids of sufficient length to permit specific detection of expression of mRNAs capable of hybridizing thereto. For example, the arrays may contain a plurality of nucleic acids derived from genes whose expression levels are to be assessed. The arrays may include the PG-3 genomic DNA, the PG-3 cDNA sequences or the sequences complementary thereto or fragments thereof, particularly those comprising at least one of the biallelic markers according the present invention, preferably at least one of the biallelic markers A1 to A80. Preferably, the fragments are at least 15 nucleotides in length. In other embodiments, the fragments are at least 25 nucleotides in length. In some embodiments, the fragments are at least 50 nucleotides in length. More preferably, the fragments are at least 100 nucleotides in length. In another preferred embodiment, the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

[0777] For example, quantitative analysis of PG-3 gene expression may be performed with a complementary DNA microarray as described by Schena et al. (1995 and 1996). Full length PG-3 cDNAs or fragments thereof are amplified by PCR and arrayed from a 96-well microtiter plate onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95° C., transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25° C.

[0778] Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm² microarrays under a 14×14 mm glass coverslip for 6-12 hours at 60° C. Arrays are washed for 5 min at 25° C. in low stringency wash buffer (1×SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (1×SSC/0.2% SDS). Arrays are scanned in 0.1×SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

[0779] Quantitative analysis of PG-3 gene expression may also be performed with full length PG-3 cDNAs or fragments thereof in complementary DNA arrays as described by Pietu et al. (1996). The full length PG-3 cDNA or fragments thereof is PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

[0780] Alternatively, expression analysis using the PG-3 genomic DNA, the PG-3 cDNA, or fragments thereof can be done through high density nucleotide arrays as described by Lockhart et al. (1996) and Sosnowski et al. (1997). Oligonucleotides of 15-50 nucleotides from the sequences of the PG-3 genomic DNA, the PG-3 cDNA sequences particularly those comprising at least one of biallelic markers according the present invention, preferably at least one biallelic marker selected from the group consisting of A1 to A80, or the sequences complementary thereto, are synthesized directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra). Preferably, the oligonucleotides are about 20 nucleotides in length.

[0781] PG-3 cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., supra and application of different electric fields (Sosnowski et al., 1997), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of PG-3 mRNA.

Methods for Inhibiting the Expression of a PG-3 Gene

[0782] Other therapeutic compositions according to the present invention comprise advantageously an oligonucleotide fragment of the nucleic sequence of PG-3 as an antisense tool or a triple helix tool that inhibits the expression of the corresponding PG-3 gene. A preferred fragment of the nucleic sequence of PG-3 comprises an allele of at least one of the biallelic markers A1 to A80.

[0783] Antisense Approach

[0784] In antisense approaches, nucleic acid sequences complementary to an mRNA are hybridized to the mRNA intracellularly, thereby blocking the expression of the protein encoded by the mRNA. The antisense nucleic acid molecules to be used in gene therapy may be either DNA or RNA sequences. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al. (1995), which disclosure is hereby incorporated by reference in its entirety.

[0785] Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to PG-3 mRNA, more preferably to the 5′ end of the PG-3 mRNA. In another embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

[0786] Other preferred antisense polynucleotides according to the present invention are sequences complementary to either a sequence of PG-3 mRNAs comprising the translation initiation codon ATG or a sequence of PG-3 genomic DNA containing a splicing donor or acceptor site.

[0787] Preferably, the antisense polynucleotides of the invention have a 3′ polyadenylation signal that has been replaced with a self-cleaving ribozyme sequence, such that RNA polymerase II transcripts are produced without poly(A) at their 3′ ends, these antisense polynucleotides being incapable of export from the nucleus, such as described by Liu et al. (1994), which disclosure is hereby incorporated by reference in its entirety. In a preferred embodiment, these PG-3 antisense polynucleotides also comprise, within the ribozyme cassette, a histone stem-loop structure to stabilize cleaved transcripts against 3′-5′ exonucleolytic degradation, such as the structure described by Eckner et al. (1991), which disclosure is hereby incorporated by reference in its entirety.

[0788] The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the PG-3 mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., (1986) and Izant and Weintraub, (1984), the disclosures of which are incorporated herein by reference.

[0789] In some strategies, antisense molecules are obtained by reversing the orientation of the PG-3 coding region with respect to a promoter so as to transcribe the opposite strand from that which is. normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of PG-3 antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

[0790] Alternatively, oligonucleotides which are complementary to the strand normally transcribed in the cell may be synthesized in vitro. Thus, the antisense nucleic acids are complementary to the corresponding mRNA and are capable of hybridizing to the mRNA to create a duplex. In some embodiments, the antisense sequences may contain modified sugar phosphate backbones to increase stability and make them less sensitive to RNase activity. Examples of modifications suitable for use in antisense strategies include 2′ O-methyl RNA oligonucleotides and Protein-nucleic acid (PNA) oligonucleotides. Further examples are described by Rossi et al., (1991), which disclosure is hereby incorporated by reference in its entirety.

[0791] Various types of antisense oligonucleotides complementary to the sequence of the PG-3 cDNA or genomic DNA may be used. In one preferred embodiment, stable and semi-stable antisense oligonucleotides described in International Application No. PCT WO94/23026, hereby incorporated by reference, are used. In these molecules, the 3′ end or both the 3′ and 5′ ends are engaged in intramolecular hydrogen bonding between complementary base pairs. These molecules are better able to withstand exonuclease attacks and exhibit increased stability compared to conventional antisense oligonucleotides.

[0792] In another preferred embodiment, the antisense oligodeoxynucleotides against herpes simplex virus types 1 and 2 described in International Application No. WO 95/04141, hereby incorporated by reference, are used.

[0793] In yet another preferred embodiment, the covalently cross-linked antisense oligonucleotides described in International Application No. WO 96/31523, hereby incorporated by reference, are used. These double- or single-stranded oligonucleotides comprise one or more, respectively, inter- or intra-oligonucleotide covalent cross-linkages, wherein the linkage consists of an amide bond between a primary amine group of one strand and a carboxyl group of the other strand or of the same strand, respectively, the primary amine group being directly substituted in the 2′ position of the strand nucleotide monosaccharide ring, and the carboxyl group being carried by an aliphatic spacer group substituted on a nucleotide or nucleotide analog of the other strand or the same strand, respectively.

[0794] The antisense oligodeoxynucleotides and oligonucleotides disclosed in International Application No. WO 92/18522, incorporated by reference, may also be used. These molecules are stable to degradation and contain at least one transcription control recognition sequence which binds to control proteins and are effective as decoys therefor. These molecules may contain “hairpin” structures, “dumbbell” structures, “modified dumbbell” structures, “cross-linked” decoy structures and “loop” structures.

[0795] In another preferred embodiment, the cyclic double-stranded oligonucleotides described in European Patent Application No. 0 572 287 A2, hereby incorporated by reference are used. These ligated oligonucleotide “dumbbells” contain the binding site for a transcription factor and inhibit expression of the gene under control of the transcription factor by sequestering the factor.

[0796] Use of the closed antisense oligonucleotides disclosed in International Application No. WO 92/19732, hereby incorporated by reference, is also contemplated. Because these molecules have no free ends, they are more resistant to degradation by exonucleases than are conventional oligonucleotides. These oligonucleotides may be multifunctional, interacting with several regions which are not adjacent to the target mRNA.

[0797] The appropriate level of antisense nucleic acids required to inhibit gene expression may be determined using in vitro expression analysis. The antisense molecule may be introduced into the cells by diffusion, injection, infection or transfection using procedures known in the art. For example, the antisense nucleic acids can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsidated by viral protein or as an oligonucleotide operably linked to a promoter contained in an expression vector. The expression vector may be any of a variety of expression vectors known in the art, including retroviral or viral vectors, vectors capable of extrachromosomal replication, or integrating vectors. The vectors may be DNA or RNA.

[0798] The antisense molecules are introduced onto cell samples at a number of different concentrations preferably between 1×10⁻¹⁰M to 1×10⁻⁴M. Once the minimum concentration that can adequately control gene expression is identified, the optimized dose is translated into a dosage suitable for use in vivo. For example, an inhibiting concentration in culture of 1×10⁻⁷ translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide approaching 100 mg/kg bodyweight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate.

[0799] In a preferred application of this invention, the polypeptide encoded by the gene is first identified, so that the effectiveness of antisense inhibition on translation can be monitored using techniques that include but are not limited to antibody-mediated tests such as RIAs and ELISA, functional assays, or radiolabeling.

[0800] An alternative to the antisense technology that is used according to the present invention comprises using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely “hammerhead ribozymes”). Briefly, the simplified cycle of a hammerhead ribozyme comprises (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Rossi et al, (1991) and Sczakiel et al. (1995), the specific preparation procedures being referred to in said articles being herein incorporated by reference.

[0801] Triple Helix Approach

[0802] The PG-3 genomic DNA may also be used to inhibit the expression of the PG-3 gene based on intracellular triple helix formation.

[0803] Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity when it is associated with a particular gene.

[0804] Similarly, a portion of the PG-3 genomic DNA can be used to study the effect of inhibiting PG-3 transcription within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the PG-3 genomic DNA are contemplated within the scope of this invention.

[0805] To carry out gene therapy strategies using the triple helix approach, the sequences of the PG-3 genomic DNA are first scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting PG-3 expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting PG-3 expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which express the PG-3 gene.

[0806] The oligonucleotides can be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

[0807] Treated cells are monitored for altered cell function or reduced PG-3 expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the PG-3 gene in cells which have been treated with the oligonucleotide.

[0808] The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above in the antisense approach at a dosage calculated based on the in vitro results, as described in antisense approach.

[0809] In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3′ end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al. (1989), which is hereby incorporated by this reference.

Computer-Related Embodiments

[0810] As used herein the term “nucleic acid codes of the invention” encompass the nucleotide sequences comprising, consisting essentially of, or consisting of any one of the following: a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-97921, 98517-103471, 103603-108222, 108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-240825; b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35,40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 2 or the complements thereof, and, c) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

[0811] The “nucleic acid codes of the invention” further encompass nucleotide sequences homologous to: a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-97921, 98517-103471, 103603-108222, 108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-240825; b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 2 or the complements thereof; and, c) sequences complementary to all of the preceding sequences. Homologous sequences refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these contiguous spans. Homology may be determined using any method described herein, including BLAST2N with the default parameters or with any modified parameters. Homologous sequences also may include RNA sequences in which uridines replace the thymines in the nucleic acid codes of the invention. It will be appreciated that the nucleic acid codes of the invention can be represented in the traditional single character format (See the inside back cover of Stryer, Lubert. 1995) or in any other format or code which records the identity of the nucleotides in a sequence.

[0812] As used herein the term “polypeptide codes of the invention” encompass the polypeptide sequences comprising a contiguous span of at least 6, 8, 10, 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 3. It will be appreciated that the polypeptide codes of the invention can be represented in the traditional single character format or three letter format (See the inside back cover of Stryer, Lubert.) or in any other format or code which records the identity of the polypeptides in a sequence.

[0813] It will be appreciated by those skilled in the art that the nucleic acid codes of the invention and polypeptide codes of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. As used herein, the words “recorded” and “stored” refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid codes of the invention, or one or more of the polypeptide codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 nucleic acid codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of the invention.

[0814] Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.

[0815] Embodiments of the present invention include systems, particularly computer systems which store and manipulate the sequence information described herein. One example of a computer system 100 is illustrated in block diagram form in FIG. 1. As used herein, “a computer system” refers to the hardware components, software components, and data storage components used to analyze the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention. In one embodiment, the computer system 100 is a Sun Enterprise 1000 server (Sun Microsystems, Palo Alto, Calif.). The computer system 100 preferably includes a processor for processing, accessing and manipulating the sequence data. The processor 105 can be any well-known type of central processing unit, such as the Pentium III from Intel Corporation, or similar processor from Sun, Motorola, Compaq or International Business Machines.

[0816] Preferably, the computer system 100 is a general purpose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

[0817] In one particular embodiment, the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (preferably implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal data storage devices 110.

[0818] The data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, etc. In some embodiments, the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system 100 may advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device.

[0819] The computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125 a-c in a network or wide area network to provide centralized access to the computer system 100.

[0820] Software for accessing and processing the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention (such as search tools, compare tools, and modeling tools etc.) may reside in main memory 115 during execution.

[0821] In some embodiments, the computer system 100 may further comprise a sequence comparer for comparing the above-described nucleic acid codes of the invention or the polypeptide codes of the invention stored on a computer readable medium to reference nucleotide or polypeptide sequences stored on a computer readable medium. A “sequence comparer” refers to one or more programs which are implemented on the computer system 100 to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.

[0822]FIG. 2 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database. The database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK, PIR OR SWISSPROT that is available through the Internet.

[0823] The process 200 begins at a start state 201 and then moves to a state 202 wherein the new sequence to be compared is stored to a memory in a computer system 100. As discussed above, the memory could be any type of memory, including RAM or an internal storage device.

[0824] The process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison. The process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer. A comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to note that this step is not limited to performing an exact comparison between the new sequence and the first sequence in the database. Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are normally entered by the user of the computer system.

[0825] Once a comparison of the two sequences has been performed at the state 210, a determination is made at a decision state 210 whether the two sequences are the same. Of course, the term “same” is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as “same” in the process 200.

[0826] If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered. Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database. If no more sequences exist in the database, then the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database.

[0827] It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.

[0828] Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid code of the invention or a polypeptide code of the invention, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the nucleic acid code of the invention or polypeptide code of the invention and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the nucleic acid code of the invention and polypeptide codes of the invention or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or polypeptide codes of the invention.

[0829] Another aspect of the present invention is a method for determining the level of homology between a nucleic acid code of the invention and a reference nucleotide sequence, comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code and the reference nucleotide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described nucleic acid codes of the invention through the use of the computer program and determining homology between the nucleic acid codes and reference nucleotide sequences.

[0830]FIG. 3 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous. The process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory. The second sequence to be compared is then stored to a memory at a state 256. The process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read. It should be understood that if the sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U. If the sequence is a protein sequence, then it should be in the single letter amino acid code so that the first and sequence sequences can be easily compared.

[0831] A determination is then made at a decision state 264 whether the two characters are the same. If they are the same, then the process 250 moves to a state 268 wherein the next characters in the first and second sequences are read. A determination is then made whether the next characters are the same. If they are, then the process 250 continues this loop until two characters are not the same. If a determination is made that the next two characters are not the same, the process 250 moves to a decision state 274 to determine whether there are any more characters either sequence to read.

[0832] If there aren't any more characters to read, then the process 250 moves to a state 276 wherein the level of homology between the first and second sequences is displayed to the user. The level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100 nucleotide sequence aligned with a every character in a second sequence, the homology level would be 100%.

[0833] Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the nucleic acid codes of the present invention, to reference nucleotide sequences in order to determine whether the nucleic acid code of the invention differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the nucleic acid code of the invention. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the nucleic acid codes of the invention contain one or more single nucleotide polymorphisms (SNP) with respect to a reference nucleotide sequence. These single nucleotide polymorphisms may each comprise a single base substitution, insertion, or deletion.

[0834] Another aspect of the present invention is a method for determining the level of homology between a polypeptide code of the invention and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of the invention and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the polypeptide code and the reference polypeptide sequence using the computer program.

[0835] Accordingly, another aspect of the present invention is a method for determining whether a nucleic acid code of the invention differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single nucleotide polymorphisms The method may be implemented by the computer systems described above and the method illustrated in FIG. 3. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.

[0836] In other embodiments the computer based system may further comprise an identifier for identifying features within the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention.

[0837] An “identifier” refers to one or more programs which identifies certain features within the above-described nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention. In one embodiment, the identifier may comprise a program which identifies an open reading frame in the cDNAs codes of the invention.

[0838]FIG. 4 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence. The process 300 begins at a start state 302 and then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100. The process 300 then moves to a state 306 wherein a database of sequence features is opened. Such a database would include a list of each feature's attributes along with the name of the feature. For example, a feature name could be “Initiation Codon” and the attribute would be “ATG”. Another example would be the feature name “TAATAA Box” and the feature attribute would be “TAATAA”. An example of such a database is produced by the University of Wisconsin Genetics Computer Group (www.gcg.com).

[0839] Once the database of features is opened at the state 306, the process 300 moves to a state 308 wherein the first feature is read from the database. A comparison of the attribute of the first feature with the first sequence is then made at a state 310. A determination is then made at a decision state 316 whether the attribute of the feature was found in the first sequence. If the attribute was found, then the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user.

[0840] The process 300 then moves to a decision state 320 wherein a determination is made whether move features exist in the database. If no more features do exist, then the process 300 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence.

[0841] It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to determine if any more features exist in the database.

[0842] In another embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of the invention. In some embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures. (See, e.g., Eisenberg et al., U.S. Pat. No. 5,436,850 issued Jul. 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are superimposed to define the structurally conserved regions in that family. This protein modeling technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of the invention. (See e.g., Srinivasan, et al., U.S. Pat. No. 5,557,535 issued Sep. 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

[0843] The recent development of threading methods now enables the identification of likely folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model, and a full-atom representation is constructed using a molecular modeling package such as QUANTA.

[0844] According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural equivalencies obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these low resolution model confirmations are converted into full-atom models and subjected to energy minimization using the molecular modeling package QUANTA. (See e.g., Aszódi et al., (1997)).

[0845] The results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of the invention.

[0846] Accordingly, another aspect of the present invention is a method of identifying a feature within the nucleic acid codes of the invention or the polypeptide codes of the invention comprising reading the nucleic acid code(s) or the polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) or polypeptide code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or the polypeptide codes of the invention through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

[0847] The nucleic acid codes of the invention or the polypeptide codes of the invention may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, they may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the nucleic acid codes of the invention or the polypeptide codes of the invention. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid codes of the invention or the polypeptide codes of the invention. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, 1990), FASTA (Pearson and Lipman, 1988), FASTDB (Brutlag et al., 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius².DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMm (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwents's World Drug Index database, the BioByteMasterFile database, the Genbank database, the Genseqn database and the Genseqp databases. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure.

[0848] Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

[0849] Throughout this application, various publications, patents and published patent applications are cited. The disclosures of these publications, patents and published patent specification referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the sate of the art to which this invention pertains.

EXAMPLES Example 1 Identification of Biallelic Markers—DNA Extraction

[0850] Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a French heterogeneous population. The DNA from 100 individuals was extracted and tested for the detection of the biallelic markers.

[0851] 30 ml of peripheral venous blood were taken from each donor in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume: 10 mM Tris pH7.6; 5 mM MgCl₂; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant, after resuspension of the pellet in the lysis solution.

[0852] The pellet of white cells was lysed overnight at 42° C. with 3.7 ml of lysis solution composed of:

[0853] 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM)/NaCl 0 4 M

[0854] 200 μl SDS 10%

[0855] 500 μl K-proteinase (2 mg K-proteinase in TE 10-2/NaCl 0.4 M).

[0856] For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

[0857] For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37° C., and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD=50 μg/ml DNA).

[0858] To determine the presence of proteins in the DNA solution, the OD 260/OD 280 ratio was determined. Only DNA preparations having a OD 260/OD 280 ratio between 1.8 and 2 were used in the subsequent examples described below.

[0859] The pool was constituted by mixing equivalent quantities of DNA from each individual.

Example 2 Identification of Biallelic Markers: Amplification of Genomic DNA by PCR

[0860] The amplification of specific genomic sequences of the DNA samples of example 1 was carried out on the pool of DNA obtained previously. In addition, 50 individual samples were similarly amplified.

[0861] PCR assays were performed using the following protocol: Final volume 25 μl DNA 2 ng/μl MgCl₂ 2 mM dNTP (each) 200 μM primer (each) 2.9 ng/μl Ampli Taq Gold DNA polymerase 0.05 unit/μl PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5 M KCl) 1x

[0862] Each pair of first primers was designed using the sequence information of the PG-3 gene disclosed herein and the OSP software (Hillier & Green, 1991). This first pair of primers was about 20 nucleotides in length and had the sequences disclosed in Table 1 in the columns labeled PU and RP. TABLE 1 Complementary Position range position range of Position range PU of amplification RP amplification of the amplicon primer primer in SEQ primer primer in SEQ Amplicon in SEQ ID No: 1 name ID No: 1 name ID No: 1 5-390 1823 2125 B1 1823 1840 C1 2108 2125 5-391 4559 4908 B2 4559 4577 C2 4891 4908 5-392 10007 10430 B3 10007 10025 C3 10411 10430 4-59 39556 39970 B4 39556 39574 C4 39953 39970 4-58 39877 40259 B5 39877 39896 C5 40242 40259 4-54 41137 41581 B6 41137 41154 C6 41564 41581 4-51 42122 42543 B7 42122 42141 C7 42526 42543 99-86 67289 67741 B8 67289 67309 C8 67724 67741 4-88 69182 69626 B9 69182 69200 C9 69609 69626 5-397 72698 73117 B10 72698 72715 C10 73099 73117 5-398 75858 76306 B11 75858 75877 C11 76289 76306 99-12738 81006 81485 B12 81006 81025 C12 81466 81485 99-109 83564 84007 B13 83564 83582 C13 83990 84007 99-12749 91743 92142 B14 91743 91763 C14 92123 92142 4-21 95196 95619 B15 95196 95214 C15 95600 95619 4-23 95865 96229 B16 95865 95882 C16 96210 96229 99-12753 97261 97747 B17 97261 97278 C17 97728 97747 5-364 97831 98275 B18 97831 97849 C18 98256 98275 99-12755 98638 99131 B19 98638 98656 C19 99111 99131 4-87 103376 103818 B20 103376 103395 C20 103801 103818 99-12757 104081 104636 B21 104081 104100 C21 104619 104636 99-12758 106272 106799 B22 106272 106291 C22 106780 106799 4-105 108200 108412 B23 108200 108218 C23 108390 108412 4-45 108223 108520 B24 108223 108246 C24 108499 108520 4-44 109123 109471 B25 109123 109142 C25 109454 109471 4-86 114217 114663 B26 114217 114234 C26 114646 114663 4-84 115630 116049 B27 115630 115647 C27 116031 116049 99-78 121991 122401 B28 121991 122011 C28 122384 122401 99-12767 123089 123583 B29 123089 123106 C29 123565 123583 4-80 126711 127065 B30 126711 126729 C30 127048 127065 4-36 128162 128590 B31 128162 128179 C31 128573 128590 4-35 128480 128926 B32 128480 128497 C32 128909 128926 99-12771 130747 131273 B33 130747 130764 C33 131254 131273 99-12774 132873 133325 B34 132873 132892 C34 133305 133325 99-12776 135029 135478 B35 135029 135048 C35 135458 135478 99-12781 139277 139742 B36 139277 139296 C36 139724 139742 4-104 157181 157832 B37 157181 157199 C37 157814 157832 99-12818 172692 173091 B38 172692 172709 C38 173072 173091 99-24807 180248 180892 B39 180248 180268 C39 180874 180892 99-12827 184662 185156 B40 184662 184680 C40 185138 185156 99-12831 190178 190663 B41 190178 190196 C41 190643 190663 99-12832 191011 191460 B42 191011 191030 C42 191441 191460 99-12836 195099 195587 B43 195099 195116 C43 195568 195587 99-12844 203585 204115 B44 203585 203602 C44 204095 204115 4-24 210079 210495 B45 210079 210096 C45 210476 210495 4-27 210979 211401 B46 210979 210996 C46 211382 211401 5-400 215852 216271 B47 215852 215870 C47 216253 216271 99-12852 216213 216728 B48 216213 216231 C48 216708 216728 4-37 221530 221973 B49 221530 221549 C49 221956 221973 5-270 225554 225845 B50 225554 225572 C50 225827 225845 99-12860 229341 229790 B51 229341 229359 C51 229770 229790 5-402 237412 237766 B52 237412 237429 C52 237747 237766

[0863] Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

[0864] Primers PU contain the following additional PU 5′ sequence: TGTAAAACGACGGCCAGT; primers RP contain the following RP 5′ sequence: CAGGAAACAGCTATGACC. The primer containing the additional PU 5′ sequence is listed in SEQ ID No 4. The primer containing the additional RP 5′ sequence is listed in SEQ ID No 5.

[0865] The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

[0866] DNA amplification was performed on a Genius II thermocycler. After heating at 95° C. for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95° C., 54° C. for 1 min, and 30 sec at 72° C. For final elongation, 10 min at 72° C. ended the amplification. The quantities of the amplification products obtained were determined on 96-well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

Example 3 Identification of Biallelic Markers—Sequencing of Amplified Genomic DNA and Identification of Polymorphisms

[0867] The sequencing of the amplified DNA obtained in example 2 was carried out on ABI 377 sequencers. The sequences of the amplification products were determined using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version)).

[0868] The sequence data were further evaluated to detect the presence of biallelic markers within the amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

[0869] In the 52 fragments of amplification, 80 biallelic markers were detected. The localization of these biallelic markers are as shown in Table 2. TABLE 2 BM position Position of Marker Localization Polymorphism in SEQ ID amino acid in Amplicon BM name in PG-3 gene all1 all2 No: 1 No: 2 SEQ ID No: 3 5-390 A1 5-390-177 5′ regulatory G C 1999 5-391 A2 5-391-43 Intron A-B A G 4601 5-392 A3 5-392-222 Exon C G T 10228 285  76 = V 5-392 A4 5-392-280 Intron C-D G T 10286 5-392 A5 5-392-364 Intron C-D G — 10370 4-59 A6 4-58-318 Exon T G T 39944 968 304 = R or I 4-58 A7 4-58-289 Exon T G C 39973 997 314 = H or D 4-54 A8 4-54-199 Intron T-G A C 41385 4-54 A9 4-54-180 Intron T-G A C 41404 4-51 A10 4-51-312 Intron T-G G C 42232 99-86 A11 99-86-266 Intron G-H A G 67475 4-88 A12 4-88-107 Intron G-H A G 69521 5-397 A13 5-397-141 Intron G-H G T 72838 5-398 A14 5-398-203 Exon I A C 76060 2102 682 = T or N 99-12738 A15 99-12738-248 Intron I-J A C 81253 99-109 A16 99-109-358 Intron I-J A C 83921 99-12749 A17 99-12749-175 Intron I-J C T 91917 4-21 A18 4-21-154 Intron J-K C T 95349 4-21 A19 4-21-317 Intron J-K G T 95511 4-23 A20 4-23-326 Intron J-K A G 96190 99-12753 A21 99-12753-34 Intron J-K A T 97294 5-364 A22 5-364-252 Intron J-K G T 98024 99-12755 A23 99-12755-280 Intron J-K A G 98914 99-12755 A24 99-12755-329 Intron J-K A C 98963 4-87 A25 4-87-212 Intron J-K A G 103593 99-12757 A26 99-12757-318 Intron J-K C T 104398 99-12758 A27 99-12758-102 Intron J-K A G 106373 99-12758 A28 99-12758-136 Intron J-K C T 106407 4-105 A29 4-105-98 Intron J-K A G 108315 4-105 A30 4-105-86 Intron J-K A G 108327 4-45 A31 4-45-49 Intron J-K C T 108472 4-44 A32 4-44-277 Intron J-K C T 109196 4-86 A33 4-86-60 Intron J-K G C 114604 4-84 A34 4-84-334 Intron J-K A G 115716 99-78 A35 99-78-321 Intron J-K A T 122083 99-12767 A36 99-12767-36 Intron J-K G C 123124 99-12767 A37 99-12767-143 Intron J-K C T 123231 99-12767 A38 99-12767-189 Intron J-K C T 123277 99-12767 A39 99-12767-380 Intron J-K A G 123468 4-80 A40 4-80-328 Intron J-K C T 126738 4-36 A41 4-36-384 Intron J-K G C 128210 4-36 A42 4-36-264 Intron J-K A G 128330 4-36 A43 4-36-261 Intron J-K A C 128333 4-35 A44 4-35-333 Intron J-K A C 128594 4-35 A45 4-35-240 Intron J-K G C 128687 4-35 A46 4-35-173 Intron J-K A T 128754 4-35 A47 4-35-133 Intron J-K C T 128794 99-12771 A48 99-12771-59 Intron J-K G T 130805 99-12774 A49 99-12774-334 Intron J-K A C 133206 99-12776 A50 99-12776-358 Intron J-K A G 135386 99-12781 A51 99-12781-113 Intron J-K A G 139389 4-104 A52 4-104-298 Intron J-K G C 157535 4-104 A53 4-104-254 Intron J-K A G 157579 4-104 A54 4-104-250 Intron J-K C T 157583 4-104 A55 4-104-214 Intron J-K A G 157619 99-12818 A56 99-12818-289 Intron J-K C T 172980 99-24807 A57 99-24807-271 Intron J-K C T 180622 99-24807 A58 99-24807-84 Intron J-K A G 180809 99-12831 A59 99-12831-157 Intron J-K A G 190334 99-12831 A60 99-12831-241 Intron J-K C T 190418 99-12832 A61 99-12832-387 Intron J-K C T 191397 99-12836 A62 99-12836-30 Intron J-K G C 195128 99-12844 A63 99-12844-262 Intron J-K G C 203846 4-24 A64 4-24-74 Intron J-K C T 210151 4-24 A65 4-24-246 Intron J-K C T 210321 4-24 A66 4-24-314 Intron J-K G C 210389 4-27 A67 4-27-190 Intron J-K A G 211168 5-400 A68 5-400-145 Intron J-K A G 215996 5-400 A69 5-400-149 Intron J-K G C 216000 5-400 A70 5-400-175 Exon K C T 216026 2283 742 = S 5-400 A71 5-400-231 Exon K C T 216082 2339 761 = A or V 5-400 A72 5-400-367 Exon K A C 216218 2475 806 = A 99-12852 A73 99-12852-110 Intron K-L G T 216322 99-12852 A74 99-12852-325 Intron K-L A G 216537 4-37 A75 4-37-326 Intron K-L A C 221649 4-37 A76 4-37-107 Intron K-L A G 221867 5-270 A77 5-270-92 Intron K-L G C 225645 99-12860 A78 99-12860-47 Intron K-L A G 229387 99-12860 A79 99-12860-57 Intron K-L A T 229397 5-402 A80 5-402-144 Exon L C T 237555 2539 828 = P or S

[0870] BM refers to “biallelic marker”. All1 and all2 refer respectively to allele 1 and allele 2 of the biallelic marker. TABLE 3 Position range of probes BM Marker name in SEQ ID No 1 Probes A1  5-390-177 1987 2011 P1 A2  5-391-43 4589 4613 P2 A3  5-392-222 10216 10240 P3 A4  5-392-280 10274 10298 P4 A6  4-58-318 39932 39956 P6 A7  4-58-289 39961 39985 P7 A8  4-54-199 41373 41397 P8 A9  4-54-180 41392 41416 P9 A10  4-51-312 42220 42244 P10 A11 99-86-266 67463 67487 P11 A12  4-88-107 69509 69533 P12 A13  5-397-141 72826 72850 P13 A14  5-398-203 76048 76072 P14 A15 99-12738-248 81241 81265 P15 A16 99-109-358 83909 83933 P16 A17 99-12749-175 91905 91929 P17 A18  4-21-154 95337 95361 P18 A19  4-21-317 95499 95523 P19 A20  4-23-326 96178 96202 P20 A21 99-12753-34 97282 97306 P21 A22  5-364-252 98012 98036 P22 A23 99-12755-280 98902 98926 P23 A24 99-12755-329 98951 98975 P24 A25  4-87-212 103581 103605 P25 A26 99-12757-318 104386 104410 P26 A27 99-12758-102 106361 106385 P27 A28 99-12758-136 106395 106419 P28 A29  4-105-98 108303 108327 P29 A30  4-105-86 108315 108339 P30 A31  4-45-49 108460 108484 P31 A32  4-44-277 109184 109208 P32 A33  4-86-60 114592 114616 P33 A34  4-84-334 115704 115728 P34 A35 99-78-321 122071 122095 P35 A36 99-12767-36 123112 123136 P36 A37 99-12767-143 123219 123243 P37 A38 99-12767-189 123265 123289 P38 A39 99-12767-380 123456 123480 P39 A40  4-80-328 126726 126750 P40 A41  4-36-384 128198 128222 P41 A42  4-36-264 128318 128342 P42 A43  4-36-261 128321 128345 P43 A44  4-35-333 128582 128606 P44 A45  4-35-240 128675 128699 P45 A46  4-35-173 128742 128766 P46 A47  4-35-133 128782 128806 P47 A48 99-12771-59 130793 130817 P48 A49 99-12774-334 133194 133218 P49 A50 99-12776-358 135374 135398 P50 A51 99-12781-113 139377 139401 P51 A52  4-104-298 157523 157547 P52 A53  4-104-254 157567 157591 P53 A54  4-104-250 157571 157595 P54 A55  4-104-214 157607 157631 P55 A56 99-12818-289 172968 172992 P56 A57 99-24807-271 180610 180634 P57 A58 99-24807-84 180797 180821 P58 A59 99-12831-157 190322 190346 P59 A60 99-12831-241 190406 190430 P60 A61 99-12832-387 191385 191409 P61 A62 99-12836-30 195116 195140 P62 A63 99-12844-262 203834 203858 P63 A64  4-24-74 210139 210163 P64 A65  4-24-246 210309 210333 P65 A66  4-24-314 210377 210401 P66 A67  4-27-190 211156 211180 P67 A68  5-400-145 215984 216008 P68 A69  5-400-149 215988 216012 P69 A70  5-400-175 216014 216038 P70 A71  5-400-231 216070 216094 P71 A72  5-400-367 216206 216230 P72 A73 99-12852-110 216310 216334 P73 A74 99-12852-325 216525 216549 P74 A75  4-37-326 221637 221661 P75 A76  4-37-107 221855 221879 P76 A77  5-270-92 225633 225657 P77 A78 99-12860-47 229375 229399 P78 A79 99-12860-57 229385 229409 P79 A80  5-402-144 237543 237567 P80

Example 4 Validation of the Polymorphisms Through Microsequencing

[0871] The biallelic markers identified in example 3 were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each individual DNA sample described in Example 1.

[0872] Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 1).

[0873] The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of the considered polymorphic base. According to the invention, the primers used in microsequencing are detailed in Table 4. TABLE 4 Complementary Position range of position range of microsequencing microsequencing primer mis 1 in primer mis. 2 in Marker name BM Mis 1 SEQ ID No 1 Mis 2 SEQ ID No 1 5-390-177 A1 D1 1980 1998 E1 2000 2018 5-391-43 A2 D2 4582 4600 E2 4602 4620 5-392-222 A3 D3 10209 10227 E3 10229 10247 5-392-280 A4 D4 10267 10285 E4 10287 10305 4-58-318 A6 D6 39925 39943 E6 39945 39963 4-58-289 A7 D7 39954 39972 E7 39974 39992 4-54-199 A8 D8 41366 41384 E8 41386 41404 4-54-180 A9 D9 41385 41403 E9 41405 41423 4-51-312 A10 D10 42213 42231 E10 42233 42251 99-86-266 A11 D11 67456 67474 E11 67476 67494 4-88-107 A12 D12 69502 69520 E12 69522 69540 5-397-141 A13 D13 72819 72837 E13 72839 72857 5-398-203 A14 D14 76041 76059 E14 76061 76079 99-12738-248 A15 D15 81234 81252 E15 81254 81272 99-109-358 A16 D16 83902 83920 E16 83922 83940 99-12749-175 A17 D17 91898 91916 E17 91918 91936 4-21-154 A18 D18 95330 95348 E18 95350 95368 4-21-317 A19 D19 95492 95510 E19 95512 95530 4-23-326 A20 D20 96171 96189 E20 96191 96209 99-12753-34 A21 D21 97275 97293 E21 97295 97313 5-364-252 A22 D22 98005 98023 E22 98025 98043 99-12755-280 A23 D23 98895 98913 E23 98915 98933 99-12755-329 A24 D24 98944 98962 E24 98964 98982 4-87-212 A25 D25 103574 103592 E25 103594 103612 99-12757-318 A26 D26 104379 104397 E26 104399 104417 99-12758-102 A27 D27 106354 106372 E27 106374 106392 99-12758-136 A28 D28 106388 106406 E28 106408 106426 4-105-98 A29 D29 108296 108314 E29 108316 108334 4-105-86 A30 D30 108308 108326 E30 108328 108346 4-5-49 A31 D31 108453 108471 E31 108473 108491 4-44-277 A32 D32 109177 109195 E32 109197 109215 4-86-60 A33 D33 114585 114603 E33 114605 114623 4-84-334 A34 D34 115697 115715 E34 115717 115735 99-78-321 A35 D35 122064 122082 E35 122084 122102 99-12767-36 A36 D36 123105 123123 E36 123125 123143 99-12767-143 A37 D37 123212 123230 E37 123232 123250 99-12767-189 A38 D38 123258 123276 E38 123278 123296 99-12767-380 A39 D39 123449 123467 E39 123469 123487 4-80-328 A40 D40 126719 126737 E40 126739 126757 4-36-384 A41 D41 128191 128209 E41 128211 128229 4-36-264 A42 D42 128311 128329 E42 128331 128349 4-36-261 A43 D43 128314 128332 E43 128334 128352 4-35-333 A44 D44 128575 128593 E44 128595 128613 4-35-240 A45 D45 128668 128686 E45 128688 128706 4-35-173 A46 D46 128735 128753 E46 128755 128773 4-35-133 A47 D47 128775 128793 E47 128795 128813 99-12771-59 A48 D48 130786 130804 E48 130806 130824 99-12774-334 A49 D49 133187 133205 E49 133207 133225 99-12776-358 A50 D50 135367 135385 E50 135387 135405 99-12781-113 A51 D51 139370 139388 E51 139390 139408 4-104-298 A52 D52 157516 157534 E52 157536 157554 4-104-254 A53 D53 157560 157578 E53 157580 157598 4-104-250 A54 D54 157564 157582 E54 157584 157602 4-104-214 A55 D55 157600 157618 E55 157620 157638 99-12818-289 A56 D56 172961 172979 E56 172981 172999 99-24807-271 A57 D57 180603 180621 E57 180623 180641 99-24807-84 A58 D58 180790 180808 E58 180810 180828 99-12831-157 A59 D59 190315 190333 E59 190335 190353 99-12831-241 A60 D60 190399 190417 E60 190419 190437 99-12832-387 A61 D61 191378 191396 E61 191398 191416 99-12836-30 A62 D62 195109 195127 E62 195129 195147 99-12844-262 A63 D63 203827 203845 E63 203847 203865 4-24-74 A64 D64 210132 210150 E64 210152 210170 4-24-246 A65 D65 210302 210320 E65 210322 210340 4-24-314 A66 D66 210370 210388 E66 210390 210408 4-27-190 A67 D67 211149 211167 E67 211169 211187 5-400-145 A68 D68 215977 215995 E68 215997 216015 5-400-149 A69 D69 215981 215999 E69 216001 216019 5-400-175 A70 D70 216007 216025 E70 216027 216045 5-400-231 A71 D71 216063 216081 E71 216083 216101 5-400-367 A72 D72 216199 216217 E72 216219 216237 99-12852-110 A73 D73 216303 216321 E73 216323 216341 99-12852-325 A74 D74 216518 216536 E74 216538 216556 4-37-326 A75 D75 221630 221648 E75 221650 221668 4-37-107 A76 D76 221848 221866 E76 221868 221886 5-270-92 A77 D77 225626 225644 E77 225646 225664 99-12860-47 A78 D78 229368 229386 E78 229388 229406 99-12860-57 A79 D79 229378 229396 E79 229398 229416 5-402-144 A80 D80 237536 237554 E80 237556 237574

[0874] Mis 1 and Mis 2 respectively refer to microsequencing primers which hybridized with the non-coding strand of the PG-3 gene or with the coding strand of the PG-3 gene.

[0875] The microsequencing reaction was performed as follows:

[0876] After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20 μl final volume: 10 pmol microsequencing oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 μl Thermosequenase buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl₂), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94° C., 20 PCR cycles of 15 sec at 55° C., 5 sec at 72° C., and 10 sec at 94° C. were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95° C. before being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

[0877] Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

[0878] The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is categorized classification as homozygous or heterozygous type based on the height ratio.

Example 5 Preparation of Antibody Compositions to the PG-3 Protein

[0879] Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the PG-3 protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

[0880] A. Monoclonal Antibody Production by Hybridoma Fusion

[0881] Monoclonal antibody to epitopes in the PG-3 protein or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., (1975) or derivative methods thereof. Also see Harlow, E., and D. Lane. 1988.

[0882] Briefly, a mouse is repetitively inoculated with a few micrograms of the PG-3 protein or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. (1986).

[0883] B. Polyclonal Antibody Production by Immunization

[0884] Polyclonal antiserum containing antibodies to heterogeneous epitopes in the PG-3 protein or a portion thereof can be prepared by immunizing suitable non-human animal with the PG-3 protein or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-human animal is preferably a non-human mammal is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been enriched for PG-3 concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

[0885] Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. (1971).

[0886] Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μM). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., (1980).

[0887] Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

[0888] While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein by the one skilled in the art without departing from the spirit and scope of the invention.

References

[0889] Abbondanzo S J et al., 1993, Methods in Enzymology, Academic Press, New York, pp 803-823

[0890] Ajioka R. S. et al., Am. J. Hum. Genet., 60:1439-1447, 1997

[0891] Altschul et al., 1990, J. Mol. Biol. 215(3):403-410

[0892] Altschul et al., 1993, Nature Genetics 3:266-272

[0893] Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402

[0894] Ames et al., (1995), J. Immunol. Meth. 184:177-186.

[0895] Anton M. et al., 1995, J. Virol., 69:4600-4606

[0896] Araki K et al. (1995) Proc. Natl. Acad. Sci. USA. 92(1):160-4.

[0897] Arnheim N & Shibata D, Curr. Op. Genetics & Development, 1997, 7:364-370

[0898] Ashkenazi et al., (1991), Proc. Natl. Acad. Sci. USA 88:10535-10539.

[0899] Aszódi et al., Proteins:Structure, Function, and Genetics, Supplement 1:3842 (1997)

[0900] Attwood et al., (1996) Nucleic Acids Res. 24(1):182-8.

[0901] Attwood et al., (2000) Nucleic Acids Res. 28(1):225-7

[0902] Ausubel et al. (1989) Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

[0903] Bateman et al., (2000) Nucleic Acids Res. 28(1):263-6

[0904] Baubonis W. (1993) Nucleic Acids Res. 21(9):2025-9.

[0905] Beaucage et al., Tetrahedron Lett 1981, 22: 1859-1862

[0906] Better et al., (1988), Science. 240:1041-1043.

[0907] Bittle et al., (1985), Virol. 66:2347-2354.

[0908] Bochar et al., (2000) Cell 102:257-265

[0909] Bowie et al., (1994), Science. 247:1306-1310.

[0910] Bradley A., 1987, Production and analysis of chimaeric mice. In: E. J. Robertson (Ed.), Teratocarcinomas and embryonic stem cells: A practical approach. IRL Press, Oxford, pp. 113.

[0911] Bram R J et al., 1993, Mol. Cell Biol., 13: 4760-4769

[0912] Brinkman et al., (1995) J. Immunol Methods. 182:41-50.

[0913] Brown E L, Belagaje R, Ryan M J, Khorana H G, Methods Enzymol 1979;68:109-151

[0914] Brutlag et al. Comp. App. Biosci. 6:237-245, 1990

[0915] Bucher and Bairoch (1994) Proceedings 2nd International Conference on Intelligent Systems for Molecular Biology. Altman et al, Eds., pp53-61, AAAIPress, Menlo Park.

[0916] Burton et al. (1994), Adv. Immunol. 57:191-280

[0917] Bush et al., 1997, J. Chromatogr., 777:311-328.

[0918] Chai H. et al. (1993) Biotechnol. Appl. Biochem. 18:259-273.

[0919] Chee et al. (1996) Science. 274:610-614.

[0920] Chen and Kwok Nucleic Acids Research 25:347-353 1997

[0921] Chen et al. (1987) Mol. Cell. Biol. 7:2745-2752.

[0922] Chen et al. Proc. Natl. Acad. Sci. USA 94/20 10756-10761,1997

[0923] Cho R J et al., 1998, Proc. Natl. Acad. Sci. USA, 95(7): 3752-3757.

[0924] Chou J. Y., 1989, Mol. Endocrinol., 3: 1511-1514.

[0925] Chow et al., (1985), Proc. Natl. Acad. Sci. USA. 82:910-914.

[0926] Clark A. G. (1990) Mol. Biol. Evol. 7:111-122.

[0927] Cleland et al., (1993), Crit. Rev. Therapeutic Drug Carrier Systems. 10:307-377.

[0928] Coles R, Caswell R, Rubinsztein D C, Hum Mol Genet 1998;7:791-800

[0929] Compton J. (1991) Nature. 350(6313):91-92.

[0930] Corpet et al. (2000) Nucleic Acids Res. 28(1):267-9

[0931] Creighton (1983), Proteins: Structures and Molecular Principles, W. H. Freeman & Co. 2nd Ed., T. E., New York

[0932] Creighton, (1993) , Posttranslational Covalent Modification of Proteins, W. H. Freeman and Company, New York B. C. Johnson, Ed., Academic Press, New York 1-12

[0933] Cunningham et al. (1989), Science 244:1081-1085.

[0934] Davis L. G., M. D. Dibner, and J. F. Battey, Basic Methods in Molecular Biology, ed., Elsevier Press, NY, 1986

[0935] Dempster et al., (1977) J. R. Stat. Soc., 39B:1-38.

[0936] Dent D S & Latchman D S (1993) The DNA mobility shift assay. In: Transcription Factors: A Practical Approach (Latchman D S, ed.) pp 1-26. Oxford: IRL Press

[0937] Eckner R. et al. (1991) EMBO J 10:3513-3522.

[0938] Edwards et Leatherbarrow, Analytical Biochemistry, 246, 1-6 (1997)

[0939] Ellis N A, 1997, Curr. Op. Genet. Dev. 7:.354-363

[0940] Emi M, et al., Cancer Res. 1992 Oct. 1; 52(19): 5368-5372

[0941] Engvall, E., Meth. Enzymol. 70:419 (1980)

[0942] Excoffier L. and Slatkin M. (1995) Mol. Biol. Evol., 12(5): 921-927.

[0943] Fanger G R et al., 1997 Curr. Op. Genet. Dev. 7:67-74

[0944] Feldman and Steg, 1996, Medecine/Sciences, synthese, 12:47-55

[0945] Felici F., 1991, J. Mol. Biol., Vol. 222:301-310

[0946] Fell et al., (1991), J. Immunol. 146:2446-2452.

[0947] Fields and Song, 1989, Nature, 340 : 245-246

[0948] Fishel R & Wilson T. 1997, Curr. Op. Genet. Dev. 7: 105-113;

[0949] Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980)

[0950] Flotte et al. (1992) Am. J. Respir. Cell Mol. Biol. 7:349-356.

[0951] Fodor et al. (1991) Science 251:767-777.

[0952] Fountoulakis et al., (1995) Biochem. 270:3958-3964.

[0953] Fraley et al. (1979) Proc. Natl. Acad. Sci. USA. 76:3348-3352.

[0954] Fried M, Crothers D M, Nucleic Acids Res 1981;9:6505-6525

[0955] Fromont-Racine M. et al., 1997, Nature Genetics, 16(3): 277-282.

[0956] Fuller S. A. et al. (1996) Immunology in Current Protocols in Molecular Biology, Ausubel et al. Eds, John Wiley & Sons, Inc., USA.

[0957] Furth P. A. et al. (1994) Proc. Natl. Acad. Sci USA. 91:9302-9306.

[0958] Garner M M, Revzin A, Nucleic Acids Res 1981;9:3047-3060

[0959] Geysen H. Mario et al. 1984. Proc. Natl. Acad. Sci. U.S.A. 81:3998-4002

[0960] Ghosh and Bacchawat, 1991, Targeting of liposomes to hepatocytes, IN: Liver Diseases, Targeted diagnosis and therapy using specific rceptors and ligands. Wu et al. Eds., Marcel Dekeker, New York, pp. 87-104.

[0961] Gillies et al., (1989), J. Immunol Methods. 125:191-202.

[0962] Gillies et al., (1992), Proc Natl Acad Sci U S A 89:1428-1432.

[0963] Gonnet et al., 1992, Science 256:1443-1445

[0964] Gopal (1985) Mol. Cell. Biol., 5:1188-1190.

[0965] Gossen M. et al. (1992) Proc. Natl. Acad. Sci. USA. 89:5547-5551.

[0966] Gossen M. et al. (1995) Science. 268:1766-1769.

[0967] Graham et al. (1973) Virology 52:456-457.

[0968] Green et al., Ann. Rev. Biochem. 55:569-597 (1986)

[0969] Griffais et al., (1991) Nucleic Acids Res. 19: 3887-3891

[0970] Griffin et al. Science 245:967-971 (1989)

[0971] Grompe, M. (1993) Nature Genetics. 5:111-117.

[0972] Grompe, M. et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:5855-5892.

[0973] Gronwald J, et al., Cancer Res. 1997 Feb. 1; 57(3): 481-487

[0974] Gu H. et al. (1993) Cell 73:1155-1164.

[0975] Gu H. et al. (1994) Science 265:103-106.

[0976] Guatelli J C et al. (1990) Proc. Natl. Acad. Sci. USA. 35:273-286.

[0977] Haber D & Harlow E, 1997, Nature Genet. 16:320-322

[0978] Hacia J G, Brody L C, Chee M S, Fodor S P, Collins F S, Nat Genet 1996;14(4):441-447

[0979] Haff L. A. and Smirnov I. P. (1997) Genome Research, 7:378-388.

[0980] Hames B. D. and Higgins S. J. (1985) Nucleic Acid Hybridization. A Practical Approach. Hames and Higgins Ed., IRL Press, Oxford.

[0981] Hammerling (1981), Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y. 563-681.

[0982] Hansson et al., (1999), J. Mol. Biol. 287:265-276.

[0983] Haravama (1998), Trends Biotechnol. 16(2): 76-82.

[0984] Harju L, Weber T, Alexandrova L, Lukin M, Ranki M, Jalanko A, Clin Chem 1993;39(11Pt 1):2282-2287

[0985] Harland et al. (1985) J. Cell. Biol. 101:1094-1095.

[0986] Harlow, E., and D. Lane. 1988. Antibodies A Laboratory Manual. Cold Spring Harbor Laboratory. pp. 53-242

[0987] Harper J W et al., 1993, Cell, 75:805-816

[0988] Harris H et al., 1969, Nature 223:363-368

[0989] Hawley M. E. et al. (1994) Am. J. Phys. Anthropol. 18:104.

[0990] Henikoff and Henikoff, 1993, Proteins 17:49-61

[0991] Henikoff et al., (2000) Electrophoresis 21(9): 1700-6

[0992] Henikoff et al., (2000) Nucleic Acids Res. 28(1):228-30

[0993] Higgins et al., 1996, Methods Enzymol. 266:383-402

[0994] Hillier L. and Green P. Methods Appl., 1991, 1: 124-8.

[0995] Hoess et al. (1986) Nucleic Acids Res. 14:2287-2300.

[0996] Hofmann et al., (1999) Nucl. Acids Res. 27:215-219;

[0997] Holm and Sander (1996) Nucleic Acids Res. 24(1):206-9

[0998] Holm and Sander (1997) Nucleic Acids Res. 25(1):231-4

[0999] Holm and Sander (1999) Nucleic Acids Res. 27(1):244-7

[1000] Hoppe et al., (1 994), FEBS Letters. 344:191.

[1001] Houghten (1985), Proc. Natl. Acad. Sci. USA 82:5131-5135.

[1002] Huang L. et al. (1996) Cancer Res 56(5):1137-1141.

[1003] Hunkapiller et al., (1984) Nature. 310(5973): 105-11.

[1004] Hunter T, 1991 Cell 64:249

[1005] Huston et al., (1991), Meth. Enymol. 203:46_(—)88.

[1006] Huygen et al. (1996) Nature Medicine. 2(8):893-898.

[1007] Ichikawa T, et al., Prostate Suppl. 1996; 6: 31-35

[1008] Ishwad C S, et al., Int. J. Cancer. 1999 Jan 5; 80(1): 25-31

[1009] Izant J G, Weintraub H, Cell 1984 April;36(4):1007-15

[1010] Jameson and Wolf, (1988), Comp. Appl. Biosci. 4:181-186

[1011] Julan et al. (1992) J. Gen. Virol. 73:3251-3255.

[1012] Kanegae Y. et al., Nucl. Acids Res. 23:3816-3821(1995).

[1013] Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268

[1014] Kettleborough et al., (1994), Eur. L Immunol. 24:952-958.

[1015] Khoury J. et al., Fundamentals of Genetic Epidemiology, Oxford University Press, NY, 1993

[1016] Kim U-J. et al. (1996) Genomics 34:213-218.

[1017] Klein et al. (1987) Nature. 327:70-73.

[1018] Kohler, G. and Milstein, C., Nature 256:495 (1975)

[1019] Koller et al. Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989)

[1020] Koller et al. (1992) Annu. Rev. Immunol. 10:705-730.

[1021] Kostelny et al., (1992), J. Immunol. 148:1547-1553.

[1022] Kozal M J, Shah N, Shen N, Yang R, Fucini R, Merigan T C, Richman D D, Morris D, Hubbell E, Chee M, Gingeras T R, Nat Med 1996;2(7):753-759

[1023] Landegren U. et al. (1998) Genome Research, 8:769-776.

[1024] Lander and Schork, Science, 265, 2037-2048, 1994

[1025] Landschulz et al., (1988), Science. 240:1759.

[1026] Lange K. (1997) Mathematical and Statistical Methods for Genetic Analysis. Springer, New York.

[1027] Lenhard T. et al. (1996) Gene. 169:187-190.

[1028] Lewin, (1989), Proc. Natl. Acad. Sci. USA 86:9832-8935.

[1029] Linton M. F. et al. (1993) J. Clin. Invest. 92:3029-3037.

[1030] Liu Z. et al. (1994) Proc. Natl. Acad. Sci. USA. 91: 4528-4262.

[1031] Livak et al., Nature Genetics, 9:341-342, 1995

[1032] Livak K J, Hainer J W, Hum Mutat 1994;3(4):379-385

[1033] Lockhart et al. Nature Biotechnology 14: 1675-1680, 1996

[1034] Lo Conte et al., (2000) Nucleic Acids Res. 28(1):257-9.

[1035] Lorenzo and Blasco (1998) Biotechniques. 24(2):308-313.

[1036] Lucas A. H., 1994, In : Development and Clinical Uses of Haempophilus b Conjugate;

[1037] Malik et al., (1992), Exp. Hematol. 20:1028-1035.

[1038] Mansour S. L. et al. (1988) Nature. 336:348-352.

[1039] Marshall R. L. et al. (1994) PCR Methods and Applications. 4:80-84.

[1040] Matsuyama H, et al., Oncogene 1994 October; 9(10): 3071-3076

[1041] McCormick et al. (1994) Genet. Anal. Tech. Appl. 11:158-164.

[1042] McLaughlin B. A. et al. (1996) Am. J. Hum. Genet. 59:561-569.

[1043] Morton N. E., Am. J. Hum. Genet., 7:277-318, 1955

[1044] Mullinax et al., (1992), BioTechniques. 12(6):864-869.

[1045] Murvai et al., (2000) Nucleic Acids Res. 28(1):260-2

[1046] Murzin et al., (1 995) J Mol Biol. 247(4):536-40

[1047] Muzyczka et al. (1992) Curr. Topics in Micro. and Immunol. 158:97-129.

[1048] Nada S. et al. (1993) Cell 73:1125-1135.

[1049] Nagai H, et al., Oncogene 1997 Jun. 19; 14(24): 2927-2933

[1050] Nagy A. et al., 1993, Proc. Natl. Acad. Sci. USA, 90: 8424-8428.

[1051] Narang S A, Hsiung H M, Brousseau R, Methods Enzymol 1979;68:90-98

[1052] Naramura et al., (1994), Immunol. Lett. 39:91-99.

[1053] Neda et al. (1991) J. Biol. Chem. 266:14143-14146.

[1054] Nevill-Manning et al., (1998) Proc. Natl. Acad. Sci. USA. 95, 5865-5871

[1055] Newton et al. (1989) Nucleic Acids Res. 17:2503-2516.

[1056] Nickerson D. A. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:8923-8927.

[1057] Nicolau C. et al., 1987, Methods Enzymol., 149:157-76.

[1058] Nicolau et al. (1982) Biochim. Biophys. Acta. 721:185-190.

[1059] Nyren P, Pettersson B, Uhlen M, Anal Biochem 1993;208(1):171-175

[1060] O'Reilly et al. (1992) Baculovirus Expression Vectors: A Laboratory Manual. W. H. Freeman and Co., New York.

[1061] Ohno et al. (1994) Science. 265:781-784.

[1062] Oi et al., (1986), BioTechniques 4:214.

[1063] Oldenburg K. R. et al., 1992, Proc. Natl. Acad. Sci., 89:5393-5397.

[1064] Orengo et al., (1997) Structure. 5(8):1093-108

[1065] Orita et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86: 2776-2770.

[1066] Ott J., Analysis of Human Genetic Linkage, John Hopkins University Press, Baltimore, 1991

[1067] Ouchterlony, O. et al., Chap. 19 in: Handbook of Experimental Immunology D. Wier (ed) Blackwell (1973)

[1068] Padlan, (1991), Molec. Immunol. 28(4/5):489-498.

[1069] Parmley and Smith, Gene, 1988, 73:305-318

[1070] Pastinen et al., Genome Research 1997; 7:606-614

[1071] Patten, et al. (1997), Curr Opinion Biotechnol. 8:724-733.

[1072] Pearl et al., (2000) Biochem Soc Trans. 28(2):269-75

[1073] Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-2448

[1074] Pease S. ans William R. S., 1990, Exp. Cell. Res., 190: 209-211.

[1075] Perinchery G, et al., Int. J. Oncol. 1999 Mar; 14(3): 495-500

[1076] Perlin et al. (1994) Am. J Hum. Genet. 55:777-787.

[1077] Persic et al., (1997), Gene. 1879-81

[1078] Peterson et al., 1993, Proc. Natl. Acad. Sci. USA, 90: 7593-7597.

[1079] Pietu et al. Genome Research 6:492-503, 1996

[1080] Pinckard et al., (1967), Clin. Exp. Immunol 2:331-340.

[1081] Pineau P, et al., Oncogene 1999 May 20; 18(20): 3127-3134

[1082] Pongor et al. (1993) Protein Eng. 6(4):391-5

[1083] Potter et al. (1984) Proc. Natl. Acad. Sci. U.S.A. 81(22):7161-7165.

[1084] Ramunsen et al., 1997, Electrophoresis, 18 : 588-598.

[1085] Reid L. H. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:4299-4303.

[1086] Risch, N. and Merikangas, K. (Science, 273:1516-1517, 1996

[1087] Robbins et al., (1987), Diabetes. 36:838-845.

[1088] Robertson E., 1987, Embryo-derived stem cell lines. In: E. J. Robertson Ed. Teratocarcinomas and embrionic stem cells: a practical approach. IRL Press, Oxford, pp. 71.

[1089] Roguska et al., (1994), Proc. Natl. Acad. Sci. U.S.A. 91:969-973.

[1090] Ron et al., (1993), Biol Chem., 268 2984-2988.

[1091] Rossi et al., Pharmacol. Ther. 50:245-254, (1991)

[1092] Roth J. A. et al. (1996) Nature Medicine. 2(9):985-991.

[1093] Roux et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:9079-9083.

[1094] Ruano et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:6296-6300.

[1095] Sakabe T, et al., Cancer Res. 1999 Feb. 1; 59(3): 511-515

[1096] Sakakura C, et al., Genes Chromosomes Cancer 1999 April; 24(4): 299-305

[1097] Sambrook, J., Fritsch, E. F., and T. Maniatis. (1989) Molecular Cloning: A Laboratory Manual. 2ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

[1098] Samson M, et al. (1996) Nature, 382(6593):722-725.

[1099] Samulski et al. (1989) J. Virol. 63:3822-3828.

[1100] Sanchez-Pescador R. (1988) J. Clin. Microbiol. 26(10):1934-1938.

[1101] Sander and Schneider (1991) Proteins. 9(1):56-68.)

[1102] Sarkar, G. and Sommer S. S. (1991) Biotechniques.

[1103] Sauer B. et al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85:5166-5170.

[1104] Sawai et al., (1995), AJRI 34:26-34.

[1105] Schaid D. J. et al., Genet. Epidemiol., 13:423-450, 1996

[1106] Schedl A. et al., 1993a, Nature, 362: 258-261.

[1107] Schedl et al., 1993b, Nucleic Acids Res., 21: 4783-4787.

[1108] Schena et al. Science 270:467470, 1995

[1109] Schena et al., 1996, Proc Natl Acad Sci USA, 93(20):10614-10619.

[1110] Schneider et al. (1997) Arlequin. A Software For Population Genetics Data Analysis. University of Geneva.

[1111] Scholnick S B, et al., J. Natl. Cancer Inst. 1996 Nov. 20; 88(22): 1676-1682

[1112] Schultz et al., (1998) Proc Natl Acad Sci USA 95, 5857-5864

[1113] Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation

[1114] Sczakiel G. et al. (1995) Trends Microbiol. 3(6):213-217.

[1115] Shay J. W. et al., 1991, Biochem. Biophys. Acta, 1072: 1-7.

[1116] Sheffield, V. C. et al. (1991) Proc. Natl. Acad. Sci. U.S.A. 49:699-706.

[1117] Shizuya et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:8794-8797.

[1118] Shoemaker D D, et al., Nat Genet 1996;14(4):450-456

[1119] Shu et al., (1993), Proc. Natl. Acad. Sci. U.S.A. 90:7995-7999.

[1120] Skerra et al., (1988), Science 240:1038-1040.

[1121] Smith (1957) Ann. Hum. Genet. 21:254-276.

[1122] Smith et al. (1983) Mol. Cell. Biol. 3:2156-2165.

[1123] Sonnhammer and Kahn D (1994) Protein Sci. 3(3):482-92

[1124] Sonnhammer et al., (1997) Proteins. 28(3):405-20

[1125] Sosnowski R G, et al., Proc Natl Acad Sci USA 1997;94:1119-1123

[1126] Sowdhamini et al., Protein Engineering 10:207, 215 (1997)

[1127] Spielmann S. and Ewens W. J., Am. J. Hum. Genet., 62:450-458, 1998

[1128] Spielmann S. et al., Am. J. Hum. Genet., 52:506-516, 1993

[1129] Sternberg N. L. (1994) Mamm. Genome. 5:397-404.

[1130] Sternberg N. L. (1992) Trends Genet. 8:1-16.

[1131] Studnicka et al., (1994), Protein Engineering. 7(6):805-814.

[1132] Stryer, L., Biochemistry, 4th edition, 1995, W. H Freeman & Co., New York.

[1133] Sunwoo J B, et al., Genes Chromosomes Cancer 1996 July; 16(3):164-169

[1134] Sunwoo J B, et al., Oncogene 1999 Apr. 22; 18(16):2651-2655

[1135] Sutcliffe et al., (1983), Science. 219:660-666.

[1136] Syvanen A C, Clin Chim Acta 1994;226(2):225-236

[1137] Szabo A. et al. Curr Opin Struct Biol 5, 699-705 (1995)

[1138] Tacson et al. (1996) Nature Medicine. 2(8):888-892.

[1139] Tatusov et al., (1997) Science, 278, 631:637

[1140] Tatusov et al., (2000) Nucleic Acids Res. 28(1):33-6.)

[1141] Te Riele et al. (1990) Nature. 348:649-651.

[1142] Terwilliger J. D. and Ott J., Handbook of Human Genetic Linkage, John Hopkins University Press, London, 1994

[1143] Thomas K. R. et al. (1986) Cell. 44:419-428.

[1144] Thomas K. R. et al. (1987) Cell. 51:503-512.

[1145] Thompson et al., 1994, Nucleic Acids Res. 22(2):4673-4680

[1146] Traunecker et al., (1988), Nature. 331:84-86.

[1147] Tur-Kaspa et al. (1986) Mol. Cell. Biol. 6:716-718.

[1148] Tutt et al., (1991), J. Immunol. 147:60-69.

[1149] Tyagi et al. (1998) Nature Biotechnology. 16:49-53.

[1150] Urdea M. S. (1988) Nucleic Acids Research. 11:4937-4957.

[1151] Urdea M. S. et al. (1991) Nucleic Acids Symp. Ser. 24:197-200.

[1152] Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991(1971)

[1153] Valadon P., et al., 1996, J. Mol. Biol., 261:11-22.

[1154] Van der Lugt et al. (1991) Gene. 105:263-267.

[1155] Vil et al., (1992) Proc Natl Acad Sci US 89:11337-11341.

[1156] Vlasak R. et al. (1983) Eur. J. Biochem. 135:123-126.

[1157] Wabiko et al. (1986) DNA. 5(4):305-314.

[1158] Walker et al. (1996) Clin. Chem. 42:9-13.

[1159] Wang et al., 1997, Chromatographia, 44: 205-208.

[1160] Washbum J, Woino K, and Macoska J, Proceedings of American Association for Cancer Research, March 1997; 38

[1161] Weir, B. S. (1996) Genetic data Analysis II: Methods for Discrete population genetic Data, Sinauer Assoc., Inc., Sunderland, Mass., U.S.A.

[1162] Weiss F U et al., 1997 Curr. Op. Genet. Dev. 7:80-86

[1163] Westerink M. A. J., 1995, Proc. Natl. Acad. Sci., 92:4021-4025

[1164] White, M. B. et al. (1992) Genomics. 12:301-306.

[1165] Wilson et al., (1984) Cell. 37(3):767-78.

[1166] Wong et al. (1980) Gene. 10:87-94.

[1167] Wood S. A. et al., 1993, Proc. Natl. Acad. Sci. USA, 90:4582-4585.

[1168] Wright K, et al., Oncogene 1998 Sep. 3; 17(9): 1185-1188

[1169] Wu and Wu (1987) J. Biol. Chem. 262:4429-4432.

[1170] Wu and Wu (1988) Biochemistry. 27:887-892.

[1171] Wu et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:2757.

[1172] Yagi T. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:9918-9922.

[1173] Yaremko M L, et al., Genes Chromosomes Cancer 1994 May; 10(1):1-6

[1174] Yona et al., (1999) Proteins. 37(3):360-78

[1175] Zhao et al., Am. J. Hum. Genet., 63:225-240, 1998

[1176] Zheng, X. X. et al. (1995), J. Immunol. 154:5590-5600.

[1177] Zou Y. R. et al. (1994) Curr. Biol. 4:1099-1103.

Sequence Listing Free Text

[1178] The following free text appears in the accompanying Sequence Listing:

[1179] 5′ regulatory region

[1180] 3′ regulatory region

[1181] polymorphic base

[1182] or

[1183] complement

[1184] probe

[1185] sequencing oligonucleotide primer

[1186] insertion of

[1187] exon

1 5 1 240825 DNA Homo sapiens misc_feature 1..2000 5′regulatory region 1 tctccccaaa ttcatctgta gagtcaacac aatctcaatc aaaatcccag cagtattttt 60 ttgtgcaaaa tgagaagtcg actctaagat ttaaaatgaa atctgaagaa tctagaagat 120 acaaaataac cttgaaaaat aaagttgtag gacataaact atctgatttc atcacttatt 180 tataagctac aataatcaaa acagcatggt gctggcagca aaaagacaaa tagctcaatg 240 gaacacaata ggaagcctaa aatgaaacac atacatatgc aacacagatt ttgatgtaag 300 cacaaaggaa atgcagtaga gacaaaaata actttttaat aaatgatgct ggaacatttg 360 gatatgtata catgcaaaaa aatgaacttt ggtccctatc ccataccgta tacaaaaatt 420 aattaaaagc agatcttatc ctttgagtcc agtaggttga ggctgcagtg agctgtgatt 480 acaccactgc attccagcct gggcaacgga gtgagaacct gcctggagaa aaaaaaaaaa 540 aagtagaacc tagacctgat atacaaccta aagcagtaat atttctagaa gaaatcctag 600 gagaaaatat ttgtgatcgt ggagatgaag aatctatcaa atactaaact ttttttacca 660 ccttgaccaa aagtaattgg tttatatact tcatcatatc atttaattct aaatctacag 720 agatcaatgt cactttctca gtaaaagtac gtgagtcttc aatgatgccc tgaactcaca 780 ctcccaagta aaccataaca ccatatttcc agagtagagt ttattagaac aataactggt 840 gataatgata aatattgatc aaagactgag cctaggaagt gggttttttg aggctgcata 900 tactcaaggc aattcttcag aaccacagag ggctcattgg atcctattaa aagctgagag 960 ttaatgaata aacagataaa acagagacct gagtagacgg tagtcgatat tcttgtacat 1020 gtattctacc tctagattcc atagaaagaa ctaaaagtac atgaatttca ctaccaacat 1080 ctccatcagt taccagctgt atcaccttgg atcagtcagg taacctcccg cgaatttgct 1140 tccggggcag gggatcgcgc tgcaggtttg agcctgggag ccggcagggt ggagcagttg 1200 gagggccaag cctttgagct ccaggggggg tggccgggac agtgggtagt gccagccgat 1260 cggcgtcctg gggattgcct gaatgtgagg tctgggttca ccccgcggtg acctgagtcc 1320 tgggatgccc ctacagtgat ttgctgcctc agggatccga agtctctttc attcccttac 1380 tggggatttg aggtctggag gtactcctgc gggggtctga gatctcgggg tcaccctgtg 1440 ggggtctgaa gcctcgggtc cccgctgggg tctgaggtat cagagtcccc tccgttgggt 1500 ctgaggtctc ggggtccccc atccccggga tcggaggtcc ggctccccgg agcaggcagg 1560 gcggtgcgtc tggccctgac agtaacgtgg cgcgccagcc ccaggtggtg tcgggctagg 1620 ggggcataac ggtgccgaaa gtccgcacaa agccgtccgc tggggtcccg ccgcgcccgc 1680 gaggcaatga ctgtgccccc tccccttcct gatcctcagc tcaggtgagc ccagatgagg 1740 cgccgggtag cttctaagtc actaatggaa atagaaggct aattcagggg ttaggggccg 1800 tcgtccttct tactcgcagg agaagagaaa aacccacggc ccagcagcca gaggcgcggc 1860 gaggcggaat cgggccccct ccccgggggc tcagctccct ccagcctccc gcctcaccta 1920 cagagaaatc ccggaaacgc ggattcagcg gagcgcggtg acggcggcgc gctcaccccg 1980 cgcatgccca gtgcccgcsc gcgccgccag gctcgcaagc accgcgtagg ccagctggcc 2040 ggatcccgcc gtctgtcatg gcggccccca tcctgaaagg tgaggtactt cctgctgcct 2100 gctccagcag cgggagtttg aggaccggca cccctcgtcg cgggcgcact cgggggatcc 2160 cgtgggagga gccccgctcg cccctccctc gctgcctgtc tcccccagac cccctgccgc 2220 ctccttcctc ccccgctgcc tgtcccccca aaacccccgg ctgcctgctt cgtctcccgt 2280 gctccctgtc cccccaaacc cccgactgcc tgcttcctcc cccgtactgc ttgtgcccca 2340 acccccgtgc tgctagttcc cctcaatccc ccgctgcctg ctccctcccc catgctgcct 2400 gtcccccaaa tcccgccttt ccccctacct gctttcaccc ctgctgcctt agtccctgga 2460 tctggggctc actggcaggc agagtcctgc cctccggaag ttggtgtggg gccctcctgg 2520 gtctggtcct gttcgacccc ctctgaggcc cacctggagg agcggcagtt gagtttctat 2580 gctaattgtt ccaataatag gagccgcctt ttactgcgga gtctttgtgt gccaggcgct 2640 gtgcttaggc tagtatggta ttgtctgatt tttttaaccg ctctatcaac tctcttatat 2700 cattgtacag gcagaaacta aggcattgga cgtttaggtg actctccctg tgtgtggcta 2760 gtcagtgctg acagggcctt agaccggagc tgctgtccta accagtatat gataccgcac 2820 gcagtcccac cctctgtgca cctggaagag cccaggagag gggaatagcg gacacgtgtc 2880 ttgtagagtt tgaccgtgag aaaaaagggg cctgtattgt ggggcctgca gtcataaaac 2940 ctcatagcca aaagtaaaga ctagaggctt tatacaaagt ctgtaatcag atgtggctat 3000 ttttctaatg ttagtatttt gttaaattaa cctggttttc ttttagcgtt acccccaatc 3060 attgaccaac ggcacacctg gaaaatgctt ttaaacatca ggttttgaga agaggatatc 3120 cactagaaca ggggtccact cactatgccc cccaggccat atctagcctg ctgcctgttt 3180 ttgtaagggt ctacgagcta agaatgtctt ttacattttt aagtgatttt aaaaaaaggt 3240 caaatgaaaa attatatcac attcacattt ccttctccat aaataaagtt ttattggaac 3300 acaggccggc ccgttaatat attacctatg gttatgtttg tgccacaacc gtgaagttga 3360 gtagttgtgg caaatactgt attggccaca aagcctgaaa tatttaccat ctgtctcttt 3420 acagaaaata ggtttctgca ctggaaaaat taagcgtaag aatttgggga aagcaactaa 3480 ttttacaaat gtaaactctc atgtattgta tgggtacagt tgttctttgc ttaaaatttt 3540 aataaattcc actgaagcta ttttgaaaag gctttcagta gaaatttatt tatgagacag 3600 agtcttactc tcttgcccag gctggagcgc agtgatgtga tcacataata gctcaagcaa 3660 ttctgcttca gcctcctgag taacttggga ctacaggcac taccatgccc ggttattttt 3720 atttttattt tttagtttat tatttttttg tagagccagg gtctcactat gttgcctagg 3780 ctggtcttga attcctagcc tcaagcaatc ctcccgcctc caccttgcaa aatgctggga 3840 ttacaggcat gagctacttt gttcagccag tagaagaaac ttcatttact tttcttattt 3900 ttgaggcaag gtctttctct gctgcccagg ctggagtgca atggtgcgat cataactcag 3960 cttctacctc ctgggctcta gggattctcc cacctcagct tctccaccct acccaccccc 4020 atttcccacc cagtagctgg gactacagcc actcgccacc attcctggct aattaaaaac 4080 aaaatttttt ttagagacag ggtttcacta tgttgcccag gctggtctca aactcctgtg 4140 cccaagtgat cccactgcct tggccttcca gagtgctgca attacagcat gagccaccac 4200 acctggccag tagagtaaat ttttgtttta cttttttctt ttttttattt ttgaaacggg 4260 tctcgccctg tcacccaggc tggagtgcaa tggcgcaatc tcggctcact gcaacctctg 4320 cctcccgggt tcaagtgatt ctcctgcctc agcctcccag tagctgggat tacaggtgcc 4380 cgccaccatg ctcggctaat tttttgtatc ttttagtaga gatggttttt caccatgttg 4440 gcccggctgg tctcaaaccc ctgacttcgt ggatccaccc acttccgcct cccacagtgc 4500 tgggattaca ggcgtgagcc actgtgccgg cctcggttta ctcttaaatg taaatagaac 4560 aaaatctatt gggcagggga tgctggaatt tcaaatgtat rtttcatgtt catatcttgt 4620 tttcagatgt agtggcctat gttgaagtgt ggtcatccaa tggaacagaa aattattcaa 4680 agacatttac aacacagctt gtggatatgg gggcaaaggt aagacactta ttttgctgtt 4740 gattcatatg acagtcttct gattggtaaa aagttacatt tgcattttct tattttggga 4800 gtttttactt agaatctgga cgaagcaatg ggtaagcggt gggagaaaaa agagccaaag 4860 tgtgaagaat ttagaacagt aggactttca gaactcaatg cctgtgggca ttgagtgagg 4920 aggaggaacc taggatgaaa tgctggattc ttacactggt tacttgaatg catagtgcta 4980 ttaagcaaag tgaggaatac aggaaaagga acaggtttct aagggaaaaa ttgtaaattt 5040 gggcatactg aaaatatctg ttagatattt ggatatacaa gtctggagct tggagtgttc 5100 aaggctagag atgatgatct agggggtcag gaccataggg gtcatgtgaa gtcacaggtg 5160 tggacatcgt cccatgtcag gcatggttag gatgaagagt ggtgacagag gagcgttgtt 5220 cagtattcaa ggacaggcga tgggagcagg gacccagtga cagagggaga gaagaatgcc 5280 aggagaagga gaaaggaagt gtggaagtca aagtagggag taattttttt tttttgagac 5340 ggagtttcgc tctgtcgcta ggctggagtg cagtgacgcg atctcagctc actgcaatct 5400 ctgccttctg ggttcaagcg attgtcctgc ctcagccttc caagtatctg ggactacagg 5460 cacatgccac catgcctagc taattttttt ttttgtattt ttagtaaaga cggggtttca 5520 ccatgttggc caggatggtc tcaatctcct gatctcgtga tccgcccacc tcggcctccc 5580 aaagtgctgg gattacaggc atgagccacc gagcccggcc aggagtaatt ttttaattgc 5640 ctttcagaac tagaatggag taattttaaa gatagaattt ttaaaaacta cagaaagttc 5700 aagaaaaata ggatgggcaa atgtactttg gatttgaaca ctgtaaggtc attgctgaac 5760 ttagtgcagt tttcagtgaa atgggcagga atcattgagc tatgaggaaa tggagatagc 5820 aaacaatttg ccttattcaa ggtttcttag tatagccatc tctgttatca gatttactat 5880 cacgtactgc ttgtgttcag gtagcctcta tttgacttaa taatgtcctt gataccaaat 5940 aggtatcttt tgcccacgca cactaaaccg atcactttga tgacgggttt tacaaaaggg 6000 aaaagattca ttcacaggga agcccagcta ggaggcagaa gagtactcac atcttcattc 6060 ccaaagataa ggcttaggga tatttatcag ttagggaagt agggtgatct aagctgtggg 6120 gaaaaatgaa gtacatgatc tgcacaagca tagttgggat tcatggaatg catgtttaga 6180 aaacaggcat tattaggagg ccaaggcagg cggatcacct gaggtcagga gttcgagacc 6240 agcctggcca acatagtgaa accccatctc tactaaaaat acaaaaaaaa gccaggtgtg 6300 gtggcacaca cctgtagtct cagtgattcg ggaggctgag gcaggagaat cgtttgaacc 6360 tgggaggcgg aggttgcatt gagccgagat tgcaccactg cactccagcc tgggcgacgg 6420 agtaagattc tgtctccaaa aaccaaaaaa ataggcacta gtaggatccg atggtgaaga 6480 ttttggcctg atgtcaaaag gtcatttctt gggcatttac acaggcctgg ttgaagagtt 6540 ggtggttgca gcctgtttga actgtacggg tgctgcccca agttcctgaa aagtaactta 6600 agcaactgtt accgtggtga catatccacc agaagttttt atcttataag gaagccagtg 6660 aaggttatag catttagtag tatgacttgc agctatatag aaataaataa ataaataaca 6720 aaaagcaagt gaccaaaagc aagcaaggca ggttaaattt ggcagaacta attttcagcc 6780 gtaaagtgca agagtgatga tgctggcaat tcagatatgc cagagaagcc ttaaggtgct 6840 ttaagtgaaa aggtgaaagt tctccacttt aaggaaagga agaaaattgt gtgttgaagt 6900 tgctaagatc tacagtgaga acaaatcttc taatcttgaa attgtgaaga actatgctac 6960 tgttgcagtc acaccaaact gcaacagtta cagccacagt gcgtgatttt tattataata 7020 cattgctaca attaccctat tttgttatca ttattgttaa tctgtgccta atttgtaaat 7080 aaaacttcat tgtatatgta tgtataggaa aaaacagtat ataacctgtt cagtactagc 7140 tcaggattca ggcatccact gggaggggtt gggggcggga cgcgggcatg tcttagaact 7200 taacccccgt ggataagggg gaactaatgt gctcttatag ggagtttagt tatgaacaaa 7260 tcctgtttat gtccttgtct ggcatttggg aggggctgac tgataggctg agtgaaagag 7320 aaccattaaa aatgggagaa aagataatcg aaggcagggc taggttaggg tggagcaaga 7380 gagctgctgt gggtataaaa cttaagaggc gctcaccacc aggcaaagag tgggtgctac 7440 tgaataccct aagagccttg tttgacctcc ctaatgcctg tcttgagtaa gaggtcagtg 7500 gagaggaatc cgaatatagg agcagggcct gcactgcagg aggggagaca tgccccctgt 7560 aatacactgg aatgtaggaa cccgagggag tctgcatgtt gcacatgcct aacatttact 7620 tgggatgagg aggaactact gtgaataaga aaaaagccgt tagacaagtg agttgacaag 7680 gtggtttgag ggtagcatta agatcttaga tcttttagaa ctttttggtt tcacctttta 7740 tttcaaaaat tggcaaacag ttcaaagaat agtgaataca gatcaatagt cgttaacatc 7800 gtaagatttg gatatttgta gtactcgtaa tccgggatta tcttaagcca atttcaggat 7860 ttgagatgat ttaaaaccag actacaggcc tgtgagggtc attataactt ctgattcacc 7920 cttaatctag atgcagctct ttgggtctca gcgcaaggtg taggggtttt accaaacccc 7980 cttgtctctt tgaggcttct caattttcgt cctgtttagt gtgtactaaa tttgataaaa 8040 gccttgtggg aagatggtct caaatgctag actcatctct ctaggtgtca gtcttaatct 8100 agaatctcag cccggtaatt cttaattgcc ttgatagctc ccatggactt gatgggggtg 8160 tggaaattga gagagagaga gagttataaa agtaatacat atttattgtt taaaaagact 8220 aacgggcagt gccatgaaat tcacaatgaa aagaaagaga aaccagcaac gctttgcagt 8280 acatttcctt ttccattttt caaagacagc tactttcaaa tcatctgttt cttttggtat 8340 ttaccttcat atttccaagc attgtacata tattacttca gtataattga atgctataaa 8400 aatcatgcag atgagttctg cttctggaaa ggatacataa aaggtaaaat ttttgacacc 8460 atgactgtct gagcatgcct ttattatact gttacctttg actaatattt tagctgagtg 8520 taaaatgcta gcacaaatat tatttttcct tgaaggtatt tcccattgtt ttctcaattc 8580 cagactgctg ttgataagac tgattcagtt gtcacttatc attgtttgca tgtgatgtgt 8640 ctctatcctc ttcaccttga ttacccactc ttttaatatt tttccctttc gccaaccatg 8700 ctggaattct gtgataagct tggtgtagtg ctgttttcgt tcttgtgccg ggcctttgtg 8760 ggggattctt ttgatctaga atgcatatcc tttagtttga gaaacttttc tttgattatt 8820 tctttaataa tattttctcc attttgtgta ttcctgtatt ctttaacttc tgttgattgg 8880 ctgttggatc tcctggtctg agctcctgat gttcttgcct tttgtctcct gttgtccgtc 8940 ttctggttct tctcttctac taccagtgag cttttctcaa cttcattgtc tgatatttct 9000 gtagaaaatt tttttactta tatcatcttt tcttaatttc caagagctct ttaggatcct 9060 attaaaaaat aatcttctga tcatgttgca tgaatacagt atcttttgtt tttttttttt 9120 tggagatgga gtcttgctct gttacccagg ctggagtgca atggcacaat cttggctcac 9180 tgtaaccgcc acctcccggg ttgaagtgat tctcctgcct cagcctcccg agttgctgag 9240 actacaggca cgaacctcca cgcttggcta atttttgtat ttttagtaga gacagggttt 9300 ttccatgttg gccaggctag tcttgaattt ctgacctcat gatccacctg cctcggcctc 9360 ccaaagttct gggattacag gtgtgaacta ccacacccag tttcctttgg ttttaattag 9420 ctgaattttt ccaacttttt gaatgattgc acttattttc aaccttctta ctttgtattt 9480 atgcatttaa gattacaggc gtccgccacc ttgcacccgg ataatttttg tatttttagt 9540 agagacaggg tttcacgagg ttggctaggc tggtctcaaa ctgctgacct caggtgatcc 9600 acccgcctcg gcctcccaga gtgctgggat tacaggcgtg agccaccatg cccagccatg 9660 gatacagtat cttaagatat gaggtatttt taattttggt taaatatgtg ttctgttttc 9720 tctgttgcct ctgaatttca tttggtttta tttttttgat gtagaaagct tttctgaaat 9780 gtccattatt atctgactct ttccatcttt aaaaatgtgg tgccttctca tggccacatt 9840 ttctcttctg tcctctttat ccttgcaggg ctccaactct attctttcag taacacttca 9900 gagggttttt agagggagta gatgtgaact tgtgtgtatg attcaccgtt gtaactggaa 9960 cagatatgtt ttaagcagcg ttatacattc ctttgagtgt ttctctgtca gattttgaga 10020 aacagaattg ctggggtaga ggttttttga tcagttgtag ttaagttgtg aatgaacagt 10080 aatgtacatt ttgttttctg cattttgtct acaggtttca aaaactttta acaaacaagt 10140 aactcacgtt atcttcaaag atggctacca gagcacttgg gacaaagctc agaagagagg 10200 cgtaaagctc gtttcggtgc tctgggtkga aaagtaagca gtttctctct tacttttttt 10260 ccttaagtat ctagtattga aaatgkgtgg agatattttt cacaggtcgg agaaccagat 10320 aaagtttgat tttcatcttt tctctgcctc ttacctcacc aagtaattta catcctccag 10380 cctcaatttc tgtggttcaa aaatggtcat gctataatac ctaactctgc ctagggggaa 10440 aaggagcctg caggtcctga agctgggtat gcaaggtgga cttaggaagc aagagggaat 10500 gtgatgaagc agattgtgtt agtcagcaag cgctgctgta acaaaggacc acagaatggg 10560 tcgcttgagc aacagaaaag gactttctca caactctgga ggcaggaagt ccagtatcaa 10620 gttgtccaca gggttggtat cttctttttt ttttttttga gacaaagtct tgctctgtca 10680 tccaagctag agtgcagtag ctggatcttg ggtcactgca gcctcagcct cctaggctca 10740 agtgattctt atgcctcagc ctcccaagta gctgggattc atctcaacct ttgcctcctg 10800 ggctcaagtg attctcctgc ttctgcctcc cgagtagctg ggattacagg cacgcaccac 10860 catgcctggc taatttttgc atttttggta gagacggggt ttcatcatgt tggccaggct 10920 ggtctcaaac ttctgacctc aggtgatcca cctgcctcgg cctcccaaag tgctaggatt 10980 acaggtgtga gccaccgtgc gcggcccaca cagttttgat tacagtaaat ttgtagtaag 11040 ttttgaaatt gggaagtacg agtcctgtaa cttgtttttc attttcaaga ttgtttggct 11100 attttgattt gagttccttg ctaagattgt ttggctgtct tgattgggtt ccttgcattt 11160 ctatatgaat tttatgatca gtgtgtcaat ttattcaaaa aacaaaaaag gcagctggga 11220 tttggtagga ttgtattgaa tctctaatta gggaagtgtt cataatattt aatcttccag 11280 tccatgaaaa tgggatgtgt ttctttttca ggtctcaaat ttccttcagt gatactttct 11340 agttttcagt gtacaagttt tttaccccct aggttaaatt tattcctaac ttttttgttc 11400 attttcatgt gaatgaaatt gttttcttaa tttttttaag ttgttagctg ttagtgtata 11460 gaaatgcagg tgattgttgt atgttgatct tataccctgc aaatttgctg aacttgttta 11520 ttagttctaa atatatttgt gggttcctta gcattttcta tatgcaatgt tgtgtaattt 11580 tgtaaataga gatagattta cttcttcatt tctagtctgg ccgcatgtta tgtcatgtca 11640 tgtcatgtca tgttatttgt tctggccaga acctccagca cagtgttgaa tagaagtggt 11700 gagaatggac gtccttgtgt tgttgctcat ctttggagaa aagctttcag tatttcatta 11760 tttcgtatga tggtaactgt ggtttgtgta aatgtccttt tttaggctga ggacgttccc 11820 attcccttct gttgcaggtg gtttgtttgt ttctgattat taaaggaagt tagatattgt 11880 tgtcagatgt ttttctgcat gactgatcat catgtgattt ttgtccttca ttatattaat 11940 gtggtgtaat tgaggggttt tgtgtgttga agcaaccttg cagtcctagg ataaatccta 12000 cttggtcatg ttgtatacgt tgtcatcttg cctttttaat tgttggaaca ggccggatgc 12060 ggtggctcac acctgtaatt ccagcacttt gggaggccga ggggggtgga tcacctgaga 12120 ttaggagttt gagaccagcc tgatcaatat ggtaaaaccc tatctattaa aaatacaaaa 12180 attagccagt catgttggcg tgtgcctata gtcccagcta ctcgggagat tgagacagga 12240 gaatcacttg aacctgggag acggaggttg cagtgaacca agaccacgcc attgcacttc 12300 agcctgggtg acaagagcgg ggaaaaaaaa aaaagagtaa ggggtccttc tctggctttt 12360 gtcaagattt tctcattatc tttcactttc agaagtttaa gtgtctcgat atggtttttt 12420 aaaatttatt ttgtttagat tttacagaac ttgttgaatg tgtagttgcc tgtgttttct 12480 acatatgatt cgtttttggc cattatttct tcatctatct tttctgcccc gtttcctcct 12540 cattttttct gattagctgt atatcttttt ctaattagct gtataccagg gattggtaaa 12600 gttttctgta aagggacaga tagtcaatat tttaggcttt gcgggccata tggtctctgc 12660 tcaacagctc agctctcttg tggtgtgaaa ggcgtaatag aaaataagta aacaaatgct 12720 tgtgtctgtg tggcagcaaa cttataagtc tggcaggaag ccaggtagtt tcccaatcct 12780 ttctgtgtaa tacacctttt aaacgtttgc atttgtccat agtgctctcc ttcttcttca 12840 ttattgttca gtcttttttt ttctcctcag attgatcttt tttcaagttc attgactttt 12900 ttctccatca aatccattct gctacttagt acctttattt gagatatttt tgatttctaa 12960 catttctagt tggtttttgt atacattctt tttatttcgg tttcatgtga gatttctcac 13020 ctttggtttt cctgtcttcg gttatgagtg tattttctat tacctcgatg agtgtagtta 13080 taaatagttg tcttaatgac cttgtctgat aattttgagg ttggtatctg ttttgttttt 13140 gtttttcttt gatagtgtgt cacatttttc tggctcttca tatggcaaat aatttgaggt 13200 tgtattatgc acgttgtaaa tactatgtag actctggatt cttttctatt gtcgcaaaga 13260 gcatgaggtt tttgttttag caagcagtta acttgtcgtt aaaatgaaac gcacactgtc 13320 attatgtggg cagttgctta gatgcgccct ttaagcctca ggtgcaggct gatttgtttg 13380 cctcaaacac atgttgttca ggggtcagcc agagacttga acttctatac tcagaatttg 13440 gggtttctcc tatggttctc ttacttcctg agtccttacc tcatttctct agtagcccta 13500 gctgcccagt ctccttcccc tggtctcttc agcgagaaag gaggccggag cttctgcttg 13560 agtgcttgct gcgccacacc agctccctca gagactgtgg ctgcctttag gggacagaca 13620 gaaaaagtgg tgatgcccag attcttttgc ttccttttaa aatttgcctg ttctttcttt 13680 ttcttttatt tccctccagc tttcaaagct ctcacatagt tggtttattt tattttattt 13740 ttcctgtatt tccaggacgt atagcttata gttcacctat atttgtatat tggtttgtta 13800 ggcataaaca gaaatggaac ttagtatgtt atttttgaag catctgatgc cagtctaatt 13860 cttcttccct tcaaaattat ttgatctttt tggagactcc ttagggatat tttttatttt 13920 atcatttttt ttttgagacg gagtctcgct ctgtcgccag gctggagtgc agtggcgcga 13980 tctgtgctca ctgcaacctc ctactccctg gttcagcgat tctcctgcct cagcctcccg 14040 agtagctggg atcacaggca cgtgccacca cgcccagcta atttttgtat ttttagtgga 14100 cacggggttt caccatgttg gccaggatga tcccgatctt ctgacctcgt gatctgcctg 14160 cctcagcctc ccaaagtact gggattgtag gcgtgagcca cagtgcccgg ccaggatttt 14220 ttttttaaga ctcatggctt tactgtaata tgttttgaat tgatcattcc agttctggct 14280 tggccttttc aacagattca ggtctatatt tctgcaaaag tttctgggaa ttatagtttt 14340 aaatattctg cttcgttgtt ttgcttttct tctgggactc caattatgtt tacgttgggc 14400 ctgcttagct atcttttatt tcagtcactt tgacttcaac ccttttatat ttatatacac 14460 atacacacac acacacacac acagacacac acacacacac acacacacac acacacaatt 14520 tttaccccaa atacttattt gacagtattt gtttttgttt tttgaagaca gggtcttgct 14580 ctgttgccga ggctggaatg caatgactca gttgcagctt actgcagcct tgacctctaa 14640 ggctcaatca gtcctctcac cccagccctc cctagtggct gggactgtag gcatgtgcca 14700 ccatgcccag ccattaaaaa gttttttttt ttcttttttc tttgagatgg agtcttgctc 14760 tgtggcctag tgcagtggcg caatctcggc tcactgtaag ctctgcctcc caggttcatg 14820 ccattctctt gcctcagcct cccgagtagc tgggactaca ggcgcccacc accacacctg 14880 gctaattttt tttttttttg tatttttgta gtagagatgg gattttaccg tgttagccag 14940 gatggtcttg atctcctgac cttgtgatcc acctgccttg gcctcccaaa gtgcaacccg 15000 gcattaaaga atttttttta tagacatggg atcttactat gtaggccagg ctgggctcaa 15060 gtgatccact cactccagcc tctcaaagtg ctgggattac tggtgtgagc cactgcaccc 15120 agctgataat atttgattca agttcaaggg ttttgttata ttcttcagtt ttgtgtttgc 15180 ttttatttta gggagtgtga tgggttttcc tcagctgaaa tgatttgctt tttctttgtt 15240 tttttaaaat agatttttaa aatggatgta gtctattcta tttccattca ttgcataggc 15300 caggcttgtg gccagagcgt cctcttctgt cagttctgct gtcttgcata gtttctttta 15360 taggtgacgc tggtgaggga gggaggaggg aggggctcgt gtatctcgtt tgcgttttgt 15420 ttctatagga tccttaaatg tttttctctt agtttcttct ttttttcact gccattggtt 15480 caagggctgc cactcccccc agaactgatg tttttcagag cctgcctgtc ctagtcttgc 15540 tcccattcag accccttccc tggagtgggt gctgtgagct gtgtgggttc tctgttgtgg 15600 cagttgtgct gggtgtcctc tttctgagac ttcttttacc tgtgcttcat gtaagttctc 15660 caggctgtac tactttttat ggagtcttaa gcgtattctc cccgactttc tgcatccata 15720 gacttgcagc tgtgttggaa tttgattatt tttctactta taggtcatct gaatttgcgc 15780 tgttatctcc gtgtcagtga gaatgtaggt catatgtgtc ttttatttaa gtttcttttt 15840 tattttctgc ttttttttcg gggagggaat ggggtaagac tcagtatcag ccagccatca 15900 ttgttttctc tacctcatct tcttatggag tccattgaaa tggcttattg atttttatct 15960 caaaatcgat ctctcataga tctttatctc tgctgttaca gtcgagacaa gtatcatgtc 16020 ttgcttcagt tactgtagca gcctcatgcc tgtctgtttc attttgtttc ttatacataa 16080 gcaaatgtaa ccccttttgt taccagtgga aggtatccaa gttaccggca gcaaacacgt 16140 atgggtttgc agcaacttca gttcttgctt cctcaaaaga aagaattcca cggaggagca 16200 taaggcaaaa gaagagcctg acgcaagggt cagagcagga gcagaagttt atttaaaagg 16260 cgtcagaaca gaaagaaagg aaagtacact gggaagagtc ccaggcgggc atggaggtct 16320 aatttgatgt ttaaccttga tcctgggatt tgtaggctcg cccttttccg cagttcttcc 16380 cttagggtgg gctgcccgca tgcacagtgc gggaattgag cacaggcagc ttgtttagga 16440 agttgtgtgg gtgcccatct gaagctttct tcccgtttct ccgccatttt gtctcttaat 16500 gtgcatgccc gggaaatggc ctctccctgg cgtctgcatt cagttaacac tttagcacaa 16560 caggtgtgga ctgtcaggaa atggcctctc cctggctctg gctgccaatt tatcactttt 16620 agagaggcaa tgtgataatt gttgagctat cacccaacat tcctagtggg tggtagaggc 16680 ctctcctgcc gggcttatgc ctaactacct gtgatacttc aacacatgga tcagctttat 16740 ccttctgaca aaatggctta gagttcagtg gtctatagca gagaatggcc aactatcatc 16800 ccccagccaa atccaccctg ccatactgtt tatttttttt taatggccca tgaggtaaga 16860 atggttaaga gaaaaaaaaa attcaaatgt ttactatttc atgatattta cattatatga 16920 aattcaattt tagtatccat aaataccgtt ttattggaac acaggcatgt tcatctgacg 16980 atgtagtcag tggctgcctc tgtactacag ctgtagattt ggatcctgtg gcagagacct 17040 tacggcccat gaagcctaag gcattcacta ctttcccctt tacagaagtt tgctgaccca 17100 ggtccagtgt gctgcatgat ggtccccttc ccttccattg tcagctgctc ccctctccct 17160 tgtttgcgtc ttccaaatgc tctaggcttc cacgtcccca aggctacact ctttctgcct 17220 ttagttcttg gcctgtgctg agaactctgc cccgtcttcc tgattctaaa cccagttttg 17280 tagtcagctc ctttatacat gttgcattgc aaggtcgctt tatcagaaga gcttcctctg 17340 tccccagttc acagttcaag ccctatttgt tattctctgt ctcagctcct tttttcctgt 17400 gtgtactatt aaaacttatt ttgttcattt gactgcttta tctgtctgtg tatctaatca 17460 tgcattttgt ctttctattg taatgtggat tccaagagca gctacctgtc tgtcttattt 17520 atggttgtgt ttctagtaag tctaacattc atctggctca tagtagatgc tcagtaaata 17580 tttgttctaa caaattatga acaaaggaaa atttagttaa gtggcgtaga gatactagag 17640 aaaatatcat gggggaaaat gatttgaaaa aaactacatt ttaaaagtcg tatagaaatg 17700 tggaggggag agtgcagaaa cagagacctt tactagaagc ttgaagtaaa tggagatgca 17760 tggacaaaat taaaatagta gccatttctg tacctaatag ggcctctcag ctaaccctac 17820 agtggggatg gtcactggta gtgtgttctg ctgagagtta gggattctta ctctgctttg 17880 ctggcccagc ccctgactca ttctctatcc cctttctctc tctctctatt tctgcccacc 17940 actaacccca gcctttctca aggggctcat gcagacccca taatacttgt aacttcgtta 18000 tccaaaagca aagttttctt tttcttttct ggagactgag tctcactctc ttgcccaagc 18060 tggagtgcag tggtgcgatc tcggcttact gcaacctccg cctcctgggt tcatgccatt 18120 ctcctgcctc agcctcccga gtagctggga ctaccggagc ccgccaccac gcccggctaa 18180 ttttttgtgg ttttagtaga gacggggttt cactgtgtta gccaggatgg tctcgatctc 18240 ctgaccttgg gatccgccct cctcggtctc ccaaagtgct aggattacag gcgtgagcca 18300 ctgtgcccgg ccaattttta tatttttagg agagacaggg tttcaccatg ttggccaggc 18360 tggtttaact cctgacctca ggtgatccgc ccaccttggc ctcccaaagt gctaggatta 18420 caggtaagag ccaccgtgcc tggcaaaagc aaacttttaa ggtcctcaga agctcaaaag 18480 tgaacttaat cttttggcat ttttcttttc tttttttttt tttttttttt ttgaaactga 18540 gtctcgctct gtcgcccagg ctggagtgca gtggtgcaat cttggctcac tgcattctcc 18600 tgcctcagcc tcctgagtag ctgggactac aggcgcccgc caccacgcct ggctaatttt 18660 tttgtatttt tagtagagac ggggtttcac cgtgttagcc aggatggtct ccatctcctg 18720 atcttgtgat ccgcccgcct cggcctccca aagtgctggg attactggca tgagcccctg 18780 cgcccggccc atacacttta gtcaactttt tattacaggt catttttttg cctgtacatg 18840 cagatacatc ccactttata tatataagaa tattttgtag tagctgtcca gtaatttatg 18900 taagcagtgt cctattggtg attgaagttt ttcatttctt agttattttt ttcaattaga 18960 aatattacag cattgagctt ctgtatgtat tacctttttg cgggtgataa atctttccat 19020 aggtttaaat ccccaaagtg ggctgttcat ttctgagagt ttacacattt aaatatgata 19080 gatgctgcca aattatcttc tggaaggagt gtactggttt ccattctcac tggaattatc 19140 aaaaaaatgc atgtttccca atacctttgc taatgttgtg agttatcagt tcttttttct 19200 aatttgtaga agaaaaataa tagtttttat ttgcatttct ctgactttta gtgagcttga 19260 attttcttca gcagagcata gagataagag ccaaactgac ctgcattttt tatgtcacgt 19320 ctgtcctttc ttggtgaact gcctgccttt ccaatgcagt agctcatggt ttccactgaa 19380 aatgtgaaca ttaacttcat aaggtcacta ggtgtcacta gaatcccatt ctgttgggtt 19440 ccttctggga gtgttcattt taagatcaga tggcaattga taaaattctg acatttcctt 19500 tggatgtaga aatttttacc ttgaagaaag aatacataaa gttgaaataa aggtcagctt 19560 ggcccccact ctaagttctg ttgaagacaa tttatcattt ttaaacaact gcaaactaac 19620 agctaggtgg ggaatacggt tcacaggctt tgtccttgct aggctgagag ttggttgctg 19680 accgaagcca tcaccccctg catttagtgt ttgctggaaa cagggacata ttcctgcata 19740 accacaacac aggccgacat taggggctta ccacggctcc tttcctcccg gaatcctcag 19800 actccattcc tatcctacca gcagccagct ccacttcccg cctcctcagc cttctcaccc 19860 tgcagccatt ccttagtctt tcactggctt ttgtgacttt gacactgttt aaggtcactg 19920 accagtgata ggaacgtccc tcagtttgga acggtctgat gtgtcctcct aatatcacat 19980 caatgtgtaa cagtggatgt gtagccattt aggactgggc aaattactca actgctgggc 20040 tctaggttcc tccagtagct cctgagttaa cttcctacgg ttatttagtg ctagaccaca 20100 gaagttcgct ctctgctggc agagcactgt tgtgcagact tctctgagtc tcctgtgttc 20160 ttccttgtgt gtcagggaca cacgtgaagg atagcgtgct tcgcggctgg aatcttcaag 20220 gagatgccat tcactttttt acctcactaa cacagtgccg tttacaaaaa agattaatgt 20280 acttttcctg aattgactta ctgactgggc ctagagaata agatactggt gctgggcagt 20340 ttggcacaag agtagtataa agaatgcagg attggcccag gtgaaggcat cgtcctaagg 20400 gtagaatggg agtcggtggt tcctggccga cctagcaggt gtactgtggg aagtgctgga 20460 gtgaatcggc tctctgggga gaataagctc atcacagcag ggcttcccga ggagaacgtt 20520 gctgctttga tttctgttgg ctctgaggca gcagcaggtc aaatagttgg ttctctgttt 20580 agagacatct cttgaaacac ttttcgtttt gaccactaga tggtgggata atgttatcat 20640 tttacatttc tgaagaaaaa tagaaatcta actggaagct tttttgtctg ttcagtagat 20700 tttggttgga cccctggtaa acatgggttt cagtgtagca gctttaatgt gttaccacgt 20760 gtgctaaagc atagctgttg gcatgcagaa cggcattacc agcagtaagt gccacttact 20820 tcttcatagt gagtgatgat agttacaccc aggtagatga aattcaggga gagcatctct 20880 gtgcacctta catcttatca ctctgaagga tatgtggttg ggaagcttct cccaaaggaa 20940 cagaacacat cttccacaac tgtataacct atgtcaggca cacgttttcc tgggttgaat 21000 caagcccttc cttaaactgc taacttaaag aatacttact ggttttgtaa agtttggcaa 21060 atgatcttct ctgctcctcg gttttctgtg ttgtgcaata ggaggcaatg gtagtggctt 21120 ttccagcacg gttggtgtga ggcttctcat gagctgggtg acctttgtcc tgatgatggt 21180 ggtgatttta atactgtgta tttgataaca cgattatcta gggtctcctc tacgtctttc 21240 gtccagatgc atctcagcca cccccctttt gctgttccct taggcataat agtggtaaat 21300 cggtgacatt ttgcttgagt aagaagaagc tgctaaaaac ttctcatgct taaaattggt 21360 aattaagggg actttttaaa aagaagcaca gttaaaaaac atttccttcc tcgttctctt 21420 ccacccgcct ccctttccca tcacttttat tagatacagc attctgctca ccccattatt 21480 gcaggctcag atagttggtt tgttttttta aaatcagctt tataaaaaca tttacataaa 21540 ataaaatgga cccattttaa gtgtacattc acggattttt tgtgtatacc tgtgtcacca 21600 ccacaaccaa aatacagagc attttcatca ccccaaaatc tccttcgtgt ccatttgctg 21660 tcggcctccc tgccccctcc tcccacccca gggcagccac agatctggtt tctgtcatta 21720 aagattagtg tcaccaattc tggggcttca gatcagtgga atcatccagc gtgtactatt 21780 ttgtgcctga catcactgaa ggtgatgttt ttgcgatctg tccgtgttgt ttgtagcagt 21840 ggtttcactt ccttttatag ctgagtagta ttctattgta ggcatgtagc ttggtgccac 21900 cagttgatgg agattgggct agtttgccat tttaggttat tatgaataaa gttacaatgg 21960 acatttacat ttgtgtcttt gtatgctttc atttctcttg ggtcattacc caaacttttc 22020 caaggtggtt atggcactgt atattcccac cagcagtgtt cctttcactc cacgtcttca 22080 ccaatagttg aaatttatcc atcttttgaa ttttagccat tcaagcagat gtgtagtggt 22140 atttcatggt tttttttttc ccaacattgt tttaagatct aattcatatg ctacacaatt 22200 tgtccaatta aagtatacaa ttcagtggtt ttaaatatac agtcaggtat tgcttgacga 22260 cagggatgcc ttctgagaaa cgaataggtg attttgttgt tgtggagaca tcacagtgtg 22320 tattaacaca cacctgcatg acatagctac tgcacaccta ggctctgtgg cacaacctgt 22380 tgctcctagg cataaacctc tacagcatgt gcagttgtga aacagtggta agtatttgtg 22440 tctctgaaat acttaaacat agaaaaggta gagtaaaaat atggtataaa agataaaata 22500 tggtacacct acatagggcg tttactatga attgagctcg ctagactgga agttgctgtg 22560 gttgagtcgt tgagtgagtg gtgagcgaat gtgaaggcct aggacattac tactatacag 22620 tactatggac tttatacacg tcatacagtt aggttacact ggatgtatat tttttggagc 22680 aactgtatta actgatacta taacgttttt ttaaagacaa ggtcttgctt tgtctcccag 22740 gctggagtga agtggcacat ttatggctca ctgtagcctc aacctcctag gctcaagcaa 22800 tcctcctgcc tcagcttcct gaggagctgg gactacaggc gtgtgccact atgcctgggt 22860 aatttatttt tatttttatt tttgtagaga cggcattctt gctacgttgc ccccactagt 22920 ctccaactcc tgacctcaaa cagtcctcct acctccgcct cccaaaatgt tgggattaca 22980 catgggagtt attgcacccg gctcctccca taagtaaata atctatctct ctgttacttg 23040 tggtgggagg aaaagaaaaa aaacacctag gttatgtata atacctaata cgagtacttc 23100 gtaagtagtt attatactgt tttttttttt tgaaacggtg tcgctctgtc gcccaactgg 23160 agtgcagtgg cgtgatctcg gctcactgca acctctgcct cccaggttca agcgattctc 23220 ctgactcagc ctcctgagta gctggaatta caggcacgca ccaccacgcc cggctaattt 23280 ttgcattttt agtagagacg ggtttcccca tgttagcctg gatggccttg aaccgctgac 23340 ctcccgcctc aactcccaaa gtgctgagat tacaggtgtg agccaccacg cctcgcctat 23400 actgtatttt tttttaattt ggccttacta tagctttttt acatgataaa ctttgtaatt 23460 ttttaaattt ttttactctt ttgtaatgcc ttaaaataca ttgtacaaca gtataaaaat 23520 accttatatc tttatcagct ttttctatgt tttaatttta atttttactt ttaaacttaa 23580 aactaggaca caaagacaca cattagcctg ggcctacaca gggttaggaa catcagtatg 23640 tcgctaggcg ataggaattt ttcagctcca ttataatctt atgtgatcac tgttgtgtat 23700 gtggtctgtc attgaccaaa aggttgttat gcggcatata actggattca cagagttgtg 23760 caaccgtcac cacaatttaa aaacattttc gtcacctcaa aatgaaactt gcacccctta 23820 gccctatccc ctattctccc gccagccaag gcagcctcta gtagtctact ttctttctct 23880 gtggattttc cttttctgga catttccaat aagcggaatc atatgatata cggccttcat 23940 gtctggcttc tttctcttag cataatgttt tcaaggttca gcatgttgtc atctgtatta 24000 gaatttcatt tctttttatg gtggaatcat gttccattgt atggacacgt gcgcacgcac 24060 acacacacac acacacacac agaagaacta aatattacaa ggcttatcat gaaaaacaat 24120 ggtctctttc ttgacccttt tcaccctcaa ttcctgttcc ccagaggcag ctcctttcac 24180 acttgtggct gcttctgcag ataagctgtt cggtgacctc catattttaa atactgtggc 24240 cgtattgctg tttcggtttt tcagtttcag gtattatcta gtgactttct gatagggaag 24300 tgagaatttc gtttttaatc cgcccctctg agtgcacctc actcccacat acactcatct 24360 gctgtttgca tggacacatt catgtgcagg ctctttccac tcttgattgc agtgtacatg 24420 atacattttg gttaaatcgg tagtttatgt ttacatcatt atgactgtgg aagttgtgtg 24480 ttaggctgaa tctcagagtg aaccatgaat atatttcctt tcgtggaaaa ctttttgttt 24540 tccctgagct tggcctggtg tcctttgagt ccagagcttc tcaggctcca cttatgtgaa 24600 catggaccca gtgcccccat tggacacagg gtggcagtga gtgggcacag gcaaggagag 24660 aaggagagtc gctccctctt ttcagccttc caccctctgc cctctgcact ttgccccctg 24720 ccccacccca gactgctgtg gcttcacctg cgcctcctgc ccttgagggg ttctgagctc 24780 caggttctga gctccagatg gactcctccc ccgccccagc tgccaggctt gggtttccct 24840 tttttttttt atttgtttga tttcatttcc ccagacagct cttatctact ctttattttt 24900 gttggtttat gtctttttgt tttcctttac tatcatttta ttggggtttt gggggtcaag 24960 agaaaagcat gtgctaagtc caccagattt aaccagaggt caaaaacctt ccatttttat 25020 tgtctaaata ttattcagtt aaggattccc cctccccatc ttagtcccca actgcctttg 25080 ctgaatcttt agcgtctcct gccacagtta ttgcagtatt ccctgactgg cttcctcctc 25140 ctggaccagt gatctgccca cgacccctcc ctcacacctg tccccatgcc ccagacccac 25200 aggacagggt ccaagctcat tagcttagaa agtacaaccc ttggaatcac atgaattctt 25260 tttttgttgc tagtctccta agttgcattc attcactcag tcatacaaat ggtgtatgtt 25320 ttccccacaa tgtcaccctg tttgctgcac tgtgcttgag tctatgctct gcttccagat 25380 ggaagatctg tgtcctccca catctgcctc cttgtcagag ttgagtctgg tgatcatctc 25440 tgacctgaag ctttctctga accatactcg ttatgcaacc tgttgctgct tttctgcctg 25500 gttgtacttc tcttgttaca attactgcac tgtgttcttt tttaaatttg tacatttttg 25560 cagatttctc tgatgcctgg cttaatagaa gacagttgcc ttctcatatc tgcctctgca 25620 ttcagtgtat tggggtggca catgtcgttt tgcttcggaa aattccactg cattgtatac 25680 tgaggggata atgcgagatg agaaaggaaa atcacacgtt agtgttgtta taaagatagt 25740 attgacttta cacaccctca gaagggggtc agggatgcca ggatgacatt cactacccta 25800 gtgtcactta ccacattgca tagaccatac tgtgccgtac agaggcacat atttctgaaa 25860 cttcctttat tcctaatata ttttgtagaa atttctatat cagtatggat atgtgttttt 25920 tattgcagtg tactttattt tttcaaataa ctgttcgtgt gttagatgtt gaacggtgat 25980 aggcctgtga gggatagttg gagaggtgac tagaggcctt ataaaaacac ttaaacagca 26040 gatgagtgag aatatgctct aaacatggga gtgacagaag gtttttatct aggttgggaa 26100 gaaatttaag attaatattt caggaatgta tgagtgaatt agaagaggag aaacaaatag 26160 tagggcagga gatcatttag aaaatcataa ttatttagac ttgagtgaca gaatgctaag 26220 aaggagataa gggtcacagg aatccagaga tacgaaggtg gacaggagaa atggcaggtg 26280 tgtccacagg gcaggaggag gaggcttggc aatgcggagc attggttgca cacctgggcc 26340 ttggggctga tcgtggtgtc tggacagaaa cacaaaaagg acaacccaat tttggaggaa 26400 agagatgtcc tctgacttca atttctttac gtcccttcta cctctgaatt atctgtttta 26460 tggcctgttt actattaaat gatccattta atagcattta cccttagctt tatgagtacc 26520 atgcactaat aattttgaag tatgctacaa gtcaaaaatt gttgtgtaaa aattgtactt 26580 cctttacctg cctcttgctt ctgttatact taaataccag atagagatga ttttgggaag 26640 tttgatttat actgactttt gtatttgctg ttgtatttat tttttaaaag tctgttaaaa 26700 tgacctagct atggatttct taaattgcta atacatgtgc agatttagtg ctgtgtcaat 26760 gtataataga agcaaatact cattagacta ccttaattta attatacaga tgcaggacag 26820 ctggagcaca cattgatgaa tcattgttcc ctgcagctaa tatgaatgaa cacttatcaa 26880 gcctaattaa aaaaaaagta agtacatgat ttcaatgtag ataatggcaa ttaggaattt 26940 attcgttttt attttttatt tctagaaaat aaaacttcta gaaatatatt caagagttgt 27000 cttaaatatg ctattgatga tattgttctt ttcacatagc atttttaagt gaattacaga 27060 gattatttta tcctatgact tcttcgatag catttgtatg aaatggaaaa gcctgtggtt 27120 ggccatggga agactaaaag gtgccaagag acaagcaaac atttaggtgc tttggtaatt 27180 acttcagaat gaagtttgtt atatctgtag tcaaaatacc tgcattctgt ttagccagat 27240 aaatctcaaa agtccgatgg acctacatcc aagtgtgcaa agtcatttat taggaaaatc 27300 tgctgtacaa atacagttgt ccttcattat ccacagagga tcagttccgg gacccccaca 27360 gataacaaaa tccactgatg ctcaagtccc ttatataaaa tgccatagta tttgcatgta 27420 acctacacaa atcctcccgt atacctaaga aagaattttt tgtagagaca gggtctttct 27480 atgttgccca agctagtctc aaactcctgg ccccaagtga ttctcctgcc tcaacctccc 27540 aattgggatt acaggcgtga ccactgcacc tggctcctcc catgtacttt aagtaatctc 27600 tggattattt aaaataccta atacaatgtg aatgctttgt aaatagttgt tacactgtat 27660 ttttttttaa tttgtgttaa attttttttc ttttgaatat ttccaatcgc gactggttga 27720 atccacagat ctggaacttg cagatacaga gggcaaactg tagagttaaa gacattgctt 27780 tcatttgaga tagaattcac attttaacca caaccttttc ggctttctat ttatgtaaaa 27840 gttctaattg tgatttcttt atctgagggt actttactct gaaacatcac agccagcttg 27900 ttttcacatg agattctctg ttagagggag gatttgatga ctttctccaa actgaactac 27960 atttcctgta gactagagga gaaataactg tgaacttcac atttcctgaa aatagtcaat 28020 gatatttctt cgttacattt catctcagac aagccatagt ttgcccatgc agtgatagat 28080 gaacttcttc agtcttacct gattataggt gaacaagtgt tcagcagtct ctggactccc 28140 tgtgacatgc taaaatcaag tgtttattgt aaaaacacat cagtagtaca tgcatatttt 28200 ctttgtaaaa catttagtaa acacagactt ctctttgatt gccctccctc aatgtaagca 28260 gctttcaatt tgatgagtat cctaggtggc atttcttcag tacattacac acatgtacac 28320 actcacacat gcatgcttga cgtgaagggg ctctgctatc ttatgtgtat catttggtga 28380 gttgccttct cttccccaat taacaatatg gttttgacca tttcatgtcg gtagctttga 28440 ctctactcag ttttctgtat tgcattatac attgtgactg tttttccggt attcatgtac 28500 ttttagtcac tgtcagtttt tgctaagtat attacttaag ccacatattt gagtttattt 28560 ctccaagtca gatatctaga gataaaatta ctgggtaaga atacatacac attttgattt 28620 taccagctcc accaatcata tacaagatga cctatttctt ggccagatac agtggctcac 28680 acctgtaatc ccagcacttc aggaggccaa ggcgggcaaa tcagttgagg ccaggagttt 28740 gagagcagcc tggccaacat ggcgaaaccc catctctact aaaaatacaa aaattagccc 28800 aacctggtgg tgcacacctg taatcccagc tactcaggag gctgaggcag gagaattgct 28860 tgaacccagg agatggaggt tgcagtgagc ccagatcatg ccactgcact ccagcctggg 28920 cgacagaagg ctctgtctca aaaaaaaaaa aaaaaaaaaa aaaacctatt tcgtgatact 28980 ctgaccaata ttggatgtta ctaatctttt taatttttcc taatctgaag cattaatgat 29040 tgcttgtaca ctttaccact ttaattttca tgtctaaaaa ccttcccttt ccttctcttt 29100 tccaaatgta attgcaaatt aaacccgact caaggcctta ttcttttggg tccttgagat 29160 ggttctgtgc ctctgtctcc cccctcaccc tgtctgctgc ctgcctgccc agcttgctgt 29220 tcctcaagca tgccaatcgt atttctgttt cagagccatt gcgttatctg tttcctctgt 29280 ctggaacatt cttcccccaa aatccttaca cgtgacccgt tttccagcct ccctatggct 29340 ttgtgtagat gttactttct ctgtgagacc tatcctgcca cccgtttata ccagcagttc 29400 cttcccactt gtgccaacta tgcaagtctc ttttcatctg cagtgctgac tggctcctcc 29460 taacacactg tagtaatgtg ggcagtttga tggaatacag ttgctagaga agattcacag 29520 gaccccaaaa taacaatgtg tccaacctgc accgtacctg agaaccagga agcgcaagat 29580 ggagtgtctt cttgtatact gctggccctg agtctatatg aaccagcccc actggcagag 29640 cctccaggca aatccttcat ctcactactc ataaacaatg ttgacaggcc agcacaatct 29700 gtccccaaac ttcccggacc tgtggctata aagcaccact gtctaattag tacattttgt 29760 gtcatgcagg tactttagtg aaagcagtgc aggccggttc caagcctgtt gaaatgaacc 29820 tcccaagaca catacaattt acttatttat tatgtttatt tgctgtcatt ccttaccagc 29880 atacaagctc catgatgaca aggatctttc taggttgcaa gaccagcgcc tgacataaag 29940 tcatgttttt tgtcaataaa tgagtgaata actaacagag caagatcccc agtataggca 30000 ttagccttga gtagctaaaa gaagttcttt ctatgagact ggagcaaaag aagttagcgt 30060 ttacgtgggt agctagctac ccatgtaagc aaatttgggc tggtagcttc gcgctgaaaa 30120 ccaaggaacc tagacagatg acttaaattt ccctggggtc ctataagaaa gaagtcaggc 30180 ataaaagtgt tataggtaaa atcgatgtga agttcagtat gtgtatttgt gctgatggct 30240 gggctaaaga cgggaagtca atgggcagtt ccaagaacag aaagtggggt gggtaaggct 30300 gggaacgtga ggtgtgtttc aaaggaaaca tttcccctgt ctgaggatgg ttaagagtag 30360 agttaaccca agaccttcct gtggatatca gcctggggtt tcatgtgttt gtgagtgtag 30420 ttacagtttt tgggttttac tggctgattg gagttactgt gatttaatga cggtagggca 30480 agcataatca tggttctttt ctttggtaat tataaaatag aaattgtttt attactgtgt 30540 cgtggtcttg cagggaggat gacgtgagaa tagtgctacc aagcaggcag tgggcgtgct 30600 gccaacccac atagagtcca agatcatgcc acttgttttg agaaaagaaa ggctttattg 30660 caagttgcct ggcaaggaga caggaggaaa ctctcaaatc cgcctccctg aggtgggggc 30720 tcaggcagtt tcataggcag agaaaacaaa gtgtgatctg attggatctt gcaatggggt 30780 gatgctggga ggtgtcatct gactgggttg tgtcacaagg tgatgccagg gctcaatctg 30840 attggatcat ggattatgcc atcaggtgtt tactccttaa tttggccccc gttccttggt 30900 ctaagtgctt aggttctgcc cgtggttaca tgcttggttc acctgggcat gctcaagtga 30960 cgtaacttgc aacttcaggg gccgtggcaa ttaaacagtt caccattttg atacacaaag 31020 ttgaactaga ttgggctggt ttggtggtaa gaacagcaaa aaatcgaaag agactggcta 31080 aaaactttca tggaaactaa gaatgctagg atcatgaaaa tgtctcacaa agcataatac 31140 agagcctttt atacagtctt ttaaattctg tccattttct ttataactgc acaaaaaaat 31200 aaatattgcc agttcacata cagtgcaaga aacacctctt ttagaatttt ttattactga 31260 tgttataaaa ggtatcagaa atgtatgcga aagggctttt tctcctgcct taagcagttg 31320 cagtacagca ttaatttttg tgttcttttt gcacagcgta aatgtatgca gcccaaagat 31380 tttaatttta aaacaccaga aaatgataag agatttcaga agaaatttga gaaaatggct 31440 aaagagctac aaaggcaaaa aacaaatcta ggtaagctaa gaaatataat acagttcttt 31500 gcatttgtgt ccatacacct tgtttaattt gcatgatgac tagtggggtt cagcatgaga 31560 gagctgatga agactatgat agctttactc tatgaaggag aaaacaaaat gtcaggagcc 31620 tgcgggagac ttggctggga gccataatag agccacgcag cttgagctaa tcgaccacag 31680 tcttaaccat tcatcaaggt ggtcgaactt tttattttcg ggaatgattt cagaagaaaa 31740 gcaaactttg gctaataagc attattgaaa taaataccta tttatttctt ctttatatat 31800 aactttgtat ttttacctaa ttggcatttt tgttttgtta ccctgaatag gcaaatctta 31860 gatgatacat tattttagtg atttgggaaa atactttaga atattatgtt ctataacaag 31920 atgtcttaga aaaaaatata tgtattctta tgtatatata ttgttaaata atatttttat 31980 atataagaat attatgggct gggcacagtg gctcacgcct gtaatcccag cactttggga 32040 ggcagaggcg ggcggatcac gaggtcagga gatagagacc atcctggcta acatgttgaa 32100 accctgtctc tactaaaaat acaaaaaaat tagctgggag tggtggcagg cgcctgtagt 32160 cccagctact tgggaggctg aggcaggaga atggggtgaa cctgggaggc agagcttgca 32220 gtgagccgag actgcaccac tgcactccag cctgggcaac agagtgagac tccaactcaa 32280 aaaaaaaaga atattatgaa acattaagat gctttgtacg tttttggtat ttctgttatg 32340 cctttttcac tgtcgtctaa agtcagtatt tcctactaat tctgacacag cattgctaca 32400 gataagcaat tatggtcact agaaattcct aggaagcatt aattcctcta gtttttgttt 32460 tctttgtttt aatctatgtt actatgtcac agattctcta ttctgtgttt tgaaattatt 32520 caaatagaat tgtcgagatt tattttattt atttttttga gatggagtct ttctccatca 32580 ccaggctgga gtgcagtggt gcgatcttgg ctcactacaa cctccacctc ccgggttcaa 32640 gcaattctcc tggctcagcc tcccgagaag ctgggattat aggggcgtac caccacgccc 32700 agctgatttt tgtattttta gtagaaacag ggtttcacca tgttggccag gatgatctca 32760 aactcttgac ctcgtgatct gcccgcttca gcctcccaaa gtgctgggat tacaggcgtg 32820 accaccgcgc ccggccaaga tttattttaa atctgtgacg ataatgcgac agaactgggt 32880 agaacactta gcccacatag tgctgccaca taattttcca gaaacatggc ctgcatcatt 32940 tgtttcatgc tcagccctcc cgctgcctca cctggtgcgt gtccatcctt ccttcacacc 33000 agctgtctcg tcttcgtcaa agctcaagcc agaaacgtgc aatcgtcctt gacatctcct 33060 tcttcctgac actaaccccc atcaagacca tggccctgct tctgaaatag ttgtttgact 33120 tcttctgttt tctccttccc tcctctctcc cctgatgcct ggatcatccc tcctgcacca 33180 ctgcagccac tccttacgct gccctccact gtctccttac agttcatctc tgtgctgcag 33240 tcacaatggt gaaaacttta aaccagaagg acatcccctc cctggtttaa aatttcctgg 33300 tgtcatccca aggaaaaata ttcaggataa aatcctgtat ttatcatatc ctccaattta 33360 ctaggtgctt tatgatctgg cctctctttc tagcctcata gcaatattgc acactctcct 33420 ataattcttt atacttttgt cactttggcc ttctttccta tgtcagtgac agtgtatttg 33480 aaaatacttt ggcaacatgg taatgataga tacaaaattt tcttcttaga ccaaatatgt 33540 atcgtaatta aaaactatat gtataaagta ttaatgattc aactaatgta catttgtata 33600 ttgtcagaac tacagtaagg gtgattcagg cttaagagtc ccaaaggaga atatattaaa 33660 tgattcttgg tatttttttg ttgggggtga gtatcaaagt tctgaagggc tctttgagca 33720 tatgcaaggt agcattccag aaaaaaacac aactctgcac ccacacaaaa cgagctcata 33780 acttcatggt tccgggacca tgctgatccc acttcatgca gtcaagttca tgtctgggtc 33840 tgtgagtgtg tttgagggta ggagtgatgg ttaatggggg cagtttctga aacctgagac 33900 aagaaacaga aactaaattg cattccagct ttacaacttt taacttctgt gtctcagtct 33960 ttgtcttcaa gtggggatac tgatttgggt ttggatttga ggttggatgc actaatgcat 34020 atattgttct tagcacagtg cttggtgagg gcagttgctc agcagatgtg agccagcagc 34080 tgtagcagca acatcactgc ctgtggaggt ggtggaggta gaatattagc aggagtaggt 34140 aatgatgttg aaagggaaga aggaaaacgg ggtgtggggg gttgttcttt aaaaggaatc 34200 acattcctga agtatgaagg cactttttgg tcttaaagtg gattttttgt ttattttcag 34260 atgatgatgt acctattctc ttatttgaat ctaatggttc attaatatat actcccacaa 34320 ttgaaattaa tagtagtcac cacagcgcaa tggagaagag attacaagag atgaaggaga 34380 aaagggaaaa tctttccccc acctgtaagt aattagtttg taaaatgaaa attatgcaaa 34440 tagccgattc aattatggtg gaaagcttct tttttctttg cctagatatt ttaatgtttc 34500 ctggtagtaa cacattttga cttatttcat ggctggcttt gttttccaga aaatcttatg 34560 catcattaag atttttgaag catatgttgg gtgtatagta ttcttcaagt ttaaaatcct 34620 atttgttgta gctcctttgt aatttctatt atctttggaa ttttttcttt cttttttttt 34680 aaaaaaaaaa tgaatcatgt cttttttttt ttttctgaga tggagttttg catttgtcac 34740 ccaggctgga gtgcagtggc gcgatctggg ctcactgcaa cctccctagt tcaagtgatt 34800 ctactgcctc agcctcccga gtagctggga ttacaggcgc ctgtcaccac tcctggctaa 34860 tttttttttg tttttttgta tttttagtag agacggggtt tcaccatgtt ggtcaggctg 34920 gtcttaaact cttaacctca ggtgatacac ccgcctcggc ctcccaaacg gctgggactg 34980 taatccaggc gtgagccacc gctcctggcc gtgaatcatg tcttttgaag gaatttgctt 35040 tagattaatg tatctaagga atcagtttgt ttttcattat ttcttttatc tttaaaattt 35100 ttaattactg aagtgtaatt cacattttaa taaaacattt atcaaagtag ctaatagtaa 35160 aagttcatct tgatacccat ctaattgtac tcttctacct gggggtaacc tgtattttaa 35220 gtttaagtgt tttcccagat ctgtttcagt gtatcagata tctgtgtata catgaaaaag 35280 atacgggttt ggtttctgtg tggaggtgta atttctgttt tacctaaatt agataatgac 35340 atatgtatta ttatccgctt tatttactta agagtatcct ggagggtttg tttgcagctt 35400 agttgttgta gacctatttt tgttttaaga tgctcaaagt agtctacagt tttgatattg 35460 aaaatctatt ggtgggtatt tttttcccag ttattagaaa ttgtgttgca gtttttattc 35520 tttttttaac catatggttt ggttgttctt gtttttttgt taagccattt tcctttctct 35580 agacataagt ctttccagct tcccaccccg actttttact gttataaccc ctgcatgtgc 35640 ctacgtgaat ccttgtattt ctgagtactt cgtgtatttc aataatacta attcatacat 35700 gcagaatttg attttttaaa gacatagagt ctccctgtgt tgcgcaggca ggacatgcac 35760 tcctgggctc aagtacttct gcctcaccct ctcaagtagc taggaataca ggtgtgtgcc 35820 acgatccctg gcttattgat agatatagtc aaattatcct tcaaaaaatt tgagtcatct 35880 tattgtcacc agttgtttat aagaatgccc ctttctccat acttggaaaa ctgaatggca 35940 ttagcctgta gcctttttca gtcggaagct tgaaaaactg gatctgttct tgaagttact 36000 tttgattaga agcaggttta agtgcctttt catattactg actgacttac cgaatgcagc 36060 ttttaatgtg atcaactatt acctcgctta attttatgtc ctttgtccat ctgtatcagt 36120 taaggttagt ttcggctgca tataacaaag acaaaaacca atgtgttaca atcgatagaa 36180 ttgcctttct ctgtcttgcc tagttcagaa gtaggcagcc agggctggga tgccattcca 36240 tggtgtcttt aagaaactag gttcccatct ttctgttgta cctgcctggc ttttcttgca 36300 aaatgtgtgt gcctcccagc taagccatct ccttttgaca gccttaccag acgtctatcc 36360 aatattcctg tctaattcca ttggctggaa tgtggtcata tggccacccc ttttgcaagc 36420 aagactgaaa tgtagtcttg actgggatgc attgctgtcc tgataaaatc aaagttctgt 36480 tgttaagaag aagtgagaat ggacattgag gtagataact agctgtgtcc caggtggaca 36540 tccaaattgt ttcagtgtgc aattatgtgt ataaactaat ttgccttaaa ctttactttt 36600 tctattactt ggcagtgtta attctgctac tttactgcgt ccagtacagt ttaaaactta 36660 actgaaaatt ttatgtgtgc ttcccttcct tatcttggtt tattctcttt tttttgctga 36720 agttttctca gaaaagtatc cttttgagtc tctaaaaaat atctttggat ataagatcca 36780 aacatttctt ttgtttcttg actattgtat gaaccgcctt tgaagataat acttacgatc 36840 ttatttgtta agtcattgac atcctaagtg ttttctatga aacctctagg atttctcaac 36900 ccagcacagc tgacatttgg gtctgggtaa ttctttgttg ggggcactgc cctgtgtgtg 36960 gtaggaagct cagcagcatc cctgcctctc cccactaaca ctagcagtgt acctactgct 37020 ctccctcact ggcgatatcc aaaaatgtgt ccagacatta ccaaatatct gctgggaccc 37080 caacgtcacc tctggttggg aagcagtgct ctagttttag aggtaactat gatgagcatc 37140 cttgaagaaa aatccatgat tatcaaataa gaagactaga acagactgga aatgttcact 37200 taattctgtt gagcttctga ttagattcag gcaagttgac tttaagatcc cttctaactt 37260 tgtgattata ggatttaata gaatcaccta tgattaatag gaggacttcc tgctggcttc 37320 gtctgctaag aaatactgaa actttatcta atgcagtgtc ttggtcctgt ttttagcttc 37380 ccaaatgatt cagcagtctc atgataatcc aagtaactct ctgtgtgaag cacctttgaa 37440 catttcacgt gatactttgt gttcaggtaa aatttttatt ttcctttctg tgatatgttt 37500 aagttttgag aataatatga ttttctgatt tagaatttca tgtagcaact tctgatgagt 37560 aaaataatta gttaaaacta gaacttctaa atttccccct gaaattaggt attataataa 37620 aattaaggca tgagttaaac ttcctttttg gttcctatag gttttttttt cctaggcatt 37680 tgctttcttg ctacagaatc cattgctcta tttaaaaaat tattgtgaac gtatatgaac 37740 taatctgtat gcagtttaaa ctacatagaa ctgaggtcag agctaaggaa atgttgtttc 37800 acacaatgta taattaacac aaggaacctg ttattgaacg gggtcagtga agtatgtaaa 37860 gatcgtcaat tgaggagata aatagaggat ttctaattag aagcagaaag aacactggta 37920 ggaattagtg cagttagttc catgttacgc acatacatgt ttgtaatgtg ggagccctag 37980 ttccacttag gatggtaatt tttcatggtc atatcttctt cgtaccaaat ttcttacagt 38040 ttcttcacct agtccccagt ggggctcaag taagtagcag tgatccctga aagtactatg 38100 ttcaaaagtg cttgagatgt tatggaaaat ttatcatgaa agccacagca atgacaaagc 38160 gcaagatggc atcaagatat tagaagtttc aaacaaagcc tcctttcagc gcagggttaa 38220 tccttgtact ctcacctctg tgtgctggaa ttatttaccc atttctctta aacagtctcc 38280 atctttttat tttacacttg ttacatttat ttcctagaag ttggaaacaa gtgataataa 38340 tagctaacat tgatttcatt tttgttgttg taggcactcc tctaagtgtc ttattcactg 38400 ttatctcatt tattctccca ttagccttaa gaggtaggtt ccatcaccat cccattttgc 38460 cagtgaaaaa ccaggacaca gaggtcaaac agcttgtcca aggtcatgtg gtttgtgaat 38520 ggcaaaccca agcttctaac ttaggcagtc tgacatcaca gattacactc ttagtgacat 38580 gtcacattgc ttatcgggtt tttgaaaagt gtgataaaac ataaaacaat tttagatgct 38640 gaataagata tattgagcat ctaaaattaa aagtgacctt atttccaatt actgccttga 38700 agacacctgg ggcacagttg gaagggaagc tttggtggtt acctgtgttc ttccttttta 38760 aagtagaact tcagtgattt cagacagaga gttctaacac ttacgtgacc tccagattga 38820 gtgatttcta caaaacacag gccctccacc agcaagtgct gagcccctat tgagggagcc 38880 agcacgggac tagagacttc ttcatattca ttccagtagc ttatagcaca gtgacgggca 38940 gatgcccacg taaccatggg gcagtatgat gcatgatggt gtgtagcaga gggggcaagg 39000 ccagggagag ctggcaaggg cagtgggagg gtcccaggga tgttgacaac ccaggtgggt 39060 ttggaaggat gaattgtatt tacccagaat aaagtgtgga ggaaagggga aggcccagag 39120 ggtacagagg agtatagaat atttaggagg tagcagcagc ttagcattac tctcaggaaa 39180 tgagtaatcc atataagagt tgaaacatta aagcctacca aatggctcac ttttgaatat 39240 cagtgtaata cgaggacttt agtggaagac agggaaggta agggtgagct gtgttcattg 39300 agggaatgtt tcatgcaagt ctagaacttt ccctagatct tacaacagta gttcttaggt 39360 tttagaatta ttgatctcct ggaaaattta gtgacaaact atggatgctc ttttggaaaa 39420 tgtgcacatg catatggaaa tttgcctaaa atttttagaa gtttgttaca cctcttctct 39480 atccccactg ctatcccata cacccatcaa agcccaggtt ctctagttaa aaatactggc 39540 ctaaaatgta cccttaagtg gaaatgagaa gaactcaagt gtggttaata gtcttcttaa 39600 ctaatagctg tactttaaaa gttgttttat tggtcaactg aaagttgaat atagaataat 39660 ttaaaccact tttaaaagtt agctctccgt taatgttttc cagatgaata ctttgctggt 39720 ggcttacact catcttttga tgatctttgt ggaaactcag gatgtggaaa tcaggaaagg 39780 aagttggaag gatccattaa tgacattaaa agtgatgtgt gtatttcttc acttgtattg 39840 aaagcaaata atattcattc atcaccatct ttcactcacc tcgataaatc aagtcctcag 39900 aaatttctga gtaatctttc aaaggaagaa ataaacttgc aaakaaatat tgcaggtaaa 39960 gtagtcaccc ctsaccaaaa gcaggctgca ggtatgtctc aggagacgtt tgaagagaag 40020 tatcgtttgt ctcctacctt atcttcaaca aaaggccacc ttttgataca ttcaagaccc 40080 aggagttcct cagtaaagag aaaaagagta tcacatggct cccattcacc tccgaaggaa 40140 aaatgcaaga gaaagaggag caccaggaga tctatcatgc cgaggctgca gctgtgcagg 40200 tcggaaggca ggctgcagca cgtggcggga cctgccctgg aggctcttag ctgtggggag 40260 tcttcatatg atgactattt ttcacctgat aatcttaagg aaaggtattc agagaatctt 40320 cctcctgaat ctcagctgcc atcaagccct gctcagttga gctgcagaag tctttctaag 40380 aaggagagaa caagcatatt tgaaatgtct gatttttcct gcgttggcaa aaaaaccaga 40440 acagttgaca ttaccaattt cacagcaaaa accatctcca gtcctcggaa aactggaaat 40500 ggtgaaggcc gtgcaacttc gagttgcgtg acttctgccc ctgaagaagc cctaaggtgt 40560 tgtagacagg ctgggaaaga agacgcatgc ccagagggaa atggcttttc ttacaccatt 40620 gaggaccctg ctcttccaaa aggacatgat gatgatttaa ctcctttgga aggaagcctt 40680 gaagaaatga aagaagcggt tggtctgaaa agcacacaga acaaaggtac cacttccaaa 40740 atatcaaact cctctgaagg cgaagcccag agtgaacatg agccatgttt tatagttgac 40800 tgtaacatgg agacgtctac agaagagaag gaaaacttac ccggaggata cagtggaagt 40860 atgtgaatct ccttttccaa gtcaccttcg ctaaataaac atgtaacagt gcatccatat 40920 tttaaattta tcacaacttt ttcataactt atttccccat ttactcctct ttttacttaa 40980 agaatgtgca tttgatcatt ccaatgataa actctttagg aatagatgac ttgctgtctt 41040 gtggaacttc tagacttatt ggttaagtct gttaggaatc tatttctcca agacttttcc 41100 ttcttatagg tcaaaaggat aagtagtcca tagtatgaat aactgagggg agtgaagtct 41160 ttttccttat tccattggag tcttggcgct gcagcgtgtg taaagatgta tacgatagag 41220 agtattttaa aacctaggtt cttaatagtg aggctattta aagaaagaaa ttaaggtaga 41280 ttaagccatc gattgtatca aagagaaagt gtgaaaaact acttttagaa atctgttgtc 41340 aatattgatt tttgaagaaa ctttggtcag tgttaactat gaagmaacat ttaaacattt 41400 ttgmtcattt gtaacaagcc ttgtttaact tgtacttatt ttgcttgaag catcacttga 41460 aaaggtttac tcctattcat aatttaattg taattataat aaaccatatc attttattaa 41520 aagtcaaaac aataaaaaat tttgcacttc acagttataa gcacaaatag gttccagcaa 41580 ccaaaattga agaaatcttg aactttgacc gtctttacct aaagattagg ttaaaatttg 41640 agtgagaatg cattctctct gcatgatttc tctgctctac aaatgtttta actgcctctt 41700 tgaaggtgga gaagtcatgg tagcgtttga aatcatcaca gacatgttac ataccttttc 41760 cttgagtata cgctccccaa aattgtttca caaaaagaat gaaaataatt ttatgttttt 41820 ggcctgctat ttatatcttg gctttctgaa catatattaa atttgacaag aaactgtatt 41880 ttatgttcca ttagccttag tatgtgtttt caaaatattt attttaaaat gttgactcaa 41940 aagttaatat aaaacaatag atgtgtaaaa ttctttggta gttaagaata tcctgttctg 42000 aggtttacat tctccatctt tccagttttc accttgtgta ttttttaaac ttttgaataa 42060 taatgacatg gaaatgtaaa ttaagtagga aaaagctggt agcaaacagt gtggcatggc 42120 ctaaaatccc cgtgttgttg ggagtgtgct agtcctcgga agcaggtgtg ttatgttcta 42180 gaacactgcc cccctgcgtc gacagcctcc ggggttgggg gtaagtagaa gsgggtgagg 42240 ggccagcact agttgactca aggcaccctg gtggggacgg agaggttttt tcgctcagtg 42300 gtgcaggcca tcaggcaggg cccgggtgca agaaaacatt ctgtgtgcgc tagtgcgaga 42360 ggatcttcta cagtcacctg ccttcatgcc attacagaca gacgggaagt cactgggttc 42420 taggacataa aaagacctac atgttggcta gcctaaatcg aacccttttg tagtaataaa 42480 gattcatcaa tgttttaaac tgtcccctgt cagccccctg ggactcaggt gaaccaactc 42540 tctttgggaa tctatcttag aagatgaaac cataaagcct tcagtttcag tgtcagggat 42600 gcacactcta tatctggtga aattatggag gggtgaaaac ttctgtacag caaactgtac 42660 ctccaaatct ttaatgtcga aataaagggc tttttgccat ttctgttttc agttcacttt 42720 tacttgttgc tgttgtcagt atctaagata cagtgtaaaa aaggcttcaa aaacaagtta 42780 caaagagctt caatacgctg atagaacggg aactgagcga gaaacaattt tggttttgtt 42840 ttgttttgtt ttttagtttt ttttgagaca tagtctcgct cttgacgccc aggttggagt 42900 gcagtggcac aatctcagct cactgcaacc tccgcctccc gagttcaagc aagtctctgc 42960 ctccgcctcc cgagtaactg ggattacagg cacccatcac catgcccagc taattttgtt 43020 gtatttttag tagagatggg gtttcacgtc ttggccaggc tggtcttgaa ctcgcgacct 43080 catgatctac cctcctcggc ctcccaaagt gttgggatta caggcgtgag taccgcgccc 43140 ggccaacaat tttgttttct aaaatcttta aaatcattaa tttttttctt ttttactttt 43200 ttattctctt aattttataa acagtacaca gatacattcc cattgtaaca aagattgcta 43260 agaagactag aatttccatc tcctcacttg cctcttttca ctaattcact tcctaactaa 43320 tgaaagacat gcacccgttg tgtctcaggt gctcttcaag tttgtgggga catagagaat 43380 gaagcagcgt gcaccctcat agaggaagac aaatagtaaa taagtgtata acaatgtcag 43440 ctagcaagca gttaatgata aaaagaaaaa caatactgca ttggatagat aaggtgacca 43500 acgaaggctt ccctgagaag gtgacatccg atcacaggcc tggggaggga gagggagcct 43560 gtgactctgt caaaatccat gtttcagctg gaggtaacag caggaacaaa tgtcctgatg 43620 gaggaaaatg cttgcaggaa caacggggag gccagtacag caaggacttc ctgagctgca 43680 ggaaggaggt tggagagggg taagagccag agctttggga ccttcagtct ctgacaaggc 43740 gggcagctgt tttgttttga agtgtgatga gaagccattg gggcttttga acaggggaac 43800 aaccaaatct gatttaggtt ttaaatgtaa ccatggacac tgaagaacag actgtgggtt 43860 ggagtgtttg tctgcacgaa gcagccactg tccacagttt aatatttcct tccacacatt 43920 tcttgtgtgt gtgtctacaa gcatacaact gcaaatagat attttaagag aattttttgc 43980 atgcatagaa ttatattgcc ttaaaaattg ctttttacaa aagcagtatg tcatatattt 44040 acatattggt accagtaaat cttcattttc taatagagcc tataggtagg gtcagcacac 44100 tttttctgta acagatcaga tagtaagttt attacgcttc atgggcaaag agaccaaatc 44160 gaggtatgta ggtactcatg agatgattac ataatgagaa aaagacattt tccacaaaat 44220 ttttattgac actggaatac attttttttt gtaatacagg tctattaatg agaaaaataa 44280 aataatttgt ggtgggggaa taataacatt tcatttaatt ggagttcaga ctgagtgttc 44340 ccatcaccaa cattgattgc aaatgtttat taaggctgat ttgtaataag atagatttta 44400 cgtatttcac ttttgaaaat atcttttcac acagacagat actcctgatt cgatgtcagt 44460 ccacagttag ataatttgca ttgagcatct tcattgctta gaagacgctg atggaattct 44520 cttagattct tctctcgatg cctgcctctt agcgtgtcct tatattgcag attcatcact 44580 tgcaattgaa aaataggtgg aagctcctca actgtgcagt taaatgggtt ttgaaatagg 44640 aaattccggc caggtgtgat ggctcacgcc tgtaatctca gcactttggg aggccgaggt 44700 aggtggatca cttgaggtca ggagttcaag accaacctga ccaacatagt gaaaccccat 44760 ttctactaaa attacaaaat tagccaggcg tggtggcaca tgcctataat ctcagctact 44820 tgggaggctg aggcaggaga atcacttgaa cccaggagac agaggttgcg gtgagccgag 44880 atcatgccac tgcactccat cctggacaac gagagtgaaa ctccgtctca aaaagaaaaa 44940 aaaaaaaaga aataggaaat tccctttgct cttgcactca gtctgaaaag tgctgctgta 45000 gtttgggctc aggaagtatg tccacagcca gtttgcatgg gaatggagat cttcttgttt 45060 taacctctga cagcacaaga gagaatcgtt gcttatttgt ggaaatgcgt cccacctgac 45120 ccttggcact gccaatcaca gctcttcaac caccgaaagt cagtttgaat tgccaagtag 45180 ttaaagccga ctggtcatcc tgaactagtg cacagcttgg cttctagttg cttttcacga 45240 aggagacaca gttgtcctat aggtgccgtg tgttcactag caaaagcaga aaagtccttc 45300 ctatacccca cttgtccatg ggtttgatac agattttctt ctttgctgtg tgtgatggat 45360 ttttacatgt cagcaccttg tacatacgtg ttgtgagctt atctgagcaa tttggtcatg 45420 tccaactacc agggtcttgt tcatcgataa tagtcaccag ttgttggagg tcaatgatgg 45480 ttaactactc ttctaccttc tatctaccag atcttgttga aggcaagtat cagaaagaca 45540 tttattaaac atttattggc aagcagttag gaagtggtcc acaaattgac caatatgctg 45600 aaggcccagt tctctgtcct ttagtgcagt gtccatactt tatctgaaag gtttgctgga 45660 ggcagacaac attctatggg caagtttctg caaacttgca ctcagcacca gaccatcgtg 45720 tatcctttga ccctgtggtt tattataggg tcatttaggg attaagcctt ggataccacc 45780 tccagggata ccagccacaa ctcatactag atggttatgc tctgttctgt gtgggtattg 45840 ggttcccctg caatatttaa gccaattcag tgttcttgaa tccatgaatt taaccaataa 45900 gaaactgttt ctcacatcca ttatgctgat taacaagctg atgatgtcac caataaccac 45960 tcatttttgt catccatttt ggcttttaac aaagcatcta atattgggct ggaggattta 46020 caggagttgg ggttttttgt tgttgttgtt ttgagatagc gtctcactct gtcacccaaa 46080 ttggagtgca gtgacatgat cgcagctcaa tgcagcctca acttactggg ctcaagtgat 46140 cctcccacct cagcatcctg agtagctggg actacagacg caggccacca cactcggcta 46200 cgttccccag gctggtctcc aacttctgag ctcatgcaat ctgcccgcct ctgcctccca 46260 aagtgctggg attacagttg tgagccactg tgcccagcct atggtatagt acattttgca 46320 aattctgagc attcaagagg aactgtgaat tactattgtt gcaaataaat agatagacat 46380 atattcatta agtatgttaa attgttgcac ttttgactct tcaaataatt cacaagtgta 46440 ttaagaaccc cctttcccat agcctgccag cctaactcac tggggctgca aaactaagca 46500 atcctagcaa cttgatgtgg gttagtcagt cttaacagaa ggctattgac cacttaactg 46560 tttggttgat tcattcattc atttacatat tcatttttta tctgtcagat gtttactccg 46620 tatctactat gtccaatgta taaacagtga gagaggtaag gttaatagaa agctctgtcc 46680 cttgctttaa agaacttagc taagtaggga aggtacagtc aagatagttt acacacaagt 46740 atcaggaaat tcaaaagtca gagcaattac tttcagtggg aattaaaatt gatattggaa 46800 tgacctctac aacgattaca aaggataaaa ttccgcatta tctattgaag agtgtttttg 46860 tttttttcag aatgaacaaa gtgaacttga tattttaata gatgaatatg aatacagtct 46920 cgttagcaga gttttacttg tgtagaaccc gtataacttg catatatacc aaaggtatct 46980 ctggaaagga atttttccta ggtgtctttt aagattcttt ccagtcttaa tattttgcat 47040 actacattgt aaaataattt catattcaaa tttttgaagc ttagaagaca tttctcattg 47100 gataatgtta agtgtatatt tttacatgtt aaaattatgg attattcagc cttcagaagc 47160 cttttcaacc cttgactctt gcatagtgca ttgtaagagt aaatactaat tgtttaaatg 47220 tgttattaat attagcattg ttagtcttaa ttctgtatct tggaagtagg aaagtaggat 47280 gtggaggaaa ataaatgtta aaaataagag ttatttcttc ggccttagct ctagacaaaa 47340 tttgacacaa gccaagtttc tcctacagtc ttttcatcgt ccacttcttc atctctccct 47400 ttcctagtat ttaagttaca tgtgtcctta tactgtcttg ccctggatct ggctccaaag 47460 tgatcatatt agtcattttc ttctcttttc cctcagtatc aatacttttc cttaatcttg 47520 cttatctctg ttgagtagct gaaggttgtg atttaactaa ttcacactga gaggtgagtg 47580 agtgatcatt tactagcttt cattgatgtg tttgcatttt gatggtatta ttaatccaaa 47640 ctaatttcca aatggtgaaa tttcagataa ctgaaagata aaaatgtggg gtctgtcaga 47700 ttcatttccg tatttgatca tttcgtgaaa acgaagtcaa tgaattgtgt gtgtaatgag 47760 gttgggagga aaatgagagg aagatatatg gctttcacag ggaaatgctg tggaccaaat 47820 tgtgtccttt gacccccaca tttatttact gaaggtctaa ccctcaatgg gataacattt 47880 ggatagggtg atctttggaa gataattagg tttagatgag gtcttgaaga tgggggcttc 47940 atgatgagat taggaccatt ataaaaagac cagagaactg gcttcctctc tctctgccat 48000 gtgaagacag caagaaggta gcctccttca agccaggaag aaagccttca ccggaacccg 48060 accatggggg caccgtgatc tcggccttca ggccaccaaa tctgtggtat tttgttatgg 48120 tagccccagc cgaagaagac agacattcat ccaactgggg tgtgttggag gaagagcagc 48180 taaagggtgc atgttcgttg gaatttcttg gagacattca aaatagatgt ccattaggta 48240 gttggatata gccagccata cctcagctgg gaggtctaga caaggtacag agaattaggt 48300 ctcttcagta atggacgact ttatgggaag tgatgaaatc accttgggga gtgagaaggg 48360 agctgatgac aacccatgaa aaaaccacac ttaggagcaa acacgaataa agagtcatcc 48420 aagaagtggg agagtcagga agaggagggt aggtgtttgt ttacagacct cctgccaaaa 48480 gtggagtcca actaatcttt ccacagatgt tttcagaagt actttgcact ctcaactgct 48540 ttgggtttac cgatgtcaat gttaaaaccc actggcaaat tagtgtggca gagtttatga 48600 aatgttttaa ataaacaaat catttactta gatcattttt tgacttcagg atttgtgaaa 48660 ttgtgaaaac atgttaacaa tatcagtctt tttttttttt taatatcagt ctttcttaag 48720 ttttaaaaga ttgtgttgca tttcttagaa ctttatgttt ataaaatgct ttacagcctg 48780 tttcgttgtt cggcaagaac tgaggcaagt ggctattata aaacttttat tgaatacact 48840 aggaagctgc aaatttattc atgactcaat aacagagcac tacgtcccaa attatatctc 48900 tagtccactg cttttccgat tttgacacac tcatgcttca agtaaatatt tgttatttaa 48960 aaaggaaaat aagtgcgtag tagatataat taataattct aattattttt aatcttaaag 49020 acgataggag attgcattca tgttctaccc cgggggataa agtgggcctg ggagaaaagt 49080 cagtgcaagt caaccataaa agatacctga ggaggtacgg gatcagtcag gatgtgactg 49140 gtttgagtct cgagtggatt cagtattagg gattatggca aagagtgtag gttggtaggt 49200 ttgtggttta gaactggacc ttaaaatctg tccagggccc aggctgcaaa taacaactag 49260 cttgaattca ggaaagtatt aacattttta ttctacatcc tttttcactg agataggacc 49320 ctgtttttga aaagagtgac agtttttacc ttagactctc caaacttagt tatagctggc 49380 tttatagcat tttatctgca aagaagtctt tctcatgtta tatgattttt aatctctgag 49440 ggcactgatg ttaatttcac gttgcattat atttattcat ctgcatctac attgtctatt 49500 gggttgtgag ctccctaagt gtgggactat atcttgtgca ttttgcatct ccagtgggta 49560 gatgattagc tatttgttaa tcattaggta atcaacagtg cagtttggct atcacctgcc 49620 tggcaggttc tagtaccccc taggctgcta cataactttt gcgtcaaagt ttgcattata 49680 ccattgagac catgttatgg tccatgttag ctcctccttc aaaatcccat gtaagtcata 49740 aagtaggcaa actgtttgaa ggaggaggaa gggtgagagt aagaggcacc ctctgaggca 49800 gtagatgagt caaatcaaag tacacatttc acatttcatc gtgggttact taggtctaca 49860 gaggttagca tctaaggaaa ccacatttca cttgaatgag tatccttttg gtttgtgtgt 49920 cttcatggca agacgctggt ctaaggtgga aacttggggg gagtaaaatc atcatccatc 49980 atttgtaggt tgaagcctga agctctgtac tgaagactat tttctagaaa atctcaaact 50040 gaccccaaaa cttagattaa ttattgcctc taatatggaa ctgcctactc tgaagagctg 50100 ttctttgtca ttattttaaa atctaagaat ttaagtttga cgagtgcgta aggtatgggt 50160 atacattttc ttacattatc aaatggacgg agttgatgct gtagaacact gtaacctgat 50220 tgttaccgac cattgaatta agtgaattgc ttgggatatt ggaatgtaat aaactgaaag 50280 ttctagatag atctcaaaga gccagatata tacaatttat ttaaaaggcc tataacttcc 50340 tgtttccatt atgcataaat gtgatttttg ttttgcttaa gttgtatttg gtccatgtaa 50400 agttctaact aatttttaat ccccttgggt tttaggtgtt aaaaatagac caacaaggca 50460 tgatgtttta gatgactcat gtgacggctt taaggacctc atcaaacctc atgaggaatt 50520 gaagaaaagt gggagaggca aaaaggtcag tgtgtaaaaa tattatttta aactttcaaa 50580 tgctgataca tcataatgtt cttctctggg tcaatgaaac ataaaccagt ctatctgact 50640 tgtcttttat tttaaaaaat tgattatggg taaatgctgg aaaactcaga atatgaaact 50700 gaaagcgttg tttgcattcc agacaaagag ttattattga tagagcaagc tttctcatat 50760 cactttgcta atgcatttct tataaaaatg cctgtagctt ctctcaagca gagaatgttg 50820 gttgtgccag tgtttcttgc cattttataa tcggaataaa tatttactag gtaggaggtg 50880 aagaatccaa acattcattc acttttgaac taaccaagtc ttgacctcaa gccatcagag 50940 tgaaaggttt atatactaac actcaggtac acccttcact ttgtggtttt ggctttaaaa 51000 ccttgctctt cctctgaaag actccgctga tcctcttaca tgagtaatag aatgaggatt 51060 ttaaatgttt ttatcattca atatctactt gcattgctta aatttaaaat tagccatata 51120 tattatacct tgtgcctcat ttttatgagg ccaaaaaagt ataatgtagt gaaacctgaa 51180 ttcagaatgg tagggaaaaa ccataccgat tgaaaagcaa cagatgaaaa gaatgacaga 51240 gtagatgggt ctgcatgggg cttccaggtc ctgatacgca ggcttgaaca gatgggcggc 51300 tgcatttgac ctgcggaaga gaaacctgac tcctttgctt cttatcttgg caatggttaa 51360 aagacattta aaattacaca gatttcatga aagttggcag taacttgtag aaacttagat 51420 ttctttattg atgctttctg gtttgtctcg gaaaaaaaag tggagcaaga aaatggaaag 51480 gaaccctatt tcaggtaaag caacagatgt ggagagagag agactgtcag ggtcccataa 51540 catgtttgtg gcgtgggcaa caccaaggca cctgctctac aatggcgttg cgcactgtga 51600 ctccactgca gcctgcggga cctgctcagc gcgctgcctc ccaggggtgg ggcccttcct 51660 agaacgctcg caacactgtg gctgagtttg tgttttgcgt cccagtttct cagtcttctt 51720 cctactgcta catggccgct tgacctagtt catttggaaa gaaataaaga accagtttcc 51780 tttgcatcta ctaccgttcc cgtgcctctc ctgctgatgc gtcgcatggc accacagctc 51840 tgttctgtgc cctcccgctt tactgaccct ttaccctctg ccagtgtctg cccagggaag 51900 ccgtggtacc tctcatctct attggtactc tacgttgtac catgtctggc tttttttttt 51960 ttaagtgctc agtaaatatt gagtgttgag ttacttgtta ctcaccataa aaatactccg 52020 tcctgtctga tcaaaaggca tgaggtttga ctttctcatt tgcccacagt ggaagttact 52080 gtttcagacg agtggtattg ccttcctgtg cctgggatag ccctgaatct gatgggctgg 52140 gtctgtggaa gcactgggtt agggacaggc atcctgggcg ggagtgtggc cccttcttcc 52200 ttatgaggca tctcactgta aatggcatat gaatgggaga tgggtacctg tttgactttc 52260 tggcattctt ctgtagatca aatagtaagt gctccataaa tataaggtgg tattactgtc 52320 ttgagtaatg ataaaagaat gagtggtcag agagggagac aaaatacaca attacaaata 52380 cacacctcca tatctgcctt caactgctgt gctcaggaac aaaaatattt tcatatatta 52440 aactgcctaa cttgctcaaa tttaagtctt cttttaaaaa tattttaaga gtattagtaa 52500 actttgccct cataatttag aatgtcattt ctgaaacgaa tccaccactt ctggttctgt 52560 gtgaagaatc actcaaagca ggttttaaat gcagattttc tgggccagtc atggtggctc 52620 atgcctataa tcccggtact ttggggcggg cggatcactt gaggtcagga gttcgagacc 52680 agcctggcca acgtggcaaa accctggcca acatggcaaa atcccgtctc tacaaaaaac 52740 acaaaaattg gccaggcctg gtggtgggca cctgtaatcc cagctgctca agagactgag 52800 gtgggagaat cacctgaacc caggaagggg aggttgcagt gagtcgagat catgccactg 52860 cactccagcc tgggcgacag agtgagactc tgtctcaaaa ataaataaat aaatgctgat 52920 tttctggccc cacctgagac cctcctggcc agcagctccc gaccccagtg cggcaccccg 52980 tccttaacgt ggaggggacg aacacctagt gagggcgaag aatccacctt ctgtattgcg 53040 tctcgccaat agcagaagga gcaagaccta ggtttcccct ctttcacagg attttcttcc 53100 taatccagtc cttattagtg ttcaccgcac agcctttgct tgaatgaatc aaaaactcct 53160 aatgccctag ggtagtgctt cctgactggg ctgcgcattg gactcacctg gggatctgta 53220 aggtttgtgg ctgcctggcc ccaagccaga catgctggtg tcattaatat ggggtgcacc 53280 ctggccacta ggattttttt aaactcctga ggtgattcta atgcaaagca gagtttggaa 53340 actactgcct tgggactttt agaatttaaa caagtaattt atcctagaag aagtttcatt 53400 tctttctaaa catttctcat gtaaagttgt ttcattttta gactctaaaa ttaaagacca 53460 aggcttaaag tcctgatttg cgggctgggt gcggtggctc acacctgtaa tcccagcgct 53520 ttgggaggct gaggtgggca gatcatgagg tcaggagatc aagaccatcc tggctaagac 53580 ggtgaaaccc cgtctctact agaaatacaa aaaattagct gggcgtagtg gcgggcgcct 53640 gtagtcccag ctcctcggaa ggctgaggca agagaatggc atgaacccgg gaggcggaga 53700 ttgcagtgag ctgagatcgt gccactgcat tccagcctgg gcaacagagt gagactcctt 53760 ctcaaaaaaa aaaaaaagaa aaaaaaaaat tcctgatttg tttgcttaaa ggttgagtga 53820 gtgttttagg agcgcaaatt tgatagcaat atagatgaag gacgtgtttt attattttac 53880 aggttagaag gaagaatgat ataaatttct taaaaggtaa cattaaattt attttatttt 53940 attttatttt tctgagatgg agtatcactc tgatgcccag gctagagtgt actggtgtta 54000 tctcggctca ctgcaacctc cgcctcctga atttaagcga ttctcctgcc ccagcctcct 54060 tagtagctgg aaccacaggc acccgccagc acgcctggct aattttttaa gttttttgta 54120 gagatgggtt tcaccatgtt gaccaggctg gtctcgaact cctgacctca agtgatctgc 54180 cttccttggc cctcccaaag tgctggaatt acaggcgtga gccacagcac ctagccagca 54240 acattaaatt ttaagtatat aacttcccag tagtttgaga tcttttgata tgagcatggg 54300 gagagaagtt tatgttgata tgtggtaatg agtccacaga aacactaaaa tttagtttcc 54360 tggttttaaa agtatacagt ggaattgtgg aaggattgaa ttggtgaatt aaaattagaa 54420 gcttctgagt agcagcctac aaatataatg ttagtatctc aaccattctt tttttcccat 54480 taaataggtt ttacctgctt attttgttcc ttgttagatt tcaagataaa ctgtgttaaa 54540 ctgaaatttg gaacttaaca cggccttttt tgtttgtttg tttgagatgg agtctcgctg 54600 tgtcacccag gctggagtgc aatggcacag tcttggctca ctgcaacctc tgcctcccgg 54660 gttcaagcga ttctgctgcc tcagcctccc aggtagttgg gactacaggt gcacgccaca 54720 tatttttatg tataaggaca tattaaggta ttagattcta ttaagcacaa aattgtttct 54780 atttcctaaa gaaaacaaaa tcttgtaatt gaatattaat gttgaaaaag ggagagttta 54840 caggaaatat ctttcaccag ctaatgactg aagcaatgcc tctactagaa tggagaacag 54900 taaggtctgg gcctgacatt tttatgtttt cacttgagag ccagcctaca tgctatttct 54960 gtagtgagga aaatgatttg aaactcagat gtgtcccgtg gccctaatga ctttattttc 55020 tttttagttt taaatctgaa gtagcacttg caggtaatgt cctatctggg cagccctgca 55080 gacaggactg tcagtcgatg agagctgtca gtcgtgagtt ctgagtaatg tgaaggtgcc 55140 aggtagaagg tacaaaggca agaaaggtgg gaaggcctgg agcctgtgcg aagagcagca 55200 cggccttggt gtggcccggg gatggatgca gaaccgcgag aagagagagg ctgacttcag 55260 ccacggccac gggctctggg gttagactgc tctcatcttt ggttttctgt aggttcattg 55320 tgattgttgt accagagtat tgtttttgtt gtttatttac ttgagagtca caggccgtcc 55380 tgtctttgat ctgttctgga aacttctcca ctgtgatttc ttttgcctgt tttctcacgc 55440 ctccattgct gggaacgcaa tctcgtgtgc tatcctttgc ttctatagcc catgtctcat 55500 gattttcctc tatttctttc ctcttgtatc tccttatttc attctggatg tcttctattg 55560 gtttcttttc catttcacct ttgactcttt ttaagtctat tctgatgcta aatccatata 55620 ctgagtttta acatgtatta tttttcagtc cctgctattc catttatttt ttttaattat 55680 tttttgtaga gatgggggtc tctccacgtt ggccaggctg gtctcgaacg cctggtctca 55740 aacaatcctc ctacctcgtc ctcccagggt actgggatta caggcgggag ccttcatgcc 55800 ctctatttga tttataaaaa ccatttccag ttctctgtca aaattattaa tcctatcttt 55860 tatttatttg aacatattat gcatatttct tttgaaataa ctcccttttc tggctcccct 55920 caatttctgt ttttcttatc tgttgttttc aatcatacgt tccatatcta atatgcctgg 55980 ttagtttgtc tttatcttcc tagcagggac tgagatgatc tggagctggg gttctgtctc 56040 tgtgaggcta gctgtcccct gggagtgtgg gcttctgact ctggttcacc tcctcttcca 56100 tgggtttctt cttccatgac tcactgattt agtagctggg caacgtctgc aaatagctgg 56160 ggcttgtttg tttgtttgca tcttgtccag cttttctgag ggctcacagt gaggagccta 56220 tttcaaacta cttagtccac cattcctgga gacgatgggt gaattttaac ggccacttaa 56280 cttttctaaa tagagttttg gtgtgaatgc ttctctgaga agacagcagt aagaggccaa 56340 gtcaagagaa atgatttttg agatgaacac gtaggtcagt ttgcaaaaga cacactaaac 56400 acctgaattg acattaattc agtttctctt aaagagtgaa aaaaaccatg attccatgaa 56460 gaattataga atctcagagc tataacttcc attagctttt tttttggtgt aatgcccatt 56520 tttaatggca aaaatcactc tataaatcag ccagaaaaag agtctgtttt tttttagact 56580 tattttaaat atacttgttt caaatttgtt gagacttttt tttttttttt ttttgagatg 56640 gagtctcgct ctgttgtcca ggccgaagtg cagtggccca gtcttggctc actgcaacct 56700 ccaccccacc aggttcaagt gattcttgtg tctcaacctc ctgagtagct gggattatag 56760 gtacctgcca ccatgcccag ctaatttttc tatttttttt ttttttaatt agtagagaca 56820 gggttttgcc atgttggcca ggctggtttt gaactcctga cctcaagtga tgtgcccgcc 56880 tcagcctccc aaagtgctgg gattacaggc gtgagccacc acacccggcc tggtgagact 56940 ttatttggag gatccagtta agcagtttta ttacctctgt aatcttagtt gcagcatgta 57000 ggtcattgac attgatagtt atacatcttt tcagagggag aaatagaaaa tattatgacg 57060 aattttgacc tgttttcttt gttacttgtt gaatattgtc agacacagaa cccaaagaag 57120 ctatgtatag ataccagcac tctggtagaa atacacgaat gtaatttttt tttctccaag 57180 tatttggttt attctactac ttctggattt ggtttttcaa aatattgatt attatcctca 57240 ggaacatttt taatgtgagt tatcaacagg atagcttttt gtaagtggct cagttgtaga 57300 atctcatttt ggagccatct ctgccaatcc agcttgttgc atgtgaaggc aagctgtggg 57360 tcagagcaca gaaatgttta cagaggcttt cctaagcctg gaggcctgga gagatgtgaa 57420 ggaacaaata gagcatactt attttgatag tggtttaaaa aaattaaaga attacacacc 57480 acatagaatg cttaaattcc tgaaagtttc tcaaataggg tgcaaaacaa ataatagctt 57540 gcatatgctg atagttgctt gttcttacat ctttgctaga atatgagccc ataaggacat 57600 agtctatatc ctgttagtct cttaatactc agcaggatat agcatcacaa acaaaataag 57660 tgctcagtaa atattttctg agtaaataag agatgcatta atttcccttt tactttttca 57720 gtgaacatgt ttaaaacatt tttggtgctc ttaaccatca ctcagtaatg atggaatcat 57780 catcatgtac ttcacttatt tttgaatatt cttccaaaac ttgagagact gtcttctttc 57840 agtaaaagat ggattctctt ctccaaggct gtgcatggca gcgcagtgtt gctaaagcat 57900 tgcccccaga gccagatgcc tgggttcagt cccatctctg ttactcacct gctctgtggg 57960 ttccatggtg ttgaacaaat tacttaatat ctgtgcctat acttctttgt gtataaaaca 58020 ggaataataa taatagtacc agtctcctca aagggtttgt gctaattaat tgagttgaaa 58080 catgcaaaga gtttaagata gtacctcata tatagaagtg ctcaaaaaat gttagctatt 58140 ttcttcagca ccagcttggg tgagggtcat gtctgcatat tgactgtgct ttgttctgca 58200 gctataactt ggagtaggtc tctcttacct gcctcctctt tgcccactcc cagagaccac 58260 catgtgtctt taatgaaaat gaccctcaaa actctgggac agtccacact gtgtttcttg 58320 ttggacttac tgaccacagg catgccagag ccaaaataga gtcttgggca gggggtgagt 58380 ataggagtat agccttttct aaaagctcct tcagtgattc tgagctgatg gtcatcctcc 58440 cattgagaac ctttgttttg ggggtgagat gtaggccatt agcatgaaat tgtgctctgt 58500 catctccccc aggaggcaga agactgagtt ctgcggtcag aaatgcccgc ttgggggatc 58560 tgcttcctca gttttcgaga gatgctttcc tcatctccag tatcattaga accttcctga 58620 aagaactgag atctttgtga gctgcgatag ggtactcaca gctgtcattt attgagcatt 58680 gtgacctctt tttagattga gttttctatt tctcagtcat atggaaagct gaaaagaaag 58740 tatatttcag agagctctaa tcatgtcttt attgcggagg cagtagattg ggaattacag 58800 ctcatttggg tgtagcatcc ccggagaagg agccttgcag tggaaagaag ataaaagggt 58860 cccagtggcg ggaataaaaa gagtactaga tgcccagagg gtgggaaagg cctagcccag 58920 atgcagtgtg gccaggccag ctaggggcag gaggaaagag agctgcaggg atacagatgc 58980 cttcctgagc agagaaaata gaatacttga gccaattttc atgtaaaatg gattattttc 59040 ctggcgtttc ctgtccttca agtaaaaggt tctggaatga gtacttcact gctgtaatgg 59100 agacactaat attttatgaa tgcagtttta cagtttgcag taatgccagg cctttggctg 59160 ttttccatta gatggtgcac ttggctggaa gcatatactc ttgtagcttt gattttaaat 59220 ttaactttca agttgaaaga gcagtgactc atccaaagga caggtgatat ttatttattt 59280 tttcttgaaa atgcagcacg ggtatgttgt tatcacacgt ttaggggaat tgccacactt 59340 cctcgaggat gacacccttt gtaaatatcc atgtaaatca tttccattgt tcagacccgc 59400 tgtacgcaga aagataggcc ctttagtgcc gaccagccgg ccagtgagct ctgtaagatc 59460 gaaggtgccc ttggtttcca acacagctgt ttcagtgatc tgtaattgct ttgataaatc 59520 acttttggca gagtgtaccc agagctggca gtggcgggga tgtgctcgtt gtaacaggtg 59580 tgcggtccat cagcagatgt tgcttgatga agccatttaa aaaacagctg cctgttgata 59640 gcctaacagt tgctttcagc ccccattagc acgttgtttt tttcttgtta tgtatgagag 59700 aaaatatttc tacagaaaac attaaatagg atcttcaaag aactccatct ttttaaaaat 59760 gtgttttatt tgttcactaa ctgattttgc atgcattgta aatgtgtggt tcagaaattg 59820 tcaaatgtgt tttggactgg acgtggtaga aatgaggacc agccagggtg gatctcctgt 59880 gcctcagtgg tcgtctttgg ccacgtaaag gtagaggcca ccgacggagg acatttccca 59940 ctgggagacc cacaggcgct aagagaggag ctagccgaag aagtctattt aagatctgct 60000 gctttggcca ggtgtggtgg ctcacgccta taatcccagc actttgggag gccaaggcag 60060 gtggatcacc tgaggtcagg agtttgagac cagcctggcc aacatgggaa aaccctgtgt 60120 ctactaaaaa tacaaaaaat tacctgggtg tggtggtaca cacctgtagt cccagctact 60180 cgggagacta aggcaggaca atcacttgaa cccaggaggt agaggttgca gtgagccaag 60240 atcatgccac ggcattctgg cctgggcaac agagaagatt ccatctcaga aaaaaaaaaa 60300 aagaaaaatt ctgctggtag gcattctatg cactgagcaa aggagagatg tggaggccca 60360 atttaaatag ttacagctgc tagctcctaa ggtctatctt actatctgca ccgtttgcgg 60420 ggagtcagct taatgatagt aaactgtgct aaatgggtct agaaatatcc aattaatctg 60480 tttgagatat tcggaaactc aatagcttgc tgaagtagca aacttgaatc cttattttta 60540 ttttaaaagg gagtaaaggg actgtagata agtaaaagat gctctgcact gcgcctctct 60600 ggtaccagtc cctctcgttt aggcagcggc cacttcccgc ggagctgttc acgccaagtg 60660 accctgccac tgcgctgctc ccaccacccc atgtccaccc cgtcctcgga cgcctggtct 60720 cagcacatca ccggtattct cttcctctta ccagtaatta gtttgagact gtgactcact 60780 tctgtccaac aagatgtgaa gggaagtctt cctgggaggt ttctggaaag cgttctctca 60840 cttgtgatag ccctgggaag aaatgctccc cgggtcctca gagctttgtt gtggctggac 60900 gcatcttctg gaactgcgac agcggaggag gaagccaaga gagtgaacca aaacaaggaa 60960 gggcggaggg cgggggaggc ctgcaaacct tacggcttat ttccactgac atcagagact 61020 catgttaata agtaacaagc ggctttgttt gttatgctcc tcagacacgc ggtaagggag 61080 acacacagaa atgcacagct gtacgtattt gtcttgaagg ctagaattta ctttaaatgt 61140 gagtggtttt cccaggaaaa atttatgtct gttctcttga ggaataatta tttcctactc 61200 aattttatct atcgatccat ccatccatcc atccatccat ccatccatcc atccatccat 61260 ccatccgata cagagcctcg ctctgtcgcc caggctggag tgcagtggcg ctatcttggc 61320 tcactgcaac ctctgcctcc ccagttcaag tgattcttgt gcctcagcct cccgagtagc 61380 tgggactaca ggcccgtgcc actacacctg gctaattttt gtattttttt tttttttttt 61440 ttttcctgag acagatcttg ctctatcgcc aggctggagt gcagttgcgc aatctttgct 61500 cattgcaacc tccgcttccc aggttcaagt gattctcctg cctcagcctc ctgagtagct 61560 ggtactagag gcacgttcca tcacgcctgg ctaatttttt ttttttttga gatggagtct 61620 tggagtctcg ctctgttgct gaggctggag tgcagtggtg ccatctcggc tcactgcaac 61680 ctccacctcc tgggttcaag tgattctcct gcctcaacct cctgggtagc tgggagtaca 61740 ggcgcgtgcc accacacctg gctaagtttt tgtattttcg gtagcaacga ggtttcgccg 61800 tattagccag gatggtctca ctctcctgac ctcgtgatcc gcccgccttg gtctcccaaa 61860 gtgctgggat tacaggcatg agccaccacg cgcagccttt ttttgtgttt tagtagagac 61920 agggtttcac cgtgttggcc aggatggtcc gatctcctga cctcgtgatt ctctcacctc 61980 ggcctgtcaa agtgctggga ttacaggcgg cagccaccgc gcctggccta atttttgtac 62040 ttttaagtac agacggggtt tcaccatgtt gtccaggttg gtctcaaact cctgacctca 62100 agtgttccgc ccaccttggc cttccaaagt gctgggatta cagggttgag ccaacgcgcc 62160 ctgccctcaa ttatatttat ttctttgcct ttccttacgt ctttaactct tcacactttt 62220 aaaaaagtta ttgccttcca aataatattt aggaatataa attatttgat attaatccag 62280 ggtaatttcg atttgttttt aaaaaagggg aataaaaaca ttattattca gaaggggtta 62340 aatacaatga caaaaactgc aattcagaat taatgaggcg ttataatagg gtttgttaaa 62400 aaaattatga ggtatttaaa atagattttt ggcatatcct tttgtgactt ttggatagac 62460 ttaagactta gtttatatat caatagtgag tctgtatagg aaaagaatat aatattcagt 62520 gactgtcaaa ccagtgactg gagcagcttg gtatgaagcg cttcttattc tggtctccct 62580 aatcagtgat tttcaatttt gaaaactttt ttttgaagtt gtgttgtttt atttttctgc 62640 agaaatatct tctgcttttc attttaaagt atatttgcta tttatttgca atctagttct 62700 catcattaaa agcagtacta aaatcttatc ccagaattta taggttgtgt cttttgtcct 62760 ttttttgttt ttagtatttt tctgtcactt tacttcctca ggtgaagttt taacaaaaac 62820 gagggaccat ggataggaaa gtaggaatga aacagtttac agggttgaag ttgtggtata 62880 attctttttt tttgttttgt ttaaagacag ggtcttgctc tgttgcccag gctggagtgc 62940 cgtggcgaga tcatagctca ctgcagcctt gattgcctgg gctcaagtga tccctccagc 63000 cttggcctca tgagtagctg agactccagg caggtgccac catgctcagc taattttttt 63060 tgtttgtttt agagatggga tttggctgtg ttgaccaggc tggtcttgaa ctcttggcct 63120 caaaccatcc actcgcctgg gtctcccaaa gtgctgggat tataggcatg aaccaccatg 63180 cctggcccat ggagtaattc ttgtggagtt ggaaggtaga ggtgtgtacg tgtctgtttc 63240 tcaaaatagt agcactagcc aggaaatcca tgaatttgca tatttttccc caagttcagc 63300 ccatttgctt tggtgagttt ggggttatac ttagagtggg tagtataagg agtttctgcc 63360 ctacacctta gcttaagcaa tttgagcaca ttgctttttg agttcaccac caaggatcca 63420 gagctcagag gcagtctttc ctgtgcagat aagagtgcac cctgcctgca cctcacggtc 63480 ttgggctctg tggcttctct cctcctgcca ctgcccctta ttgtgggtag gctggaattc 63540 cctatggtcc tttgtttggg gaagggggat gcttggatgt tcccgggtgt cacctgtgca 63600 tgccccctat gctgtcctcc cacctgccct gtcctacaag catgacctgc acccttctcc 63660 cacacaccca gaccgcagct tattcttact ctccctggcc agcccctctt cttggagagg 63720 agaaaggatg atgtgaaaat aatatctaac attggggctc cccagcgact tccacaagga 63780 gcaaggagct aggtgcatgt gtagacccca tgggagcttt agtgttagat accgagtttg 63840 ctagatgaaa catcttttta attgaggtgg tgcagatgta ttgtttgaac actttagaca 63900 ctaatgatga actacttgga tgtacatttt tttggttttt tttttttttt gctatgaaaa 63960 ttagaaaaaa tatttatcca agacagtaag tattgaaaac tgatactggt gctgtatgga 64020 tcactattat tgtattattt gaaactgttt ggaaaaggta ttgtagtttt tagaaaaaca 64080 aagcaacctg aatattaaaa gtctgtgaat ttgagtaaaa aacagtccac ataagggaaa 64140 aaatatataa ggaaggacaa tgaagttttg aaactgttac tataagaaag ctaaaggctg 64200 agcacagtgg ctcatgcttg taatcccagc aatttgggag gctgaggcag gaggatcgct 64260 tgaggccagg agttcaagac cagcctgggc aaaggagtga gacctcatct ctactaaaaa 64320 taatttttta aaaatattag ttggacatga tggtggccac ctgtggtcca agctactagg 64380 gaggcttgag accaggaatt cgaggctgct ctgagccgtg attgtaccac tgcactccag 64440 cctgggcaag agtgagaccc tgtctcaaaa ataaacaaaa aagaaactta aagattttag 64500 tctcaatttt ctacattgaa cccatcttta gatcatagca tgtataaaat taaaaatggg 64560 ggaatatcaa cattattata tttaatgcta tagcttatta ttgtatttaa taagctactt 64620 gtttaaagat ctggggtctc ttgggtccac agactgagtc tttctgaagg tgctttacac 64680 gatgtagctg ccagggatct aggtcatata atatcctcag gatgggattt gaagacattt 64740 ttccagaatt tatcttttgt catattggat tttattttta aaaatttcct ctatagtcaa 64800 aatttatata aatatatgat tctgatagta ccatatatat ttagatgggc ttatactggg 64860 cgtgaacaag gttaataatc tttgtgaata tgtgggttat ctccttattt tacttattct 64920 taaggaaaat taatttcact gtttaccaaa gaactgatag ctaaacccaa aagatttcaa 64980 agaatgtttt gtttttgaaa tgtttctatt tatcactaat aaaacgggta tatctgttta 65040 agttgaccta tctttggtct tactaaaaca aaatcagcta gaccatttcc caaataatca 65100 tgcattcaat actctttttc tctctctctc cctgctccct catctctact cctttagaac 65160 tttcagaaca ttcttttgtg tagatacagt gtttcatgtc tgttattgtt tctcactggt 65220 cgttggattc tttcatgtga ccaccttttt cacgtttgct ctgattgcct ttggatgcgc 65280 ctaactgtgt gcttttcctg ttaaggaaaa gaatcctgca tgtttttttc tcatcgaata 65340 acaatgttaa aaacagaaaa gggttgtttt tcttctttgc agtaggcatt ctgtagtaga 65400 taccttgaca tacttaaatt tgtgagatgt gtctagacga atggaagagt aatatctcat 65460 attaatatat tgctaataat aagataaagg tttcagcttc ctggagctgt ccatataata 65520 gaatttgtac ttgttttttc atttctgaga tcctcatact ttggggtttt ttttattttt 65580 ttattttttc gagacaaagt ctcgctctgt cacccaggct ggagtgcagt ggcgcgatct 65640 ccgctcactg caacttccgt ctcccgggtt caagcgattc tcctacctca gcctcctgag 65700 tagctgggat tacaggtttc ctgccaccac acccagctaa tttttgtatt tttaggagag 65760 ataggtttca ccatgttggc caggctagtc tcgaactcct gacctcaagt gattcgccca 65820 ccttggtctc ccaaagtgct gggattacag atgtgagcca ccatgccagg ctctgagatc 65880 ctcgtacttt taaataaaat gttaagatac atgctttatg cttttgctgc ctctcatgtt 65940 tcatgaatac aagtaaaccc atgagtaact catgaataca cataaacttc tgggcctcca 66000 aacgatgccc tgccagtggc catgccacag gaatcagagg ctgtacttca ctttgtggtt 66060 gctttattat tccaccatta taagctttag tagaaaatgt aaagagggtt gttaaactga 66120 aggagtgttg tctcaaactg aaggagaaaa gtagtgttgg tgctgtaaga tgtacataaa 66180 ctaaggggtg tcttttctac catccagtta gcaattagga aagtccttct ttgctcatac 66240 cattccaaag ggagtcatct tattctttct ctaaatttcc ttacaatgga ggctgctaca 66300 gtttaagtat cgaaggtcct tttttttcag atttcacctg cagtgcctat aaatttgggg 66360 gaatgccttt ttttgggggt gaccaacata ctcagtggat cttggaccta ccaccaagtg 66420 accttccttg ctcacctgta aggctgagaa caccgtaagc aaagtaccag gcttctttcc 66480 ccaagagggc tttgtaagcg ttggcgccat aaaatcaacc tgaggactta ggtggctggt 66540 tatttctgag taagtgaata tcactctcaa atacgacatt ccagcaaagg ccatggttgc 66600 atagccactg tttttagtta tgtcctggta actaggaaga tggattgttt tttaatctat 66660 gcaaataatt atattgcgct gaaaaaaatg atactcaatt acagtttcac aattctggag 66720 ggatcaggca gggataataa gataccattt ccagatgttt cctttctgtt tataaaagca 66780 tagtcgactg aattgttagg agatacaggc agagggagaa gagaaagggt tccttatgta 66840 tccagaatat agagtgttaa aatagcaaca atactgtaaa caaaagccgc agtcctcctt 66900 cagtagttca tctgggccta gtcattaatt tttgttccac ttgatcttgg gttagcagtc 66960 tcatgaatcc gtctgcttct caatgagggt tatagaaatc ctcttcccct ggtggggtct 67020 cagcattatt tagacaatgc cataagaagc ctgtacccaa aagtacccag tatagttctt 67080 ctccacgggg ctctaacaca gccccctctt ggtcgaaggt aagtcactct ggcctatagc 67140 taattgcaga tgctgatcag ggaagtgtca gagaaacaca gaaatctgta ggtgacaaaa 67200 gattttaaat ggctatggtt ctcgtattac tgataatttt caaaactaaa tttattgaga 67260 gttcattaca acagtattgg caactgataa gtaaagttag ttatggtgtg caaaacagag 67320 tcaacccgaa aaagttctag atacaacatc tagaaacacc ataattaacc ttattttaaa 67380 agaacagtgg atgttacatc taatttataa aaatggaaga acataatctt tacagaaaaa 67440 atcttcagat ataacaaaat agtcccaaga catartatac aatgaatatg ccaagcatat 67500 aattagaata gaccaagaat atcacatcaa gagggttatt ttagagggga cataaacacc 67560 tatgtattaa taacatatat ttaacctagg gctggctatc ttttttgatg tgacaatttg 67620 tcccatataa cttatcaata gtaacacatc aaatggatct cctaattatt tcaagcatct 67680 gttttttatt aaagtaaaag cacaaatact ttttattttc caggtatgtc tggggaatct 67740 tagacagttt tttgttttgt tttgtttttt tgagatggag actcactctg tcacccaggc 67800 tggagtgcat tggcccgatc ttagctcact gcaacctccg cctcctgggt ttcaagccat 67860 tctcctgccc cagcctccca agtagctggg attacaggtg cctgccacca tgcctggcta 67920 atttttgtat tttttagtag agatggggtt tcgccatggt gtccaggctg gtctcgaact 67980 cctgacctca ggtaatccac ccgcctcggc ttcccaaagt gctggaatta cagggataag 68040 ccaccatgtc cagcctcaga cagttttaag tacaaaatat atcatttagg atttgatttg 68100 cggaaggcaa aatatcaaaa attatcaaga aattttgaat acctgattcc aataggatca 68160 tgtaacttag aaacaatttt tgactaccta tttaatcaaa gtgactgtaa aaggttttaa 68220 aagtaaacag agaggtaaca tgattgtaaa gaaccttagc tctttcctaa gagacacgaa 68280 ttcttgaata ctcaagggta aaataaagtc aatataaacc atagaaggtt attctcataa 68340 aacacagaat ctttggaatc taagccaatt atacagaaaa aagaataagc ctttattttt 68400 taggtgaatg tggtaaacag taaaccaaag aaacaggctc atcaatattg ggtaaacttt 68460 tctttgtttt taaatgttta gtctttagtt ttaagagatc atctgcattt tttctgtaat 68520 aaacttaaaa gatatccact tatatttctt cagatttatt aattctgtag cattttaagc 68580 attgaaatga cagtttttct ctcaatcctt tttttttttt tttttttttt tgagacggag 68640 tcaggctctg ttgcccaggc tggagtgcag tggcacgatc ttggctcact gcaagctccg 68700 ttctccccag gttcacgcca ttctcctgcc tcggcctccc aagtagctgg gactataggt 68760 gcccaccacc atgcccggct aattttttgt atttttagta gagatgaggt ttcacagtgt 68820 tagccaggat ggtctcgatc tgctgaactc gtgatctgcc cacctcagcc tcccaaagtg 68880 ctgggattac aggcgtgagc caccgcgccc agcctgtctc aatccttaac aatgctatat 68940 ttgttgtatt tcatatgttt agctttctca tggagaaaaa gaaacatagg cataaacctt 69000 tatactatcc gcctgctggt cctgcaacat gagtttaata aagcgttcct gatacttaaa 69060 caatttctat gatgtcagca gagagatatc agcaagagtg attgtaaagt agctagcctt 69120 ataagtcaag agttataatc tttgatccac tgctcaatcc atttcaagat ctgatctaca 69180 ttattttcta gctcttctgg tttattgctg ggcagccgat gcacaacttc ttccttgtag 69240 gatgccgtgg cttcttcata aagaacttgg aaaatctcac actgaatatt gtcttttagt 69300 ttcttctcat tataacccct catttgaagt atttcgtaca atatgttggc atctattctc 69360 aacacaaaaa ctatgtgaaa ccagcgttca gggaagaaat cacaaccgtg gtaatcaaca 69420 ataactccac attctctcat ttggttatct aactcatcag ctactctgtc ttcatctaaa 69480 atgggacaat tatactcttc atcatagtcg tcatacaatt rcttttctca agctaaatca 69540 cccacattaa tgtatttcaa tcctgatttt gattctgata tgtggttttt ccaacccctg 69600 gtgtacctgg ctttctatga cacgtttcta tcaccaagtc agaacaaagt gacactttag 69660 gactgaactc agggagtctg tggggtcaaa actaatttca taatactact aagactttaa 69720 catgcaatgg gttcaccttg ctgtctccaa aaaaaaaatt gcaccactgc actccagcta 69780 gggcaacaga gcaagaccct gtctctcaaa agtaaataaa taaataattt aaaaaattat 69840 tgttaaaaaa agtttgtcag gttaatgatt caatttgatt aagcacaaat ttacattttt 69900 tcatagtctt aaactttagg agtaacgttc acttatttga tcagtaaatc tgtatagctt 69960 ttgtaagaac atgtaaaagt agaatagcaa tgtatagtgt ggctgggcac agtggctcat 70020 gcctataatc ctagaaattt ttggagtcca agatgggagg attgccgagg gcaggtattt 70080 gagaccagcc ttggtgacat agcgagagac cccatcttaa aaaataagaa taataatact 70140 taatgctgac aactcataga agacatgact atttttatta aaccccaaat attcaactag 70200 tctcatttgc caaatattta cctaaatgtg tgaacttgaa ttcttaaaac atttacgttt 70260 ctataggaat acttttttta gtgctgttga aagtattatt ggaagttcaa tttccttaat 70320 ttctgggaat tttaggaaga ttcaatttat aggtgtctct ttatttctaa gccagtcaga 70380 acagaacatc cttaagagct atcacattct cacttggtaa gaccatctca tgatggttat 70440 cccaggatga gagacaatag ctgctttgaa agttcccctg ccacactggg cttccagtac 70500 cagtgcagct aatgaccctg ccctaacagc aaatgctggg gagcagggtg caagtgttta 70560 cttgggtgcc cttcacgggc actcctttta cgtggtggac agcctgatgc tttgttctct 70620 aaaccagtat caggcattcc tctcatggga gatgtgctta tcctggcaga cgcccttgtg 70680 gctcttttct gacccctctc cagtttatga ctgcctgacc atcgctctgg tgctcagagc 70740 ctgcccttgt gttcctcccc agcatcccgg ggaaaaccca ggtagcctgg gagagcccct 70800 ggttcttcag atggaatgtg caaattcagc acaccaacac gataggaaat aagttccaag 70860 atttattact tccagatcct agagagggag ggcgccatga gtcgggaggg caatgctcta 70920 tccccaggtc accagaagaa tgaatgaagt gtcaggcata gagcaagaga gagtgggacc 70980 catgggccac cacctttact gggggccagg gcattgtcca agcaggtttc ctgcagggag 71040 ttttagttgg tgagtttaaa acaggcagcc atgagtttca ggatcacaca gcaactgaga 71100 ggtggtccct gtggcatact ccacagtcca tgtggggtgt ggggttggca gggcagccag 71160 gtagactgtc tcttagagag gccgtcacca gaaagaggag gtgtataagg cagatccctg 71220 gatcaacccc attgaggact gggggtggca ggtggaagct gtcgagggaa actaagccct 71280 gtttctggta tgagaaggtt aaacttatca tcaaaataga tgccaaggct atatgaaact 71340 gtcagtattc actacagtgg catttccaca gtacaataca gacatacaaa cagacataga 71400 taatttgtaa gctgtaattc taaaatttca ggccaggcgc ggtggctcac ctctgtaatc 71460 ccagcacttt gggaggccga ggtgggtgga tcacctgagg tcaggagttg gagaccagcc 71520 tggccaacat ggtggaaccc tgtctctact agaaatacaa aaattagctc ggtatggtag 71580 tgggcgcctg tgatcccagc tagttgggag gctgaggcat gagaattgct tgaacccggg 71640 agatggaggt tgcagtgagc cgagattgca ccattgcact ccagtctggg caacaagagc 71700 aaaactccat ctcaaaaaaa aaaaaaaaaa agaagaagaa aaaaattcag tcatagacca 71760 aacttaaaag cagaaatata aaattttact cagatgtcta cttcctgatg gcatgaaatt 71820 cttaattgtt ttgaaaccaa agtagaaaag cagacaaacg aaaaatacta gcaaatcaga 71880 ttctgttatc tttcacccaa cagagacaag atctctataa accagcagtc cttccccaaa 71940 tacgtagtat acaaaccgct tcatgtctgt cattttcgtc aaccctgggg tccttcaaat 72000 gccttttgtt ccttctcatt tacttcacct tgacttttca agacatattg gttatactac 72060 acagttggtt acatttgaag tatttcatgt aaattacaaa agtatatgaa taatgtgaat 72120 tcatttttgt ttatatatgt atatgcatgc atacacatac acacacactc ctatagagtg 72180 aacatttggc tgaatatact gccaaattgt taaacaatag tcatttctag ctggtggaat 72240 tacaggaaaa tttgtgtttc tgattatata tttctatagc atttaaattt tttgcaagtc 72300 agcgtgcatt tcttagataa gcaaaaaaaa aattaaacat tttatttaaa ttttttttca 72360 attccagtta atagcagatg tcaatagaac aaataagttc ccttatccat gcttctgtat 72420 gtgggggatt cacttgacag gtgcaacaga agcacaagca ttattgtgca cctgtgtctg 72480 aaatgagaat gaggctgcct agaagtcttg agaaaagtgg ctgacgagtc tacaaaaaca 72540 cccttcttac cctttctcac tttgaagtgc atgaagacgt tgacacactt ggaggtctgc 72600 tggctaactg gtggaacaga ttcctggggg aaattttttt gttttgctct tgtacctcat 72660 gtctggatta ttttggattg ctttggggac agtatctgag tttctatctc ttggcctgtt 72720 ttttccagga atataaaggt tttttttctt tgacatatgc ttaaatgttt atttttaagt 72780 gatgtaactt ttcaaaaaac ttattacagt ttatttctgt gggaaaaata ttttttakgt 72840 ttttgactgt tttttgttcc ttcttgtttg aaatctctag ccaacaagaa cattagtcat 72900 gacaagcatg ccatctgagt aagtacttgt tttgatttct gttcaatgta aaatgttaac 72960 cttttctctc ttatactcta attctgggtg cctttaggca acttgtcaat ctgtcctgta 73020 tcacttttac tttataaaat taatatctga gttagaagat cactgaaaat taaacatgta 73080 ccaaatgtga gcgacttagc cttgaaaact ctggggttgt ttaggcagca ttaagaggtg 73140 tgtgctcgtt ttggtgttct tttgcttgct tgataccaaa tagcttcatg aatgttcaag 73200 aagtggaaca tcattgacca aaacatttcc cttaaaggtc ttaaagcaat actgcagcag 73260 aaagctttcc acagcagtgt taaagttgct atgtatgcat tttgtggaag ggtcaatagc 73320 ttgttggcat gctcttatca tctcccttaa acatttaaca caacaaagaa catccaacaa 73380 aaatacagtg ctatattctt tgcaacagat ttttgaattc ctgtttaaag gggaaaacca 73440 tgtttttgat atcaatcata ggttttaagg ttttaagaca tccatcaaaa cattggaaca 73500 tttcagtgaa aaatatgctg cagagagggc acctttagaa cattttcagt agtgggatcc 73560 ttttcctgcc tggggcttag aaataaaagc actgatcatc aaacaccata cattatatag 73620 tgaaaaaggg ggtcactcaa aatttttgta aatatattat gaaatatatt gaacattcta 73680 aatagtctaa tacagaagcg aatattgaat atatgtgtaa tattttttaa agtctttgta 73740 tttttccaaa ataaaagaaa aattactagt taactgctta ttttctcatt caagatttaa 73800 aaataaaact tttcatttag gccatcttct tgtcttactc tttttttctc cacatggact 73860 tcttgtgata cttaagaata agacctggac attctgattt tatgtggatt agctgagcct 73920 tgcagagaca cttgttactt actggcacat ccagcaagca gctgccagcc tcaggatgga 73980 gttctaggga gtgtgtagtt tagagctttt tactttttgt ttttgttttt gttttctttt 74040 atcatttttg cctttatttc tttccaagtt taattatttt tcttgactca agcacacatt 74100 ctcgggttga agtagtgatg aggcccagat cttgactcac acatcttttc taccctaagg 74160 atctcttaag aatttaaaag catgatataa ttcagccctt tcattttaca gataaagaaa 74220 caggttttga gatggacata cctaagatca ctagagataa aactaagaag gctgggtgtg 74280 ttggttcacg gctataatcc cagcactttg agggtcccag gtggacatat tgtttgagcc 74340 taggagttca agaccagcct gggcaacata gcaaaacctt gtgtctacaa aaaaatgcaa 74400 aagttagcca gacttggtgg tgaattgcct atagtcccaa ctacttggga ggataaggca 74460 ggaggatcac ttgagccctg gagatcaagg atgcagtgag ccatgattgt accactgcac 74520 tccagcctgg gcaacagagt gagaccctgt ctcaaaacaa taaaataaaa ctaaggaaca 74580 ccatcatttg gaaggaagag tgttagaggc agtctgtata agcatagaca ataacctctt 74640 cccctttgta atataatttt tggagaggag agatgtttat ttctttttct atttatttat 74700 ttatttattt atttatttat ttattttgag acagagtctc cctctgtcac ccaggctgga 74760 gtgcagtggc gcaatctcct cccactgcaa gctccacctc ccgggttcac gccattctcc 74820 tgcgtcagcc tcctgagtat ctgggactac aggcacccgc gaccacgccc ggctaatttt 74880 tttgtttttt tagtagagac agcgtttcac catgttgttg tatatatcac agtgtggctt 74940 agaaagccct ccattgggga ttttttaaat tttctgggag agagggaaaa ctaatgtcag 75000 aactaatggc atagaaaggt tattataaaa gggaagaaag aactgagggt tgtttggtaa 75060 ggaagttgga cggaaagaat atattttttt aaaggatatt ttaagtatta agggaatgac 75120 agagcaggag ataagccata atggtcatga gctttgtgac aaataggtcc cagatttgat 75180 ttgatgattt aataaaaagg gtcttttttc ccctcttagt agaaaaacta tgtgttgata 75240 ctcaataaat attacatttt caaaataaaa taagtgaggt tcttggttct gagcatgcac 75300 agataggttc aaataggcct gaaaaacaaa tcattgcccc agtgggaaga gtgttggtct 75360 gatgtcaggg gcctggttcc tttttttctt ttttcttttt ttcttttttt ttttttgaga 75420 cggagtctct ccctgtcgcc caggctggag tgcagtgaca cgatcgcggc tcactgcaac 75480 ctccacctcc cggattcaag ctattctgtc tgcctcagcc tcctgagtag ctggaacaac 75540 aggcgcgtgc caccacgcct ggctaatttt tgtagttttt agtagagacg gggtttcacc 75600 atgttggcta ggctgatctt gaactcctgg tgatccaccg gcctcggcct cccaaagtgc 75660 cgggattaca ggtgtgagcc accgcgccca gccaggggcc tggtttctga tgctggctct 75720 gtccctaccc agcccagcca ctgtgggaag ccattgacag cctgtgggct tgtcttctca 75780 gccattaaaa tagaattgag atctgaagtt tatttcccca ggtttcaaag cattgattat 75840 aagtcagtta agatatacgt accataacca aaatcagttt caaattttgg ctttctagtt 75900 ttattagtac taatattgag tgtaactgct ttgatgggca tgtgcaacaa agtcattcat 75960 tttgttaatt tttcccccga tttgacagaa agcagaatgt cgtcatccag gttgtggata 76020 aattgaaagg cttttcaatt gcaccagacg tctgtgagam cacgactcac gtgctttccg 76080 ggaagccact tcgcaccctg aatgtgctgc tgggaattgc gcgtggctgc tgggttctct 76140 cttatgattg ggtaagccct gtgtgtgaat gcgtatttta aaacaaggca ttttgataga 76200 gtgggtcacc ctgaggtgcc gacatcagca ctcaggccgg cgtgcaccct tgtggatctg 76260 cacactttcc tgtgagctgg gaacacccgt ctttcctcct gttggtctcc cgtgggctgc 76320 tacccttcaa ccagggccaa gttctggggc aacaggagga cggggagggt agagagcagg 76380 aagtgagtag cctctaagat aaagcagaag caagattaca aagatgctga aagaaacgca 76440 aaatgcatgt tctcacagtc aaagagcttt cctctatgtg tgaccaagaa acattgtgag 76500 ctgtggtggt ggtggtttgc agagccaaaa taattcagtg attgtttgta cagatggatt 76560 tacttaggat gaaggatgtt cttttaatcc catttggata ggttttatcc tatgtatatc 76620 tatctgtaac attatttgcc cttgtttctg tagattaaag atagctttta aaaatacata 76680 attattttcc ttattcataa aaactgaaat gaactgttat tggttctatt attactttca 76740 tcctcaacct aaggttgctc caaagcattc ctttctggtg acagtagcat cacttgttac 76800 gtatgttacc attctgcatc tgtgggatcc gtcttccctc ctcctctccc aagaatgtat 76860 tctattcata ctcatactgt gttcatttaa accagtagaa ttataacatg caaaagctac 76920 acatgtattt tcaagaatgg ccgtcgtctt ttttccgtgt tgtgacagag gttaaagaga 76980 ttagtgcttc tagttgtgaa gtggaaaacg ttgaaattcc aaaagtaagc actgttcatt 77040 tgcattggtg gcaatggggg atcaccttac ctgattatat attagtactg ctttatgttt 77100 atttggatga aagacagtag tgcccctctc atccagggtt ttgttttgtg tagtttcagg 77160 taccatggtc tgaaaatatt aaatgggaaa tcccagaaaa taacaattta taagtcttta 77220 aatgcattct tttctgacta gcatgaagaa atctcaggtt atctggctcc attctccctg 77280 ggatgtgaat cgtccttcag tccagcctgt gcatggagta ggtgctgctt gccctcactt 77340 agtagccatc ttggttatca gatagaatct cgtgattttg cagtgtttgt cttcaaggaa 77400 cccttatttg gcctaataat gttccccaag cacaagagta ttgatgctga caactttgat 77460 atgccaaaga ggagctccaa ggtgctttct ttaagtgaaa aggtgaacgt tgtccactta 77520 atatggaaag aaaaatggta tgctgacgta gctaaaatct atggaaaaaa tgactctttg 77580 acctgtgaaa ttgtgaagaa ggagaaaaaa ctgtgcatac tatatatata gggttcagaa 77640 ctatccacag ttttaggcat cccccagggg gccacggact gtgccccctt tggatagggt 77700 ggactactgt ctctttaata actctagcat cagtgaatga gttctgtgtt ttatttctct 77760 ccaattcaaa tcgtctctgt gtcttcatct gactactctc ccttccctca ggttttggag 77820 gaaaaaatgt tatttctaag gatatgcatc tgtacaggat tccttaccca acttattctt 77880 ctgggacttg gagcagtcca tagaggtcag acgtgagaac gtactgcctt tgctgtcgac 77940 atggatagag acctgctccc tggttgtctg catgtctctg ctcagtgttc tgctagtact 78000 ccacagctaa tcatacatag aaacagaact gggtgaaatt ttaggttatt gtatctcttc 78060 tgggattacc tgatatgata aaggtgggca ttaaaacaca ttatttaata aacttctcac 78120 ctttagtcta gactccttgc ctggagggaa gaacctgggg cactcagaca cataagtgaa 78180 tgaatgaggt acaaggcaat cagacaagaa aagataataa aaggcatgta ggttagaaag 78240 gaagaaatag agttatctct atttataaac cacacaattt tctatgtaga caagtcacaa 78300 gcaatctaca aaacagcaat tagaggtgac agctgagttg agcaagtcat ccagatgcaa 78360 gaattccatt gaaacttcag tataaagcta ataaaataag tgcaggatct gtgtgctgaa 78420 aactacaaaa tactgatttt aaagctcaaa gaactaaata tattaaaaga catacaatgt 78480 tcatggatta gaagacatag tacagtgaac atgtcacttc ttcccaaaat gatgtataga 78540 tttaacacat tctcattcaa aatctcagtg gactctttca agatacagac aaactggttc 78600 taaaatttct atggagatat taaggagcca gaatagccaa aacaatttag aaaggaaaga 78660 acaaggagga ggactggcac tacctgcttt tggggcatcc tttcaagctg tggtcctcaa 78720 ggcagtgtgg tattggtgga cacacagaac agacagagaa tccagaaata gacccccaaa 78780 atacatccca tgggttttca caaaggcatg aaggcaattc agtggagaaa ttcagtcttt 78840 tgaacaagtg gtgctggagc agttggacat acacaatcaa gaaaaggaac cttcccaaca 78900 ctttgggtgg atcacctgag gtcaggaatt ggagatcagc ctggccaaca tggtgaaacc 78960 ccgtctctac caaaaataaa aaaactagct cggcatggtg gcacctgcct gtaatcccag 79020 ctactcagga ggctgaggca caagaatcac ttaaaccggt gagatggagg ttgcaaagag 79080 ccaataccat gccactgcac tgcagcctgg gtgacagaga gacaccctgt caaagaaaag 79140 aaaagaaaag gagaggagag gaggaaggaa gggagaacct cattctatac cttacacgag 79200 ccacaaaaat tacctccaaa tggatcatag acaaaattta aaggtataaa acttctataa 79260 gtaaacatac aagaaaaatg atcttggtgt aggcaaagag ttcttagata caccaaaagc 79320 atgatgaata acagaaaaca tagataagtt agatttcatc aaaattgaaa gcttttactc 79380 tgtgaaagat attatgaaga gatcagaaga aaacgtttgc aaatcttata tctgacaaaa 79440 gatttatgtc tggaatatat aaagaactct taatactgaa caataagaaa acagaacagc 79500 tcaaacaaaa aatggcaaag aaaagatttg aatagacagt ttactgagga cacacagatg 79560 gcaaataagc atctaaaaag atgctcatca ttattgctca cttcagaaat atagtgagat 79620 ccactacata tccattagaa tggctaaaag aaaaaataac agtcgcactc tagcaaggag 79680 ccagggcagc tggaacggct gctggtgcgt gtgggaagtg gtccagccgc tttgagaaac 79740 agtttgacag tttcacagaa agctaaatgt ccactcagca gtcccactcc cagatatttg 79800 cctcggagaa atgaaagctt gtgttcacac agagtctgta cgcgaatatt tgtagcagcc 79860 ttacttatca tcagctggac ctggaaacag cacagctgtc cctccagtgg gtgaatggat 79920 caaccagctg gaccaaccat actgtggagt gtcactcagg agtcgaaagg aatggtgata 79980 ggtacagcag cttgcatgac tctcaggggc atcatgccaa gttgaatagc tggtctcaga 80040 aggtcacatg ctgtataagg ccatttcttt gtcattctag acaaggccaa actataggga 80100 aggagaacag atgagtggtt gccgcgcatt aaggtgggag tagcatctgc ctctgcagaa 80160 caatagcagc tgtcacatct ttggggcatt ggaattgtgc tgtgttgtta gtggcaatgg 80220 ttacagaatc catgtattaa aacacagaga actgtacaca catatgcaca cacgagtaaa 80280 tcttattgtt tctaaattta aattaaaaag aatatctagg cggggtgcag tggctcatgc 80340 ctgtaatccc agcacttttg gaggccgagg cgtgtggatc acgaggtcag cagttcaaga 80400 ccagcctggc caagatggtg aaactccgtc tctactaaaa atagaaaaat tagctgggca 80460 cggtggcagg tgcctataat cccagctact caggaggctg aggcaggaga atcgcttgaa 80520 cttggaggga ggaggttgca gtgagccgag atcacgccac tgcactccag cctgggtgac 80580 agagtgagac tctgtctcaa aaaaaaaaaa gtatatctta catatctaac gtgctttcca 80640 aatggagatg tttgagcact ggtaggaccg ggctagtgtc ttggtttcag aactaggttt 80700 ccttctgtgt gctgaagttt acaggctcct gtaccttcaa ctgctgcctc tgtacctata 80760 cttcctgtta gcactgaagc ttcatcccag cttttctatc ttaaaaaaaa aaatgaaaag 80820 aatttaaaaa cataactttc tctaaattgc tctttgccct ctgtgctacc tttttttccc 80880 ctcattcatg gcaaaacgtc acaaatgtat gtctgtattg cccttgcctt actgatgatg 80940 tcgctatttg ttaatagtat caactcttgg gagattgcga aggctcaggt ggcctatggc 81000 ttcaggtgaa atatctgttt gtgtgattac aaggtaacca tgatggcagt caggtatatc 81060 acacatatat aaatgacaca aacagatata aatatatgtt tgtgtgatta caaggtaaac 81120 gcaatggtaa ccgcaatggt aaccacgatg actctcgctg gcacaacagg agtattgatg 81180 ttcacaggtt gctcctgact tgcaccctca aaaagtttag aaacaagccg agtcactttc 81240 tctgttcatc tcmgtcttca agaagacaaa gacgactgct gcttcttgca tggcccccct 81300 cctttaactt ttaaataaat tgaatagtac aaacataaga aatttgagag aggatagttg 81360 ccaccaccat ttacaaagcc attctacata atttttaaag cttagcaccc actttaatat 81420 ttatctatgt cttgcatata acttcagata taaacttcac agttccaatt tcttttaggg 81480 tcaagattta aagtatccat atcatatatt atatacattg actttgtgta caaggaatct 81540 ctctctctct ctctctctct ctctctctct ctggcactct cgctctctcg ctctctcgtc 81600 ctcctccttc taaccctgtc tccaatgtag ttgggggatt cttaaaatat tctctttggc 81660 tagcagtata aactggcctc caagaaaaac actgctgagc atgtttttat ttcagggttt 81720 gtgtggtatt ctctggaaat ttcttgtaaa ggagatttgt agcagttctt cagaattaga 81780 tggttgtatg tggcccagct agtcttatca gaaactgtgg cgattttata acaaagttca 81840 gtttgaattt tgacttaata tttttgagaa gtttattggc aatttttcca tgtttacagc 81900 agttcacacc tccagtgtta gcgctactgt tttcaggaaa gagaataatt tatgtttttc 81960 ctccttcatg actgaattgt ctggcagata catggaaata gaaaaccatg ccaggagttg 82020 ccgagcttcc tatttatggg agacaggaag taacacaaca gaaaaataaa gaaattaatt 82080 tgaccaaagt gtccctttag actcacattg ttttgttatg tgttgttcaa gcatagcaca 82140 atttgaacct ttaaatactc tttatcccac tctcacttaa tttgatgttt cctgcacttt 82200 cctgtgactt gtctaaaatt ctactttccc tcgaaaccct tttgtggatg ctaacataca 82260 agcagagtgt cctgtgattc agtcttccct ttttccagct accactccgt gtcactctgt 82320 ccagcacagt gaggaataac tcagcctgta ttcagatttt aatattttga ttctgaacag 82380 cttatgaaaa ggatctgata atagagattt aaagctaatt cacttataaa tacaagtgta 82440 gggcttaaaa gctaaatcag ctttacaaca aaatgtcaag gccgctaact atcaacagat 82500 aatctagtgt tttcttaatc aaaaatgatg tcatgatgac tattttcttg agataatgtg 82560 atccacattg aacttagtaa gcagtgagtc agatgagata tgtttttatc agtggtgagc 82620 atagaatcaa tgaactgtta gaataacaca ctcagttcat tccgttcacg cgtctcattt 82680 tacattaaag aaatgctgag ccgctctcct aaaattataa ctcatggcag aaccagaact 82740 ggaatctcag cttttcactg gtgttagttc atcaccctgc attcctaagt ctgttcaaaa 82800 gggatcatct tgaaaaacca ttctcttttt aaccttcagt tggcagatta acttcataac 82860 tcatgttagg aagaatcttc aggcacattg tacttggtgt gtcacactga cactgagttt 82920 ctgagggtgc ccttcaggtc tctctggcag acatttattg ctcgcacttg caagctgact 82980 aggatctcag gcctgggtct ctgaactttc acggcttgat ttcaaagtcc tttttatcct 83040 gctacagatt ataccttggt aaaggacttt atacttcaca gagtgttttc acatgcactg 83100 tctcactgga tcctgacaga acatttttgc agccgagaag gacgctgcaa ataattagtg 83160 agtttagtga tggagactct gggcaaaaat agcttgtctg acttgaatgt ggatcttaga 83220 aacacatctc tgtcaaggca ttgttttaag gcagtgacta tggtcttaca tttatctcca 83280 ggacacctaa tttatacttt ttcctgatta aaataatgga ttctggtttt gcccagacat 83340 agaacccaca gagtttgtct gcttctttca cttgaggtgg ttcctgagca gtgccagagc 83400 tcattctctg cggaggctcc tgcaggctgc ggcagcgtgg cctctggccg ctgggagcat 83460 gggaagcagg cgctgcggtc taggtcctcc atccccctgt ctgctgctcc tggcaagacc 83520 ccaaggtgcg catttcccag gttggagccg ctgtgcttcc caggaccata atctgctgat 83580 tgaggacaga taccaaaaag tgattcatct gtaaaattga gggctgtggt gctgccctct 83640 aggaggacat ttggaaagat gtggagaaac ctgtgagtgc taagaatgac tgatgttaaa 83700 gtttgaaaga gtcaaagtga tttttttagt gggagaagac tgtggagtca ccctgagatg 83760 caaccacagg cttgattaga aataaagttt gatcaccatt ttcaaatttt tacattaata 83820 ttttttaatt ttcgaaaggt gctaaacaga atctacttaa tgcacctggc acagaaaagg 83880 cagtgcccgg gtcctaaggc tgcacctttg caagaaagag maatacctga ggcaccggga 83940 gtgaggagga caggtgttgg agaaggctgt agggccccag tatggctgtg tagttcaaga 84000 cgagggatgc agaagccatc ggactatttt aattacagag tggcagcttt tgtctctgtg 84060 gcctctcagc aaagaatgga ttgcagggag gtaagaacag ggtgagaagc aggaggcagc 84120 tagggtcatc gaggtgaaaa atgactgcgg ctgtgtctag agggggggtt gataggtgga 84180 gaggagagag caggtcggcg cccttcctag gaagatctag tggaatctgt aacgtcaggt 84240 gtgtgggaat ggagaagtca agaagactcc cacccaaatt ttttcctggg gcgactaact 84300 atagataatg gtgccatttg cagagttagg gaattctggg gcagaagatt gtgtgcaagg 84360 tttggggtac aataaaaaat tgatgtaggc atattaggtc tgagattcct actggacatt 84420 caaatagaga tactacatat cagattatat atatgtacat atattcagag gaaaggttaa 84480 ctattcactc cagccatggt acctggaagg gagtgtgaat gaagaaatga agaaaacagt 84540 gagtttaggt ttgatctctg ggctgtgccc tatgcagaag tcagggggaa gggggaggca 84600 gggggacccg ggaacggcta gctagcaacc tgggggagac accaggggaa catggcatca 84660 gtcagaaggg ggactgtctc aggaaggaag gatgctcagc tgtgctgagt gctgctggaa 84720 ggtgaataag aggagacaga agccactgtt tgatttcttc aggtggatgt tgtcagagac 84780 cttgaaaaaa gcaggatgaa tccaatgact aagacagttg aagagtcaat ggtacataaa 84840 gcagtggaag cactagggtt atgtgtaatg gtgcgatttg ctgagttagg gattattatc 84900 agacatattg ctgatatgtt attcctagac ataatgctgc tgctacatca gagagattgg 84960 ttggcagcga atggggcact gtgaagtgtg actcgagcct tctcgtgttg ccaactgcaa 85020 cacagatcat cgtcctagtg cttggcgatg tggttgcatt atggtgagtt gagtgtggcc 85080 ttgggaagca tctgaatctg ttggctgagt tatcagggaa aaaaaattta aaaagtaaac 85140 taagattatg tatattaatg aaaaagttgc tgtatttggc aaatacttta aatggataag 85200 gctaaaaacc aacaagtcga gagggtactt gttgccaccc atccttttcc aaatcatggc 85260 cttcaaggat cacactgttg gtctttcctt ttcttttaac ttggatcaac tgtgaagtaa 85320 cacaggtctt cagtgtagat ctcagttccc caacatttgc cttatgactg agacctccag 85380 gacgtcaact tggtccatgc tgaactgcag cacaaattcc aagctttgac catacctcaa 85440 ggtgcacttt aacctttgca gtgttctgcc agacatctga actttcactt ttgtttctga 85500 catctcaatc acacagttct cactgtaaat attaaataat agcacagaat attttaactt 85560 caggtattca ttggaaaatt caaccatggt ttggttttat ctgtcacttc aaaaactgtc 85620 ttcagctgtc catcatttag atgtcattta gatgttcctc agggactttg gggacattgt 85680 taacaatctg ttatttcaag gcttctaaac tctatcccca agttaaaatg atttccaagg 85740 aacatcatac ttctcttaca gtctgtgtgt aagcaccctc tgtgaattcg gttttaggga 85800 caatgttagc ttttgaagag agctgatgta agaaatacta gattttagga aactgttgta 85860 cttttttcaa agctatattt gacgacattg tacattttgc tacctgatac ttttgatgta 85920 tgatccacct aatgcctttc tcctaaaatt aatttccagt gaattgaata ggaattccaa 85980 atgaaatgaa tttcatagga aaatctcata cagaaaattt gttaggctgt ccttaaccag 86040 agaatgagaa ttatgtaatg cggttttgtc agctagagta acagcttgcc ataggttcat 86100 aatagagctg ttttttagtt ctttttcttg ggttcttgtt tctgaaagaa agtttctctg 86160 ccagaatatt gaagtcgtgc ctaagttaat aatttaacaa gcattgtata tattaataat 86220 ataatatcaa taattaatgc tattaatcat taataacaat tatttaatat taatattaaa 86280 tacttaatat taaattttta gaatattaaa atttaaaatt taaaaaataa aatttatcaa 86340 aaaaaatttt ttttttactt ttgaagcatt ggttttatta aactttcaaa gtagtatggc 86400 aaaaaggtgg ccacatacca aatagtgtca tacatttctt aaaatctctc ctagcaaata 86460 aacttaaatt gagatcatga gtcagttgaa aagacaattt aatttttttg ccatacaatt 86520 aaagtatttc tgagaagtca gagtgctttg caatgtttgg tgaataattt acacaattcc 86580 agaataatgt ctcacttatg gagaatacac ctaccactta cttcgataaa cagaagtaga 86640 gtctatggtt tctttctttt tttttttttt ttttagctgc taaagattat tattaggaca 86700 gaaggacaat tagctttaaa agcattcctc agaacatgta tttttttttc tagtattctt 86760 ttttttttat tatactttaa gttctagggt acatgtgcac aacatgcagg tttgttacat 86820 atgtatgcat gtgccatgct ggtgtgctgc actcattaac tcgtcattta gcattaggtg 86880 tatctcctaa tgctatccct ccccactccc ccgaccccac aacaggccct ggtgtgtgat 86940 gttccccttc ctgtgtccat gtcttctcat tgttcaattc ccacctatga gtgagaacat 87000 gcggtgtttg gtttttttgt ccttgtgata gtttgctgag aatgatggtt tccagcttca 87060 tccatgtccc tacaaaggac atgaactcat catattttat ggctgcatag tagtccatgg 87120 tgtatatgtg ccacattttc ttaatccagt ctatcattgt tggacatttg ggttggttcc 87180 aagtctttgc tattgtaaat agtgccacag taaacacacg tgtgcatgtg tctttatagc 87240 agcatgattt atagtccttt tgggtatata cccagtaatg ggatggctgg atcaaatggt 87300 atttctagtt ctagatcctg aggaatcgcc acactgactt ccacaatggt tgaactagtt 87360 tacagtccca ctagcaatgt aaaagtgttc ctatttctcc acatcctctc cagcacctgt 87420 tgtttcctga ctttttaatg atcgccattc taactggtgt gtgatggtat ctcattgtgg 87480 ttttaatttg catttctctg atggccagtg atgatgtgca tgttttcatg tgtctgttgg 87540 ctgcataaat gtcttctttt gagaagtgtc tgttcatatc cttcgcccac ttgttgatgg 87600 ggttgttttt ttcttgtaaa tttgttagag ttctttgtag attctggata ttagcccttt 87660 gtcagatgag tagattgcaa aaattttctc ccattctgta ggttgcctgt tcactctgat 87720 ggtagtttct tttgctgtgc agaagctctt tagtttaatt agatcccatt tatcaatttt 87780 ggcttttgtt gccattgcat ttggtgtttt agacatgaag tccttgtcca tgcctgtgtc 87840 ctgaatatta ttgccaaggt tttctatgct atagaaatag catatttcta tgctattcat 87900 cattaataac aattatttaa taatattaat attaaatagt taatattaaa tttttagaat 87960 attaaaattt aaaatttttt taaaaataaa tattttatat taaattatca aataaatatt 88020 aataataatt atttaatatt ataaaattaa taatctttca ttattgaatt attgattgag 88080 ttaagtaatt aattgattaa ctgataagga ttattgttaa attattgtac tcttgggtag 88140 tacagagact gcatactgcg ctttgccatg taaatactat tgtctacttc ctggtacgtg 88200 gctctaggga ggctatggca gagtcaagtg cttttgccct taatgtgaac aaaaaatagt 88260 gattgctctt agtagccata atatttggtt tattgtctgt gttggtaata atttctgctg 88320 tgttttcata cagtgaagtg atgtttctgc tgtttatttt agttgcattg gaatttgtta 88380 tatttatttc tttgttttcc ttttgataag agaagtacgc acttagttat ttataaagat 88440 gtttggactt cacatgtgag tacagtggtg acatgctggg ttttcctggt cattgcttag 88500 ctgtatttat aaagtgaata ttactgagca gttaagcctt aacatcgaga atcacccatt 88560 ttcatttttg aaaactggaa aggattaggt agaatgcaag gagaataaat tgaacttaaa 88620 tgtttgtgtt caattgaggt gagctttttc ataagaatat tcaagcctag gtcaacatgc 88680 agcttgtttt ccctctcacc acctggaatt cagtctctat cggtcaatgt cttctaaaag 88740 ggaaatgggt tcttaactat atacttttag tactttattg cttatcttcc ctttcttggt 88800 tgaataggct gtgttggata tttagcttcc tgcccctttc tttatgagac agctagggca 88860 gtgcttttca aaaccttact aatgtgtgga tcacctgggg gatcttactg aagtgcagat 88920 cctggttcag tgggtctggg tctgctcagg cttgaggtga ggtccacgct gctagtcctg 88980 tgacccagca ttaggtcccc aggatacaaa atatgaccgg ggatctctgt cgtattcggg 89040 ggtggagatg agacagcgtc ccaatgatgt tagtcacatg gaacatttag agatgcggag 89100 tactttgtca gtgttttaca catcgtcaag ctgttagtca agacagtaat cctctgtgga 89160 aactgtgggt tgaacacttt cagtaaattg ctcatggtca tagtgcttgg aaatagtaaa 89220 tttttttttt tttctttgag acagagtttc gctctgttgc ccaggctgga gtgcagtggc 89280 acgatcttgg ctcactgcaa catctgtctc ccaggctcaa gcaattcttg tgcctcagcc 89340 tcttgagtag ctgggattac aggtgcatgc caccacacct ggctaatttt tattttttgt 89400 agagacagag tttcaccgtg ttgtccaggc tggtctcaaa ctcctgacct caagtgatcc 89460 gccgaccttg gcctcccgag gaactgggat tacagatgtg agccactgca tcctgccaga 89520 aatggtgaat tttgaatttg aattcagctc ttcctcaatt catagcccac attctttcta 89580 gcatctactt ccaaagatag cctagagagt attttttatc ttctatagct gtaaaccttg 89640 atatgggcat tctctgatgg cctgtgtgtt ttgaaaagat taatggataa ggcagtggat 89700 ttcactgcta accttgctac accgtagctg tgtaaccttg ggtaaggcag tttctttatc 89760 tgtaaaagaa tggaaagatc acctaaataa agtactcagt aaacactcaa taaatattaa 89820 atatcgttat tattcaacaa gcatttttga cgctgatcac tagccttcat taaaagtata 89880 acttggatga acgttgaaca caccgagtga aaggagccag acacaaaaag cacatgttgt 89940 ataattcctt tcagacagta tatccagaat aggtaaatcc atagaataga aaactaatta 90000 gaagttacca gggatggagg ggagagaggg atggggagtg attacttaac aggtacagga 90060 tgtttttctg gggtgatgaa agcattttga aactagaaag aggagctggt tgcaccgcat 90120 catgatataa aatgccattg aattgcacac tttaaaatgg ttaattgtat attatgccaa 90180 tttcacctca cttaaaaaaa gtcatatatg gaaaatagct ttaaggcacc actacaacta 90240 ctaaataggt ttgtattttt aaaagaactt tatggaatta taggaagcat ttcttgatgt 90300 tatgagatgt gttggaaata cagaagaata gcttattttg gaacagatat tattggcttg 90360 aaattttgcc agttcaagct ggtctctttg gaagactaga cctttatttt ctggcttgaa 90420 aatgctttgg acataagtac cctattattt tgttgttaaa aattatacta ttgacatccc 90480 caattttttc tcctgaagtt cagtataacc tagaaataac ttcattgcta cactatttca 90540 ttaactacat gggtgctttt ttagttaata atgatgcata atgtcttcat gtggcagaaa 90600 cactaacctg ccccttgtca taaatctgta aaaagatgga cattggttta aacccagttg 90660 ttgaattctg tgcctttaac cagtatgtta cactgtctag ttggggaaga atcccaaatc 90720 ttcttctttc tttagaaaaa tccaaaacag catacaaact agcaaactct cataaatgtt 90780 gtttgagaaa atcaattgcc ctaactacta agacaaagga tctataaaat ctgatgagaa 90840 caatctttgt aatttgattt ttataatttt gtcagcttaa attagtaaaa agttaataat 90900 tattactttt gttacgctta taataaataa tgtgtttcta caccttccat aaacacctac 90960 aaccacactt tttaccacag ttggtggagt gaagggtgga tggaggagat agtggcaaaa 91020 acaccccaat cactttcagt gattaaagta aagatgtgtc taactttact cctaaagtat 91080 catccagtaa agtggaatgt aaaacatact tttgaactgt ttgaaatcaa ctacattcct 91140 atggcttacg actgtgggac aagtttctaa ctatcagatt tgatttttaa ttaatcagtg 91200 atattttata ccagcagtct ccaacctttt tggcaccaag gaccagtttt gtgaaagaca 91260 atttttccag ggacttgggg gttgggaggg tgagggagga atggttttgg gatgattcaa 91320 gcacattaca cttattgtac actttatttc tattattatt acattgtaat atataatgaa 91380 gtaattatac aactcactgt aatgtaaaat cagtgggagc cctgagcttg ttttctgcaa 91440 ctagacagtc ccatcggggg gtgacgagag acagtgacag atcatcaggc gttagattct 91500 cataaggagc atgcaaccta gatccctcat ctgcacagtt cacaataggg ttcgcacttc 91560 tatgagaatg taatgccact gctgatctga caggaggtgg agctcaggtg gtaattaaag 91620 caatgggaag tggctgtaaa tacagatgaa gcttccttca ctggttcacc caccactcac 91680 ctcctgctgt gtggccccgt tcctaatagg ccacagactg gtaccaggac ccctgtttta 91740 cacgatgtgg agtcttttgt atgcaaagaa tattgttgac tttcgccaca cggaagcccc 91800 cccgccccgc ttcccccgcc tttttccttt ccagttacat tcccacaggt attcttagta 91860 ccacaactgc agttgaattt cacagtatgg tgggtggtaa gctatggtgg gcggtaygct 91920 tggataagcc tggctattta gaaatttgga ataaatgtag tgttatgact aacagtaatg 91980 ttgcctatca aaaattgtga atgttaataa atgttttcaa cacaatcatt aatgctttcc 92040 agtgagttaa accagcttca tgttacagtt gtattttcca tcccagtagg gagtcattat 92100 taaatggggt catgttttca agcccaactt aaaatccctc ttacagattg ccttccccac 92160 cccaccccca gttttctctc atcacttata cattgaaata attgcttatt gttttccctc 92220 tttaaatttt ttttgagaag tcaaaaattg agtaccttgt tcagtgtttt tgcttatgaa 92280 atactttgtg aataaatttt gttcttagct gaagaaaatt tcttaggcag ttaagaaaat 92340 actaataagc taattaatga ataaaaacta atttcattgg tcctgattgg aagtgcaaca 92400 tttaccgata tttagctata atccttttga tcagtcagaa atttgtaatt attctttgag 92460 aaataaaaag ttgagagggc tgggtgcggt ggctcacacc tataatccca acacgttgag 92520 aggccgaagc aggtggatca cttgaggtca tgagttcgtg accagcctga ccaacactgt 92580 gaaaccccat tctctaccaa aaaaaaacaa aaaaaaagaa aaaagaaaaa aattaaccag 92640 gcattgtgat gtgcgcctgt agtctcagct acacaggagg ctgagtcagg agaatcactt 92700 gaacctggga gacgatgctg cagtgagcca agattacacc actgtactcc agcctgggcg 92760 acagaggaag actgtctaaa aaaaatagaa aaggaagttg aaaacagctt agggaagagc 92820 tgcaaccact gaccagcacc agtactccat cataatatat gcttttcact tataaggaac 92880 tgtaatgtaa actgtggact ttgggtgata atgatgtgtg aacacgggat gactgggtac 92940 aacacatgta gcactccagt gggagacatc aaaatgcata tgtggcggca ggaggtgtat 93000 gggagctctc tgtaccttcc tcttaatttt gctatgaagc taaagtggct ttaaaaatac 93060 aaatacagaa aaaaacttgt gctttctata gattaatttg aacatagaca cattaatata 93120 atagatacat tgatttgaac ataggtacat taagttgaac acttaaggtt tttatgatgt 93180 cctataccac aataaactga agaagtctgc cttacaaatt tgttcaaaga actctcaatg 93240 ctctcactgc tccttccctg ccttgaacag gaagtgtcat ccagtgcaat aagggggaaa 93300 ataaaatgtg catagcaatc agaaaggaag aaataaagca gtttctattc acagatgcag 93360 ttcctattta aattcatcag caaggttttg gttttatgaa tgataatatt aaaatgtaaa 93420 aaacactatt ttcattatgt aatgtgtcac ctacaagatg ctgaattcct gttgcagcgg 93480 atgctgaatt cactctgccc ttcttataag aaatatgttg ggccaacctt ttgtttttaa 93540 gtttgcttac agccttacct gtgctctttc aaagtagatt ttcactattt tgaacactct 93600 attaaggtaa agatgtgttc ggccaatgaa actactagag caaaatgttt acactgtatt 93660 tctgatttga ttgttttaat acaactgaat tagtgttttc tcctatctct atgcaatatt 93720 aattcctggg atgtctgtgt aaattaatta atttactgac cagaactcta ctttagcttc 93780 ttatggtttt gttttcttaa catttagaaa cggctaaatt tagaggacat aaattttctc 93840 catgagattg tttaaattca gttgactttt taatgtggat tatatttgaa cttgaatgcc 93900 gcacgcattt ttaatgctgg ttcatggctt ctgtcactgg tacgttgtat ttctcactgt 93960 actattcttt tacgttgcct cttgtctgaa atgaacttga ttttaacctt ttattttctg 94020 gtctaattat atgagcttgt ggggagcctc acatattgtt agtatatctc cttaaataac 94080 atgcattgag gctgaggtca gcagatcact tcaggccaga agttcgagac cagcctggcc 94140 aacacggtga aacccgatct ctactacaaa tacaaaaaaa attagccagg tgtggtggtg 94200 ggcgcctgtg gtcccagcta ctcaagaggc tgaggcagga gaattgcttg aacctgggag 94260 gtggaggttg cagtgagctg agattgcacc actgcactcc agcctggatg acagagtgag 94320 agtttgtctc aaaaaataaa taaattaaat aaataaataa aataaacatg aattgtataa 94380 tccagctttg ttattttagc tctaaacttc tggtgtatgg agacagattt tcagggagtt 94440 tggtcctgga ggagagacgg ctgcagaacc tcaaatatta ctgaattaaa aaggaaaaga 94500 ttgtattgat cattttaccg tgtggggatt caaatactaa gaggataatg atgatgataa 94560 tgatgacgat gaaagcttgt ttatgggaca ttttactctt ccaaagtctg ggaaggaatt 94620 tcaagtgtat tctggggact tctgaaaata ttagccaatg ttagaaacaa agtcgcaagc 94680 caaagggatt gcttttgaat ttaggcttgt gatccatctt cttttaattc actgttttaa 94740 ttaataaaag tctggaatat ttacagagga ttgtttataa aacttcacaa attagaaact 94800 tggaattaaa aatatatata taaaatattt catatgtgta aaaacaggat aatatttaaa 94860 tatctgacct catgagaata atgactcaga tttcttgtta tcgtgagact ttttctcaat 94920 caacttttta ttaatattca taacgtttat gcaacatgaa gattctgaag ggactttgtt 94980 gtctgagaac acatctattt cagatctgcg gagtgtatca ctttttgctg tgtcttcaaa 95040 gtgattcttg gtttattgcc tgctaaggct aataaatgta taataaatct gcttgttgtg 95100 tcacttgcag gtgctatggt ctttagaatt gggtcactgg atttctgagg agccgttcga 95160 actgtctcac cacttccctg cagctcccgt aagtcagatg ttgttttacg atggtaaatg 95220 cagtttgctg ttctcaagaa attattataa acataagggt ggacttaagt ttttatccag 95280 tcaagcacaa ttatgcccat aattaaaaag acattcacag aacttaacac cttttatcaa 95340 tttattcgyg agaacaaatg tgagaacgtg agaccactgt gcaaaaagta gtgaggaatg 95400 cagtccaaag aaaatttgac gattaacatc ctcagaactg agaaaaacaa aaatgaaaaa 95460 agactgaatt cttgggcagg tagtcttata tcttgcttaa tgtttttact kttaatagaa 95520 atagaactga taggtataaa gattatggct tgctggtgct gtgataacag tatttatatt 95580 tttatggctt tcctaaattc cacttcaact ttcaaatgct tcattgaaaa gttctgggtt 95640 ctaatttttt ttaagattaa gtaataatta agtggataat ttaaagtttg cttggataca 95700 ggattgtgca gaagttgcct ttcctgttca aaaatgttaa tttgtttgtc acagtttatt 95760 cattcaaaag attaatagct gaaagataaa tggtgatttt tatctgccac tggtgttgtt 95820 atttagctgt ttgagtaggc catatgacta aaacataaca aggagttgaa ctgtgctccc 95880 tgatcactgt agttatctag gttgttgggt tgttttgttt tcatttttaa gattactgtt 95940 tgatttcctt tcagctttat aaacattttc ttaaggagag acaaaagctc ctctcagcaa 96000 aactgtttgt ttgaaatacc gtgtaaggaa ctgaagtgta aagtaaaaac acaaattccc 96060 cccattctcg ctcataagag attatatatg atgcacaatg acataatgag atttgtcctt 96120 gaatttttta tcacctgcct acaaagagaa ttgatataaa ttgtgttgtt gccagttttt 96180 cctgcattar cgtttcccta cctaagtatc catcactctt gtcattgaga tatcctagaa 96240 acttgttgtt gtctttcgag gctgtgaaat tttcttattt tcagttgttt ttcaacttga 96300 tacaaggcca tgataccgtt gttgaattca taaaaccttc ttaaatataa agtagataca 96360 gttctaagat agggaggttc ttaactagtt aaatagttgt tggaaaagtg caccttggtg 96420 gaaataaaac agagccttga ctttgccaga gtccatcatt gactccaaat atgtagcaac 96480 acctgtgtgt tctaaaacta cgtcaagtgg tggggagaag ttggggtaaa ataaattaga 96540 ttttgaaatg gaataaagaa aaaataatgg tagaacactg taaggtgaag acagacatat 96600 agtagatgct agttacagac tggactctga acttccttgc aaatgattca gaaaagaata 96660 tatgagaaat tgcctttaaa ttataaagct ttacacaaat gttcattagt attaattgta 96720 ctatgaaaat ttcaaaagga gttaaaactc caggagttta tggttttgta gtcccgagta 96780 taaagctgtg ttctcaaatt ttcttttctt tctttttttt tttttttttt tccgagatgg 96840 agtttgcttg ttgccccggc tggggtgcag tggtgcgatt tggctcactg caaccttacc 96900 tccctggtgc aagcagttct ccctgcctca gcctcccgag tagctgggat tacaggtgcc 96960 cgccagcacg cctggctaat ttttgtatta tttagtagag acagggtttc accatgttgt 97020 ccaggctggt ttgaactcct gacctcaggt gatctgccca ccttgcctac caatgtactg 97080 ggattatagg tgtgagccac tgcgcccagc cctgtgttct caaatttttg gtaaatattt 97140 aaatatatta tgaacatcag attttgtttt tgcactttga aacccttttt tttttttcag 97200 tttgctgatt gacataaaaa aacttactag tgtcaattat ttttttcctt aagtaaattt 97260 aagggtgaat cttgagacat atagctttgt aaawttctta aatagaaggc ttttctcaac 97320 cagaaattaa attgtagtct agttctataa aaatatatct tactaggaaa gaaaacagac 97380 ctctgtttta gaatagtgag aagatagtaa agtttctttg tcatagaatg aaatgtataa 97440 ttttcctcat cattaaaagt aagaagtttc cttatcacaa ggcacaatta ggtcttttgg 97500 aaacaaatta taaaattgta aatattatca taaaagttaa acataggcat atcccctaat 97560 aagttatatt taattactaa aaataccttc atatttaaca atcaggcaga aaaaaatagt 97620 acggtctgca tataaactaa aatggcacgt ttctgttgat aatttcagag attctggaag 97680 tttctaccat ataaatttga aatacgtatt tgagcattaa cttataacta agctgtcaac 97740 ataaatgtaa atacgctgtt tttgaaataa aaatttaaag cacctaagag atggagtaaa 97800 aatgcactaa ctgtttttcc aaatattaaa cttctagtaa ccccttctca gaatatccct 97860 gaatatgtct ttttatggct tagagagttt ttttcttcct tttaattgtg atagtgatgg 97920 tgaattcagg acatatgggt atttacacag tgtataaaca gtgctcagaa gaatgcagtt 97980 ccaagatgat ctgtattgta taacataagt gttctgtttt ccakttattt actgataaac 98040 ttgcacataa cattcttggt tgtgacagca gcgtctgtaa actgtcagtc tgattctcag 98100 cctcgggttc atctttgcat aggtgttctg tctaatcaca attatggatg tttagggtct 98160 tgctttggtc cgttaagtga tgcaagttta agtgataaag tttacaggct ctaatctgga 98220 gcatgtgggt cccgtcagca ccgagcacac gccctctgtg gtggaagagg acacagtgcg 98280 caccgtgact ttcagtgcac tgggcttaag tctttgaaaa tagttcgaga cagttcctca 98340 ggtggactgg gatgtttaga aatctgctgg tcggatcatc atggttgtgg ccttgagcga 98400 atagcctgag cctttccagt agtaccattt aatgccgttg aacttatttg tgttctgcct 98460 ctgtggatag tacattccgt tcaagttgga aggaccacat gcatcaaacc accagcctgt 98520 gaaagtaaaa cacagaagga attaggaact aggtgatgcc agctcccacc acgaagacag 98580 caatactcag ctaaggcagg aggcacactg caggcgtgtg gagtaggcac atgcagatga 98640 tggtgagtat aggatgtgca ctggcagagg gattgttttc cagccataca cccatgacat 98700 cacagttcca ttacggcaaa tgcttttaca agccttcttc caccttttcc cttgtgctgt 98760 gtggagaggc ctgaattctc cacagtccta tttggtaagc ccacagtgtg tacacactta 98820 cagcaggagt aagcaaacat ctgaggcaca gttggaaaac tctccttcaa ccaggattac 98880 tttgcagtcc cagcaacatg gtgggctgga ctcrctcagg ctccccttgc tctattaaat 98940 gattttttcg gttgaagttt aamctaaaat attaagtact cagtggagct acataaaaag 99000 gaagtctcta tgtttcagag acaaaaagga aatttaaagt gagagtgtgt gctcgctcag 99060 ctaaagccag ggcaggagag gtgtccagca caggggctgt gggagtgaag ccccatctgc 99120 accttaattt ctgggcttgg ccaaaaacag gagcatgctg gggtttgtga gagaaagaaa 99180 cacagtagtc cccccttatc tgctattttt gctttctgca ctttcagata cctgaagtca 99240 gctgggccaa aaatattaaa tggaaaaatc tagaaatatt ctataagcag gggccgggcg 99300 cagtggctca cgcctgtaat cccagcactt tgggaggccg aggtgggtgg atcacgaggt 99360 caggagaccg agaccatcct ggctaacacg gtgaaacccc gtctctacta aaaatacaaa 99420 aaattagctg ggcgtggtgg cggacgcctg tagtcccagc tactcgggag gctgaggcag 99480 gagaatggcg tgaacccggg aggcggagct tgcagtgagc cgagatcgcg ccactgcact 99540 ccagcctggg cgacagagtg agactccagc tcaaaaaaaa aaaaaaaaaa aaagaatgta 99600 taaaccttaa attgcatgcc gttctgagta acgggataaa atctcctgat gcccacttca 99660 tccctcccag aacatgaata atctcctcta tccagtggat ccacgctgtc tacatccggt 99720 ctcctgatca cttagtagct gtcttggtta ttagatcgat tgtcacagta tcgcagtgct 99780 tatgttcaag taacgcttat ttgacttaat aatggcccca aaagtgcaag agtgatgatg 99840 ctggcaattc agatatgtca aagagaagct gtaaagtgct tcctttaagt gaaaaggtga 99900 aagttcctga cttaataagg agagaaaaaa atcgtacact aaggatgcta agatctatag 99960 aagaacaaat cttatatcca tgaaattgga agcaatatgt tgtatattat tcagttttat 100020 tattgttaag tctcttgtga ctagtttaca aactaaactt tgtaagtatg tgtgaacagg 100080 aaaaaatata cacatagggt ttgatactgt gtgtgatttc aggcatttgc tggacatctt 100140 ggaatgtttc ccctaaggat aagggaggac tgctgtaacc ttgattttac atatgttaaa 100200 ctgaataaat ctcaaaaaca ctgtgttgga ggaacacata cagtatgata ctccttatat 100260 taatttttaa aatagagaaa ataattatga ttgatatctc catatgtagg aaaattaata 100320 aataaagtga attaacctcg acccaagcgt caggtaggga atggcactgg cagctcctct 100380 ttagccttac ccgtaatgca ttatttctta ataaaaactc tatgccaaag aatatatata 100440 tatatattct tatgtatata tagaatatat acatattctt tatatatgta tatataaaaa 100500 catacacata ttctttatat atgtatatat ataaaaacat atacatattc tttatatatg 100560 tatatatata aaaatatata tatattcttt atatatatat atgttgtgtt tatacattgg 100620 tttgttattt catccaggtt cctacattct ttcttggtgg taacagctca gtgacttcat 100680 ttgattcagg tgaatgcaga ttggacggaa gtttgcgtgt tctattcaga atccttcaca 100740 tattcaggac tttgacagat tcataggtca gtgccttctg gagcttgtcc aactagagaa 100800 gttgctgtcc atgcaaaatg gagctgctca ttaggctggt tcattcatgg tccagaccac 100860 tggctggaat ttgacctctt cacaggcaag accactccac tttctctctt gggctgtttt 100920 tcctctcccc agtctctttt ccaattacat tctcagtccc taaatcttga tttgcgtaag 100980 taaatatatt gtttccttgg ttattaatgc aattctccta ctctcctgag aagctcagca 101040 catacgggtg gtctaataag cacacccttc tcaaggagag agctgggtcc agcatgtggg 101100 gaaatggtag acaggaaaca aagtcctagg tgtctgtggc tcctccacct gaccctttcc 101160 ctgctgttca gctttaaaaa ggatgattgt gccaggatga aggaaacagg aagcttttgc 101220 aaaatcaata ggagggcttt gctcattggt gtaataatgg tgtaacatag ggaggacctg 101280 tggtaccaaa tagtagtcat attatctcag gaaccagagg attgcttttt ttttttttta 101340 tgaggcctga ttctttcagc ataaaaggca tgaaatttaa agacatgaaa attactgaat 101400 ttcatattat tttcattact aaatcctcct tttgactgtt aatgatgctt tttttttttg 101460 agacggagtc tcactcttgt cgtccaggct ggattgtact ggtgcgatct cggctcattg 101520 caaactctgt ctccccggtt caagagattt tcctgcctca gcctcctgag tagctgggat 101580 tacaggcgta tgccaccatg cctggctaat ttttgtattt ttagtagaga tggggttttg 101640 ccatgttggc caggctggtc tcaaactcct gacctcaggt gatccatcca ccttggcctc 101700 ccaaagtgct gggattacaa gcgggggcca ccatgcccag ccctattaat gattcctata 101760 gtgtaaatgc atcataactt gggtcatcca tttgtttaat gtagtaactt tcatttataa 101820 aacatgttga ccatagctgt tacctttggt tttcctgggt gggtaacata ttaatttttg 101880 cagatatgat ttatgttctc tagaaattaa accctgccaa ttttcctgtt attctttaca 101940 ttcatcttgc actattggca gagtttttgt tgctacttta aatctttcag tgtttttcaa 102000 gaactaactt gacagcattt gtcacacttt tttcttgtct cagtcactaa gtagcgtttg 102060 ttcctgtcag tgaatttcta aacttttaac aaatcagaaa aataacactt tcttttcttt 102120 tttttttatt ttttttgagt gaattcttgc tctgtccccc aggctggagt gcagtggcac 102180 gatcttgggt tactgcaacc tctgcctccc aggttcaagc cattctcctg cctgagcctc 102240 ctgagtagga gtagctggga ttacaggtgc cagccaccat gcccaggtaa tttttgtatt 102300 tttagtagag atggggtttc aacatgttgg ccaggctggt cttgaactcc taacttcagg 102360 tgatccaccc tccttggcct ctcaaagtgc tggcattaca ggcgtgagca ccgggcccgg 102420 ccagaaaaat aacattttct aaaactttat tcctatgttt gaactctcaa atgtttctga 102480 ataccaaccc atctgtttta agtgactact acaatggttt ttggcttatg agtgtggttt 102540 tcattgtctg ttttatggca gtgtaatacc aaacctacaa tacaagaaag gtctcaaagt 102600 agaagatgac tcattttaat ttgatttact aaaaaaggcg gattaactca tttgtgttta 102660 taggtgttgc tatatattaa tggaatcttt tttaaaaaga cagctggggc cgggtgtggt 102720 ggctcacacc tgtaatctca acacttctgg aggctgaggc gggcagatca cttgaggtca 102780 gcagttcgag accagcctgg caaacatggt gaaaccctcc ctctactaaa aatacaaaat 102840 tagccgggtg cagtggtggg cgcctataat cccagcactg gggaggctga ggcaggagaa 102900 tcgcttgagc ctgggaggca ggggttgcag tgagctgcga tcacactccc ttctggacaa 102960 caaagtaaga ctctgtctca aaataaataa ataaacaact ggagactgtg tctctaaata 103020 aataaataat aaatgacagc tggaaattcc ttctttgaac attaaattat tagttggaaa 103080 tatttctata atctatatta ctgttgtggt tgctacttgg aatttttaac tttttacata 103140 aagcaaaatg taattaaacc atctctctag tatccagcaa gcacaaacgc aggagagctt 103200 gctaagaatc aaatatcccc tctccttgcc agggctaggt cctgaggaga cacagttggc 103260 ttgctgacaa gtctagctcc atatcatatt ctcacttaaa acttagtcta aaaaaagtga 103320 aaaacacatt tacctatatc aagctagtgt gtctacatat gaaattgtgg acatcgttac 103380 aaatcacaat ttgtagtcca aattgccagc ctttccctct atgaaatcat tccttgccaa 103440 tacaaatagg aagacagaaa gtcatcccta cctcctgtta gcatttgtga acatttgcaa 103500 atacatttgt cgttgtctcc atcctttgtg ctaaaatcat ttcctggttg gctgatgctg 103560 cttattttgc cggctgtccc tgtaagtcct ttraggtgaa tcctgtaagc gtgcaaagaa 103620 aaaaaacaca ttggctaggg tcattgattt accgtagtgg caaatttttt gtgatgaaga 103680 attccattct acagaagcgt gttctgtact cgttaatgga ctaatgcata ctctggacaa 103740 aatattttgc actggtataa acaggaacca acttatcatc aaatccttca gcaaagaggg 103800 atgttttcat gaaaccttca acacatatca cttgcacaac tatcagaagc gactgtagag 103860 ccctgtaatt tattttcctg ctgctttcag ataaacagaa gagaaagaaa tgcagcacca 103920 ggctcctcct cccaggtctc cagtcatctt ccatagagac ggagtcctga gacaactggg 103980 caacctcaaa cattattttc cgcaggggcc ccggggggga tggagaatgc agcagacaag 104040 gaatggccac tgagtttggg gaagaaatct acagaacggt gctgaaaata aatccttgtg 104100 gctacatttc ctcatgtctg tatagtaggg taatgtaatt aaacttttag acattgagaa 104160 aggaacaaat gtcggagtaa gttagacact atttacaata cagacgatcc ctgacttccc 104220 atggggctat gttctgataa gcccattttc tgttgaaaat gttgtatatt gaaaatgcat 104280 ggaatacacc tgacctttgg agcatcatag cttagctctg gccttcctta aatgtgctcg 104340 gaacactcac attagcccac agtcagacag agccatttgg caacacggtg cacgcagygt 104400 ctgttgttca ccctggggat cacaggactg actgggacct gtggctcgct gccgctgcct 104460 ggcatcatga gggagcatcg tgccacatat cactagccag ggaaagatcc aaatttaaat 104520 cccaaagtgt agtttctgct gaatgcgtat caccttcaca ccatcgtaaa gtcgaaaaat 104580 cttaagttga accattgtaa gctgaattgc aaaaatacgg cttacatcgg tcatctgtgt 104640 accagcaagg agcatataag ggaagggaga agacaatatt tttgaggttg ttttttcttt 104700 tttttttttt tttttatttt ccataactat gctcaagagt ttctgctgca aagaagcttc 104760 ttggcagatg gttcaggaca gatcagagca ggcattcacg taatggggta tgccatgttg 104820 gcacgttggg tcctcacgtc ctgatggaga aacaggcaca cgaagaccca ggcgaggagc 104880 ctacaaagca aatcctgcaa tggtggcagg agaagtgtac ttgaagcacc aagatgatgc 104940 ccttctttgt aaaacctgct aatgtttgca agctgccaca ttggaataat ataatttcta 105000 acagtttgta ttggaagaat acaaagaaga gagaaaatgt tcttttagtt ttacctgctg 105060 gtcgggccag gccaggtgct tacacctgca tgcacactgg atgcttataa ccacgtgcag 105120 tggtggccgc catctttgtt ttggcactga aagtcactga ggttcagaga tataaacttg 105180 tccgaggtca gactcttaag tcatggaggt aggatttgca ccagatgcag caaatgcctc 105240 tgccatgttt caacactggt gcacacctaa acagagatgt ttgtttgttg aagaagttgt 105300 gaaaagatga gggtagggcc atgtgatgtg gagttccgta agtgttgctc ctaagtgact 105360 tcagtattaa ggcagcccta gaaacttcat cctaaggcat gaactggaca tgtgagtctc 105420 agtattttcc cacacgtttc aaaagtgaga ctggccgtag ctcagtctct aaatgcctgc 105480 tgcaaaatgc taatgtcata aatactcatc tctgttggga ttttgaaaca ctgtactttc 105540 tttccattgt cttcccatta atcatagaca ggattgagat gaaccacttc ccttgcttat 105600 cttttaactc tctcttgtct cctttgaaca tgtttagttc tcatggaact tgttaaatta 105660 tccccagagg caagaaaaat aagggagaat actatttttt atgagtctct gttagaaagg 105720 ttttgtgtaa ttttaggtcc ttttgtggcc cactggttta aagtgctttc tttaaaattt 105780 ggttattaag aatggccatg ttcttgaagt tgctttacat tggtatgggt tgattttttt 105840 ttttcaatct ctgcagcttt gccagggatg attttatata acagtggagt aaagaggtaa 105900 catcaacatt aacaattaaa cctcagtgtt atataaaact gccagaatgt gtgtgaaaag 105960 tgatgaattt ttaagattta atgtacgcat agcttttagt ttcactagaa agaatgaaat 106020 tctattgatg catttatgca tttcttataa catgtatttt ccagttttcc aacacttggg 106080 gaacatttct tctgggaaaa aaaaatccct tacatgctgc atacaactgg cgtctcaaag 106140 catttgcagt tatgagaagt ttcagtccct tcacagttct cttatcatgc tagcatcatg 106200 ttttattagg ataataattt tcgatgtaat atctatttta tcttgccaag caaattaagc 106260 tttaaaccaa tgtgtgtgtt tttctaaatg gcctatccaa aaattgattg catttctaaa 106320 ggaaatatct gttaagaacc atctcagttt aaaatatttt tataatgtca gcrtacaagg 106380 gtaatgaccc attttgtaaa aatcttytta tacaaacagc ctaatcctta atttttgtgc 106440 ttcttttttt tttttttttt taattcttct gttgtagatt cctaactgtt gccagttgaa 106500 aaaatattta acttggaggt aaaacactga ccaaccactt gtgtctcaaa attcattgaa 106560 gttttgatct ctttggagtc aagttggaac tgctgtgagg cccaaacacc tatcttctca 106620 ttcatctcgg ttgttgcctc tccaggagag cctgatcttt ccataatgag aatagtgaat 106680 atgcttcact gatgtttaaa gagtcacatc catgtatatc tgtttctcaa acatgcttct 106740 gaattttcat ccactgtttg tacagcagga catactgggc attgtagagt tttcagttgg 106800 ttgttcaggc aacttgacat ttagccgctt ctccgtgctg cccaccacaa tcctcccctg 106860 ggcagcctgc tcaaggactt taacattgtg tctcctttca gactgttcag gtcgtggagc 106920 ggagtgtctg acttgggcat taatgagatg aagacgagac tgtaggtcag atgatgactg 106980 tttttgtgat gttcgtgttg accttcattt gctaatttct gacctcaaag tgggtatttc 107040 ataatgtgtg ctccatgatc acgaggcgcc accagtctgt gctctttaga ctcctttagg 107100 ctggcgttgg tgccagtggg cacacagtct cacttctctg cccctcccgt tgcacacaca 107160 tttcggagtg cctctatgtg ccttgtgtac cagcattact gtgcatgtgg cttcaccgta 107220 cttatcttgc acactaggtt gtcaagtccc attgctgttc tctctctcta ctctcatggc 107280 attttagagg cagaaagtaa attcccagtc aaggttgccc atgctattac ttatgattat 107340 tgctgccaaa tgggtgagga caaggtaaac acccagggaa tgctgtgaat ctgatgtatt 107400 tcctgtagag gagagcagag ttgactaacc atcccaccta actctgccat ctctaaactt 107460 gacaactaat cttgactttg agattgaaga caattgaatg tgtttaaact tcataaagac 107520 agactaactt ttgaaacctt ttggaataaa acagcacagt cacaagtatc catcatttat 107580 gctattcatg tgacatatta tcatgggaac acttactatt cactgatttt acaaatacct 107640 atgaaagcca attatctacc aggcagagtt cttctaggct ttgaagatac acagtaaaca 107700 caatggacaa aatactgttt gtatgaagtt tcttttatat tgttataacc aaagttagaa 107760 ttttaaaccc agagaaactt aaagaagtaa tagtttagat cttggttaaa tcattgtgtt 107820 tctcattttc tggaatagtc acccagcaaa ccttttaatt ttttttttct ttttcttttt 107880 cttttctttt ttttttgaga cggagtcttg ctctgtcgcc caggttgcag tgccgtggca 107940 cgatctcggc tcactgcaag tccgcctccc gggttcacgc cattcttctg cctcagcctc 108000 ccgagtagct gggactacag gcgcccacca ccacacctgg ctaatttttt tgtacttcta 108060 gtagagacag ggtttcactt tgtttgccag gatggtctcg atctcctgac ctcgtgatct 108120 gcccacctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccgtg cccggccaca 108180 aatcttttaa ttttttcttt caattaccat gaactcactt acctataatt gagttcttca 108240 cttgagagat agaaatgttc atacaatgag taagcctcat tcccttccca gtctttaagg 108300 tgtattttaa gcacrtagcg ttgctgrtta gtcagttgcg aaacaaactc atttcccagc 108360 caatattctc ctgaagggtt accaaatccc tgtaatgcaa gttgttaaat tcaattattt 108420 catgtaattt tttctttgta tatttgaagt ggatagtccg tcaacttaac ayagaataac 108480 tatcaaatag cagaaattcc ttctggtgct gtgacaattt agggtccttc ccaaaggaaa 108540 atggatttta aataggtcag ttattagata ctaagctgct gctggaagaa aacttgtatt 108600 aggataatga gaactacttg gggagccacc agcagaagcc ttggcataaa cagctcagtt 108660 catgggaatg tgaagcacca ttaaacagtc ggcttaccaa aaaaatgctg agtccacctt 108720 taaaaataag ctaagtagtg gcagccttgt ttatttgaga gtcttactct gttgcccagg 108780 ctggagcgca gtggtgtgat cttggctgac tgtaccctct gcctcccagg ttcaagcgat 108840 tctcctgcct cagcctcctg agtagctggg attacaggtg tgcaccacca cacctggcta 108900 atatttgtat ttttagtaga tacagagttt tgttatgttg gccaactggt ctcaaactcc 108960 tgacctcagg taatccatct gcctcggcct cccaaagtgc tgggattaca ggcgtgagcc 109020 agcacgtctg gctgcagctt ttgttttgat acagtttacc ttatattggc cattctttaa 109080 aggggagact gaagcaccaa ttttaaaaac catgtcaaaa gtcattggtt agtttgggat 109140 tggtggttaa ggttccgcag atcttgaaag ctatttttca caagggaaat tctttyctga 109200 tgccttaaag aatgtcctta ccactttata ttctttccaa gtcctctgaa aatcaacgct 109260 gccatcctca cgtcgctgaa taattgtcca cccgcctcct ccagcttcca tgtcacagta 109320 ggcctgcaaa caggaatgca gggtataagt gacagagccc ccccactccc cccttacgta 109380 gcagaagcag gaggaatgta gaccctgagt gcaggactca gccgagaggg ttctctggga 109440 tataaggcac ggagtagacc atcggggttg tctaagaaac agatggtttc aaataaattg 109500 aaagtgatgg attaaaatga tggtaaaaca taaacagtaa tataatataa agtgttgatg 109560 agaatatgac tcacttgtca tcatctgttc caggctaaag accccaccct gatggctggt 109620 ccaggagatt gctgtttttt tagagattca ttatgaatgg cacattttgg cagattggcc 109680 ccgaacccca catctccatc ctgtagaaaa ccattgactt gtgttcacag ccttgaaacc 109740 tttcactaaa tgccagcccc tgcccctcca cagagagcta tgtgaagggg atactctttg 109800 atcatagggt ttggaggact cctgttacat tctcgtactg tggggctgtt tggcttcctt 109860 tatgtgcaat actaatcaga ttttttggtt cacatctgag cacaagggcc ttgaggctcc 109920 agtgtcctgg tgcaaggtgt gtgacctggg cttggcttag caccttggcc tcaagggcat 109980 gacttcacgt ttctctgtac atagctcact gcccacagtt tttctctaag caactctttt 110040 tatttctgct cttaaactgg ctctgtgggt ttaaactttg tccagaacac agaattcttt 110100 cttaagctaa gcgcatgcat gctcaatttc aactcagctg gagttttatt atgaaattaa 110160 aaacccctga aaataagatt acataaatag ttttaaataa taaagattac agtagaacga 110220 aacatgtttt ccagaaagta agataaattt tctgccacat acaaggtagg aaatattgaa 110280 gttaaggttc aaaaccaatt gtaaatattc ttcttgtgtt gtgtcccatg gtctttttga 110340 gaataatgga ggcgatttgg cagggtaagc ttcaacgcac actgttctct gtttacgagt 110400 tagaatccta aagaggagag cgaaaagaga actaagagag tgttattcct gttctttcat 110460 ttcctacatg aggaaagagg ggtgcagagg aagtgcagtg gctgcctgat gcctcattgc 110520 cagtgcaacc agagaactgt ccctggaaca gcctggtctg caggggactt ctccccagca 110580 tggttctggt ctctctccag gaaggtcacc cggctcgtat tgccttcccc agtggcactc 110640 atgtttggaa agataggtgc cattaatgaa agttacattt attaagaaga aaattatttc 110700 ctcattttaa attaatctga tgtagaaaat cagtctgcac aagctaaccc cttgttaccg 110760 ctctgtattg ctatgatttt tattatcatt gctacacacc actctcatcc aagtactctg 110820 ccagatactt tgtgtatatt atctataatc tcacagcaac tctgctgtag tatcataatt 110880 ctgcattttt gaaaggagaa aagatttagc aaagttcgat tttgatcagt tactcacctt 110940 ctaagtgata tataggattt gaataaggtc tctttgattc ctgttatgtt ttttttccac 111000 tgacatcatg ctgccaaaaa tagagaaacc tgaccctttg gtaaataggc caaaagtccc 111060 tcaacacagt tccaagttta tatcagttca tgaataatac tgcctcttat ttgcctgcag 111120 tcaacaaaat ggtcagtgct gctcacttct atcaatattt ctttttaaaa atctatttca 111180 taaaccagct gaataagcta ctttggtttg aggattcatg tacatatatt gaagttaatt 111240 ctgtatccta aatggtatgc tcttgggttg aaagcattga cgtggctctt ggtgagccta 111300 tccttgttcc aagaatgttt gattcttcag cgtcaaaatc actgctatga agttaccagt 111360 acttaaatac atgttctgtc ttgttcagag aacaagttta tcttgttatg gaagtcagag 111420 gcaaaactct taaatgtctg agagtcactg ccagcacata aatgatttga gccatatgag 111480 tattcgcttt gattccatta gtgatgatga taaggttatt agaacatttt cttagtactt 111540 catccaggtt tttagaaaaa agaacagagg atttgtaaaa actggagtat tatggttaat 111600 tggactataa aacttgcaga gaaagatagt gttcaaatag agttatctac ccagccagaa 111660 gatactgagt aaaagtgctg aaattgatta tatcaggatc agcaaagcag aagtcctcag 111720 atacttccca agaccttacc actccaatta caacaaacct aagggcagtt aatatcttta 111780 atctgtccac tggtgcacgg tgcaggaacc tgatatcttt ctgtaaagct tgatgttttt 111840 cagcaaataa tacttgactt gcttcaactc tgaggcaatg attaagtgac gggttaaata 111900 gcaaaccata gagacaaacg ttaggagtca ggtgtcctgt gaaatttagg gaaggaaatg 111960 accatacatg cttttgataa atgccatctt gcagtctctc tctcgtagaa gaaccaaatg 112020 aatttttcaa aactaaagct gcagtatttt ggcctttcag gaaaagatct gctcaaagac 112080 caattgaaca ttcttttctt gaattagata aatgagtgca gaatcgggtc tcctgccagg 112140 cagagaagtt gtctggtagt ctttgaaggc agcgaaaatg gtgaccacta ccatttactg 112200 tcccaagttc taccccaggg gctgtccctg tgttgtcaca acccccaagg ctgagggtat 112260 cattgttctg ttacagatgg ggaaactgag ctctcagaaa ggttaaatga ctcgcccaga 112320 gccacaaatg gcagagctag aatttacatc caagtctgtc tatctctccc tggatcagat 112380 tgtgacttac agagtcttaa gtctgcaagg gaatttagaa gtaacaattg acaccactta 112440 tttttcaaga tgagaaaatt gaggtttgtg aaagcttatt gttccctgct gtgtaaatga 112500 gtttctttta ctgcaaatgt ttaaagggaa tataaatcct aatgtttcca accatgacct 112560 gaggctcata taatcccaga gtactatata ttttcatctt tctgcagaat atttcagtta 112620 ttctgggggc catggggtgg gacagtgcac tggggtggga agcttgcact tagactgaga 112680 aacatagatg aaacaatgtg atggggctgc atggttagcg gctgtccctc tgcatcggtg 112740 tccatggcat ccccatttca catgcatcct ctgtcccccc tcttgacact cctgtcccca 112800 ggccaagaac acgccaacat ctggtgacag acaatggcat gcacagaatt gtcatgaaaa 112860 ccagatagca aaagagattg aaaggcttag cctagagtct gttcgttgcc ttttcatctg 112920 cagcagaccg tgttgtttgt gggtttgttc ccttccttcc ctgttgtatg gcttctaggg 112980 cgttagggac attaactaat tttcagggtt gatttaacac agcattaatg aattagaaag 113040 gtttctttgg aaagcattat gttgaatagc acaatattta tcttttccgt tcataatcaa 113100 gatacatgtt actgtttcaa gttccaggtc tttaaaaccc taatgcttgt atttttaaag 113160 tgtttttctt tgatactgtt ttaaatactt aggataatac tcaatttaaa gagataatac 113220 ttccaagagc ctcgaaaatt tccactttgg tacagtatcc actgtattct ctgtagttat 113280 ttgtgttggt tcaatatgta gctgctttta catttatatg caaacatatt tatagacatt 113340 taatatatac agttatccag taattacata acacttcacc acactgattc tcctgtaata 113400 tcattcttcc ctatcaaatg tttaagagaa gccacattga aatattctcc ggaagggttt 113460 ttttttttcc ttatctaaag ttcagtgtct cccaaagcac cttcaggagt caggctctct 113520 gagtgaggct gcagaactag gaatgactga ggtaagctgt gttgtggctt tgcctgctgt 113580 gagtactgac tgtccactca cgttacatgc agtaattgga catatgcctt gaagtgaact 113640 ccgctgctgg agaagaaaat gaacactgtc tttatggtgt gtttcgagtc ttccagactg 113700 cgttagatga ggttagaatc gccttcccca gcggttctca tggtgtggac ctcagaatcc 113760 tgcgtgtccc tcagaccatg tcaccaagtc cacaggttga aactgttttc acgatgctaa 113820 gacaccaccg gtctgtggca ctgtgttagc gtttgctcag atagagcaaa aaccatggtg 113880 ggtaaaactg ccaccatccc cgtgtgaggc agggcagcgg tagctaactg tacaagtcac 113940 tatgcagtca cacacaaaaa agaaaggaac aataatatca ctgaaaaatg actttgacac 114000 agcagtagaa attattaatt tcatgacacc tctatggctg atgcactatg gttgttcaac 114060 cttcagtttt tggaagatac tttctttaag gaaatgagtc tgacacctca ggaaaaacaa 114120 ctgacagtat gcattattca agcaaaatgc aaggagaatg tatttgttgc cgaagataag 114180 atagacattt ctacatcatt catatgcagc ttttgtattt tctgcacagc agcggcactt 114240 agagcccttg gcaagcactc taggcgaggt agctgcccag taactatggc tttgtactgt 114300 gtgaggctgg ggaagatctt tggggagaga cttctgctct ctggttcctc actctctaaa 114360 gtggcctgcc tagagccagg gagttagtaa ggggagacga atacctcacc ttgatctctt 114420 ctgtagaatt agggaatgtt aacgtgtaga tgccattcgt ggtgtgtcct gatttgaata 114480 cttcagcaca gtctctgaag ctgatttgtt cttctttagc aacagtgggg tccttagctg 114540 cttttaaaaa atagtaaggc atttaaacgg agttcatgaa aagacaaaga cttgttattt 114600 caasagccaa tcatttggtg agttttatta ctttggaatt cttaagtaag caaaaggctg 114660 taccactttt ttaacctttc tagaaagttt cctttcagcc tgttttcttc ttaattctca 114720 aaagattaat acttactttt tggtcattaa ttccatgtaa ttaaaatact tcaaataatc 114780 caaacttcct ttgctgatga tcaattacat gtaatgaaag tacttcacaa tcacataaat 114840 taaattatta cttttgaaga tctttcatct tgagtagaat agggtaaact tagtatggaa 114900 gaatttaaaa agaatgtccc taaacactgt tatctgtatc atgaccccat tgcctgcccc 114960 ttcaggccat tatcccactg aggacatagt ggggtgcagt gacacatctc agcttaccgc 115020 atcctcctcc tcccaggttt aagtgattct cctacctcag cctcccaagc agctgggatt 115080 gcaggtgccc accagcaagc ccagctaatt tttgtatttt tagtagagac aggatttcac 115140 catgttggcc acgctggtct ccaactcctg tcctcaagtg atctgcctgc ctcagcctcc 115200 caaagtgctg gaattagagg cgtgatccac catatctggc ccttccctcc aatatataag 115260 agacgctgca aagtgaaaca ataataagga aggcaaaatg tgcttaagaa cctggcaaga 115320 taagggaact agcatctctt aagtgccagt gtattatctc atttaatctt aatggccatc 115380 ccatgggtct gatattattt ttcccatgta aaacctaaat aaatgaatat cggctgtggt 115440 ttagtaattt gcccagtctc atccttctaa ttaatgatgg aactaactaa aagtaggctc 115500 tttactgcca tgaatcaaaa gtatgcttgg ggtgtttgct tcataataat tagtataaca 115560 tatatttccc cttctcttct tccttcattt taattggtag atatttcatg tgaaatatat 115620 gagaaatagc gccttttctg aaaggtgaga attttttagt cttttgagtg ttttactgac 115680 taaaggttat taacgctgaa gaaagcatga tatgtraact tacagtttga tgtggacatc 115740 atagtcagta agttattaac tgtctccatg agatcatgtt gctgcttctg aagaactgaa 115800 ttattcaccg tggcagtcac tatttttttt tctagttctt caatgatgga attttgcttg 115860 gatactaaca cctgtagctg atctttctct tcttttattg actgtagttg gatgatgtgc 115920 ttgtcttcca tagctagcac cttcttttct aggaaacttg taaggaaaag aattgttagt 115980 tagtgaaggc tattctaatg aaatatttta tatttattga atttctactt ctccaaggta 116040 ctctgttaag atattgtagt ggttataaag taatatgatc ttaccagagc cctaaggaat 116100 ctctgaaact tgctgagaag attagatata taaatgtgtg tatatatgta aacgtataag 116160 catatatgta tgtacatgca gacttatgca tacacacaag aaaaggtacc ccatctggtc 116220 caggataggt gggatatggg tgttttttgt attagatgct acagcgctca gaagaaaggt 116280 gctgctcttt caagcttagt gctcatgaag tgcttttttg agaagggaga gtttcaactg 116340 ggctggaccc ttgggtagga tattagcttt ctcctaaact atttatattt taatattaat 116400 cctaatgata ataatagcac ttaatgctat gtgagaaata ctccttcatg gggaggtgaa 116460 tacttctccc agactcaagt cctggcttac cagccctgcg acttggaaca gtttacttag 116520 tcaccctatg cgttaatgtc ctcacctgtt aattaggata ctatcaccta cgtcatgggg 116580 ttggtgtgag gaacaaatgg gttttaaaat gtaaatgctg gccgggcgca gtggctcacg 116640 cttgtaatcc cagcactttg ggaggccgag gcgggcggat cacgaggtca ggagattgag 116700 agtatcctgg ctaacacggt gaaaccccgt ctccactaaa aatacaaaaa attctccagg 116760 cgtggtggcg ggcgcctgta gtcccagcta ctctggaggc tgaggcagga gaatggcgtg 116820 atctcgggag gcggagcttg cagtgagctg agatcacgcc actgcactcc agcctgggcg 116880 acagagcgag actccgtctc aagaaaaaag aaaaaaaaat gtaaacgctt agactagcgc 116940 ctgtcataca ttaacactca atgaatgttt gttaacgtta atatagacat tattattccc 117000 atttccaatg aggaaattga aacttaggga cattgagggc caggctcagt ggctcacacc 117060 tataatccca gcactttgga aggctgaggc aggtgtatca ctagagtcca ggagcttgag 117120 agcaggctgg ccaacacggt gaaaccctct ctctactaaa aatacaaaaa ttagccaagc 117180 gtgggggtac atgaatgtaa tcccagctac tcaggaggct gaggcaggag aactgcttga 117240 acccgggagg tggaggctga agtgagctga gattatgcca ttgcactcca gcctgggcaa 117300 aagagcgaga catcgtctca aaaaaaaaaa aaagaaaaga aaagaaatat aggaagaatg 117360 aatcacatac ctaaagtcac acacagcagg tggcaggggc agaatacaat cccagcactt 117420 tctgactctg aaatctgctt ctctcctttt aatgtggccc cattccttct ctaaaaaatc 117480 taaccagcct atcgcatgta cttaatacat aacagttaat atgtgagcca agcccttgaa 117540 aagctttttt ttctcttttt ttgagatgga gtctcgctct gtcacccagg ctggagtgca 117600 agggtgccat cttggctcac tgcaaccttc acctcccagg ttcaagctat tctcctgcct 117660 cagtctcccg agtagctggg actacaggcg catgtcacca tgtcaggcta actttttgta 117720 tttttagtag agatgggctt ttaccgtgtt agccagaatg gtctcgatct cctgacctcg 117780 tgatccgccc gcccctgcct cccaaagtgc tgggattaca ggcatgagcc accacgcctg 117840 gcagaaaagc tttttaaaaa ttatttagag agctggtaaa attatgccat gtaagtccta 117900 agacacttta ttaatggtta tatagtttgc cttcctaatt tcaacttata aacatacgtt 117960 gctataaata tgttcaatga agagcatacc acttttaaac taaaaatagt tcctgtccat 118020 taagccagag gaaacaaatc caagagagta gagactatgt atttgagaat gttaactgtt 118080 tcccaggaac aaactcaaag acatgcacag tcaaggtatt tggcagggtt ttttgttttt 118140 tgttttttgt tttgagatgg agtctcggag tctcgcgctg tggcctgggc tgttgtgcgg 118200 tggcgcgatc tcagctcgct gcaacctccg cctcccggat tcaagcagtt ctcctgcctc 118260 agcctcctga gtagttagga ttacaggtgt gccaccacgc ccagctaatt ttttgtattt 118320 taagtagaga cgtggtttca ttatgttgtc caggctggtc tcgaactcat gacttcctga 118380 ttcgtccacc tcggccttcc aaagtgctgg gattacaggc atgagcaccg tgctggctgg 118440 catttttttt ttttttaata agatacaaga ggaaaattgg atagcctgac actacattat 118500 tcagcaccta aagaggcttt ctgtgataat tgcaggaaaa gcagcaacta aagatgtttc 118560 aatatcttca ttttgtttgt acaaggccag taaataaagc tttcaaaata tagacacttt 118620 taaaaataga aaaacagtga ccagatgtca gattcctctc tctgacattt tccttccaat 118680 ataaagttta gtacacatga atttgcacat tgcagagttt tgttttaaag gaaggggacc 118740 tcatattccc ttttttgagt cccgtataag tcagctatct tatttaataa tgaaatatgt 118800 caatgatggc atctttatgt ttcagaatta ttttctgtct actaacaagt taccacagct 118860 tctgttaatg tcacattaga agctggtgaa atattctata catttcacta gcttttctgc 118920 gaaggcatat gaagagcaga gaaacattat tttcccacct gcttgataaa gaaaccttga 118980 accggccatt taacactgct gtgagttatc tgaagcctcc tgagtcactt tgcacttact 119040 ttcctaggaa ccgaaagcat gtgaaattga catacacgtt tcactgagtg atagttgggt 119100 tcagatcacg tcttaccttc cgtttaacag agatgtattg aacacctacc atgtacgagg 119160 tgttttttag ggttttggag aaaaatcaag aaatgaaagc atcatgaacc atagtcttaa 119220 gcctgcggaa atttagatgt tttgatggtc ttcacatcat caagctaaaa agacaaggct 119280 atgaatgtct cccttgagga aaaactaccc ttgtggccat gtaaggtctg taaatagaag 119340 ttatcacagg gaatacatat gaagatcatg gtttcactga agagaaaatg gagaccctga 119400 gaagtcacct ttggtgtcac gagcaccttc aggtgaaagg aaggagcctt aggctgggaa 119460 tcccacctct gcacatggct tcctgtgtca catgggcagc caccctgctg tggacctcag 119520 gtgcatgtct gtctaggtga atatctatct aaataaagct ctatgtaaaa tgaaggcatt 119580 cgatttcatg gcctctcggg ccccttttag ttcgaatgat ctggtaaatc cacctttttt 119640 tgacagtaac attttctgac tctttaaccc tgcaaacaat attaaccagc caaggaactg 119700 gctacccatt acatgtctcg cccataagca ataacaatca gtattaataa taattattag 119760 atattcaatt gtagctctta aatgtattcc agccccctga tcgttgtaaa ttagtatata 119820 attttggaga gatgggggtc tgtctttgtt gcccaggttg gtatcaaact cctaggctca 119880 agcgatccac ctgcctcagc catccaaata ggagagatta caggtgtgtg ccaccacatc 119940 tggctaattt ttgtattttt tgtaaaaatg agctcattat gttgccctgg ctagtctcaa 120000 actcctggcc tcaagaaatc ctatcactct ggcctcccaa agtgctggga ttataggcat 120060 gagccactgt gcctggcttg aatctattct ataaagaaag caattgcact tttggggaat 120120 tataaaagat tatttaaaat gtggtttgtc caatgtgaaa caccatttgc atatttttgt 120180 aatgatatac ttgcaaataa aatcataggc cagtcagaat ttaaggtaga aaacacagca 120240 tgcagaactc atacacctgt aaaatcatca acactatttt ctttttttat tatttatagc 120300 tgttgatgaa aaaaaccttt ttatttcctt tcatatctgt gacaaaaaaa tacgatttct 120360 acatctgatg agaaaaagct tattcttcct acaggcatag ttgaaagcca atatgattgg 120420 aaaactattt gcaaagatga tatttggggg acataattga cccaaattgg tagttttagc 120480 attgtagcat gctaaatttg aaacccaagt ggggaaacag tattcagtat tagggtatgt 120540 tctacaaact ggacatatcc taggtttgtc acggacatca ttgtataaca ggcaagagaa 120600 aagtaatctc cagctcccat gtgttccggg aatcactgca gcattttgaa gagaacatta 120660 ctaagtaaga ctattaagaa aacgacgcca ggacggtggc tcatgcctgt aatcccagca 120720 ctttaggatg ctgcggtggg cagaaggctt aaattcagga gtttgagacc agcctgggca 120780 atatggcaaa accttgcctc tactaaaaaa aaaaaaaaaa aaaaaaaaaa aaatcagctg 120840 ggtgtgtgac acatgcctgt agtcccagct actcaggagg ctgacatggg agaatcacct 120900 gagcccagga ggttgaggat gcagtaagct gagatggcac cactgcactc cagccagggc 120960 aaccagagtg agaccctgtc tcaaaaaaaa aacacagaaa agaaaatgaa attagcagga 121020 ttgttatatc tcaatgattg gtctcaaatg ttcatttact gtttgtagag gagaaatctg 121080 aaacatgaaa gaaaaatatt tgaattttaa aaatctattt gcttttcaaa accctaaatc 121140 aataatgact taaacttggt atcctaagga cagaaagaat tatttcagct tagttcttga 121200 ttaacagtaa agaacaatta ttgaacaaga agtttatcat ttttggttaa gaataaagaa 121260 ttatttaaat tgtcaaatag gatatattgt tatagccatg ttccatgttg tatatacatg 121320 tcttcattaa aaacaaggaa ataggcacac caggtatgtg cataaaatta tcctcttttg 121380 tcccaagtgg aacagacata tgaaaacagt ccccacctat cccctacaat tttttttcta 121440 ttgttgatct tgagattttt ctatatttta tttaaatatt aatataatca tgtttaatat 121500 ttttggtttt actttatcgt gtgtttgaag aggaaacatt ggatcataaa atgtgcattg 121560 gcttacagta taagtgtagc tttcatacta tagaccattc tgcgttgagt gaagctaagt 121620 ccccaagggc aaaggatctt ggtcaagtta atactgaaat aaaatgcctg ggccagtggt 121680 tctttcactc cacagcacta gctgtatttt tataatagat tagcatgtag aatactgagg 121740 cagggtttgg aggattactc taagaggatc ttttgggcca gtggttcttt cactccacag 121800 cactagctgt atttttataa tagattagca tgcagaatac tgaggcaggg tttggaggat 121860 tactctaaga ggatctttaa ggggccaggg aatgaaaggt aaaatccagg actgtgttag 121920 gagagctgtg cctgtgcagg aattttctcc aagccctctc ccttctcctc cctcatgagg 121980 tttctgaccc ttacactaga catgaagaaa ctcaccattc tgataattca tcatttgaga 122040 ccgactttca tatctggaaa gtgtgcagtc ctgaattata aawgttttag tactgttatt 122100 acctgttctt atcttgcaat ttgtttattt cactggtctg gtccaaaatc tgtttttcca 122160 atttgtttgt cgagagggag tgttccaaga gctgaagttc aagtctcgtg gtctgattta 122220 atacctaaat gtaacaaaat gaagttccta ttaattattt tttaattagt ttaactttct 122280 aacttccttt tcattaaagt acccaagcta caggaaaaca taacaaaaac attatttatt 122340 aacccaagta tcttattttg gcatattttt cattttcaga aaaggctcaa tgtcttagat 122400 cacatctgag tgtgttaaac ctttttactc ttttccccac gtctctattt tttttttttt 122460 tgagatggaa tctcgctcca ttgcccgggg tggagtgcag tggcatgatc tcggctcact 122520 gcaacctccg cctcccgggt tcaagcaatt cttctgcctc attctcccca gtagctggga 122580 ttacaggtgc gtaccaccat acccagctaa ttttttatat ttttggtaca gatggggttt 122640 caccatgttg gccaggctgg tctggaactc ctgacctcaa gggattcacc tgcctcggcc 122700 tcccaaagtg ctgggattta caggcattag ccactgcacc cggccgttat gtctctatct 122760 tggaaagtgg ttagtagttc tggacaatgg ggtctgtgcc aaatactaaa tgttattttt 122820 ctagtctgcc atattttatt tcatacaatg agacaagtag gagtagaaaa tggtcatatt 122880 tcataggtcg aaagtatttt ccctttgccg aaaacaaaat gctattctca tatttatttg 122940 tcactagaca gagagattgg aagtcacatg cttccattat ataaaaatat agataatttt 123000 tagcctggga tttcctcatt tgtcaccact tgtttagact tttatttctt cttgccattt 123060 ctccttcctg ttttaaaact tgtttgaacc aatcgaagcc gtatagcgtg agtgtgaagc 123120 ggascctcag ccttgccgtg cgggcctttg tgagctactg cgtggcatga gcagtgcggc 123180 tctcccgcgg attctctagc gcctggttgc ccttcagcag gaagaatcga ytactcactt 123240 cctccatgtc atgcttattc aggatgtgat atcacaygca aatgtcagtc agcattgttg 123300 ccaaggaacc ggggaccttg aaagaatcat tgtttgctgg tgtctttatg tcatttgcag 123360 gagccttggc tggtccacag cgtgagtttc agggatggtc ttatccttag agctggttta 123420 gttcttatca caaaaagtct tctgtgagaa taaagtcctt ggccaacrta aggttttgtt 123480 tgggttttaa tattaacacc tggaatatag atttggccta cgtcttcttt gagtccaaac 123540 attctatgtt ggttatttct aaaaggaact ggaaaattgt gtcctgttta attcataagg 123600 gttataacat gagtaaaatc ccgtggggag gcagggaagg atggcacata agtcatgatt 123660 ggcccagtag taattgtaac cattttcaca tcacttttct ggagagcatc aaaccgctgg 123720 accagcctga aggcgtccat ctgcagggga ctgtaaatta cccaggccag gtaatgatct 123780 ctcattccct ttaagatatg agacctccag ccacccattg ttgctcaatt tgatcgtctc 123840 tcattctgac cggcttggag aatcttgctt ctaatcagaa attttcagat ttgaatttaa 123900 gtctgtttca caaaatcagt aactgctcag caagtacctt caaacagagt gggtacataa 123960 ttcagtttct ttgcggcctt ccttaagctc agccattttt cttttttttt tttttttgag 124020 acagagtctc actctgttgc ccaggctgca gtgcggtggc accatatctg ttcactacag 124080 actctgcctc ccaggcttaa gcacttcttg taacctcact aagcctccca agtaactggg 124140 tctacaagtg cacacaagca cgcctggtaa tttttttttt tttttttttt tggtagagat 124200 ggggtttcac catgttgctc aagctggtct cggactcctg atctcaagcg atccacccac 124260 ctcggcctct caaagtgcta ggattataga tctgagcaag cgtgctcagc tggctcagcc 124320 attttcatgt gttcaattgg gcttcacatg gaaaaactgc ttactttcca tctgttttct 124380 tattttcctg ttatcctgga taacatgata tctagtttca caataggcgt ttttttttta 124440 aatcatatga cgcaacacaa gtacatcaaa tgctatgaag tctctgaccg ctataggatg 124500 tagcaaggtt tgcattgctg ctctgtccta acactttttc attactatta ttatttttta 124560 tttttttaaa tttttgccaa gctcccatgc ttggatctaa ctattatttt aaaatataag 124620 aaatgttata gtttaaaaat gcttatgaga cattttttgg atgagctatt caattaccca 124680 tcagtgttag tatcaaaagg tggggcatgt gacttaatca ttactaattt attttaatag 124740 gttggtgcaa ttttgccatt gaaagtaatg gtggccaggt acggtggctc acgcctgtga 124800 tcccagcagt ttgggaggcc aaggcaggtg gatcacctga ggtcaggagt tcgagaccag 124860 cctggccaac atggtgaaac cctgtctcta ctaaaaatac agaaatttag ccaggtgtgg 124920 tagcctgcac ctgtaatccc agctacgcag gaggctaagg cacgagaatc gcttgaactc 124980 gggaggtgga ggttgcagca agtcgagatc acaccattgc actccaacct gggcaatgca 125040 gtgagactct gtctcaaaaa aaaaaaaaaa aagtaatggc aaaatctgca gttacttttg 125100 gtccaaccta ataataattc gctttagata tatattgata tattgacttt taaatcttta 125160 gtttttatga cttcctagga tttaaatttt tagtacctta tgatccatta tgtaaaatat 125220 ttatgtatgt ttttcctgaa ctgttgtgat attgtggaaa gacctggtaa tcaagtaatt 125280 tgttattcta ttctcttatc tgtaagtctt ttgttaatct atcatttcgc tactgttttc 125340 tctgacctca tccaaccatt tttaggaaga caatgaaaga acagctgtgt ccttctagaa 125400 tgagtcttac gagagtggca gggcttatgg catctcccct ctcatgtcct ctcctggctg 125460 atgtctagca tttcttgatc cttttagctg aagtagcatt taggaataat atggagtggg 125520 gattgtttca cttaaatctg ctcttttttt taaaagcatt ccttgtagcc cagagtagga 125580 agccactgac ttcagaagca tgtaaagaag ccaggatgag gagtcagaaa gcgggcttgg 125640 ccgccgagag tcacgaccac ggctttgagc ttggagcgtc tgcatttgta ctgctaatag 125700 cagcttttcc ctttcccacc caggccgttc gctgggtcac atgttgtgca tcatttagca 125760 tgtctctcgg tgaattttct tcttttgaaa ttttcctatt ttgctgttat tttactagtt 125820 tctttctttc tttctttctt tttttttttt ttgagttgaa gtctcactct gttgcccagg 125880 ctggagtgca gtggcacgat ctcaactcac tgcagcctct gcctcctggg ttgaagcaat 125940 tctcctgcct cagcctccca agtagctggg attgcagatg cccgccacca cacctggcta 126000 atttttttgt attttttagt agagacgggt tttcgccatg ttggccaggc tggtctcgaa 126060 ctcctgacct caggtgatcc acccatctcg gcctcccaaa gtgctgggat tacaggcgtg 126120 agctactgcg cctggccact agtttactat ttcagtcttc tttctgttat tattaatcac 126180 tagctcatag aatctcacag tggaaagaga acttagcaat cacttgtctg gcccaaccct 126240 ttatattatt tgaggcccag aaaaggtgag tgcctcattg tgatgcattt atttggttag 126300 tggcagacct ggagccatgg cagcgctcag ggctcttgct cgggcgtgca ccatcttttc 126360 tgtggctaga cgcttctcac tgtcccactt gtctccttct ccataatctc attccacagg 126420 ctgtgttagc tgttgagatt caggtttcat cttaactcaa gagttagatt taaggccaga 126480 gtttctagct ctttgcctca gtgcttttca tttctcaaat gttcaaagac tttaggactt 126540 agaaatggaa aatgattccc ggagtccaga aagcaccagg gagacagagg gggtattcat 126600 cttgcagtgg ttgggatgcg tggcatgaaa atgactcaca tgtcttcagt agatagaaca 126660 catgaaattt aacctcagta ttaaaaacaa aaacagattt actgattttt aattcataag 126720 cagccataca tccttaaytt cttatcaatt cattcctttt ctcctgtggt ggtgctttct 126780 ttagtttctc atgccttcat tgaggaagct cctgacgcga ctgagtgcta gtctctagct 126840 gcagggacac cgtgtgcttt atgtggcatt acttacttgg gcttccacat cagttaactt 126900 ccgcgtttgc tccgctgttt ggttcaacag gtttgtccct atttctatca tcacagccgt 126960 ctggttctgt actgcattct gctgtatctc taccatttct ttcttcatgt tgtcctggat 127020 ataattctca agctagaaaa gaacagtgtt ggaaggcagt cattagtcaa atgaccggaa 127080 acctgattcc taaatgtttg tcatctcctc cctatcttta aaaaaaaaaa aaaaaaaaaa 127140 tctatcaaaa gacttgtacc ttgccttccc ttttggaatc ttactatttt tttttatcat 127200 taggaaaata cagtgtgatt ttatttttat gcaaaatctg gcaacttagt cacatcatgt 127260 aaaggaggga gacaagctac tggttgcttc tgtgttcttc tagaagtcca tgtcatggca 127320 ggccacagag ggtggtgagg gcagccacag ggactgctgg gtgctgccac tgtggggttg 127380 tgtctgtcct acccagctgc aactctgacc atgcagtcag gaaatgataa tttgacacaa 127440 agaagcatca ctatttctct cacattctag acttttggtt tctccacata gacttgagaa 127500 gacactctaa gacagcatat aaggagagga gcaccctttt gattttcctt ttaacctacg 127560 gaatcaccac tcagttccac attctgtggg gtcttcccca ccttcctccg tattgagtta 127620 attcgaccta ttaaattttt cctaacatgt atgcattttt cacaattttg tcatttcatg 127680 tatcaagcaa acttttaatc gcaccttggt ccatttatca cctaacgtgc catgggctgg 127740 ttcttctctc cctcagttac taaagatgat gatcatgccg actaatttta gcattaactg 127800 aaacacaaga gaaggaagaa gctcatttca ctgccattgg tatagctatc cctgtctatg 127860 gcagtaaaat tacatgatta tgtataactg caagacaact gagtacgtgg gaagagcctt 127920 tgggcttgga gccagggaag cctgccctct gctttatagt cttggttcta ggaaagttgc 127980 ttaacctttt gggaccctag tttcctcata tgtaaaatag ggtttctggt tggtcagagg 128040 agtgtcttaa agaggggtta agctgtgctt ttaaagtcat tgtgtatgcg taactccaga 128100 tacttagcgt ttagtttctt tttttttttt tttttttttt taaataatct aatgatggga 128160 accattcttc cattccctgg tccaaagtat aagctcgtga gtgcacaaas catgttttct 128220 tccttttcac atagtgtaac aaacattgtt tattacattg aataattgaa agatgattat 128280 aaaactggtt ctggtgccct cctttaaaaa cttagaattc tttatagagr aamcattcgt 128340 ggagtcagtc atcagacatg atttccccca aaatgttaac cactaaataa ttctgtgctt 128400 tctgtcttta agagtaggaa aataggatgg gaagggtaga gtttctctct tagagcttct 128460 ttgttgatgc atttcataga ttgtgtcttg tgactggtat cagatggttt taggattagg 128520 ctggaactat aagtttcctg tttccgatgc cccctcgcca tcgactctgc cccacttctc 128580 taagctccca gctmcctgca tgcccctcag cctggtcact aaggctgcct ccctggcagt 128640 cgttctcccg tggatattgg atgggtcaga tgagcaggat gcatgasagg cacagtcagc 128700 cctccatctg tggcctccac atctacgggt tcaaccacac catcaatata tttwaaaaaa 128760 aaataacaat acaacaataa aaaacaaaaa ttgyaaaaca atacagtata gcaactattt 128820 acatggcatt gacattgtgt taggtattct aagcaacctc gagatgattt agagtatacg 128880 agaggatgtg tataggttat atgcagatct accctgtttt acggaagagg cttgagcacc 128940 gtggattttg gtattctcgg gaatcttgga atcagtcccc cacagacatc aagggacagt 129000 tgtactagag ctccaagcat gtgtaaaatc attttgttga aatgttactc aagccatcca 129060 cccgcctcag ccccccaaag tgctgggact acgagcgtga gccagcacat ctggctgaag 129120 ccttagtttt ccatatgaac caaaacagag tagaccacta ctttaaaaaa ttaaagtatt 129180 aaaaaatttt taaaaattta aaaaaataaa aaatcagtca ctgatacccg gcaggccagc 129240 aaccatctct attataggct tcataaaata tgaagagtct gaaatcttac taaccctttc 129300 tcagagttag ctcaggcttt ttagtgtgtg tgatctttct taattcattc tttctccttc 129360 ctcccctgcc tttataaaac tgtaactttt gtgattgaaa taaactattt aaaagaagcc 129420 ataaatagca gttcgtaatt ctcccctccg ctcatcgcca tgggagtaat ggaatttttg 129480 aggttgcagt taaagctgtg tgtcacccag aggcactgtc ttagttactc ctcacagcac 129540 cccagccaag ataatattta aaaagtttca ttccgggagg cttggaacta tagagataga 129600 ctccagctgg agtttagttt aagcccatac tcagaaataa taatttacaa agtggtataa 129660 ataaaaagtc ttaacctcct tcttgatttc agtacttaag agctaaataa aaattattgt 129720 attttgtcac tctaaatcat acaaccagag agggaaaatg aatcctctaa tactgccttc 129780 ccccatttct agagctactg agtcagatgt gtttgcaact ctccagagat atgagaggat 129840 tgtttataat tgaaaactta aagtcaaatt ccaatttgaa attaaactta ggaactttga 129900 aagacataca ggcccaattt taaaaaataa aatttcttaa cctgccatat tgttttctaa 129960 acataaaaac aatagaatgc aagatccttt ttaaattgct actttttagc tattcaggat 130020 gactaagtat aggttcacag tgggtgagct aatgtgtgtc catttatgtt aatcttacat 130080 aaaagcagat tacaaataca catgatgtgt gtatatacag ataggtatat agcatatatg 130140 tatatagtgt ctataaatat atacagctct tgaagcatgt atcatttaaa taaaagaaaa 130200 ttctgtgtga tactgactgc attgctaatt aattgaagtc tttgggagaa gaatggaaca 130260 gaaccaaaaa tgtgcagtag tagatatttt gtgttgattt aaaaagatat ttgagccagt 130320 cgtgatggct catgcctgta atcccagcac tttgggaggc cgaggcagga ggattgcttg 130380 ctctcaggag tttgagacca ggctgagtaa catggtgaaa cccatctcta caaaaaatac 130440 aaaaaaaaaa aaattagctt ggcctggtag tgcgagcctg tagtctcagg tactggggag 130500 gctgaggtgg gaggactgct tgagcccagg agagcaaggc tgcagtgagc catgatcgtg 130560 ccactgcact gcagcttggg cgacagagtg agaccttgtc tcaaaaaaag aaaaaaatta 130620 aaattaaaag taaaaatact tatgttctta ctcttgaagt cattaaatta aggttttaag 130680 agaaatatat gatgtgacag tcaggtactc tttaaaaaca aggaagaata ctgtatattt 130740 agccccagaa acactagcga caggaacagc cacagtaatg gtaggtactg tttcttggtt 130800 gccgkcactg cctgtgctgt atgggaatcg ctgtgtcggg atcccaggcg cctcacatca 130860 gcacaggtgg atgcagggct gagcactgga atgaccctca gcaaaatgtt agctcaaccc 130920 agaggccgct tcatactttt ccagcctttt aagagccaaa agtgatatat ctcaaaattg 130980 gcttgagtat accttccaat tccaggcttc acaatgcctt aagaaaacag acagaccacc 131040 cacccctcag tggagggcca tttttaccac cagaaaagcc cagaattaaa gatgaccaat 131100 gccaattcta tcttctggga gcatcctgac aaaagaatct gtgttttctt ccaaagatta 131160 gtagtaattt ttagagatac agaaagacta tggatgtcca tcatatagta taaaaatgaa 131220 catttccaaa taaagatgtc ccatttaatg tagcctttcc ataaatcacc acgtatcaag 131280 gataatgaga acaaacctag aaacaaagcc atctggctca tccacttgga tagacagacc 131340 ttgaaatttc cctgtctctt gaccttgatg aattagttat tttctagttt attgtcctag 131400 aatgtctttc tgtttagtgt ctctcttatt tttactggct gtgactgaaa cccagaaata 131460 tagaaacctg cccagaaata tgaaattcca ttctaagtat aaggaagtct tagtacaagg 131520 aaaaaaaaaa aaaaaccaac ccagtaaata agccatcctc cactggcagc accaaactcc 131580 acttgccttt ggagaatgtt tcccatccct gtcatctgca ccgaactgct ctcatcaaaa 131640 cagttccaag atacttgaac ctcccgtggg aggggacccg gctctttcca atttcacatg 131700 catagcatgt gaaacatatt catgtttcgc aggaatgttt gccatcgcct tcatatctga 131760 agaggattat tccatgagcg tgatctgtag gcacacgtgt ctgaataggt cctgctgtat 131820 atgtgtgcga ggacagtgtg tgttcatttt gtcctcttct tgatggttga cacagtcggc 131880 aaagtgtggg gccttgggct gttcttcctt tctcagaact caagtgagtt atgcaagttt 131940 aacattgagg gccacagtga tccttctagc tgcatggttt gctgcttagt gttatttgat 132000 ttgctaaaag agttgcgccc cagacatagt ctttaaaact tggcagcgca tcgaaactca 132060 agcaaccagg atgaaatatt ttaatgcaac atatatatat atatatgttt acattaatat 132120 atatatattt tagtgcaaaa tatgttctga agttttttat tactcccaca acgttttgaa 132180 tgatcaaatt tgacaggaaa aataggtcca tttgtgaggc aactatggca gattgattac 132240 acatttaaaa gtttatctgg ctatcttcct tctcaccaag attgtcatca ttatttttta 132300 taccaaaaga aaagtaatct tgaaactggc tcagtaaagg aaaacataga taatatatga 132360 aaactatccc caacttggag attctgatgt tgatttctca ccaactgtag atgctggttg 132420 agagatcctt tctatttaaa taaaattcaa ggtccttaga cctttttact aattagtttt 132480 tgtccatctg agtgacctaa ggtggacaaa aactaattaa tcagagggtc taaagacctt 132540 gaattttctg gtaaattaac aaataatttg agatttcctt ggaaactttt tactgttgcc 132600 catttcaatt tcgaaatagg attttgcaac catctctcac acacacatac acgtttttct 132660 atcccaatga tccatccatc ttcccaccca gcccttccat ttttctagta aacccttgaa 132720 tttttctagt aaattcacaa ataatttgag atttccttgg aaacatttta ctgttgccca 132780 cttctattta gaaataagat attgcaacca tctgtcttac acacacacat acacgttttc 132840 taccccccat gatcccatct tcccgcccag ggtccactgt cctctctgtc tcttgctggc 132900 cacgcatccc ccagctgctc tcctttcatc ccgctgtcag agtcaggaat ccacatgcaa 132960 agctggtgac cgcagctcac tttcttccct tgcaggtttg cctgaggata aggtccagat 133020 tccttctttt taagacacac accgcctcct gactggcgcc cctgatcttg tgggcctcag 133080 acctgggcgc gcactgtcct tggctgtccc agctgcccag cggcctcata ccacggccgc 133140 ctttgtatct cctccttgag tcttctcttc ctcctcaggt cccaccatcc cccattgcat 133200 gccctmagca aagatactcg ttttgtgttt ccttttgata tcaaaaccat tttgtatttg 133260 tgtcatttca ttttaatctc cacagacaat aggttaatgt tcttgcttgc ttggtgaaga 133320 gtgaacagaa tcctcaaact ctgcaaccat tctacatata caccctagta acaacaagca 133380 aaacatccac tcttagaatt agtttgaaaa cttgagtgta agattattaa atccagggat 133440 attctatttg ggaggctttt gacctaatgt tcttggttcc ctgtcatgag gaaactctga 133500 aacatcattt gaggtctcca gacagaaaag tggcaaaact gggctctcct ccccctcctt 133560 ttagagttgg gcttgtgtgt gtgtgtgtgt gtgtttattc tggagatttt gctgcctaag 133620 cagctgtgta ctcagcagta cttcatggca gaggctgagc ctaaagaggg aagggctggg 133680 agatgcggat tttgggcagc actttgtcct cctaaacccc tcgccagagc ctggggggta 133740 ggcacagtac ccacagtgag aggtgatgtt cacatgccct gtgacgtggg aagcaagttt 133800 tctccatata ttgatgccag atttgaattt ctagaaccta gaaaagccca tgccaaagct 133860 acttgccatc tgttgactgt ttttatagtc ttggcctttt cttcacgttc agtgtaaggc 133920 cctagaagtt gaggcaaaag ctaaaggccg agggagggaa gcctggcctc tggtgccaat 133980 ttcctagtgg gtattgtgac ttctcttagg gagcacactt gccttcacct gccctgacca 134040 catggacgcc tgcccacata gggtctttta agcacttcct gaaatggatc tgttctgatc 134100 tagccttttt gcttttttct agtcatactt ttttattgtc ttttttttga gatggagtct 134160 cgctctgtct ctcaggctgg agtgcagcgg cgtgatcttg gctcactgca acctctgcct 134220 ccctggttca aacgattctc cccgcctcag cttcccaagt agctggggtt acaggcgcac 134280 accaccatgc ctgggaaatt tttgtatttt taatagagat gggttcgcca tgttggtcag 134340 gctggtctga aactcctgac atcaggccat ctgcctgcct tggcctccca aagtgctagg 134400 attacaggtg tgagccactg tgcctggcca tttaataatt tatgagtgac tatctgatac 134460 tgtatctaga taaccaaccc ctttcctact ttcgctagta taagagactg aaagttcact 134520 tttggccact atataactcc aagatgtatt aggaaataag tttgtgggcc tcagctggtg 134580 gcattctaac attaatagtc catgcctctc ctcctgtgga taggtacacc ctacagtaat 134640 ttgagtgtac cagaatgtct gtgctctggc aaatcctatc cgctttgctc ttctttgagt 134700 gcagctgcat attctttgca ttaatttttt tcacatatat ttgaatatat gtttttccac 134760 atatattcat atcattttac ctctttgtgt gtttccctta ccactactcc aaaatttgat 134820 aaggaaatgt gcttttccct tcaaaatgtt ccatttattt tctactgata aagtggctat 134880 ttctcatcaa tagcaggcat tttaaatata tgtaagttta aggagactgc tgtagtaacc 134940 tcatgtaaat ttctttgggc atttcatatg caaaaggtgt cacattttac acgagtgtct 135000 tttagaggtc ttgtagggca catgtatatt taccagatgt ctgtgagcgt gcagcctcat 135060 ggcacgttat gcatacctga cacttgcaca gattcctgga agatgaggag caaatacagt 135120 gcaacagacg ttgtcaggcc acgtctgcat atatagatat atacacagca agaatagtta 135180 cagcagctta caatgacaaa atgcttctca gtgtgtatgt gtgtgtacct ctgtctcacc 135240 agattctcac actgccttag cttgggtttc cccaaaagca gagcctgaga caaaggcagg 135300 catgcaggaa gtttatttag gcagtggtcc cagagcgcag ccatgccgaa caggcgcggg 135360 aggcaggggc gccgcagggt ggttcrcaca cgtggactca ggcggccacc gccgcgctgg 135420 ctggtaagaa gccccacagg atctcccaag gagccctggg acagtgtctc agaacatcca 135480 cctggggcaa gaatggggac tgctgtcccc agggggcagg tggagcctag tgggcattca 135540 tgacccaggt tttggagctg tgcttgcgag agtgccgagg aggctctcat gggtgtcccg 135600 aggcagcttg gagccaacgt ccctaggcat ggcctggggg tttgtgggaa ggcctgaggc 135660 aaggcctgtc tctgagatgt cctgaagagc aagttgggcc cagagggtta attccgagca 135720 gcacaagagg gtgaattctg agcagcacca gagggtttcc ctgacacagc aggggatgct 135780 ttgaggcccc tttaatgaag gagaaaaatg aggcttagag aaagtcagtg cccaccccaa 135840 gtctcatggg ccccaggctg tgggcagtgg ctaaagacag gctagtgggt aactcggggc 135900 cacgtggaag gggagcttgt atttatagcc cccagtcagc agcgctggag aggagaggag 135960 aggaaaagca gtgctctgag aaagacaata tttctagtag attggggcag ggcaggcctg 136020 gagacaggaa accaaagcca gggttgtcat gcaggagtga gatgaggttg cagcagcaga 136080 gcgaatgcgg agacgctcgg caggtccttg gtggcctctg agttattctg cagacttctg 136140 ccattcgtct attttttggg atactttgtt aaattctcag cttagaagat agtagtgatg 136200 ttttccctac agagatagaa gaaaatataa aactattttc tttttaaaac tgtactgaat 136260 gtagggccgg gcatagtggc tcactcctgt aatcccaata ctttaggggg ccaaggtagg 136320 aggatcactt gaggtcagca gttcaagacc agcctaggca acatggcgag actccatctc 136380 tacagaaaat ttttttaaaa attagctgga catggtggct catgcctgtg gtcctagcta 136440 ctcaggaggc taaggtggga ggattgcttg agcccaggag gttgaggctg cagtgagccg 136500 tgatcgtgcc actgcactcc agcctgggtg acagaatgag actcaatctc aaaaaaaaaa 136560 aaaaaaaagt actgaatgat aaatgattac aaatagaagc agttaaaatt tagctctagg 136620 aatgagattg atgcatttag gctacaatat accaggaact tcctttttaa atgaaactag 136680 agcgttcttg cctttctgaa tttaaggcac actgaaagaa aaaataataa taatgtaaca 136740 aaatgtctca gtgtttttct atgccaaata gaatcttatg tatatctgtc tagagacata 136800 tatgcataca tttgtctaca catgtgaggt aggggtgtgt gtgtgtgtgt gtgtatctgt 136860 gtgtgtgtgt atgtatgtgt gtgtgtttca gttctctaag aaacagacat tccaaaactt 136920 gtgtgtgtgt gtttcagttc tctaagaaat agacattcca aagcttggtg ggcaatggcg 136980 ggaggcttta gaccctgtaa tattgtcgga gtgtcactgt aagagggacg ctagcgcctg 137040 ggtcacagtg ctagctggta gcagagtact aacttaaacc ctggtctccc aacaccccat 137100 ccagcactct catcgctgta ctgatatgcc tattcttatc ttaaaaaaaa aaaagtgctg 137160 tctgaggagc attaacattc ttactttttc atttttgaaa tgaagtataa agatactgat 137220 ggccttttac gtctcctctc tgccctgttt ttgctgtctc tttctgtgtt acatgggttt 137280 gccaaaatac tgggtggagc tctgtggagg aggtagcatg atcatctctg aagtgggcag 137340 tttttttctt tttccaataa actgaattta cttggtcaca atgactatcc taaatggcta 137400 gaaaagggaa aaggctagcg aaacttagat gattttctaa atttagataa ttttctagaa 137460 gacattttca aggcaaacta gtttttgctg tcctttataa ggccggcagg aagcgtgtgt 137520 tgtttctgtt ttaaaaaggg agaggagcgg acttgggaat gctgatggga atgcttgaga 137580 aatctcacag cagggctgtg cgtgccctgc cgggtcccac tgcctctgga cagaaacccc 137640 cgcaactcca cccccagcca agactttctg cttctttatc tcctctttct gctagcaccc 137700 aaaaagttga aagaattcca atggatagaa tttttgagat aatattggaa gatgctcaaa 137760 atacacagga ttaatttaca cgaagactca gcgggaacac aagccatctt ctgtacatga 137820 agatgcacta ctgacccgcc gtccgcaaat gtgtttgtac agttactttc tcagtatggg 137880 tgatggctct ccaacgaact gctcctcgtc tcctgcctgg acacccttct ctctgtgctt 137940 tcctgggtta gagtaaatgg atgcaaacac acatttccgt gctctgcagc aacttgagac 138000 tcctgtgagc aaaacgcact gacgggcaat gtgcgtgggt cgtggggagc atccagctcc 138060 catctgcgga ataaacccgc ccaaaccata gggaaaagcg ctgtcgtata aggccagggg 138120 attttcagaa aagaaatgtg ttctttcctc tttgattttt gtgttcataa agctgtaggt 138180 gcagcttttt ttaatgtaat gatttcataa ccgctgaagt tcgtgctttt ctgaactatt 138240 taggaagata atctacccct tgtattggat gagatgatct gtcccttcga cctctggttc 138300 agttcccatt ctcccaagta tttaaagctg cgagtttttt catattttca tatttattta 138360 cataatttaa accccctgtg tgcatggact ttaaggagct gtacatctgc ctgggctttg 138420 cagaagctga aagggcgcaa tctttttata actcacatta gaaacacaga ttatttaacg 138480 gggctatgtt ttgcacctta atctttaaag ttgcaatata ttttaagcat tttaaccttg 138540 ttttagatct gatcagcagt agaatgtttt cagataagaa acaatggagc aaaagcaaaa 138600 caatattcaa tacctagatg atgtggcaag acagagaata gtataacttt ttgttttcca 138660 aatataactt ttatcttcat ctcttgatct gaaatttggt aggaagtgta acaagtacga 138720 atcaacatat ttaccatttg ccatttcaaa tgttgatagt gaagctggga cctctgttta 138780 ttatggaaga ccatagaaaa ccccataaac acgttctact tctgtctgtg gccagcagtc 138840 cagcaaaaat gttctaaaag cacatgcact gtgttccgtg atgattatag tttgactgtg 138900 ctggaaagag agactgtgaa ctgcacatgg tgattatgac tttgggcaaa tcactgaact 138960 tgtaattatg tcttccaaga cctcctaacc caaaataaga gagtatttta ctacaaaata 139020 tatgttacgt caaactgttt tttacaaaat accagctcta gggatgtttc caagtcattt 139080 tcggagagag tttgtcgaag tttttttcag ggtgtgtcat tcatgtattg gagggggaga 139140 gggttgagta agaaccgaca tgcacaactt ggccatgaaa tgaagcgcaa gcacatattt 139200 tatttctata ggattcctca ttctaaagta atttttacag aaaatggcac tctaagaagg 139260 aattcattaa gataaagaca cagatacagc atttagagtt acactttgcc ataaaagagc 139320 ctcccttacc tcctgacttg aatctataac atctgctgaa ctgtcgacat caggaagact 139380 cgaaatatrt tttgaggcca attatgtcat ttcagattga acctgctaac atcagattct 139440 ttggtcagta gtctcactag ttttgttctc acaatggaat tattattttg atttttaaat 139500 gttgctccat ggagactggt atgatgagct catgctctgc agttccattt taacaaataa 139560 cataatagat cgctgtcaaa tgaatgccat cacagacatc atgttgggtc acagaagcca 139620 caccctagga gtgcttacta gatgatccat ttccatgaag ctcaagaatg gaccgaactt 139680 actaaaggtg atagaagtca gaataatgtc ttccgggtgg gaggggtttg aggctgtgaa 139740 ctgagcagtg gcacgaggga gccttctgga gtgctgaaaa tgtttcctag atcttgacct 139800 cggtgctggt tacatgagtg aatccatatt tttaaaagtt atcaagctgt aaatttcagg 139860 ttagtatact ttatccattt cctgtgtttt atatctcaaa aattctttta aaaactaaaa 139920 gacatttaga aatgaaatgt ttgacaagtt ttgttgtgac actatgaccc tagttactat 139980 gggtggtttt atttgtctct gcagttttca tctgggagca cctaaatcat gcctaatgaa 140040 atgaactttg gaaaagtaat tttaaagtaa ctatcttaga gaactgtgga ttaaaccatt 140100 ccagccatct gatgagggtt aaaatgtata ttcgtaatct gacattccaa aacacgattc 140160 tttccggatc aagcataaaa ggcatttgct cttggaagac caagaaagaa ttcatgtggt 140220 tcccattagt ctaaaaataa ataataaata aataaatgtc tgagtcatgt attggatttt 140280 gttggatttc agtggcttca agtataggaa gaaaatgatt tgtgctatta ataatagttc 140340 tacccattgc ccattggaat aaatacaaga ttactctgag aaaagtgaaa tcgattgaat 140400 ttagttctgc tttgagctac tgcaatgcaa gtgtttctga cttttgagac atagtataaa 140460 aaactgaata aaataacttt gttcatattg aattgagttg gggaagtagc gatatttgtg 140520 acattggaag ccattgtcat tacagattca tcattacagt acagatttga gaatcaaaca 140580 cacccggtgt gagtcccagt tcagttcctt aggaactact ggctcaatac tttctaacat 140640 cacatttctg gttggtaaaa caggtatata aatacctact gtgctatgct agtgtgaaaa 140700 ttaagtggaa tgagttagca caattcccaa actgtgtgcc aaggcaccct gggtccttgc 140760 agcaaacaaa ttggagtaag ggagacagtc tgaatattca agggcaaccc agcagtgttc 140820 aatgactgtc agccactgga agaattcata gctcaaagca gctcaccgtt tcaacagtat 140880 cagcttgtac ctctgtaaag ctaggttttt ggtggttgct gtttgtgaaa agcaagtgct 140940 acaggaaaat tagcatagag cgtaaaatgc aggtggcagt gtccaatttg attccaaagt 141000 ttgagaagcc aggtgtgcct aactggcaaa tatattccat tcatacgtca ctggggttac 141060 ttaagaaaga aaataaagga tctttttttt aaaactcaat ttatatgtat attggtattt 141120 tcaaatagct actaaattgt cagaacataa atacttaaat tatttggagc taaccgctta 141180 atacaagcaa ctgttggcct agagataaat agagaaaaaa tagtgaatca ctaagggtcc 141240 catgagctga gaaagtttga gaacaactag cctagaacct tgcacttggt aggatataaa 141300 ctcaacgtac cctcttcctc cccttccccc aatccaggta ttgcctttaa ttgtaatctc 141360 tatgatttga tatgtttatc ggaaagcgag taagtcaaaa agaactaata aattgtgtaa 141420 gaccttcatt aagatgtacc cttccgtgtt ttcctaactt ctgaaatcac taggaaaaac 141480 agccatgttc cttgcaagct ggctggttag tcctgtcttc tttcaggtga acagcattta 141540 taaccacggt gtacctcgga agaagcgttc tcagagcaac atgcacgtgt tccgtgtgta 141600 ccgtggttgc cttcgggcta atgcgttttt ggaagtgtag attggtgcca gttttacaaa 141660 actcatgtgg cctatttctg cttgtaattt atagtttgcc tcctcaccat cctcacttgc 141720 tctaaggtga actagtttta taccattaga ttatacagaa aagccaaatt tacttgcatg 141780 ccacagcaat tcgggaagta aactttcagt gtgattctcc aaatgcttgt ggtaaaagta 141840 cagagacttg aatcattttc ccataattag tttcagttct ggaggcccgc cccctctctt 141900 taaccctctt gccttgcata tgtgtctctt gcaatggaag ctagtggaaa tttcctctcc 141960 cctttcactc cactgccata agttataaaa agcatgccat tcagaactga cgttttcttc 142020 tgcatgcttg aatttttact caacaactgg aaggggaaga agttatttcc agagatgttt 142080 ctctgtttat caaaggggcg cagagtcaca gtagcacttt ggaccaccgt agaatggctg 142140 actcacttgc ctcatcagta gaggggcaca tgttcctatc aaacagtgag tgcctttgag 142200 tgacggtgtg tgacacacag cacagcagca ccatttctca gagctgcagc aacactggtt 142260 cacacaagtc actagagatt cccatctcca ctgactcact cggtgggaac aaaagctccc 142320 atgccggtgg gaatgcgggg ccaggggagc accggaagaa gggagccgtg gcagaggttt 142380 tcctattgtt aggtttgttt gtttgtttca gtgagtcatc ttacccccat tttttttttt 142440 ttttttaacc aaaactcact gtggttactt ctctagtttg ggttatgact cctacgagcc 142500 agtttaattt tatcagtggc agtgaattct tgaacgcttc cctcagttgt agaaatttag 142560 tttcacattt aagtggtcca agtgccagct taaactttgt ggtttagtgt ctttactgaa 142620 tcccccctag tggaagaacc tacattggag ttttggctgc tctttgggat tcaaattatg 142680 agtagttggt tccactggaa tcttggcctt ctcctggagt ggcttgaggc ggcacacttt 142740 gactttagaa ggccaaagtt agaacctacg tgaaggcttt gtccaaaatg cctttcctgc 142800 accctggcat tttcaggtgg tgtgtgtaga cctgacagga ctctactcgt gcgtcacttc 142860 ccagctgttg gtcccctgcc acttagatgc ctttcatggg caagtccatg ctagcctagg 142920 aaatttcccg aaaatggcag tgataactca gaattaggat tttgatcctc atctcaacca 142980 ttatccccag tggtcgctag ctctcctctg cccagctcga ggaaaatgct gggtttttca 143040 ttgcagctta cttgcatttc agtggtccca gcaagcactc aagaggaaag atcagaccag 143100 ccaaacttgc aaggcaggct gatgagccaa ggtacagaaa gtacacctga tggatttttg 143160 taatgatggc cgtaagtcat agaaggtgaa gcttaatgca atttagaaag atttgaaaaa 143220 aggaagaaaa gtcctcgtgc tcacagaagc aagctcccat tggcaaaatt attgtgtata 143280 acaagcatct ctctctgatg atgctggaaa aaaagaaggt gctatcaggg agggagggaa 143340 gatttgaaag accagagtga gcagcagata ggcccttggg tccttccttt tattcccacc 143400 ctcttttcca ttggctgttg ataaagtttc atcacttttt agctgcctgt tgtatttcac 143460 tacctccttg ttaacctctg gttataacct ggggggaatt atgtttaacc agtacttaat 143520 gaatcaatct attcctcaaa agttggttct gggcatcacg gaataaacac caagaccact 143580 cagcgtattt tctgaagagt ggatttcatt agaaggcagg ttagtcttgg aactcagtca 143640 aaacagcttt cagtcagtcc aactccacag atttcagaga tagcagtaca agaaaaatga 143700 tacatgggtt tgtacagttg agtgttgaag tgttgacttc cataaaagaa cacaaatgtc 143760 aatctacagc agtaccatgg gtacgtaaat tgtgttatac agcgaaacac tgcacggtga 143820 tggaaaagaa gaaactttaa catgcacaac aacatggatc catcacagaa ataataaaag 143880 agaccaaaaa ggagtatgta ctgattgttc caattacatg acattcaaaa cctagcaaaa 143940 ttaacccatg gtgggtgaca gagcagagtc aggattggcg ttgagaagag ggggatattg 144000 acgaggaggg gcctgaggaa gccacgtgca gggtgggaag ccttctgtat cttgagctgg 144060 gcagtcatta cacaggtgcg cacatatatg gatgaggagg ggcgtgaggg agccgcgtgc 144120 agggcgggaa gccttctgca tcttgagctg ggcggtcgtt acacaggtgc gcacagatac 144180 agacaaagag gggcgtgagg gagctgcctg caggggaaga agccttccgt atcgagctgg 144240 gcggtcatta cacaggtgcg cacagatatg gatgaggagg ggcgtgaggg agccacgtgc 144300 agggcagcaa gtcctctata tcttgagctg ggtggtcatt gcacaggtgc gcacagatac 144360 aaaaatttac caagttgtac actcaagatt tgtgaatttt attctgtgta agttatatct 144420 aaaaaaagaa aagaaaagaa aaagctagat tccctaaaac agagacagca gggctcgagt 144480 ctgagctagc tatagccatg ccagcagcta gatccatgaa aaggttgggg ttggctttgc 144540 ccaggtgatc attcggggac gggggacgtg ctgtgaatgg aagatgtgcc tgctgtcagc 144600 actgatgttg cccacccttt atttctacaa cgctgtcttc aaaagaatta catttcaatt 144660 ttataccaac tatcgtgcct cctcatgaat cccttccccg cacaacctgg aaaccctcgc 144720 ctggcgtcgg ctccatctcc agatgttact cactggctac cgctaggtgg ctgcgaaggg 144780 tggcggcgtc actgatgcgc actcaggcag cagccatggg gaggttgaat ccccggggca 144840 tctgcctctc cctatgtgtg tgggtcctgg gagtgaggca gtgtggcgtg gggctgttgc 144900 acacaccccc gactgtaggg ctgcacccag acacgtgcgg tgaccccgtc tctacagccg 144960 cttgttgccc tggcaccaag ccaaccactc agcatccagc gcgtcctcac cctccctccg 145020 gggtgaagcg gaaacaaggg tatgtgccaa aactggcctg ctcaccattt cccagatttt 145080 ccacatttgt tcccactcgg ggtgaggggt gtgcttctgg tgtgacagct gtgggctgtg 145140 tagggtggcg ggcgttggtg gtgaagtctg tcggccctcc tgacccacac acgagggggt 145200 gtggatttta tattgaaatc tttttaaaat ctgttttttt gtaagaggct ctgaaaggaa 145260 gaaattttat cagagttttg cggcctgtgt acgttctgat acctctcaga gctggagttt 145320 cttacccata taggacaagc tgttgtgaaa ttgagtgaga cgatgtaagc acatggcgtg 145380 cacctgataa atgccagctg ccaccacagt gatggtcagc agcgtggtca ccactgtcgt 145440 ttcacaatta cagcccaagg agcccaaggg gaaggagtgc ctctctctgt tttgaccttc 145500 tctgactgct gtcctaataa acagtgtcct ttctacaaga accctgtaga cttttgaaac 145560 caacaagtga aggcactcca aggcccttgt tttgagaagg ggtaagtgtg ctaggtaagg 145620 gatttccttg ggtgcttacc ttccacggct cctgggcccc tgactcgaag ctgaccatct 145680 gtgctgatgc tgacttagga ttttaaatca cttaaatttg agctggatag agaaagggtc 145740 ctagttaagc tgagagggct gcttattcgt gatttttttt ttcttctttc tcatgcagag 145800 actgtttatt ttagtggtag cggtatttag gggtgaagaa ggggaaagga agaatagtgt 145860 gccatcaatt aattctatgc atgtcagctg caacgccttc atggcacggg acaggccaat 145920 tatgtaactg taaacaaatt atatgtatta aaagttgtcc aattaaagga aaaaacatgc 145980 atggatttat gtgtttgtta ttacccagaa gggagccatg ctgtacttga aaatatgcaa 146040 aatttcacat cacaaaatca ccagttgttg tttgaggggc tggtgttctg attagtctta 146100 atttttttta actcataaca tttttgtccc agtcatcaac actgttaaga acatgtcact 146160 ggtgcagtta agttaaaaat gattcaggtc aggaattcct gtcattaaca attttttata 146220 ttaaagttgg aaaagtttaa ggaaatttaa gaacctattc cttaatagtt aaaaatagta 146280 aggaatttca tataccccca aatattaagc ataggtaatt agcttgtggt tgggatttga 146340 tggttttctg tttttcagca aaatacaata acgtactttc tcgagcagaa tttttacacc 146400 aacatttccc attaagacca gtttgtttag ggaattttta agctacatct gtatgtaata 146460 attttttgag attccaaaga ctacgcagtc taataaaact ctaatacttc aactatcttc 146520 agactaatgt ttataattac ccggtagatg accaagaatt gatatcatct gttgattcca 146580 gaaattatgg cagagaaaat gctgtcagga acccaaagaa aatcagagga aatggtacct 146640 ctaagaaatt ctgaatcttt tctactaaga tatgtggctt gactgcttaa ccccaaaatg 146700 cctgcttaga aggtagtttg gggctatctt gtaatactca tttagttcct gccttcttct 146760 gccatagaaa caacatgcag aagcagcatt gcttacgact cacactgaac ctgaagggat 146820 gaaattacat atgacgatgg aatgtggcca tattcacgca gtcacagcag tgtgttgccc 146880 aatgacagta ctggagcagt ttccacagag gcactcatgc aatatgcaga atacagacat 146940 tttacacaca cacttacgat ggtccttttc attgtcgaaa aggaattcat tatctttcga 147000 gtaaacatgt gctttgaggt atataactct gaggtataga agttagaaca tttaacccga 147060 ttagggtgac tggaattata acctttaact aatgtgagat atagtataga tcttgataag 147120 tgtctttctg gtgttcctat taaaattcat tataattacc gttcctgcaa ttgtgtagca 147180 tcttacagtt tccaacaccc tgtgctagcc atcatcttat ttgaaacaca taataaccct 147240 acaagttcac tgatgtaggt aagaaaactg gtaccgtttc tgaagataca cagtgattgt 147300 ttcggccagt taattaaggc aagagatcac tcaacaattg ttctacagtt attcctgctt 147360 tttttttttt aactcactca ttaagtgaaa gaagccagtc tgaaaaggct gtatatttta 147420 tgattccaac tgtatgacat tctggaaaag ggaaaactga agatagtaaa aggatcaggg 147480 tttgccaggg gttaagggga agaagggctg tgcaggtaga gcacagagga ttcttagggc 147540 agtgaagctg ctctgtgtga tgctacaatg gtggatccat ggcttcatac attggtccaa 147600 acccacagaa tgtacagcac cagatgtcaa ctgcgggctc tgggtgataa tgatgggtca 147660 atgtagattc atcagttgta accagtgcac cactctggtg caggatgttg atcgtagggg 147720 aggtggctgt gtgtgtgcca cggagggggg atatgggaac tctctgcact ttactctcga 147780 tgtggctgtg aacctaaaac tgctctaaaa aacatagtct tttaaaaaat catttactac 147840 atatgaaaag gaacaagtaa agcaacaaca acaaaatgtt attgtgtact ttcagattgc 147900 accagtaaac ctagccagcc ctcactaggg tcttctgatg gttacatagt taaaagtaca 147960 ctagcacacc gggagaataa cttcagaggc ttgctggtct aatggtaatt gcgtcggctt 148020 cacacgtcaa cattttttta aaaattagat tttcttgaat ctgatcatgt ccaagatacc 148080 tcttattttg gtatagaacg cctttattca aacaacggga gaacatgaac atatcccttt 148140 gccatagttt ggctaaattc ctgaggctgg ctggggccag aaacaaaatc cctgaaatgg 148200 tctcaaaatt tttttttttt tttttacctc tccccttttc cttctggttg gtggtctttg 148260 gggcctacga ggccctcagg cagaggggaa atggcagttt ccccatcccc ttttgggact 148320 tcttgagcag aaaagcgaat gtcagacggt ccttataaag tcccacgtga ttcagccact 148380 gaggatggca ctggctgtgg atttacatgt aagacaactt catggcgtat tttcgccttt 148440 tgctgttgaa tataactacc aagatatggt ttgggcagac aaaatagaaa tcttctgtgt 148500 gtagcatgtc cagttggata ctgttagtga catagagaga cgagcgcaca actcaggttt 148560 aaccttcatc cctgaaattt gccggaacag tcataatgaa ggtgctaatg tatttcctga 148620 aatactgagt acttcagaca gggagatatg ggtggtatct agtagccttg tgataagacc 148680 catattagac taatagtagt cttatcacca gattaaacca cctggatagc ccacctcaag 148740 tcatcaagag tgttaacatg ggagtaagtg tgacaaatgc ccaggtggtc tggactaaat 148800 gtgacaaaat tgagaaatag accctacaag atctggattt taaaaagaga gaaaaaaaaa 148860 aatggaaagg ctggctgctt gcttcctttt aagactttgt tcacgttctc gcccccaaaa 148920 gccaattatg attataattt atcagcccac aggaaatgat tgcttctcta tgagacatcg 148980 tcaacatgat aaaataatcc atttcccaag atttctatat cttagtatct catctcttta 149040 aaaagctcca ttgtccataa aaaattataa aattacatat ttttacatga caggtaattt 149100 ttaatgtata tttttaattt ggttgttggt ttttaaaata gtaaaatatt aaatatcaac 149160 tatgaatatt ttgtggtggt aagttgtcag gttaatgtaa agattccaaa aataattcac 149220 agacatgtgg aaagttgctc agagggagaa ccagtctgat tttggagaaa gtaattacca 149280 tcagagcagc cctcggaggg agcgggagag tccacaggtt tcaatcaggt tctagatgaa 149340 ttgcaaagag aaaggtttta gctggttgca ggaggggctc tggtaaaagg attaagtcca 149400 gttctcagga gttttttaat aggtttcaca tcttttgtca actggtgcaa ggaaggatta 149460 ggacagaaaa gaaaggtgat ttcatggaga aatatctaat taaaatatta aagatagtcg 149520 gatggcacac ctgacctaga gtccaggcag tggtaggcag agttccttcc cctttttttt 149580 aaaccacaca taaaacagtc attttaattc caacaaatgg ttcatactgg tattctaaac 149640 cactactcat gatttttttt actcttttta tttacatcaa atcattcaac ttcacatcat 149700 tttcttttta agcattaaca taatccaagt gccaggccat ttttggtgat ccaatctgta 149760 gaatgtgaga tggacaataa caatcaaacc gttttcaaac tctaatagtg ggaagagaag 149820 gccacatgga acttccctga ggctgaattt cgtcgtcctg cctttcaagt ggtgtcctgt 149880 gaaatccagc gtttccccct gtcaacttcc agaacagggc tgtaactaga tgtatggttt 149940 gtaagaatat cccatgtata cttcctcttg gttataacat aatttgtttt gcggggggtg 150000 gtttgccctt tttttttttt ggagacagga tctcactgcg tagcccaggc tggagtacca 150060 tggtgccatc ctggctcact gcagcctgtg cctcctgggt tcaaatgatc cacccacctc 150120 atcctcctga gtagctgaga ctacaggcat gtaccaccac gcctgggtga tttttatatt 150180 ttttggtaga gacggggttt catcgtgttg gccaggctgg ttttgaactc ctgagctcaa 150240 gcgacccacc cgcttcggcc tccgaaagtg ctgcgattac aggcatgagc cactgcaccc 150300 agccacataa atttgttttt agtcttctga acgattaaat agttgtacca attataccaa 150360 ttgcaccaat tctattacaa ggtggaattt cttatcgttc ctttacaaac aggatattcc 150420 cagttgcttg tttttgcttg ttttcctagc agcttcagca ccatcctcac atagaagggc 150480 tggcatctca cctatctaga ggtgagaaca aagctgtgct ctcagcaatc ggaatctgtc 150540 aagtctgctg tggggacttg gtatctcagg cctgatgctg gcctaggagt gccctgcact 150600 cgtctcaaga tcgatgtccc agtgggcgag aattgctgcc aagactaacc aagggtgtca 150660 accagtgact taacttctca ggctcacttt tttttttatt tttaataaaa acaaattgtt 150720 aaagaggtaa tttaaaatat gtactatata ataagtacta cagcatatac agtgtttaca 150780 tacatatagg cattaaatat taagaatgtt tatttcagaa tcatataatt atacctgata 150840 tttacttttt gtcattcttt gtatattctc cattttttgc agtatctata tattacttgg 150900 gtaataggaa tagcaaccat tgagaaatag ttctaattga ttttcctttt ataaaagggt 150960 ttccgtgtag tgaccaagga cttaacatca tccccacccc acagtccctc acacgcctga 151020 ctccctttgt gctgtgttta atttctcatt tcattcattt acccttctgt gcagcacata 151080 ctagctgctg ctacactaca cgttctgacc aaagcatagt gtccccctgg ggcaagactc 151140 ttgggaattg tcttttttta tttttttttc attttttagg gtctcacttt gttgcccagg 151200 ctggagcgca atggcaccat catagttcac tgcagccttg acctcttggg ctcaggcaat 151260 cctcccacct cagcctccca agtagctggg accacagctg cgtgccattg tagagatggg 151320 ggtctcactc tgttgaccag gctggtcttg aactcctggc ctcaaagtgt cttcccatct 151380 tggcctctca aagctctagg attacaggtg tgaggcactg tgcctggctt taggcatttt 151440 cttccccctc tgacttcttc taggcaccta gaaccaacac tgcctggaca tgtgaaggca 151500 ctcgataaat attttttgaa caaataaatc aacttgcatg gctcctgccc caaactggaa 151560 accccaccta ggaggggtgg gcggggtcat atggtgttca ctcacttacg ctaatgaact 151620 gagaaataac gcacttctgc ccaaattcat gttcattcac actcctctca gcagttttct 151680 gcagtcttcc cagccccacg gaaaattctg cttttgtcag aggaggggat atgcgtgctt 151740 tcccgtgttt gctttaccgc tgggcaatcc atacaaggct actaaactgc agagggtact 151800 ggtgttagca tgccccgtgt ttataaggga cttaaaaaaa tatacaggct tgcatccacc 151860 atacctacca tacttgtgta ctagagatat tctcggggca aaatgaggtg aggtgtggaa 151920 agtgctttaa ggtgactcag agccaccctg ttgcgattgc tgccttcgtg atgactggtg 151980 tggctgcaaa gttcagtggc tgtctttata tcagaataat tctagaataa tttaggagaa 152040 aattctcatt gttaggttcc ttcaagccaa aggaggatgt agtgaaaaga gaataggtgt 152100 tggctgtcta gatgggccct gtttaattag agtcgactgt atcagttgcc aaatgaagcc 152160 aatcttacag ggccatccta tagaacaaat atatattttt tatatttaat atgatatata 152220 tgtgtgtgta cacacacaca cacacacaca cacacacaca tacatatata cagggagaga 152280 tagaatggtt tgcctgctga cttgccatta agtaccgtaa acatcctgga aattgtgaac 152340 agctaattgg aaaacagtct gtccgtgttc atgattcatt gtatgcatcc tctagatctc 152400 aactcaggaa atccacaaag ctgaccaggc cctgctgtca ttttgtggcc agatatggaa 152460 agatataaac cacctccttt cttccctgtc aaaacagttg tgccacgtcc tccccctctt 152520 cctcatcttg actgactccc tcacaggtgg tgtctctgtc tctcctgccc ctgcccccac 152580 acgcaccttt agttacctca gtctttcaaa ttttgctctt tgttcctaag tacagtcttc 152640 cttccaacct ctcgtcatgt catttttggg ccaggaaaga tcctgattat gctataatgc 152700 cactgtacgt gttttaaaaa gaaggaacgc tgtacatttg atattaaatt tggcatttta 152760 aataaagggc tggtaaaaaa atctctgagt gctaatctcc aagaaaggga tggaagactg 152820 gggaaagaga atctacttcc tatttccacc attttaatag cctgacatat ttttttacct 152880 tgcccatatc ttactttcat aacatttttg ttttattttt taaattactc ccatggcggt 152940 agagttgatt tgaactcttg tttttcaatt ttaaatgtac aaaatttcaa ttattttatg 153000 gattaaaata agcaccccag accatcctga gcatctgatc accaatggta agaccattat 153060 ccttctcaag tttcatctac ggtaactggc ttacagataa acttgtggat tacaacctgt 153120 ttgacaactg taaagagcca cattgattaa aatcagaaga ttttcagagt tcagtattta 153180 gactatatgg attatctagt gtctcaatag aaggtaaggt tatggaaatc catttcctag 153240 ttctaaactc tgcaagcaaa caatcatctc cccatagtgt gatatctaaa tagttaatcc 153300 agtatgtcag acaaccccat ttagtaaaca aagactactt gaccatagaa aacatatgat 153360 atatgtataa tatataatcc atatagagta aacatgtatt atattttata tactgtatag 153420 gcacatatca tactatacat atacatatcg cataagagat acagtaaact atatttgtat 153480 tttccaaaat taaatatgtt gcagttcccc taccatagtg aaactgtctc ttctacattc 153540 cttactgcat tccttactat atagtaatac taacactgag cacaatcata tttcaccact 153600 caggatgtag ccagcggata cagtaatggt tcttgtcctc cgcaggagga ccacgggaga 153660 ccagtggctg tgaatgggat gggatttttt tctttcctct aatgaaccaa gccctgggtt 153720 ttattgttgt tgttttaata tacagctatt gagtgttttg tagccacaca cgacaacaca 153780 cacacacaca cacacacaca cacacacaca cacagagtcc ctagcaaggg cagggtgggg 153840 ctagcgggct gggttcccct gggagcccct caccatccgt ttctcccagt gacggcagct 153900 atgtttgaag agcataactg catggtttcc tatgcattca ttcgtgagta gtagctctca 153960 tatattatta aaaagataca ctattattac ttttaaagaa agaaaaggat tgcaattcac 154020 atttacactt tccagcctgt tcttgtgttg tttaaaaaac aaacaaacaa aaaacgatgg 154080 cagaggaaat gtttgcctcc gtagtaggca tcaactttat ttttcaaatc attctgtttt 154140 aacgtgttca tagactgcag ttgtttatag gtatgaggca ctcatcagtg tgaaatagtt 154200 ctttcctttc catatttcct cttatcagaa aaaaaaattc ctgtggtctc ctagcaaaat 154260 acaatccatt ttgctaaatt atttgtgagt ttttataaag tgtgtttaat atcaccaggg 154320 cagaggttca cactagttgc aggattagca agagagacgt agcatgagta gtgtttggtc 154380 cactgcagtg tgttttgtgt gctagcgatc atgagtttat ctgatccttg tttaactact 154440 acacagtgag taagctgtcc tgtattgttc cattcatatt cctctgagtt cattcagaag 154500 cctgacactt cctttgccgg acagattaaa ggggcagcgt gggacctttt gatgatgtga 154560 aacctgcttt cttagtctaa gctccctagg ctatgctgac cactcagagg ttgaactact 154620 atttatttgc cctaaaatga accagaaact tggtcttagt ttccttcctg acacatgttt 154680 taatttccta aaagtgtacg gattttgtag tgggttgttt ttgaatcttt catttttagt 154740 gctgatccag gagagaaagg agatatggaa acattttttt caaaaaatag ctcaaaagaa 154800 aatatgtaaa accatgaaaa acccagaatt gtgctgctgc tttctgtgct aattaaatca 154860 gtgggtgtta ggttgtaatg ataacccttt aactgtgtgg cttatctctc attccatttt 154920 atattatttt cttcctcatg agaaaatcag tgtttattat cacaggtgac aaaacacagg 154980 agaaaaacaa acagtgaggt tacatttaat cactttaagt gggtttcatc tttgcttttt 155040 tgttttcatt cccaagccag aagccgtaaa ccgagcgaga gtgcaaattg cctttctcag 155100 gtgcacgttg ctgagatagg ctgggagaac aggtgtggag cccgtgaaaa gataaacatt 155160 aagtcattct tggggaaacg gtatttagct agacagctga agacggactt ttgaaatacc 155220 attgtgctac tgctgttcaa atattgacta agtgaacctg gaaaggaaga aattttggtc 155280 gcctaacata gaactcgttg tctttttctg tctttaaatg ttatctcaaa gacccaagag 155340 aaggggtagt ttacctaaga aagaaatatg agctttgctt atggagtttc aggtatacct 155400 aatgtaagtt aattaagcaa atacaatgta gcagccttgc atttggccta gcattctttt 155460 atgtttcctg gctgtttctt cgaggagatg acctgcctgt cgggcagatt agaatattta 155520 ctgcagtgca tctttcatgc ctcgctgtga ctctgtaacc acggtggatg tgggaaagcc 155580 attaaccatc agcttgacgg tttacaaaga aataggaagt tcaagttaag cagatattta 155640 ggatatagtt tgccttccac atatttcaac ctgtgttgct gcatactttt taagcttagc 155700 gtaattattc acacagctat gaattttaga agatgtttaa aagcaaacca cagtgacctg 155760 ggaaaggagg gaaacttact ggagcgctta gccaggagct taaaaagaca ttgctagtga 155820 gttttatgtc acatgaaatc tacatttgat aggtcatttt ggtaagtttt tgttgtttta 155880 aatgactcct cttgacacag taaccagtgg tgctgggaac attcattcac attcattcat 155940 ttaagctcat gactcaaata ataacttagt cgtttcctct ctgaaggtag gggaggtaat 156000 gaggagcacc gattaggctc caagatccgt tctgagattc agataaggtg tcctaacaaa 156060 aggtttatgg tgaaatgaaa gagtgagaaa ataattgtgc tttttctagg gtcatgcgtc 156120 aaatgaggct caccaacttt taaaagactt tacatagctt tagataatca cattccctgc 156180 catgtaagca ttgtgatgta atggcatcat catgctactt aacaattaat ttatgcattt 156240 tgtttaaact tcctttagaa tatatatagt ccatataaag aaaattccag ggtcgttttg 156300 gattttgtat aaatagctcc catgtttaca tgtgaaaaaa aattatttat gaaagaaaaa 156360 cagagctttc aatatcctat tttggttacg tctccataaa aactctagga aacagtggga 156420 tcatctgtga aacagtggaa tcaccccaag aacaaactgt cagacagacc gtcctgtcgt 156480 ggcatgactt gaacataacc gtcccacgtg gggacgcatt ccgcaccggt tgctggaact 156540 gacgggggct gcagtgctga atacctctgg gacgcttggg aactgtgccc ctgtttacag 156600 acggcaagcc cttagtggta gggccctgag attctgagaa acataaggtc tgctttattt 156660 aatttcctct cgtttaccaa gagtcacaac ctattttagt aaataaattc aggaaattgg 156720 taaagcactt tactccatcc gttatgcctc ggtcatcagc atggttgtca cggtctctct 156780 ggctcacggg ctgctgcggc tcacagcctt ccctcacttg cctgcaacca gctgagagcc 156840 tccctggtga tgggtgttac tgagcttaaa cgatgtaaac aaacagaacg gcacacaagt 156900 tgtgcaggga agtatatttc ctctaccttg ttaataaaga tttctaactt tagagatttt 156960 ctgtattgac tctggcattc tttccaaata attattttca ccccggggac tacccacaca 157020 ccctgggatg aataaaagaa attatctttc atttgagggt accagcaacc cgctctccag 157080 ctctaatcct cttcatcctc cttctttttt tatttttttt tttttttttt tttttttggt 157140 tgttaaaacc tgagctgctg ccaagctgat cttaatagca tgttcacaaa gacagatgga 157200 tttttttcct accttcatta gccactgagt gttgttttcc atgatgttct ccagcacttg 157260 cagcctctgc accgagtcat cgtattcgag cggcgcgtcc ctctgcacag cattggacac 157320 gtaggggctg gaggaagagc ggcagttgtc catctctggc aggaggaaag tgtagctgca 157380 ggacccatgc tggacctgat attgcttctt tcctatgctg tccatgctct tccgaaagtt 157440 gttataggct gcggccaaga caagatcaca gctcagagta aagaaaacaa tctgccacat 157500 tctttcttca gtaataaacc agcagcttag caaasttgag ggcaaacaca cgtccagagt 157560 cccgagctgc tgccgtctra aaygcagggc tgctacgctg ccatggctgg gtccgtcart 157620 gaaagtcttc tctttcctct ttttccagta gcaaacctgg tttttactgc tgtgttctct 157680 ccaggcatgc agtaaactgt cagattgcag tgggaagaac agtcctgctc acttgggagg 157740 gctgtgtcag cttttacaga gcagctttca cggtcctttg ttcctctctc cccagatcct 157800 acagtgtcag tatccgaatc aatcactttc ctttccttat atgataagtt gataagagca 157860 gccagacatg tgtagtgggc tgctccgccc tcctggctta gccgttatct tcctgtaggg 157920 ggtcactagc caggcaacag gaaaaatcag agcagaatgc ctgccctcca accaggaccc 157980 atgctgcaga aaccctctgg gaaaaaccga tctgttacag gacccctggg catttcctag 158040 gcaccacccc aattaagtat ttcctagaga gagcagttga tctcttttgt ctgaaactga 158100 tttttgccgt gctaagctgg caaaatatct gaggtaataa ctttaatgtt gaagtacaat 158160 gaaagttcct gttttttcct ttaggaataa aaatactaca aataggtcag gacttcggtt 158220 tatttttgtt attacaaata aagaggaaga agtttggctc ctgtaaacgt gtgccttttc 158280 agagggaaaa atagattcat tgattttagt tgattcttga accactagcc aagttacaaa 158340 agattttcat ttccgaacag ttggatagaa agatctgtta ttaagtcacg ttagaaacat 158400 cagtttctga gctctgacct ttattcttta aaaaaactcc acttggatat tcactctaaa 158460 aatacactgt actgattaag ttcattacat tacaatagag aaattagaat ttaagtgtct 158520 gtgtagaaag aggaatacaa actttttttt tttttttttt tttttttttg agacggagtc 158580 tcgctctgtc gaccaggcta gagtgcagtg gggcaatgtt ggctcactgc aacctccgcc 158640 ttccgggttc aagtgattct cttgcctcag gctcctgagc agctgggatt acaggcacac 158700 gccaccacac ccggctaatt tttgtatttt tagtagagac agggtttcac catgttaggc 158760 tggtctcaaa ctcatgacct tgtgatcgac tcgcctttgg cctcccaaag tgctgagatt 158820 acaggtgtga gtcaccatgc ctggcccaca aacttcttta ttgtgtcaga atttgttgac 158880 atctcagcat tttgtaacac attatcaatt acattagtcc cccttggtat tagactcggg 158940 caagtcactt ccctgtttta attaagctct aatgttctca tctgtgcaat tcaaggggtg 159000 cactcacaag atttttcacc ttcaatccta tggctctgta agttctacaa gtcacttcct 159060 ttaacaacta aaacttaata cttcagagat taataatatg ttaactcagc agcccaagtg 159120 tacataggga aaaagccccc tgcctttgct gcggtttgtt tatctctcaa ggtacaaggt 159180 ttattattcc cagcgagcgc tgaatagctg gtacactgac ttaacagacc acatctaccc 159240 ataaaagatc tttatttttt actaagctct aaccgaaaga cagcctttcc cttatcaatg 159300 aatagttaac gaacaacagt gtgaatatct gtgactttct catcctcaga aatcagctct 159360 ttttatttgc tgccacaata ctcagaacta catttttatt aaacccagcc ctagatcttg 159420 ctactgaaca ttggaataaa gtagcatgtg tcttcttttg agaaggtgtt tataggcttc 159480 accagacaac caaagggttc tgtcacacag aaaagctgga agacatgctc tggaaggatc 159540 tcattagtag aagaggtagt atgattccac caaggttctg gacatggttt ccactaaggg 159600 aaccaattaa agatgctata cccatccgga cagtgcaccg tcgaagaaag catataggtc 159660 ttaaagatga gacctgtgtt agaaccctgc ttctgtgtga cctccagcaa atgcttccat 159720 tcttggagcc tcagtctccc tagtcataag atggagatca ttttttctct gtagggtttt 159780 taggattaag atataattgt atgtttagaa atatttgttc cttttcttta caggcatgct 159840 ccattaaatg gggatcagtt cttccaccat caaatagtat aactctgcta ttctctgaat 159900 gcaaagcagt ggcagtggca tagggtacaa tttttttatt tcctgtttga aaaagcatat 159960 tgtaaggtat taatatcaca tatgtggttt tacctttttt caagattatt ttttgtagag 160020 acggggtctc actcttgttg cccaggctgg tcttgaactc ctggcatcca atgatcctct 160080 tgcttggcct cccaaagtgc tgggatcaca ggtgtgagcc actgtacctg gcctgcatat 160140 atggttttaa aagtcattca gttgtcttcc aggcaaatag agtagtttaa aaggaacaaa 160200 tagaaagagg gcacaccaca gtactttttg tctaccagcc ttgtgtcaga caccatgcta 160260 tgcactgggg atagagatta aggcaactgg gtgtctgacc taaagaagct aatagtgtat 160320 ggagagggag agacccataa acaaattgga tgtggtaaga gagagcagtc ggagcacaaa 160380 gaaagacagt gatgcttccg ggtgcacaat atgccatgtg cagctggcat ggactccatc 160440 cttttcaaat tccctcaagt tccgaacatg gaaggaacag ctctttgtag attcctaaat 160500 ggaaattatc ggaaccagag agtcagggga agctctagta gagccggagt tggcaaactc 160560 tgtccagtgt cagatggtaa ttattttcgg ctctgcaggc tatacggcca ccatcgccac 160620 cactcaaagg taatgcggtg caaagcagct gtgggacagc attaactgag tgagcgtgct 160680 gggctccaat aaagctttat tcgtgatact gaaatttgaa tttcttgtaa ttttcacatc 160740 atgaaagatt ctattttctg caatcattta aaagtttaaa aaccattctt agctcatagg 160800 ctgttagaaa ccgggcctgg actgtagctt gctggcctct gagagcctag gtggtctgtg 160860 ggggtaggag gtgctgggca aggccgtcca cagtgcacgc ggtgtggtga ccgtgtgtgg 160920 ttggcaaggc tgtcagcagt acacacagtg cagcaaccac cgtgtgtggt cagcaaggcc 160980 atccacagtc cacacagtgc aataaccgtg tgtggcgagc aaggctattg acactgtacg 161040 ccgtacagcg accgtgtgtg gtcagcaagg ccatggagag tgcacacagt acagtgacca 161100 cctgtggtcg gcatggccat caacagggca cacagcacgg tgaccatgtg tgatcagcaa 161160 ggccgtggat agtgcccgtg gtgtggtatc catgtgtgat cggcaaggcc atggatagtg 161220 catgtggtgc ggtgaccctg tgtgattggc aaggccatgg atagtgaacg tggtgcggtg 161280 accgtgtgtg atcggcaagg ccatggatag tgcacgtgtt gcggtgacca tgtgtgatcg 161340 gcatgaccat cgacagtgct tatggtgtgg tgaccgtgtg tgatccgcaa ggccatggat 161400 agtgagtgca cacggtgcgg tgaccatgtg tgatcagcaa ggccatggat agtacacgcg 161460 gtgcggtgac catgtgtgat cggcaaggcc atggatagtg cacgcggtgc ggtgaccgtg 161520 tgtgatcggc aaggccatgg atagtacacg cggtgcggtg acgatgtgtg atcggcaagg 161580 ccatggatag tgcacgcggt gcggtgacca tgtgtgatcg gcaaggccat ggatagtgca 161640 cgcggtgtgg tgaccgtgtg tgatcggcaa ggccatagat agtgcacgcg gtgcggtgac 161700 cgtgtgtgat cggcaaggcc atggatagtg cccgtggcgt ggtgtccatg tatgatcagc 161760 aaggccatgg atagtgcacg tggtgcggtg accgtgtgtg atcggtaagg ccatgataga 161820 gcatgcagtg cggtgaccgt gtgtgatcgg taaggccatg atagagcatg cagtgtggtg 161880 accgtgtgtg atccgcaagg tcatggatag tgtacacggt gcgatgacca tgtgtgatcc 161940 gcaaggtcat ggatagtgca cacggtgcgg tgaccatgtt tgatccgcaa ggccatggat 162000 agtgcacacg gtgcagtgac caccgtgtga acaggggagg actggtgcct cggctcagcc 162060 ttctgtgtgg ctgcttacag gggcttacta acgggataga ataggtgctt agagaaagtg 162120 ccacactgaa gtgaattaag gatgccaggt ggggagaggg gccaggaagt ggcctgggat 162180 gcaagtgtgc atggatgggc gctcagctgt ggcccctagg gaagtggaga catggtctgc 162240 caggccactg accaggaagc ctcggggagc caatgggagg cgcttgaagg cattaggtgc 162300 aaagcctgga gttgtgggtg tccagtaaca ccaccatgca gcctgggggt ctgaggccac 162360 ccatctggga ccccttcact ctaaatgagg cttgactagg gggatctcag aagtccacag 162420 aaaatcttgg gtgttcctcc ctgctgtact gacgggacca caagaggcaa gtgagactgt 162480 cagatgagaa acattattac aggttcccaa aatccacctg cctacccacc caatttttgt 162540 ctgtaatagt tctgctgaac agctgtgcat agtgcaattt atttccttaa tactgtttgt 162600 tttctccccc atattctgtg tcggcaactg acatttcaga ggttcccatg tgttctctgt 162660 ggaactgtct caagttctta ttaccctggt tgacgacacc agaaaaacca tagctaccta 162720 ctcccagaaa gaggccagtg ttacaaagaa tctcgtggcc agcccttttg gctcagtttg 162780 cccagttgga ggccctaagg cgcaaaccag aaaagccaaa gggcctcctg aggaccgtgg 162840 aagtgggtgg cgcgtggacc catcgctagc tgaatgtgga atgtggaccc atcgctagct 162900 gaatgtggaa tgtggaccca tcgctagctg aatgtggaaa aggacttatg acagtcagac 162960 catcccaggt tcccccagag caatccgtgc agctctcata agcaaccaga aaccaaaaaa 163020 ggatgctaag tcagcacaaa gtggagcagc cccccagcta tgggttgcca aacagaattt 163080 gcttgtgggc cccgtgaccc ctgctgttgt ccagtttaat gctcagcatt tatccagatc 163140 aagggatgga aatggggcca ccagcctgac ccaggcccgg ggtcgttttg cttttccaac 163200 ctgtaccatc ccagcaatgc attgccagcg tgcaatttga aaaagccctg ccgagctgaa 163260 aaacacatgg gaagggctca gacacactta aaggcacatt gctgccctgc atttatacgg 163320 cattttgtgc tgacatcgtt ttccatcagg cctgggcagc ccctcctgag actgtctccc 163380 gcctgccgtc ctcagcacgg cctgcccggc tacagtctgc tttcctccca ctgcccctgc 163440 ctgcaggcct tggaggcggt gactgctgca gacttatttg ggcagcctgg ccttaatttt 163500 tggaaagtgc cttgttgatg tatgaggaac ttccacggct gaaacagtct aaaaaaatga 163560 agctgggaca ctatgttttg attttagcca tttgcagaca gaggggcaca ctcgggactc 163620 ttgggcgcct ggcacactaa gctgggaggg acttttgaga catcttggcc atctaaatca 163680 gtcaacatgt ttatatatac aatttaatgt tcagtataca gggaaaacca ttagaaggtt 163740 agctgcacat aaaactgttg ttaaagttat ttttattact tccccccaca aatcgtatgc 163800 aataattaat aagaactaga gaaatagcca caactggcac aacacctgcc cctctgccaa 163860 aagaaaaaaa tcttctttct gaaggcaggc tccctatata gtgattcctt tatatgcctc 163920 ctggaagatc tgtttcgact ccattttgat atatgttgaa ccagatttga agacccacaa 163980 atgcagtcta gagccatttt gcaaaagtgt tgctgcatca accatttcca ttccccagtg 164040 ctgctcatca tgttacacta gtgttaaatc ctgactttgg aatgcgagga aggacagttc 164100 cagccatggg atttcaaaaa agtaccaaag gaaagcccct tcaagttacc gttaagacag 164160 aagaaaagga agaaaaatat aaacacacac gtataaacat gtaaggtagc tttggtccct 164220 ataacagaca aggaaatcaa ggctccgtga agagagagac aagaattccc ttagccaagt 164280 gcctgtgtgt gtctgtcttt tatgttaatg gttatgaatt taaggagaat tgaaagcaat 164340 aattttgccc ctctttaaca tggcaaatac agcctgcttt agagatgatc agcaatcacc 164400 atttagtact ggccgtcacc tctgtgcagc acaaacacac atcccgagtg acagaagcca 164460 tttcactgcc agagactctt agcggccttc agttctcttg agctggagcc actgggtctt 164520 gtatgaaagc tcaccagaca tctcatgtgg acctcgggca tctgagccgg gaccatccta 164580 ttacaagtgc ggaaaccaga tcattaatgc agagctgaat tcaaattgtt acttgctagc 164640 ttaggaaaga atccttggaa atccaacata ttgtctaaat ggatcagtta atcttactat 164700 gtgcattcta catacccttt cattgtttgg gcttaaataa cttttctgct ttgtctggtt 164760 taatttcatc caatgtggat cgctggaaga atatgatgta tgttttagaa tagaaacagt 164820 tctgagatga agttgagcac aatttcctgt tctagttgca attaaatata aatatagcat 164880 ttgacataaa atagctggcc cgatatattt agagtacaag ttaagtgtca tccccttaga 164940 attgggcatt gactccgtag aattcccctt tgtacaaggt gagcaaatgt atattttgtt 165000 aaaaataagt atctgactgc caaaacggac agaaagctct ttgccatatg tgttttcagg 165060 ccatttcctt tcctgggaaa cagccatttc ccccgcatta tagttgtgtt ttcatttgcg 165120 ggtagataga gtaagcgcag gagttaaagg acgcgggcct ccacagccaa ggccttatct 165180 gggacaatta tctttctcct tgcagctgtg taacttctgt ttgacacaga accacagaaa 165240 ccctgttagt gggaaggatc acagttaata ggagaaaaat cttcattgtt catgagactt 165300 ctcaggtgct tggcattctt atttaggtgg cttaaaaaag ttccaagtac tcattcattc 165360 taacttatct gtgttcattg tgaaatcgtg tgtgaatgac atttggagca gatggattgt 165420 tgtttttttt tttttttttt tttaacaaac ttaagagatt cccgaatctt tcacagtttg 165480 tactaccgca aaccagcata acatctgcta aagaatttca tattttaaag ctgcactgta 165540 catcatatgg aaccttaagg actttgaagg gaagagcttt ttatttactg gtagcttggg 165600 aaatatccaa gtaactattt tttaagaaaa aaaaattcct tgagttttta gaaatagttt 165660 atataactgt tatgctgttt gatttttaaa tattttcatt ctctagtatt attatggaat 165720 attttatctt cccatcaaaa aaatgccaga aggtcaagat agaagtcaca acattaaaag 165780 ggagtggata caattgtaaa acaatagatg agtacatttg cctgataata tttttgccag 165840 taattctgtg tcctgttttc tccctgtaga atgaaatgct aaacattttt ttcaatggat 165900 tgatgtcagt gtttactaac atgacctgtg ttaagtcaaa taaagtattt cctttgacaa 165960 acaccatatt tcattagtgg ctttgaggtg ggcttatttg ttataagtca cattaaatgt 166020 tcccaaatcc atttcataaa tgttgtcgag atctcaaact ccgttgcttc taaaaaaata 166080 tgtccagtct ctttgtcata accatcctaa taaagatcta aatttcttag agtgaatttt 166140 catttgaaag tggcttaatg ccagctagat taattcttgt ttaatctaaa tttataaaat 166200 ttttatctta attattgaga aaccttttta aaaagagata aaaatgtcat atgtgctatt 166260 tacattaaga tatattatct ctcttggtta taggttaaga taaataaaat tgcttatgtc 166320 aaagaagtaa aaaaaagtcc atgacctcct tttggtatcc ccatccatct ggcggactta 166380 atatgaaaaa atcttcctgt gggaaattag gcttgattat agagttacaa gtacaaaaag 166440 tagtttttga agaattataa taaatagtta cacataaaag gaagtgatgt ttgcttgaag 166500 tatataaaaa tattccttgt cactcttgtc ccctcatgaa tcttagttgt ctgatgatgg 166560 ttcaagtctt tcctaataat ccagaatgta tccctccact ttttctctta aaaacgctat 166620 ttcaagcatt ttctttggta ccccattaat aataaagcat acttccccaa aatgttccat 166680 ttcaagtaag gggtctaaaa gtcaaagacc gactgataca aaagagaaaa gtaaattgta 166740 caaagactga agagaggatg cagtattaaa cgtaccaagt tcttgacatc ggtttccctc 166800 aagaaaaaaa aaaatgagta acgttttttg aaagcctgaa actattctag taaaatattt 166860 acggaaaaaa taatatgcgc tctcctccca aatcctgatg cgcatttaaa tcaccttttt 166920 tatttataga tcaaaaatct tgcttgacta caataaaaat taaaaaatgg tacctattta 166980 agaatgcaag tatcaaatcc acttgtaata ctcactagct ccctctgctg atctcctatc 167040 aagcgacagg caaatctatc catgattgtt attacaattg ttaatggaaa tgataggtaa 167100 tttaggacct acatcaattg caactaaaat acaagctaca atgctttcat tttaatttta 167160 atgcaaaagc acatcacacc atatacagat gttaaagacc gacgtgcaca cacacagtga 167220 aaaaatattt ttaggcattc atttagcata catagaccta ggagctgtct ctgtatcctc 167280 aggtgataag gttactacta ttacaacagc agaaaaagag gtctgtactg tctgtctcca 167340 taaggagcca atttagagac ccaatcctgt tcaccccaag cttacagtct aacgaggtga 167400 acagatgtcc catctggatg cacaagcact gctggctaag gccctgggta gtgcaggagg 167460 gagcccccac acgggaagcc tcccaaacca cgtaagggct acgtgaacag caagaatagt 167520 ttcactgttt atttagatcc acactgttac ttatttaaga agaacatact ctgccctttc 167580 tccctccctg aagaaagacc aaaactgagg gaaattatat tccaggctga gaaaattgcc 167640 tgtgcactta aaaaataaat aaataaaagg cgagaccacg gaagttaaaa taaattaaca 167700 ataattgagc caagagggag gagatgggtg agtcggagat gcggtctgga actagctgct 167760 gaagagtctg cttaggaatt ggggttgtac cctggacata aagcatttgg ggcgggggag 167820 tgtcctgatg tgactgagaa aggactgtgg agtgctgtgt gcagtagggc ttagaggagg 167880 tgtgagtaga ggcagagaga ccagagcaga agctgctaca gtaattcagg ttagatatta 167940 tagtggcctg tgctagaata ttaacatcag gctcatgatg ttaaagaggg gtgatcaata 168000 ggccttctag atggatggaa tacagggagt ccaggaatgg gattggtctg gtactgggac 168060 tgactcttac acttaaaaat gctaaaataa aataacttgg caatagtttt taaagcatct 168120 gtaaaatgac aagataataa acacatattc tgctcaaact tatgtgaagg caggaatcct 168180 gtgaactatt aaagagcttt gccatcaagt catttgccaa acctggccaa cttaagccta 168240 cttcaaggcc tgagtggttc agacagaaga caaaggccag gacctaaaga aatgggagca 168300 tctgatgaga tacctccttc caggaaggct ctaccccagt gtcagggaag cagaagtaaa 168360 cctgcccacc ccactctcca gagcagacaa gaaaacatgc ctggatgtta aacagaacta 168420 aaagagggga gcccatccct gagaatttaa ctacaagctc acccttttgg gttttacagt 168480 acacataagg tggccagaaa aaaccacaat gaattgttct aaggtggtcc caggctgatc 168540 atcttattcc cctaggtttg tggaagaagc aaatgaaaat cctttctggg agaatgcact 168600 ttcatcatgg gtctcaaaac attcttacaa tttcccaaga ataatgggca actcacagac 168660 aaaaataaac acacaagaaa acatagtgct attagcaaaa atcagcagaa agaagaaata 168720 gtaaaaacag accagccaaa aacatctatc cctgctgtat tggtttgcta aggctgcggt 168780 acaatgtgcc acaaaccggg tgcctaaaac aatgggaatt tattctcaca gctctggagg 168840 ctagaagtct gtaattgagg cgtcacaggg ccatgctccc tctgaaacct gtagggggtc 168900 cttccctgtc ccatcctagc ttctggtgtt gctggcctca tcgtctcatg gtattctccc 168960 tgtctacacg gccgtctttt tataaagatg cagtcacatt ggattaagag cccaccccac 169020 tccaggagga cctcctctca actagttaaa cctgcagtga cgctacttcc aaataagccc 169080 acatgctgag ttgctgtggc ttaggactta catctttcta tcaggaatgt aattctatcc 169140 ataacactta cgatgtttaa agatgaaagt aaaattttga aaacacctaa aggggacaga 169200 aaactaaaga agaaaatctt gcagatttaa aatgaaaact tatagacatg aaaaatacga 169260 tggttggaat ttataattca gagtcatgtt taacaagatt agacacacct gaagctgaaa 169320 gataagtgaa aacgagtcat cccaggtgta ggacagagag acgagataag gaccaggaga 169380 gaaagtgaag gaagacctgc aggatggagg aagagtgtct gacaaagtcc atccaaattc 169440 cagaagaagg gagagagaac agggcaggca atatccaggg agatagtcac tgaagctttt 169500 cccaaagtga tgaaagatat caagttacag attcgaaaaa cggcaaaaaa tgacaaacag 169560 gataaataaa atgatgagat aaagcagtaa gagggaagtc aagaattact ggttctgcag 169620 tttctggcct ggcagctgca cagataggat tctcaagggc tcggaagggg agaggtagca 169680 gagaggcaat gcatgcagct tgcacacatt cagtttaaat tggctatgag acttccggtt 169740 agagttttcc tattgcatat ttgggtctga gctcaagaga gccacctggg ttggaagcag 169800 caggaagacc tattttcctg attaatctca atgccagcct cattacacaa tcttaactaa 169860 tattaaacag tatatgaaac aggtgaagaa gaacagctgt ataaattgca taaagcttag 169920 caatgtgggt ttttctagac aaagttaagc agcaaagcag ctccattatg agggaccctt 169980 ggccacggtt tcacaggtgc aggttctgca gatcatggca tgttgtcctg ttctctggat 170040 tatggctcta gaagagataa tgataaagaa gacccagggt ggtcagtaaa aaggtcctac 170100 gtggtgtcta tacaatgttg caagtgacta aaaatgagta aaacttacaa gatataatta 170160 gtagcatgca actcttcata aatttgtcac ttctttgaag gtccttgtta tgagttgaat 170220 tttgttctcc gaaaattcat gttgaagtcc taaatgccct cagcacgtga ccgtcttcgg 170280 aagtagggcc attgcagttg taatcagtta agatagggtc atactggagt ggagtgggcc 170340 cctaatctaa tgtgacagat gtctttataa gaggacggtc atgtgaagac agatacagga 170400 ggaacgcctc gtgacaacgc aggtagggac agggtgaagc ttctacaaaa cagggaacac 170460 caaagatgag cagccactgc cagcagttag cagagaggcg tgggacagat cctgcctcgt 170520 ggctttggct tccagaagga accaaccctg ccccacacct tcacctcaga tttctgctct 170580 ccagaactgc gagagagtgg atttctgttt aagcaagttt gtggtacttt gttacaacaa 170640 ccctagcaaa ctaatacagc ctaaaaaaaa aaaaaaaaaa aagtaatagg aaaggaatta 170700 aaatataacg ctaccttgca gcctccacca aacactgttg ccatttggtt cttctccttc 170760 ttgttcaacc tcaggagggg gtgaaaaaag tccaggcagc tcctggtgat agctatgcaa 170820 agcttcattc tgcagcagta aaagtgtttc ctagaagtac taaggctcgt taattgcagc 170880 caccctataa aagaaggtcc tctttcatga agagcctgtt tctctgcagg aagatggggc 170940 tgacctcagg gcctccagca cttaggcact tatccatatg tctgtaacca ttgttgtgag 171000 gttagttgat aatggctcat tatcctcgct aaaatgaact cgttgaagta tgaggccagg 171060 ccttattgga atccttccct ttccctttcc cttcccgttt ccttttccct ttcccttccc 171120 cttccccttc cccttcccct tccccgtccc tttagatgta gtctccctct gtcccccagg 171180 ctggagtgca atggtgcgat ctcagttcac tgcaatctcc acctcccggg tcaagcgatt 171240 cttctgcctc agccttctga gtagctggga ttacaggtgc ccgccaccat gctctgctaa 171300 tttttgtatt tttttttttt tttttttttt tttttttttt tttttttttt tttagtagag 171360 atgggttttc accatattgg tcagggtggt ctcgaactcc tgacctcagg tgatccgtcc 171420 gcaggtgagc cacccgcctc ggcctcctaa agtgctggga gaggcacagg cgtcagccac 171480 agtgcctggc ctactgtctt ctctaaaatg gcatctgtgc attcatctca gccgcccctg 171540 ctcagataaa agcaatggcg cctcctttga aatctgagag acgcagggcc ctgcccattc 171600 tgcggaattc cttctccctg ctgcctgctg tgaggaggcc ccctttgcca cggaacctga 171660 aattcctgcc actggaatta cgctctggac aagcggcaag atactccttt cagtcccagc 171720 cactgggttc ctgctgcaca ggaggccagg gtgctgtgaa cctgctctca gccccgggca 171780 aagggaatct cgttaatcca ggtggccagc gcctcttcct cagagcatct gcagtgctgc 171840 agacagggcc tccctgcgtg gggcttctgt cctccacact gtggtgctgc tgggatgttt 171900 tcatggggcc tttcccttcc cgtcaccacg tgtgctccag aacccggtgc atttggatga 171960 agccactaga tgtataggtc agcagctcca catagaatcg aattatcaaa tgcacactac 172020 ctgatccaga atagatcgtc ctggggtaaa cacattcaca tattctgaat gtacaaatgg 172080 ctgtctagta aacacactgg aacttccata attattgtcc ttccagataa tttttcaaga 172140 ttatatgcac gtattctgcc attccttttc aagacaactt tagaacttcc tttggacagc 172200 tactgtaagc caaagggctt gcatttgaat atcttgcatg aagctaaatc tttgttcatg 172260 aaaggcagaa taattttata tgccacaaag ctgcagtagt gtgttaggtt tagtagatgg 172320 ctaagcacta cactgtatta ttctaatcct attttcacaa tttaacaaat gtgagacacc 172380 gtgctacttg tacaagagat acaaattaag gaatcttcaa tgaccttgta gcctagaaag 172440 acctttagta attcttctta atctccctac agagctaagt gatccagagc tgaattaatc 172500 cagaatctat gtcttcctcc gcctccggag tagctctaga aaggtcaaac ccttccgaga 172560 tggagtgtct gtgggggtag gtcctctttg ctgtgtgcga tcctgtgaga cagcgggatg 172620 tcctgcatct ctgaatttga agcgaggagt ttttctgcta tgtttgggga gagcctcact 172680 cccctgctca gtagatcaga cgtgttctct tctttcacca cagctacaaa caacacactg 172740 gcattgtttc ccagacactc gactgtcccg atgggcattt ggacatggtc tatgagagga 172800 ataagctcca gccactgtag tggctcatgg gagagggaaa tgggtagaaa ttctttccca 172860 aactggtatt tctagtaaag cactcagcca gagcctgcag ctgttcacta ttccatatca 172920 attctaaaca gcattttcgt tggcaaaaga aaagtgagaa aacaacaaag cttgaagccy 172980 aaaactttgg gaaacccctt tcctgaatgt gtttacttag ggcttaaaaa tatgcctgtt 173040 ttcagaacag aagaactaat atccatgttt tctatgccga tttttcagag tacattttaa 173100 atgtaagtac atttagtgat taaaagggaa aaatacttga tcgttttcta aacataacca 173160 aaatctcact atgtaattgt tttttcctct atttaagagc agaatatttc attgctacca 173220 aaatgctagt attttggaga aaatagaaga actagaataa gtagtcagca atacaaaacc 173280 ctgcgtggaa gatgtgtatt ttggataggt gtcaacatgt ccaagctctc agtgacaaac 173340 acaggctcat tacaggtctg agcaaatgtg ccacttctca ggaagacaag gcagatcaat 173400 gtaaaggcag gtggcacctg gtatggctca gactcgcacg tggttctcca cagagctgct 173460 ctcggctcct ttggaagagg ttcaacgttg ggagcacagg ttgcttctct ggcccatgtt 173520 attcctggag ctactacttc ccagggcaga gttcgtgttt ttcgttcata aatggcctgg 173580 aaatcctagc attgggccag ccatccagaa cagtggagct gcatgatctg gtctggggat 173640 atttcaaagg gaatagaata ctgaggccct gtgggatgga ggctgcttcc cgatattgag 173700 aactgcacca gactgagctg tgtccagagg aagggagaac gtctttcatt cacttaaaac 173760 tcacccaaca cctgacacct ccatcttggc atcatccacc tgtagcctct agccctcttc 173820 atctgttaag tgagagtaac tggcaggtta tttggagagt gaagtgacat cggcagagtt 173880 ccaggtatgg tgtctgatgc gtgagttcgc cccctttccc ggtccccttc tcctccattt 173940 gactaattat caaagaaaga ttgctttagt gaatgagaca gtttagatcc attcccttgg 174000 gaaattatgg tggtcagccc tccgctcggt ctcactttta gataccagaa actatatgtc 174060 cttgtgttgg cagagctgga ttgtctgtcg ccctctggtg caatcctgca ttagtaaggg 174120 aagtgttttt ctggggcgtt ctaatgaaaa gtgcttaagc atttgttttg gtgcccagat 174180 aatgtgactg tagttagtat gtagtgtttg gactttttgc tcatgctttt gttgttgttg 174240 ttgtcattgc agaaataaaa ttaacccctt aatcttatgc ttaatgtaca caccaagtgg 174300 tttgcatatt atactgagaa aataaaaaga ttgttttaga aaaaccaaag gacaccaaca 174360 gctctttaca gccccaaagc aggtgtcgcc agaggtcaca ggaggggttc ttagttatca 174420 gcaagggaaa ctgaggcttt ctcgtttatg cagaagtgga atttattgaa taatattaag 174480 ggggctatgt cgccaatgcc acagtcacac tgcccacaca gaactggcct ggcgaggtgt 174540 tactttgacc accattgctg ggccaggacg ctgccaccaa ggccgtgccc ctgccagaaa 174600 ctaaatgtgg ctgccccatc cctggccctt tctgtcagta gggtcaggtt caaactcctg 174660 ggtagtcagc ccagctctca ttgactcagt ctgaacagct gcctgttccc tagaatccac 174720 atgcgctggg acaatgggaa gtatcggtag acgctatggt gggaagatga ctctgtgtcc 174780 accaaggttc ttgggctggg gaatggtctg agcatatgac ggcctcagac cccagccaac 174840 caaagggaaa ggtctcccct gtactcacga agcctccacg atgtccatca gcactttctt 174900 cctccgttgc agtgtaggtc agcccttcgc agatgctcac aattccctga tacagccggt 174960 tgccctttgt tgtgttaaac tgaaagaatt tcagagttgg ggccaggcat ggtggttcat 175020 gcctgtaatc ccagcacttt gggaggccga ggcgggcaga tcacgaggcc aggagttcaa 175080 gaccagcctg gccaacatag tgaaaccccg tctctactaa aaatacaaaa attagctggg 175140 catagtggcg tgttcctgta attccagcta ctcgggaggc tgaggcagaa ttgcttaaac 175200 cgggaggcag acgttgcagt gagctgtgat catgccactg cactccagcc tgggctacag 175260 agcaagactc tatctcaaac acaaaaacaa aaacaaaaca aaacaaaaaa aaactcagag 175320 ttggagaagg actcggacaa atgtcatatt atagaggagg aaaaagatcc aggaggcaga 175380 aagacttccc tgagggccat gatggtagtt agtgcatcca ttaaatacaa gtcttctgct 175440 tcttattcct gtaaataagt ttgcatttaa catttttgta cattaaacgt tactgattca 175500 tagtcaatga ttatggtcag ccctccacat ccgcaggttc tgcatctgta ggttcaacca 175560 atcgtggacc aaatatattc aagaaaatga aataaaaata caacaataaa aaagtacaaa 175620 aaatcgagta caacaactat ttacatagca tttacattgt attaactatc ataagtaatc 175680 tagggatgat ttaaactatg tgggaagatg tgcataggtt atatgcaaat actccatttt 175740 atataaagac ttgagcatcc atggattttg atatccaagg tgggggtctt ggaaccccac 175800 aaataccaag ggacaactgt gtattatttt cataacccat ttctgcctag tgttccatta 175860 gtggaatgct aaccatgtgg gaattattta tatcctactg ttcaaggtca tcaccaaggt 175920 ctgatttttc acacacacac agaattgcaa cctccagcat aaatggggat gaatttacta 175980 ctaacatgta gtttccatcc acaaatccaa tgtccctatg ctatttgtaa ctgtggagcc 176040 aagagaagct gttgaatcat gtggtgaata tgatcaagaa ctcaagatta gggataaaag 176100 caatcattct gttattcctt tttaaaaatt attagcctgt aatttaaaca tcaggatctc 176160 atgtaataca gaacaatatc ttctgacatt tttacaatac tagtattctt acaaaacaca 176220 gttaggaagt tacatgaaga aaacacccag actgtgtgtg gctaaatctt tagtacctca 176280 tttccatagt cttagagaaa gtttaaatta tattgaaact tttctcaact gctatcttaa 176340 tgtgttcagg ctgctgtaac aacatatcat tcaaactggg tgtcttataa acgatagaaa 176400 tttatttctc acagttctgg aggctgagaa gtccaatatc caggcagatt ccatgtctgg 176460 tgagggcctg tttcctggtt catagatggc gccttctctg cgtcctcaca tggcagaagg 176520 ggtgagggag ctctctgggg tcccttttat aaggacacta atcccatttg tgaggatttt 176580 cactctcatg acctgctcac tttctaaagg caccacctcc cagtactctt gcattgggga 176640 ttaggcttca acatgaattt gagggaggcg caaacattca gaccatagcc actggtcaac 176700 attaggtaac ctgcagtgct tggctgtggg atgggaagcc tgtgttgtaa aggacgtctg 176760 agtgggaaca ggggtctcaa gctgccttca catctaacgt cagcacacta gagatggaca 176820 ttgcagctgc aacctactgt gcctgtaaag catttagaat tacgccttgc atacacaaag 176880 tgctcaataa atgttaactg ttattatggt tgggcatcag ccactttaat tatctctttc 176940 aatcctcata gtaactcttc aacataggta gccttatttt gcagttgagg aaactggagc 177000 ttagcaaagt ttagtgacgt tgcagagcta gagttcaaac ccaagtctga ctccaaagtg 177060 catctatctg tgtatttgct tatttaacct cagacacaca gaatcggatt aattagagtc 177120 cttgattcag cacacgttct cttcattgat ccttactcct ttattttatt ttttaatgct 177180 attttttgtt tgtttgtatt taatagtaag ataaacactg tgaactcacc acttacctct 177240 catcatgaga gcgctggtgc ccacctccac ctccgagttc cacatatccc attaccctgc 177300 cttccccgtc caaggaaacc actgtctgga atccttcgtc attcaagcct tttcacagta 177360 tggctctttc cagcctttta tttctctact gtttcgcttg gaaactctac atttctaaga 177420 cagtgtggtg cctctgagct ctgtggcttt tgctcctgct agcctttctt cataaagtct 177480 ttcagcccca caagtgtcgc agcttttcaa agcctttccc atcctttaag gtcctacttt 177540 tcttttccat gaagtcttct ctgggccacg atgactgggg aatcctcact gtcttctgaa 177600 gttctgcacg tacttactct gcacatagtc ggcggtgagg tattcatcac attgaaatcg 177660 agttacatgt ggtcctgttc tatagtcaac caaaactcct ggggtaaaaa tgctgctttt 177720 catcttggca atctctatcc taaccagcac agtgcctcgc tgaatattag aggcctgaga 177780 attttctttg tttttttttc agagtgattt ttttttctct gctttatttg atactttgaa 177840 gcagcacaca tttcagtttg ctttatgctt gatttttttt tatttcttct aaacaaacga 177900 gatacatgtg cagaacgtgc aggattgaca caaataatag ctggcagagt gtcctaggaa 177960 agactcctca gatgttataa ataatacaca aacaaaaaca cacacaaata tttactgaag 178020 acttttcttg ctctgcaagg cactggctgt gtgatgcaga ataaaaccga caaaattctt 178080 gccatctggg atgtgcatgt tatgtcagca cagggaagag atcaagtgtg tgtgcatagg 178140 acatcaagaa tacaataaaa caaagtggac aaaaggaagc gagggtggtg aacacaggac 178200 acctgaatga aggacagagt tgttggaaaa ggacccctga gtgcccaagg gaggagctgg 178260 cctggagtag tgagggcaag gtgattgcaa atgaggcctt ggtgattgga aatgagctca 178320 tccccacatc ttataaatag ttctccaagt tatccgaggc aggttattct gtggcaaaga 178380 cgcctcagct aactggatgc agaagagaca actgaataga gcctcatggt ctcggagtct 178440 tttttttttt ttttttaaga catatctttg gcattttgta cctaccttct gttctaaatt 178500 ttgcattttt actactttca agtgggtgga ctttgttgtg gtgggtagtt caagattcat 178560 catacaaatg tgattgtgct tcgaaactcc caccagtctg acgcacgcat gggttttctg 178620 gcaacatttg ccatctacag cactctcttt gatcaccttc atcatcttcc aacattcctg 178680 ccacagtcac ttcccagaaa cttgctaatc tgtaatagaa accctcagat tcctatggtg 178740 aatttgtaat caaaagtcac atattgattt caaaatcaat acacacttta aaaataacac 178800 tacagattta gcagctcagg gaggaaggaa accgtaagtt catctggtgc agctacccgt 178860 ctgggatgtg aattcctcct cttcatgaaa tgtttacatt catatcacag tctagggttt 178920 agtgaaccat aaaaagctga aagttaatgc aaacagaagt cgcccccaaa acatatacca 178980 actgatttaa aaggagacac agcagatgga gattattgtg aaaagaactc ttactggaca 179040 atttttttgt tattttaatc tctgcttatc ccaattcttt tagctgcata tactgagaca 179100 cttcacatct ataataaact tggtaccaga acacaattca ttccagacct aactctttta 179160 gatcattata accgggggag gaaaaaagtt aaaaaggctt atctatctta agaagtattt 179220 ctcagtgttc gctacacgtc acttaatctt ttccaaaatt tgacaatata caaagcagtt 179280 tgtagtgact tttcatagtg actctacaat aaaatgggcc tgtcctcctt gcttttccaa 179340 atgcagtcat catctgacaa ggtttagcta tttggggaag tccttgcttg caaacgtagt 179400 tcttttgcca aacaggtttg gtcaaactgt gtcccctagt tgcacagtta ccccatattt 179460 gattaacaaa tagcaaaaca gagataatct cagaaatatt caagagtctc aaaccccaaa 179520 taaaatatag gcatcctcct gttgagtcga attggcaatt ttgattagca aggctcatga 179580 agcagtagat atcccctctg atccccatcc cagtgcgagg gcacagtgag ttgtattttc 179640 taagtataaa ctattctcta gcagttcggc tggagtattg ggagcaaaac tgtatttttc 179700 taatattttc agactaagac agtgtctctg ttttctggac ttttccgtgg caaatgaagg 179760 atttatcagc aatacaaaga aagttctccc agtgggtact ccacggggag aggagctggg 179820 gtctcactag tgcacagcca taaaagacac cacaagcata ttacacgtga agcaggatcc 179880 gtgcccacca cagcagttgt cccaggagtt tcctgtttga atgagacact ttgggtggat 179940 actgcaggga gggagaagct gtgtgtggcc accacagctg gaagcgtggc ctggtgccct 180000 cacagctgtc tgggagcccc ttcccgggaa cgccggcttt tcccgggtgc accattgcag 180060 ctggagccgt tgtcggccgc ctcgaaaaca tgcagttggg ctgctctggc aggcttctcc 180120 agccctcctc ccaaggttta cctctctaaa tgtcaaaagg gagagaatac tgtatttgtt 180180 tttccctcta ctgaaattta tttgtgacat caggcatcac tttcacctta gtcattttgg 180240 ctggattccc atactcaatt aaatatcctt ccttccatat ggcccatagg aagagagaga 180300 aattacatgt aactggtctt tcctcctctt tataaagtct ggtggctgag caacttggcc 180360 tgtacttcct tcatgaccca ccatcccatg actgcagggc agttttaaac acagcagctt 180420 ggtttctatt gcacggaagc tggccaacag tcacagtgtg catttttcta ttgcacctcc 180480 ttgtgttaac ccaagttcac tcacagctgt aactacagaa gtttttctga aagcaagtga 180540 agccatcctt cttttattga gtttttgagc tagggtctca ctctgtcacc caggctggag 180600 tgcaatgatg tgaacatggc tyactgcagc cttgacctcc tgggttcaag tgatccttgt 180660 acttcaacct cctgagtagc taggactgca agcatgtgcc accatgccca cgctttctga 180720 tttttttttg tagagacaga gtctctctat gttgcccagg ctggtcttga accactgggc 180780 tcaagtgatc ctcctgcctc agtctcccrg agtcctggga ttacaggtgt gagccaccat 180840 gcccagctca tccttccttt aaaaccggca gctgggcaat aatacagatg ggaccaacta 180900 agtttctcag accactcagg gaagctagtc ttgcatagac aaaatataca ccctcttacc 180960 tgccccacct ttaaggctgg tccccagggt ccgcgctctg tcctccagcc tccacgcttc 181020 cctgtgacta gcctctgtgg tcaaaggtgc ttgctgatgc agcctctgta cagcctccat 181080 gcagtgcgtg tctttatgtg gaggagaccg cccttctttc agcagttatt gagcatctac 181140 ccactctgtg ccggtcatag ggcttagaac tgcatgtctg gggggaattc tgcaaagaga 181200 gcctgaaata aaggcaaaca gtgagagacg gccaggagaa accatgagca ctgcagtgag 181260 tatcaaggga caaagctgaa aaaggaagac tgaacgctga gcttcaagcc attcatttct 181320 atgggccgcg ggagcccttg aaagtctgtg ggcaagtttt ggtgagatta agctggtagt 181380 tctgttcagg acaggttgaa gggatgagag attaggacac ttaccacctg aatcctgtcg 181440 ctggctttag tttaaaccac ccgtaatgta gacatcctga cttagaattc cctgtgctgc 181500 ttcctttctg atggaaacag ctctgctaac agagtgcagg ctgtgggagc cgagccccgt 181560 tgcaggcagc ctgcaggccg cagtttcctc ggcttaccac ccagcgcttt tcattcggct 181620 cagcgctagg gacctctgct tccacttctc ggtgttggaa attgccattt atttttgctg 181680 tcgatgatct gtattgactt ggcctgagta tgcgtgcacg tctctggtgg tctgaattat 181740 atagaccaga agggtgtctg atgccgcttt tataaaaaat aataataatt tgaaaggaaa 181800 aatgactcac tgaagtctgg caaatacaga gccctctctc tgaatcgact tctcacttgg 181860 ccatgttgaa ttccaactgg gtgtcctcag acatttctat cccaagatct actcctggct 181920 tagaatctgt tttgttttgt cttatttcag ctcatggttc ttgttccccc agctttatgg 181980 ggtataattt ccatacaata gaattcaaca ctttcaatgt gtggttggat ggcttttggc 182040 aattgtatac agttttgcga tcacccctac actcaagata tagaacactg tttctcgtct 182100 ggtgattgct ggacattgaa ttctttccag ttttcactgt tatgaatctg actatgattt 182160 ttggcatgga tttgtatgta gctataaatc acttggtaat ttttcagaag aatagcagtc 182220 ttggggcctg gatggcttat tgtggtctca aaaagttcct gatgataagg ttgcagcctc 182280 atgcttcttt ataagaatgc agtattactt gcaagggagc ttgggtagat aagaaagcaa 182340 gaaagtccat gtggagaccc tgtccagaga gcacagacat ggactaagtt aaaggatggt 182400 aaattagcaa tgcccaaaag cacatggagg agatacttcc cctcctgact ctattggtga 182460 tgcagtttat ttgtctgagc tatctgagca agtttcctct cacttacgtg ctggggacag 182520 cagattccaa tgcagagtcc ttagagctca ggctcccctc aacctgacgc atctctcaac 182580 catttgtctt aagctgtctg aagtcagctt cccatcttgg ggaggtagaa gtgaaagggt 182640 ttccactttg ccaagtgagc gtatatgggg agactgaggg tgtggagttg atgatggttg 182700 tggggtggct gacagtgtcc acagggctag tcttgaggca ggctgacact ggggccagat 182760 gggaccactg tgcctcctgt cccctccacc ttctcctagt ccaggaaggg aatagcagca 182820 gctgctctca gtggggcatt ctttttccag agacaggcca gcccagcagt gatcccttga 182880 taaagcaagt caccgttatc agagcaagaa ctatacattc acttaaaact tttttttttt 182940 tttaagtgta aaatgggact gcaacaaaaa gaaaattgtg cttaggagaa tgtccctcag 183000 aaaatgtact ttatgattgc gaggaatatt tgccaaggtc tttggggtag gctgagcccc 183060 ttcacctccc tggggacatg ctaggatggc aagagaggat cagacatctc ccagggaggc 183120 tgtgtccagc cgggctcctg gagtggcgta agtctggttg aaccagcact gaactgcctg 183180 agtccatgtg aacgcattga actgttaaac cgtgtctctg gcggccacat ctccgggctt 183240 cacccgctgc tctcccctgt cctgcaggta caaagtcaat agtcaacctc agttttgaat 183300 gttacaaaat tattagcctc tccatagttc ttcccatggc ttctcaccca agccttctgc 183360 tcctctctcc tctctgccca ggtctcacca gctgcccttg ggccaggtca ctgcagtgtc 183420 tgccagcacc acgacaggca ggctggaggc ccagttctca cagaaaagac tcgaaagggg 183480 gctttccatc ctttatagtc tacctgctac ttataggcca ccaggacaaa ggatcaaggt 183540 ggcaaggcag aaattgcagc acagagcgaa tggaaaggca gtcactgaag ggattctttt 183600 gcttttacaa gtagattttt cttaaacaat cactgtatga aaacaaaagt acaaaattat 183660 taaaacacct ggatgatgaa ttgacaacaa gagtttttct ggaacatcct cctgtgggct 183720 cggggaagac agtttttttc tgtggtgata gatggtcagg aaatgtagtg acatagaagt 183780 gaaggcattt tacagagctc accttaatca atggcttttt cacttattaa gttttctttt 183840 attttttcct tcttcaaaaa cgactgatac cttaatttat gggaattgtt tccagtaaaa 183900 attgggacaa tgatagtgag tggagaatat ttatatgcta tacttcctgt cttccttcat 183960 cttttattac tgaggatatt gacatgaaaa caggatcttt gtatccaatg agttcatcga 184020 cggccgattt cccaccagaa attccaggct ttctgacatc agcgtgcatt gctctgcatg 184080 tcacttggag caccggcatc tggaaatgat gaaatcctga acaacaaagt ttgttttcag 184140 gaagacaagg cagtggggaa gggaagggtg ctaagcttca gtgactgcct actgtgtgcc 184200 aggcattttc atcttccatc tcgatagaat gtctaactgt gctctgagat gagaactata 184260 aatagctggt cagccaaaag ttttctgctt tttcttagtg atctcaagtg tttccatgac 184320 acgtgctgca accaaataca ttatgtgtaa attgccaaag acctgttgat ttccaaacca 184380 ttatatagtc atgggaatgc ttgtatacct gaattgtcat aaaattgatg agatgcgaag 184440 atacagcaga atatatcaga taattctgca gaactcttat tatggaaatg aaaataattc 184500 aatagagaag tctcgattca taaaagacta gttttactct aaagtatcta aaagacatgc 184560 attaaaaaga catggcactg tccccgaaat gatcttgctg tgttgcattt caaatggtac 184620 cttcattttg aaactttgca cattagcacg ttctttataa tagcaaaaag tgggggagtg 184680 aggaacattt ggtgccggaa gaatgattag gtaaagcaca ccaagctgaa aaaagtattt 184740 ttgcagagcg ttttcaagag catggaagag tgttataatg ttaagtgaac aaaaaaaaaa 184800 aaaaatacag atccaactat gtaatcatta cacatagaaa taaaaatgag caataaagcc 184860 aggatgtcag tgaggatgga gtggagggaa tgtcctaaat gtgcgttggc ccatcatcac 184920 ctcatgcatg aagtgaatgg aaacatttgg tttatgtttt ctggaatgtc tcataagcca 184980 ttgtaaccaa aaactacacc atgaacaaaa agcaaagcag gccctgcagg ccctgggtgg 185040 gaagctgagg aggttggcag tttctcaaac tcatgtcaga tgcccctcgg ccactagaca 185100 gaatctgctg ctatttgggt tctggttgac cagaggccta atctggaatc tggttctaaa 185160 aaccaatttt tgttataggg cttgctggat acaaatctgc aatgagacat tgtcacaagc 185220 aatagcttaa gaaaaacata aaggaaaaaa taataataag tttttggaaa taagcctgga 185280 aaagcagttt attgccatct gctaactcat ttgattcttg cagtaaccct agggtaggta 185340 tgatggtgat ctctgcttca aagatgagaa aatcgaggct gcctcaggtc acttgacctc 185400 ctcacaggcc agtggagact ggcttcagac tcgggccttt ggacctcaag gccctggtct 185460 tcttttgttg tttgtttgtt tttgtttttg tttgtttgtt ttcctgagat ggaattttgc 185520 tcttgttgcc caggctggag tccaatggcg caatctcggc tcactgcaac ctccgcttcc 185580 tgggctcaag taattctgcc tcagcctccc gagtagctgg gattgcaagc atgtgccacc 185640 acacccggtt aattgtgtat ttttagtaga gacgggtttc tccatgttgg tcaggctgtt 185700 ctcaaactcc tgacctcagg tgatcagccc gccttggcct cccaacgtgc tgggattaca 185760 ggcgtgagcc accacgagcg gccaaggcct tggtcttcct atcgcatttt gacaccttgc 185820 tcagtacgat gagtagttaa aatcactgtc attggctaca tgcctacttt ttatagtcac 185880 tctacttatt gtggttttgg ctacatccta gttgaactct agggctagtg tttattaagg 185940 tcttgatctc atatggcatt tgtagacaat cgaatgttga gtgataagcc ctggtaacgt 186000 gatttctcac tgctggcccg tgaagccatg gaaatgttcc catggaaatc accccatgtg 186060 tggaatgaat ggtcagtgga acataggcat ctttctctcc tgtcctctag gttttaaaat 186120 acctgaatgt cctgaaatgc aagagtatcc taagagcact ttagaaatat ctttgcggtt 186180 tctttctggt gtgctttgtg ggttgggtga ggtaccgtat tccaggacac gtggccctta 186240 gagaaacaaa taatttcctt tcctcctgct tcagtgttat tggtaaagtg ggaaggtagc 186300 cccaagacac tcagctcctg cactgcattt ggatagaagg gcgttcaaat tccaccaggg 186360 acaacttcgt ctaaccccct agaattcctc attttgaccc ttggcatact ctatatttgt 186420 tgaaatacaa aaaaaggagt tgaaagtgag tctatctata tgtagtaggt atatcgtgtt 186480 cactgtaaaa ttccttactg tatgtttaaa atttttcaga atacaatgct gggggaaacc 186540 tatggaacag aagtagggaa aaaattcgac aacgcaaagt gagagtggga aaccatgtga 186600 agctctgtta gagtatcatc actaatctct tttttcctta tacctatatt catgaaagca 186660 aatagagaac aatacaatat agtgtaacac cgtgtaccca tcactcagca ttgctcaatc 186720 ttagttatca ttatggttat tattattatt attatttgag acaggacctt gttctgtcac 186780 ccaaactgga gtgcaatggg gtgatcctgg ctcactgcag ctcaacctct cgggctcaag 186840 tgatcctccc acctcagcct cccaagtagc tgggactaca cgtgcgtgcc accacacccg 186900 gctaattatt tttggtagag acagggtttt gccatgttgc tcagggaggt ctcaaactcc 186960 tggactcaag caatcctccc accttggcca attttaatat tttattatag ttgtttccat 187020 tttttgtgtt tttcataaat taaatcttgt aactattata tatttcacag aatattataa 187080 agttaaagct ccctttgcat ctttccctct ccaattccat tcttcctctc tctctaaaag 187140 taactgctgt cctgaattta acgatgattt ttaaagtcat ctaggctctc gtttttcttt 187200 cttttttttt tttttttttt tttttttttt tgttgctgtt gttgtttgtt tgttttaatt 187260 gaaaaggggt ctcactctgt cacccaggct gaagtgcagt ggcgctctgt gggctcactg 187320 caacctctgc ctcccaggct gaagtgatcc tccaacctca gcctcctggg tagcagggac 187380 cacaagcacg tgccaccaca cctggcaatt tttttttttt ttttttgtat ttttggtgaa 187440 gacgaggtct tgccatgttg ctcaggctgg tctcaaactc ctgagctcaa gtgatttgcc 187500 tgccttgtcc tcccaaagtg ctgggattac aggcgtgagc caccgtgcca ggccggctct 187560 tgtttttctc ttccccctac accccaaata aacacagagc tttattcctg cctcagtcaa 187620 attgctgctt caaggccgca gtttggacac tatgtttttt agggtgtggt tttttttttt 187680 ttttttttta gacagagttt cgctcttgtt gcccaggctg cagtgcaatg gcacaatctt 187740 ggctcactgc aacctctacc tcccgggttc aagtgattct cctgcctcag ccttccaagt 187800 agctgggatt acaggcatgt gctaccatgc ccggctaatt ttgtcttttt aatagagatg 187860 ggatttctcc atgttagtca ggctggtctc aaactcctga cctcagatga tccgcccacc 187920 tcggcctccc aacctgctgg gaatataggc ataagccacc aaactcaact tataatttat 187980 gattaaggct gcagtgcaat ggcgcgatct tggctccctg caacctctgc ctcccaggtt 188040 caagtgattc tcctgcctca gccttccaag tagctggaaa tataggcaca cgccaccacg 188100 cctggctaat tttgtatttt taataaagat agcatttaat tatgttgtcc aggctagtcc 188160 cagactcctg acctcaggtg atccacccac ctcggcctcc caaagtgttg ggattatagg 188220 tgtgaacccc tacagctgac ccagacacca tgtttttatg gctggatttt gtctttgctc 188280 tggttgcggt cttaggcacc cttataaata gagctttgaa gagaacatta ccaatgtatt 188340 tttaatgagg tcatgttata aaattgtcgc ataggacttc tcaagaaaag acagcctctt 188400 ccttgcaaga tactttcttt tgcaaagatt gagatcattc cacaacaata gacctctgtt 188460 cattgcttcc ttcttatgca aaagtggccg tccctcccat cagaaggacc cccgctggca 188520 ctctgtcagg tagacagaag catggataga aggctggtgg tgagctccag gtgccttccc 188580 tattgtctct tctctcctat aacctcgtat aaccttcctg ggttttcctg ggtgcatgtt 188640 tttttgttgt cattggtgtt ttgacagctg gctgtccagg caaggctgct gtgtttgagc 188700 agaggtttgc tgagttgagc aggggtgtgg ctgcagggcc tagcctggcc tcccaggagc 188760 ccccgctccc cgtgtgccca ggtcataccc aaacaggagc attccttatg ctggtcctgg 188820 acagcgtttc tattaaaggg ttctttgtgt taggaatgtt cagcagagcg ccatgagccg 188880 ggtgagagtg gaatgagtgg tttacccagg gcacctctgg accctgggag tcacagctgt 188940 ggaattttac tggagttttc actgcagtgc agcccagggt aggacacaga gggcttccac 189000 tcccttggag catgctaatc tttccaaaac actcattcgt gggccctcat agaagctcct 189060 agggcattac caagaaatag cagtccttga tcatatccag tgaattctga aacagtgaag 189120 gaatttagat ctcatgtgtc catgttgctg agggcgtcct gggcacagag cctgctcgca 189180 tcaggccaga ttgtttggag tattgccaac tggccttttt tctggagaag aaagtactga 189240 cgctacgaag acttcagtgt tctcctgcag gggactgcag gggactgcag gggaagggag 189300 gattggcctg tcacttgcca tctctcattt ctgcgatgct acagagaggg aaggggaggc 189360 atacatatgt cagaatctaa attacagcat gtggaaagac ctgccctcgg ggtcagagca 189420 caccaggctg gggaggacct agtttaaagg gatagaagag acattacttt agctccttct 189480 cttcaggggc tccataatgg ttttaaactg ttctttaaaa tcgaagtttt tctaatctac 189540 ttttgactta tgtattaacc aagaacctct tgtaaatctt aagactatat agttgtcaaa 189600 gacaggcaac ttgaggttga gtctgttgct aactaactta ctgacttcgc acaaatcact 189660 ttgtctttgg gaacctcgct cccctatcag taaaacagag atgattgatt gattcaaaag 189720 cattcactga gcacccactc agctgcgagg cactgcctgc atacttggga tatgtcaggg 189780 agtgagagag gcaaggatcc ctgtcaacat ggagacttca ttccagcaga ggagacacac 189840 aggaatgagt gaatggaata agcaaatagg gtatgtactg taggagcaaa caagggatag 189900 aaacatggga gatgggtcag gagtgtggac tcgagtccac agcgctaaac tgtcccattg 189960 agaaggtgaa tgagttaaaa gagatcagga agttggccaa gtagatgcag gggaaaagtg 190020 ttccctggag agggagctgg ccagctgcat gcacaaggcc tgatggacgg ctgagccagt 190080 ggggaagagg aggcagcagc acagtcggga tgaactggca ggtgggcttc tgctccagaa 190140 gagatgcggg agccctgcag gtttgagtga agagtgcatg gtccaacacg gtcttcagag 190200 catcgttcca gctgctgcag gtttgagtga agagtgcact gtccaacaag gtcttcagag 190260 catcattcca tctgctgcag gtttgagtga agagtgcact gtccaacaag gtcttcagag 190320 catcattccg gctrctgcac agggaagagc atcaggggca agagttgatg cagacagtaa 190380 tagatggtaa tagagtcaga tacaattggg caggcaaygg ccctttacag atgacgaagc 190440 atcagaaaag ttagggtgca accatttgtt ttcagtttac aaaaagggaa gacgattaat 190500 ccccaaaaag gagcctgtga gagtcagatg aagaaattaa gaaatgaata atatgggtca 190560 catgagacag tctctttctt tttattcatt tatttatttt tacaaaaaag tatgtttctg 190620 tgtccttcag cacagtttgc aggagcattt agagcacacc cgtggagtgg cccttttatg 190680 cttgccaagc atgctgaaca ccgtaagcca cgtgtgacac atcttccatg gacatgaaag 190740 atatgttgat cattttattg ggctccagtc tcagctctgc cacgaactgg cactgtgcct 190800 tggaccaagt cacttcatcc ctttgggttt gcgtttgctc ccctggaagg taggggaggg 190860 gtgcagtgag ctctggcgtt cttcttagcc tctgctgcag ctgcatgagt gggtctatgg 190920 cacagccccc tgcctgcatc atggcaggtt atacacagta aagagatgaa aggaattttt 190980 ctgctaaggg aagtagcccc atctgtcagg atagttggct ccattgtgtc taacgtaggt 191040 atcttataag cctgtacaca tggcagccaa ggggacctgg ccgccagagc cgtaggagat 191100 gacccagcac aatgggctgg gcagtaagga agccagactc tggagccagc gtggaggtgc 191160 aggagctcgt gagtatgagg gcatgatgag gggtgcacag aggaacccct gggctaacag 191220 gggcccagga gacagtatta cggcattggg ctttgtattg ccggagacca gcacagatcc 191280 cacaatgcaa cgatgccaaa aaacggtaga actgaaaacc ccagccagat caacgcgaga 191340 ataaatctct tttctgctga aattgatagc ctcctaaaat gctaagacac atgcagygga 191400 gaataatcat tattgaccat gaaatagcta agaaccagct gagaaaatac agaaggacac 191460 acagtaagaa tgaatgagaa aactcttgca tagaggatac ggtcagagtt agcaaccagt 191520 tgcttcttca tgtaaattaa atcagcggag aatctaaaac catcccgtag accacattta 191580 gagggtagga aggatgcaat ggggcaaggt gggcaggaga tgggcttagc atccaagcag 191640 gctggactca cagccctctg cctggtgtgt gatctcagca cttcttgtac cttatctgag 191700 cctcaatgaa ggtaataaaa tcacctgcct ataagcctgc agtgagaatt agaggagcaa 191760 atggatgagc ctcagtcctg tgtggggtct ggctgctcac aaggcaccat ggacgccgtc 191820 tttaccatca tcactgtcga cccggagcca atggtgaaag caggacacag gcaagcccca 191880 gcgtttccca ccattgtctt attttttcgg cttcaggaag acattagact tctaggaaga 191940 gattccttaa agccaggact agaaggtaga ctccagattt tggctacaag tggcaaatat 192000 gtcttgtaag atgaatttta tgtacttgtg ccaagtgcca ttggaaatac cgaagactgt 192060 gcaaaaataa aagacaacaa acagccccag gaacccggag ccctctccca gcccagaaca 192120 ttcaccagct cggccaagag ttctgctggg ttttctctgg gggctggtgc tgctgtggac 192180 acgacaaccc ggaacacgga gggagggctc agcgctagga agggagaggg aatgaagagg 192240 agtttccctc tctttgctaa tttcttcgtc tctgggaaca tttccttcaa cagagtcctg 192300 cttttctcat cctcacacct cactgcgccc ctcctgaacc cactcctttc tgaatatggt 192360 ctactgtcct tccgtgaccc acatcacctt ggtcctctcc ctcataagca catcctaggt 192420 gggcctgccc ttcacttacc catctcctta gaagaaacgt gagctctcca aagggaaggg 192480 cagaaccctg cttgttggtc tttctgcccc cagcacttga cctagagcct tgcactgagg 192540 acgtgccact catgtctgct gaataaacag ccacatttcc agatgacgat gtccttttcc 192600 agccaacatc agctcagcgg gccttcacgt atttagttat acttgtgccc ccgctcaaca 192660 gggtgaggat gctcctggac acagaaatta gctctgaggc aggaaggagg aaaggggatg 192720 cttctgggag gcaaaggcgg tcaatcagag tgagcaccag agactccgtg tacctgggaa 192780 atacgtgggt tcccacacca gccttgggga gccagggtgg ggaagagggt ctgcagagca 192840 agtttaggat gcagcacatg ccaagctttt cagagtctca cagtcaggaa cagaactcat 192900 gcagggaggg gagggattgg aaagtaggag gcaaagcaga agccccgaac ccaaagacag 192960 agccggcgac cggccagagt gcagctctga gcctcagaca tgaggggaga agaaggggat 193020 ggggtggggg gcggtcgtga ggaatgtcgt tgtccaggct ccacccggcc caccagctcc 193080 gcagaggaag gagtgggctg ggagaggcac acaccagaac agctctcctc ggggcaaagc 193140 aggctttctt cccgaacacc caaggctttc caaaaggtaa acaccatttc ccccaagcga 193200 ccccaatgtt tgctgaagca aaacctctcg tgtgagccgg cgggcggctt cacgacaggc 193260 gtgagaaggc catggccctg tgtgggtgag gaagcgcagt gcggctcccc cctgcgtggt 193320 gggactaaga agagccccct gccacccgaa aggcgcccta acacttcaga gagcggatgg 193380 ctgccgaggg tggccaggct ggagctgcgg cttcccaccc gatgcattgc agaatgtaac 193440 tttccaaaat gcattgctct catctcagct cagcgttaaa acacatgtgt gcacacacgc 193500 acatgcagcc ccgctgagct gggtggtgaa aagaccctaa ttagttctga ttccttaagg 193560 catgtatttt aaaaagcgtg aaacctattg agatgctact tcctagcgcg aatacggggc 193620 tcttaaaagt cctgataaaa gtgaaaatcc gaggcgcgcc tgggaagtgg gaatgttccc 193680 tccaactcag gcttccacgg tcatgagtag gaagtcctct tcctaatctc agtatcttaa 193740 aaagaagcct tgatgttgtt acgtgattac ctaaaaggaa tgccttcctc cgcggaccgg 193800 aaggatattt ttaaaggaat gtgaagcttg tgacaggaat tatcgatacc tttggaattt 193860 ttttttccaa gtgactcagg cttacttgaa gccattacct cggagttagt cagggactgc 193920 atgacgccag gccccaactg tttaaagcag agcgcggctt agtgaaagaa tgaaaaaacc 193980 gaggatgttc tttgtccatt attctcaccg tgatgaatga tgcttgtttt cctctccact 194040 ttaattagaa tgtttctaca tttgccaaag aaaatgttgg aatggagaca aaaacctgaa 194100 attataggaa cagggcttga tgtaatagct tatttgtaaa ggaaacacaa cttgtttggc 194160 attttattga aacaggaagt tcagaagctt agtacacaca agtacaacaa attctcaggt 194220 gcttgttgag tcatctgttg ttggaaatag tctcctggta gttttcccct tgatttactt 194280 tttatcttca ttttgttttt ttgaaagtag tgagggtagg aagttacaga gagattcaat 194340 tagagattat gtgtattttt aaaaatcagc tatcaagatt aaataaagca agcgggaatt 194400 ctctccttgc tcccatgtac caatttttgt aattatgtac aagatgaggg aaaccaaaga 194460 aaaacaataa cttgcttcaa tgcaattact aattcaaaag taaccattac tctggggaat 194520 tgtattagag attaacaaag aggaaaagta ctgtggtttt ctttctctat gttctatttg 194580 ctaggaagcg gtcaataaag taaccttttc cccacaggag ctggttaata gttcgcttca 194640 tgctaaataa aagttacaga aatatctgga gctgagttgc tggagacaca gaaatcttca 194700 ggttggaatt tcttgccctt ttccaaagga ttaggccagg acattgctgt caaatctgca 194760 aaacctactc atcctggcaa gagtgcggta tttttaggac tcactagtgt gctacttcta 194820 atagtgctta gtcagggacc cccaggggag tgcaagggag agagggtccc cagcagggac 194880 gccagacctt ctctagctgg ccgtgggtgc tggcctggcc acctgtagcc ctcagcgcac 194940 aggtggaggt gtaactggta ttcctgtggg agtgacagtg tccatctttg acatttaaga 195000 gcctgctcct tcagatacat ttaccattgc caccattggg gattggggca gtactggcca 195060 cccttggcgg cacatctcca gcttacagca gagtctgagt gtctctagca tacctctgac 195120 tgaggcasgt taggcttgtg acatcacatc ttcctaggtg gggcagagac tttacaatac 195180 atgtgacaag agaaaaacct tacagctttg tattgaaaga tttcttaagt ttttagttta 195240 ttgactaaat aacactgaac aaaatgattc tactatgaaa cgaaaggatt ggacctctgt 195300 gagggttgtg gcaatgtttc aatagctgag caacgcagga ggcacacagg ccatcgttgg 195360 gggcaggttg gaggccttca gttcctttac agctatgggc tcccatcaag ggtgagtgca 195420 ttgaggagac attgcctaga actactggac agacatctca cccaggagac gggagcatgg 195480 tactcaacac acttccatgc accgttcaga atcgctaaac acagcagtgc agaggcagat 195540 gacaagggcc attacggggt caccaaggga ggaaataggg actggagccc ccaggaagga 195600 gagctgagtc tccctgtggg ctgggggctg gctttgtggc cctgcagcca ccacctggag 195660 atgagagacc tgtccctagg cctccctgca gccaccacct ggagacagag tccctagacc 195720 tcccagctgt gcccacctgg gcagctgcac tttccagagg attattcctg cagcttccac 195780 cctcacatct ctcagctgtc tttgcaggtg catctctgga aaacagttct catcagggca 195840 ccctgtgctt cccagtttct agtcatttcc cttctctgaa ggttctagtt cagactcttg 195900 agcaaagcct tcaagacctc tccttaaact gccctcctcc tcttccgtcc agccacctgg 195960 ttgcctcctg gctcttcctg ccctaatacc ggctgcccgt acgggactgc tcacctcctg 196020 cagggagccg gacgtctgtg gcgatctccc tcccgccatg acacccccta cctgtcctcc 196080 atcatatggg acacacacac acacacacac acacacacac ccctacgcac acccacaccc 196140 cacatgcaca tcatacatac atgcccacca gaaatacaca caccatacac accacccacc 196200 cacatgcaca ccatacatac acatacacac aacacagaca ttaaatacac atgccactac 196260 acacagtgca taccacacac aacacacacc acacacacac acccaatcac atcacatata 196320 cccacaccac acacacacac acccaatcac ataccacata tacccacacc acacacacac 196380 aagcctttcc taattatcta aaggagaagc ttttctggaa agcattcccc agagcttcta 196440 gagaaattag tgtcaccctc ttttatggtt tcatagtaat gtttttatat caccagtata 196500 aatactatca tataaaaagg gtaatcagtg taccatagta attaattctt taagtatgtc 196560 tcttctgcta gatgatgagc ttcctgaatg caggctctga agaatttttt catagtttta 196620 aatccactgc atggaataga gaaggctctc cataaacttc ctgagtttaa atggaatcgg 196680 attggaaggc agtagcaagg cacaaagtgc agtgagagcc aagctcagga aaaccagtgt 196740 ccttgagcag aaagacttag gaagggtgct cgctagcgag gagggaggca acaaggggcc 196800 agcccgtggg gagccttaag caccaagagc agggcggtgc acactttgtc tggcacgggc 196860 tggagcagga gagggaccgt ccttgcattc tgtgcggatt tctatggcaa tgacatggag 196920 ggaaatgaag gtaggatcaa gagtcccact gggaagtggc ctggcaacca gaggtgtccg 196980 caggacacct gagcctcagc agtgtctgtg aggataggag ggaaagccag accccagcct 197040 ctctggggag aatctggatg catgcgggag gaatggatgg aagggagggt gtggggctga 197100 gtggcggcgg ctgggctgtg ctctcccact cacagagcct tccccaaagc ggggaaggct 197160 gcttgccttt tggttcattt cctttcttta atacacagca aattcctggt caccctttgt 197220 tgttggctgg ttgggtttgt cgctttcctt gttgtttaca agctccaggt atttgtgaca 197280 gatcttatca tctccttccc tcttagtcac ctcttggccc aactctgcat attttacctt 197340 tttaactctg ctcctgttct gacctcccca ctctcggaag catatttgct tggtgttttc 197400 agattttatt tcattttggc tatttaaaga gatgcaataa actaaatatg gcctggcaag 197460 tctggtctta aaatagaaaa tatatatata tgtatatttg tgtgtgcatg tgtgtctgtg 197520 tacataggcg catgtgtgtg cccttgagtg tgcatccgtg tgtgtgtgtg tggccggtgt 197580 actataaacc cagggcatca gtctcctgac gtcattgctt gcactttttg ccattctccc 197640 ccaaacacta gttttcagcc tgtattttct cagtttcccc aaaaatgatt ttttaagaaa 197700 agtcaaatca gaaagtgatc agcctctacc gccggactct gcttcagtat ccatccatgt 197760 ctctgaggtc ttggggctca taggaatgtg cttattttca tagtcccatt aacatgaata 197820 gtttcagaag ggccagctca gttttgtctt cagttttctc actggtgatt gtgcaggggt 197880 ggaatggcaa tggaatgcat aggggcatga gtgaactttt cgggatgacg gaagtactct 197940 atattttgat tgaggtgtta ttaattcaat gtgtcaaaat catcaaaatt tttacatttc 198000 atcattctta aattatacct cagtaaagtt gattttaaaa gttaaacaca taccctttgc 198060 tcgaaaatga tcctgtagag cgtttatgcc tttatatgaa tttagctaat gcattctctc 198120 cccagggcca tttgcatttt aggatataac tgatgatgtg gaaggtacta gcaaggaagt 198180 atgggatggg aatctgggga tggaagtacc ttcctgcttt cagtaagtta cataggcact 198240 ccttattcat aaggctgagc ttggtttcag ataaataatc agaaagtagg ttgtgcaagg 198300 ttttaagaag aggatccaaa ctgggactta gtaacgaact ctgaaactgc cacttgcatt 198360 ctctgaactt cacatcaagt caatactctg tatgctacaa ttccatctta cattaaaaag 198420 caggtctact aagggacccg attcccaaga aataaatgtg ctttttacaa tgcttgattt 198480 gcaagtcagt ttcaaagata atttggtgaa gatatcagag ttatttttac aagattaaaa 198540 atcagtattc aacaaattat tttattcact ttgacttttt ttttttttta acctgtctgt 198600 gacatatgtc tcctttgatc cgcacacaca ccctggccag taggaaacag gcacactctg 198660 ctggtggcag agggatgggg actggagcct gatcttggac cttccctgtc tcatctagct 198720 cagcccccat gctgtcatag gccgcagcca agtggccttc cacagcccct ccatggagcc 198780 atcgcagaca cagcttctcc acggagccct gttctcagcc ctggaggccg gcaatgtgct 198840 tcacccactg cctgccacat tccagccaac agaagaactt ttgaccgaga agtagaaact 198900 aggtgattca gatcagatct ctgttgtaga ctccactacc ctaatgatga atttttaaaa 198960 ttaaacattc cctaacaaac ctccaagact ctttgcttgg gtcggtcaaa atacagtgga 199020 atgtgagagc acatgtcaga attctccagc ctacgtttgc tgttgttgtt gttttgagac 199080 ggagtctcac tctatcgccc aggctggagt gcagtggcgc aaactcggct cactgcaatc 199140 tctgcctttc aggctcgagt gattctcctg cctcagcctc ctaagtagct aggactatac 199200 gtgcgtgcca ccacgcctgg ctagtttttg tatttgtagt agagacaggg tttcaccatg 199260 ttggccagac tggtctcgaa ttcctgacct caggtgatct gcctgcctcg gcctcccaaa 199320 gtgctgggat tacaggtgtg agacaccaca tccagcccag cctactttta tactatgaac 199380 aaaacttctt agaattacca acttaagtac aatagaagct tttgaaatta gctgggggga 199440 aattgagtct ctaagtaagg aggagtaaga gcaagaagat cagaaggaac cacagaatca 199500 aacactttca aaaggaaaga aaattaggaa attgttcggt gccatccctt catttcagag 199560 gggaagaact aaggactaga gaagtcaggt caccccgaca ggaccctatg tccctccttg 199620 tcgcctgacc tctccctgtg agtctcagtg gtcctggtcc cacagcaggt gcttggggac 199680 ccagaaagag gccaggtctc ctgacaccca gccccgctct tgttgggtcc ctgaatctgg 199740 aatggttact catgttgggg gaattttata ttcttttttc caaaagttga tatccagcta 199800 gaatctgtcc ttcctgagag cttgtcactg ccctttctct cctccctgcc tgtactcctg 199860 ttcgcttggg actcacactc cttgcaaaaa agcttgtttc acccaggggt gagttttgta 199920 actagagcag ggagtccttg cctttcattc caatgcattc cccaaaagca gaaaagtgtt 199980 atgcgatggg agtttgcatt ttggaccaaa gactccgcag caaataaatc atggaaacga 200040 acaatatgtc cttaaaccaa gatgtaactg taaacctcta ctgtcttatg aaataacaat 200100 actgtgcttt gagtagccag accacatagt agctggactc tagactctaa gcagggatga 200160 agtcagtggc tgctgatctg ggccttcccc agaaggatgc caagagatca agttttgttt 200220 ttaagttctg tgaatcacag acattatttt tgtaatcttt ttttttatga cacagagtct 200280 cactctgtca cccaggctgg agtgcagtgg cacgatctca gctcactgca acctccacct 200340 cccaggttca agcaattctc gtgcctcaga ctcccaagta gctgggatta caggtgtttg 200400 ccaccatgcc caactaattt ttgtattttt agtaaagatg ggtttcacca tgttggccag 200460 gctggtctcg aatgcctgac ctcaagtgat ctacccccct tggcccccca gaatgctggg 200520 attacaggca tgagccacca tgcctggctt tgtaaaaaat ttttaaagcc aatttgcttg 200580 tttaaaaaac tgaatccaca ctggtaagtt ttgttttaat aaaaaaattg tgagtaagtt 200640 gtaaagcttt tgataagttc agtggctcct gtaggcagac aataaattgc taagtcccaa 200700 agtgttgcaa gattctggag agtactttgt tcatactttg aagaatatgc ctgattataa 200760 ggcaacacaa attactgaag ccttgaaatg atgaggttgt ttccatttac tcgcacataa 200820 aataatatat ctaaaacatc tagcaactct caaaagaaga gagtaaaaag cttttgagaa 200880 atcaaataca attcattcca attcaacttg aaaattccca acagtccgtg ttgcatttta 200940 tacatcttga accaaaccat ggctttgagt aaaggcttca tttaaaaacc taacctatat 201000 atggtgggtg ttcatgttct attaaagcaa ggtccctgtc ctagttggag ggaacttccc 201060 taggttcggc agcataaacc agtgcctgtc gaccagggag tgtcaggagg atgtgctgct 201120 tcctgccccc tcccgcacag ggagcaaggc tgtgctgaat ggagatattc tagtaaggag 201180 gagagtgtat gtgagaaggt gtatgtgaga aggtgtggca tccacaacaa aactaataaa 201240 gcatcagcaa ccttaggtga tgcggtttgg ctatgtcccc acccaaatct catcttgagt 201300 tcccacatgt tgtgggaggt aattgaatca cagggacagg tctttctcat gctgttctcg 201360 tgatagtgaa taagtgtcat aagagctgat ggtttcataa gggggagttt ccctgcacaa 201420 gctctcttct cttgtttgcc accatgtgag atgtgccttt caccttccac tatgagtgtg 201480 aggcctcccc agccacatgg aactgtaagt ccattaaacc tctttctttt gtaaattgcc 201540 cagtcttggg tatgtcttta tcagcagtat gaaaacagac taatgcattt ggaaaccaag 201600 aggctgatgg tgttcaggac acactgtccc catttatagc accttggcat ttcagaaaat 201660 cgcaaaagca ggaaggcccc tctcactttc ccctccttgc ccttctcccc tggggcaggt 201720 tataagatcc tcatttggga gagtctttcc caatacttgg aggaaaggaa catccttgtc 201780 tctgaagaca cagagcacag agaagaatca gaacaaacag gcctttctca gtgaccccag 201840 tttatcacca ttagctcact cccagtttgt ctaatcacct cctccaccac tatccactct 201900 tcatcaaacc taagtacaaa atacccaagt ttgcctgttt ctgtgggtct tcctttcctt 201960 gtgataactc ctgagtcaca tgaaacacat actaaatatg tgtgcctgtt ttcctcttgt 202020 tactctttag ttacagggaa gggccccagc catgaaccta gcaatgggtg aggaaagaaa 202080 tctttccttc cctactgata tggtttggct gtgtccctac tcaaatctca tcttgaattg 202140 tagctccctc aattcccatg tgttatggga gggaaccagt gggagataat cgaatcatgg 202200 gggcagtttc cccccataca gttctcatgg tagtgaataa gtctcatgag atctgatggt 202260 gaataagggg aaatgccttt cacttgcttc ccatttttct ctcttgtctg ctgccatgta 202320 agacatgctg tccaccttct gccgtgattg tgaggcctcc ccaggcaggt ggaactgtga 202380 gaccattaaa cttctttctc tttataaagt atccagtctt gggtatgtct atatcagcag 202440 catgaaaacg gactaataca cctaccaggc ccggatttgt ttggcaataa agtgatccat 202500 tcacgcccaa gaagtgggtg gagctgggaa aggccagacc aaccatttgg aatagtgttt 202560 tttgatccac ccccaggagg tgaggattgg caggggctga ggggagtgct cacctccagc 202620 aaggtgagct ggagcccaca gcaggactcc agcctcagca gaggaactgg agagcaaacc 202680 aggaaaggca gacagagctg actcacgtgc gagggtggga gaggtcgcac ggcctgcccg 202740 gaccctgatg agctgagcac agtgaaaaca atgccaggcc tcacctgccc gtgcttaccg 202800 gctggtggca ggggggctga gcaggtgttg aggtgttcac aggtgagtag gagaggaaag 202860 gcagacgtcg gcctaaaggc aatcgcaagg agaaatgcgt tgagaattgt agcactgtat 202920 ccatcaaaaa ggaagctcat ctttcactgg gtgtctttct aattgttaga cttgacactg 202980 catttgctgc cctgatttct tgtcctaacc ttcaagcttg ttagaacagg gactcaggga 203040 ctctgttttc ttctcctgtg ctcagtgcag ggcagcagga ctcacttgct aagtgctcac 203100 tgacagatgt aagattattg ttagagatat ggacccgctt gctcttctga gcttccgtga 203160 ttctcattcg gtcctttgct gtcattagaa tcgtctgggg agaattttgt cactcctgct 203220 actctgacca aacctcgtat acttcaatca gaatgctcgg agttggggct gcagcaactg 203280 gaattgtttc aaactccccg ggtgactgcc ctagcagtca agtttgagaa ccacgggcat 203340 ggtaaaatct tttctcagcc tgagcagccc attagcttca cctagggagc tttaacaatc 203400 actaatgcct aggcctcacc accctccatc ccgtgttctg acttaattag cgtggggtgg 203460 ggcccctaaa acaacattct aacagcttcc caggcgatga gaatgcacag ctaggatgag 203520 cttctcctct gaagcatgaa gacccacaga atactgcaga gttgctgggg gtggccctgc 203580 ccaaattctc gcctaaaacc ccaactttca atgacattgt ggacctgctt tcgtgttatt 203640 ataaggttta caaatttcta tgccacctat cagaccattt tttaaggatg aaatcaaagt 203700 ttctataagt tgtatagttc tttccctgtg cattttatcg taatattgaa aaacgacagt 203760 gaaaagcaac caaggcatct cggcagcatg ctgctgacta gttcacgcag ttaccaccaa 203820 agcgcatgga cgggacccag agcatsagcg tgtgcccact atcggggaca gaaacctacc 203880 gcgttcgagt tttgacatat ttctcgcagt tgttgaaaac tatgaggcat gaaatccaga 203940 tttatgactt tttaaaaagt tatttgtgga ttcccaagac gattatgttc ccatcactta 204000 tgtagcctta aaagaaaaaa acctcaaatg atgctttaaa aaaatccaag tttggcgctc 204060 attgagttcc agtgtcagtt gtctgaatcg ccttcagcga aagtcagggg gaaaaaatac 204120 attccgcctt cctttaactg ctagttcgtc atggagaaca gaaagtccca tttgcatgtg 204180 gcttttggaa aagctaagcc gggagcgatt atcctgatgc gcttttactt tttgcataaa 204240 ataagaattt gaggaggatg tcccgggaga gtgagccact tctcatttcc caggcctcgc 204300 ctgccatgct ctttgacaac atcatagatt ttatttttgc cgggaatctc attatcaaag 204360 caatgccccc cgcccccccc ccccacacac agactgccag gtaaaccaca gagggtgagg 204420 ggggtgcagg tcatggttgc cttattacac accctcctct gccatcacct ccttttttgt 204480 ctggataagt tctttggcag ttctctcaac ttttatttct gaaacatcct gaaacatctc 204540 agtattaaaa gcaaggccga ttatataaac gatactccca ggcctgacaa cacatggttt 204600 tgcctgaggc ctttactgcc aagagccgta aggaccctct aagtcatgtt cgctattttt 204660 actggccttg agagtctcct tgctttgaca tcctcttgtc tccattgtca gactgttaaa 204720 tgctcatgct tctggttctc ttaaatagat gcagatgtgt ggggctgggt tgccactgag 204780 ccctcttctc ttttgcaaga gctgggatgc agacagaagg cggtttggaa aacacgagcc 204840 accttgattt tagacaaact ctaagttaca atcaggtgtc ttcatttatg acatttaact 204900 tttacttaac ctaatcaagc catgttgttg gctactgatt agaatatcct tttataactt 204960 accttaaatc tcactacttg ttccaaccat cccaaagtct ggcgtcaact gtcattgcat 205020 gctgctcttt tcagcctttc tagttcgact cttagcaaaa gccataatct tcctccagtc 205080 tgtttccttt ctgcagtgac aaaattgccc agggaaagga aaaagaacag catctatctt 205140 ctttcttttt agctccctgg tttaaggctt tcttttcccc catgatgaaa aactataatc 205200 attctgctta gaaagtacag acccctaagc ccacttccaa aagaaggatg cattttcaag 205260 tctgttatct ttactttccc agagcctggg ggtctcccag gccagaagtt gacagaactg 205320 tcttcataca ctcgagacaa cttcatgccc atttccttaa aactaagaac ataagacgct 205380 gatttttctt ccagaaaaaa aaaaaccttt cttgttcttt caagaactgt ttcacggaca 205440 gtgtttcata ttacaaaatt gaaacttggg acttttgaac tgcaaattta gcagaaaatg 205500 aatccatgcg cttgtggctt tgcttgtcac ctctactcag atgtctccca gacccctctc 205560 cagctgcaag ctgcaggcag aactgttcct ctaaaagaaa acaaactcct gtttttccta 205620 ctactgctac tgcttctact gttgctacac acacacatac acacacactc tctcacacac 205680 acactcacac acacacacac acactcagaa aacacttctg acaccaaatg tatgggtttt 205740 tttcatgcca aacaattctg cagttcactg cagacaccag ctgagtgtcc tacaatccaa 205800 ttgtggcacc gcctgcctgg agttagcagg tgaaggactc agccccgcaa gcctgccccc 205860 ctacccatgc caattgcttg tcccagatcc ccgttctaac tgaccagcgg taaatcaggg 205920 gttgccacaa ccccctcctg ggatttgtaa cttgctacag cagctcacaa aactcagaga 205980 aacacttaac attgaccaat tcatcacaaa cgatattttg aaaggatgtg aatgaacagc 206040 cagagaagag atgcacaggg cccggggccg gggagcaggg catacggagc tgccatgccc 206100 tctcaggggg catcacctcc tgcaccaggg tgtgttcaac cccaaagctc ctgaaccctt 206160 taacgtcagg attttttttt attttttttt aaagacatag tctcactctg tctcccaggc 206220 tggagtgcag tggcgccatc tcagctccct gcaagctccg cctcccgggt tctcgccatt 206280 ctcctgcctc agcctcccca gtagctggga ctacaggcgt ccgccaccac gcccggctaa 206340 ttttttgtat ttttagcgga gacggggttt caccgtgtta gccaggatgg tctcggtctc 206400 ctgacctcgt gatccaccca cctcggcctc ccaaagtgct gggattacag gcgtgagcca 206460 ccgcgcccgg cctaacgtcg ggatttttaa ggagcttcat tacataggca ggactgatga 206520 aatcattggc cattgagtga accccagacc ttgcgggggt ggggctgaaa gtttcaaccc 206580 tccaaagatt gggcacgttc ctctggcact cggcccccag cctccaggag ccacctcatt 206640 agcatacacg caggtagggt tggaaagggc ttgtgataaa tgatgaagga cgttcttctg 206700 catcgctcgg ggaattccaa gggtttaggg gctcactgcc aggaacccgg ggcagaaacc 206760 aaatacatat ttctcgttat agcacagtgt caccccctca ctctgcctaa tttggtgact 206820 agctgcccca tcacattctg cctatttaag ccaagccccc cttccccaag gccaacctcc 206880 tctcctccac agccagccca cttcccgggc gtgataactc ttctgcctca gctggagagt 206940 tgttctgagg ctttcatcct tctccacgtg ccgcctggca gtgctgctgc ctgtcttttg 207000 agggctaccc ctttctccat tacctctgcg acctggctag tccacatcct ccccgacccg 207060 tgctcttcag caccggtgcc tgccccgctc agtgcatgtc ctcatccctg cagcctccac 207120 cctgggcttc ctgaccccca ctgcgtccgg caccgctggt tgcgggcctg ctccggctct 207180 ctctgcccag ctggctggcc tgcctctgtt ccgacctccc ctgcctggcc tggtgttctg 207240 ggcgcctcct ccgctcacat cgccgcttca cctgcttttg ctatctgcac tttccatgtc 207300 ctgctccttc tcccagctgg tggtgcctct gagaagagga ctgagaaccg cctgtgaacc 207360 ccgcaatttc gtgggtgtgg tggaagcaaa ggcagagcgt gtgagtttag tgggcgtgcg 207420 ccactctttc aagaagtttt gttacaaaaa gatgcaaagg aagtgaagag ggaaggggtt 207480 tgcaggttgg gagaaataac agcatttgtg ttgtttgttg ttgtgacggt tttgagccaa 207540 aacatgacaa acgggacaga aggaagacct gatggagcgt gtccttgaga aggcgagagg 207600 catggggttg gcctgctggg ggatcggcct tccatatggg ggttcctctc cagcagcctg 207660 gggttctgag gaaggcaggc ctgaagcagg tgccgggtgc cgggaagcag gagacatctc 207720 tgttactcca ctgtcctcag tggggagcca cggctgagcg tgagaaaggg cttataggct 207780 gaaggccagg cagacgggaa tggccaggca gaggagggga ggacgagccg ggtagaaaca 207840 gtggatagaa acacggaggg ccacacggcc aacggtcagg ggactggcac accagccaga 207900 ttcacccgcg gcgatgccgg tgcagagaag ctcggcatct gaatttaacc cgggttgtgg 207960 tttgactcag tctgacgtgg agagaagggc cagggagtca cgggggggtg gtgggctgtg 208020 tgctggttta ggggctggga catggagggg tgaaggcggg agtcagtcgc atccgctggg 208080 caggggcctg gggctgcaga caaggtggga ggtggcagct acggaggaag ctacaaggga 208140 ttctgcagtt ccccggggaa acaggagccc aagggaccgg ggggtgaggg ggttggaagg 208200 ggcacctgtg gatgttctga gacttccagg aagtgggaca ggatcagtga tggagataga 208260 gacagagtca tcagggccga gaggaatgac agtaacagcg aggttgaagt gggcaccccc 208320 gtctagcagc acggggtgtg gagctggctt gtggacggcc agggaacagg acgctttgag 208380 gtggcagcca ggggcaggga tgcttttgat cgccaaggga gaagacttga tgcagagttt 208440 caggagcctc catgacttcc ccatctgaag acctttttta ctttaatggg attgaagtga 208500 tcaccagaat agttaatggt gtgctccgtt cctatttctc tggtttttct aaggtccaca 208560 ggctgcagac atcgtttgta cttctccccg gtgccaaaga ccagttaatg ccgactttga 208620 tgggctcagt gcaggccaca ttgtcacgtg taactctaca ctgagaatta ttttagaagg 208680 ttagactcct aaaaatgttt tgtttttcca aatggtggcc tctgggtctg acttcacctc 208740 ttttgcaatg atcagcacta ggatatggtt ttggagacgg ttgtgcagag ccagggcttt 208800 caccaaagct tggccgctcg gacaggactc acgatggaag acggtcaggt gccccaggtt 208860 tcagatgcct gcctcctccc atgcgtggtg aggggcctgc ctcctttata gctttccgct 208920 gccaggctgg cgcctcctcc cctcaccccc atctcctcca gaggaagacc aacttaatca 208980 aatcttacca caactacgta ctgcctcctg gaaaaagcct gatttctcgc cccctcttgt 209040 ccctccctgc gtggaggcag gccctttgtc cagtgcccat gtggcttggt gggtggtctt 209100 tctaagttat cagaggacat tagcaaacac acacgtccat tggcctaacg cccaatctgc 209160 agccagcctt atgaataatc aacgtgactt gtctctgtag ttcaatgcct atatctgcct 209220 ctcagttgtt attgaagctg ggggcaaaaa agatggatta ttcattggaa acctcaaaac 209280 ctcgacagct gagctttctt acacatgcct gtgtggcccc cgtggtatct tagtgttcac 209340 ctccccattt gcacacagga agccagtcac attactggat tcctggtgag tttgactttt 209400 cattctgtct tgaatctccc tcccttcccc aaccccatac cccaccctac tccatccctt 209460 tttcttgggt cttcctgatc tcaacccctc catctgtcct ccacgttgtc tgcatagtga 209520 gcctcctaac acacggatcc ccccatggcc ttgtctgctc aggtttctaa ggtccccagt 209580 aaccacgctc acactgcgta acacgaacgg tctggtccac acctcatcac ttggcgtgca 209640 tgtgaatgtt ttagcaagtt agctcttgca attattgcct gccgatcccc tgggctgcat 209700 tcacacatgc cgtgagtctt cagacaccca ggtctcagga cctgaggggc tcctgtgtgc 209760 tttccgtgag gaactgtctt tctgctcacg actccatgtc acatgccacc atcaggaagt 209820 cctccctcaa tgccccaagc ctactcaggc tcccactttc ctgcccatga aatgtgtgta 209880 acttctaggg tgtcctgaga agcaaagacc atgtccctgc atttttgcat cctcagaact 209940 tagcctgata ctcacaatga aatgagttca cttaacgaca caacgaacga atgtgcaggt 210000 acttctgcag ggggtgatgt ggggatgcgt gcattgattc tgtggctcag ccctgagttg 210060 ggggcaggag gcaggtgctg ggaggaggat tttatgtctt aggaagcaca ggaaggcctt 210120 gccaggatcc aagaaaaaat ggaaagtaga ycaatgtaag cgttaaaaga acacatttta 210180 tcttttaaat gtgtgtacac agtacagttg acttttttgt atacaattct atgagtttaa 210240 acacacatat agattagcgt aaccactaat tataagattg tagggaactg gggaaaaaat 210300 gcatgcatta aggaatgata yggcatattt gggggacaga gaacaggctt gatgaggaca 210360 gagtctattt aaaagagaca gtgggcacsg caattggagg ggaaggcggg gcagggtttt 210420 agagaacccc tgagtgctgg gctacaggat tcagtaaagt tattgatgag attggctgca 210480 ttgtggattc tgaaatattt atttaatacc tcgaggaggg tgtgagtaga ttgtgctgat 210540 gatcgcataa ctctgactat actaagaacc actgagttgc acccagagct tgcattactg 210600 agcgctttac cagttaggaa ggtttcgcgt attccgtact ttaaatctaa ggtgacttga 210660 ctgtaaggcc tgcgagtatt tcctggacca ctcagaggaa gaatgctgtg aatgagaact 210720 acagccctgt aagacacgtc ctgtatcgtt gttgagatgg gaaagtgcat cttaagacgg 210780 ttagcaggcc gaggagcgac tttaaagggt gagctctgcc tagagggaaa agcgaatgca 210840 ctaattgaaa tccaacaccc tgggctggag taaatgaacc gtcagccacc catggggctt 210900 catttcttgg tgatggataa atagctggga ttccttgaag ctagaagcca tggggaaatt 210960 ctgttctgct tagctttgtc aacagtacag tctgccttaa ctgacttgga ggtaaataga 211020 ttcggagagt gtgagctaaa acccattaaa tcaggtgaag acacaaaggc aagcacagcc 211080 aatgtggttt aaggcaaagc taatgtcctt cggccttaac tgacggactt tcctagcagt 211140 cctcaccctc tgcaacccag ggctcctrgg aggagctcat ggcagagaaa gccttctggc 211200 ttctgccact gcctcctcaa ctacatgtat acatcagtgt atatgcatgg gtatgaaatg 211260 aacattttat gtcaccatta gcagaggaaa gctggaactc tttcaaaccc cacccaaaat 211320 tcactctgac tactgagcag tcctgttgtt tattttggag gccacttaac cctggagcag 211380 tccataagct ccacttaatc ccctcttctt tcatgatttc ttttaaagag acatcttggg 211440 ttctgtaggg gaacatttgt gcttcactgt aaaactccat ttgaggcctg ctcacggcct 211500 gccaccttat ctgcttgcag ccttcattgc ttgggagctg ttttacagct tcataagttg 211560 taaatagctg ctggcaatgc aaacgcgctt gtctgtgggc aggaaatgaa ttctgtctgg 211620 tagagggaat gcttcctacc ttgtaggaaa gccaatattt tttgtccatt agcaagttta 211680 tatcagtatt cctaatcatt aaatgtgttc ttcggattgt cctttgaacc agttatagca 211740 tttgagttaa gtaaaatgaa tacactgttg tttattttat acctgtatga aagttatggg 211800 ttttttggtg gggggggggt gttttttttg tttttttttt ttgttttttt tgaggtggaa 211860 tctcgttctg tcgcccaggc tggagtacag tggcgcaatc tcggctcact gcaagctcct 211920 cctcccaggt tcacaccatt cttctgcctc agcttcccaa aagttatgat ttttaaaaaa 211980 ttatctttta acatttttta gctagaaact tctgggtcaa tatataaata gatgagcctg 212040 gttatatctg aggttttcac tgaggtaaca acaaaaataa aacaacacga tgccaccgag 212100 ccatcgttcc ccaacttacg tctgtcccct ccacatgtcc tgcacacact cctgtttctg 212160 gggtgtgtgc atgtgtgtgt gtgtgtaaag gtttgcaatg aaattagaat cattggtttt 212220 tgttgggggt ggggagttgt attgttttga gacagggtct cgctctgtca cccacgctgg 212280 agtgaagggt cacaatcaca gttcactgca gcctcaactt cctgggctca agtgatcctc 212340 ccacctcagc ctcccaagta gcggaaacta taggcatgtg acaccatgcc gggcttgctt 212400 atctatgtct gtctgtctgt ctgtctatca tccatctatc tatctatcta tctaatctat 212460 ctatctatct atctatctat ctatctatct atctatctat ctatctttct atctatctag 212520 atggggtctc cctatgttgc ccaggctggt ctcaaactcc tgggcttaag caatccaact 212580 acctcagcct cccaaagtgc tgggattaca ggtgttagcc actttgccca gctgaagtta 212640 gagtttagag cacattgctg taaattgcga ttaccaaggg tattgaaaaa tccatgaaaa 212700 taataaacag caagttgact tcagaatttg tgcgtttgag gcttttcgcc ttgatctcca 212760 ggtaacacac aggctccttg gcgagagcca gtggtgatac aatgagaaca ccgcctgctg 212820 catctaatat ttgcagctta gaattcacag ctaacttttt aaaatgtacc agtgtggggg 212880 aaatggtgct ttatttgctg gataggaaaa ttggccaaga tcagaattct gaaggcagtg 212940 tcacagcaca aagaaactag ctactgaagt cacatcctaa acattcgaga ggttgatttc 213000 cttttctact gcattacaaa aaggtttatt tactgcttat ccatatagtg agatagagat 213060 tagatctcag tttttggtta agaacaagca ttatcataaa tgtgtgtgtg tgttgtgtgt 213120 gcattttaca ggatttttaa aaatacacag agaatttttc acagttgtta actctggtaa 213180 atggtgggga aggcaggggt gagaactgat ctattattca taatctcaat gatgaacaag 213240 ctatttccaa aaataggtgg attatttaaa attattatta ttaggatatt ttgggcttct 213300 agaaacaaaa acttaacaaa aaagtcactt aaagaattta ggggtctttt tttctgacat 213360 gaaaagaaca aaataaagga tgatttcagt ttggtccgtc agtgacttag aagtgttttt 213420 caggacccaa ggctttccgc cttcccactg ggccattttc agcgtgtccc gtggcctctg 213480 ggggcttcag tgatccaggc gtcacattag acatgacagt gtccagcaaa gagaagtatt 213540 tctgctttgc atctgtttat aacagtgaga aaaactcccc cagaatccca ccagcaattg 213600 attctcacgt tgcattggcc aggattgagg ccagctgtgc catgcttagc gcagtcattt 213660 gtattgcgat caccgtgatt agctcagacc catcctggga cttctccttg ggcttgaaga 213720 catggccagg tggagatcgg tgccccccag aagaagtctt tgttctgcca ataaagaaga 213780 cacagacaac agtgtctaac aggaaaagcc cctttttact ttataccctt ccgtattgct 213840 tcaacaatca aatactttat tttattgttt gagacagagt cctgctgtgt cgcccaggct 213900 ggagcgcagt ggcgccatct ctgctcactg ccacctccac ctcccagatt caagcgattc 213960 tcctgcctca gcctcccgag tagctgggat tacaggcgcc taccaaaatg ctcggctagt 214020 ttttgtattt ttagtagaga tggggtttct ccatgttggt cagaccggtc tcgaactcct 214080 gacctcaagt gatccactca cctcagcctc cccaagtgct gggattacag gcgtgagcca 214140 ctgcgcccag cctttttttt ctttagatag agtgttgctc ttattgccca ggctggagtg 214200 cagtggcaca atctcagctc actgcaagct ccacctcccg ggttcacacc attctcctgc 214260 ctcagcctcc cgagtagctg ggactacagg tgcccaccac cacgcctggc taatcttttg 214320 tatttttagt agagacaggt ttcaccatgt tagccaggat gatcttgatc tcctgacctt 214380 gtgacctgcc cgcctcagcc tcgcaaagtg ctgggattac aggtgtgagc caccgtgccc 214440 ggccagatac tttcataatt aactttttga atgtatgtgt gtcctacttt aaaatgaaag 214500 atactctttc ttgattccat ttccatgcag cttggccccg tgatgctagg gaccatggct 214560 ttttcttgca gtgtgactca ccatttgcca aagcaaatct cttgccttgc atcagctcag 214620 tctctttgtc tgcaaattaa atcaatagcc ctttccactg cctatctcgc aggatatagt 214680 gccaaaaata ctcacaaagt caccatccag gaagaatcat ttgcccctgc tgccactgtc 214740 tcctgcaagg cacatgaaag ctgctgaggc tcggtattta ttatgctata aaattcaaca 214800 caaggggaga gaacaagcaa attccatgag catatataag tgtatcggat ctactccatt 214860 gatgctggag ctatattttc acagtaggat cctcttttgt taaatattac agtagtagga 214920 aaacctagca gaagaatagt tcactgtttc tctgattttg tgagtgatgt gggctgtgga 214980 atttactctt tgctgctctt cccccaacct gcaccctacc cctgcctccg aggtcagcct 215040 tgcctgctgc ccctgactga gaggaccccg acgtcacccc accccaggtt atactcctct 215100 gagaaggtcc cttcatccct tccccgaaat acatcccctc aaatctctaa tttgtgtgaa 215160 ccattaattt cagatattgt aggaaaaata agcagggaaa atacgcaaaa caaaacgtgg 215220 atggcacata acccatagca tctcgcaggg tgtgtacact gaagaagtct ttaccaaccc 215280 gtagttagga aaatgcgtgt tcagaataac tgggccttcc cgcggtcctc tgagtcaaac 215340 agatgaccac acattgccag aatgagaagc agagcagctt cacatccctg cttctgaaat 215400 gtttcccaac agctcattga aacaatctcg agacacctct ctcccccaaa cccagcgtgt 215460 ttcgggaatg gctctaggaa ttctactttt gcattgcctc actctccctt tccccgtcca 215520 aaccatggta ttggatttac agcatttctt acatcctata aaagtccttt tctgccaaga 215580 gcctggagcg cgctggattg aatgacgctc tcccagcaca gccggcattt gcagtgcatt 215640 agaatcttgc cgtcacttgc acacgtcacc aagttacttt agtgagagtt cagcctagct 215700 atggctctgc tgtgctaaca gttgcttttc aatattttgt ttgaggcttt ggaataattc 215760 aaaggcctac actttttttt ttctaatttg tttccttgga gttttacgca tggctacttc 215820 agaaaacgtc agttttatgt cattaatgtc atcatcttct ctggattctc agaattcaaa 215880 attcacagga gcatggcagc cttacattca gtctattctt ttcataaaaa aggaagtaaa 215940 ctgcaacagt tcgcctacgc tatggagact ggagtggtcc cacctctgta attctrtcts 216000 tgtctgcccc acagctgtgc cgaagygagt gccacttgtc tgcagggccg taccgcggaa 216060 ccctctttgc cgaccagcca gygatgtttg tctcgcctgc cagcagcccc ccagtggcca 216120 agctctgtga actagtccac ctgtgcggag gccgggtcag ccaagtcccc cgccaggcca 216180 gcatcgtcat cgggccctac agcggaaaga agaaagcmac agtcaagtat ctgtctgaga 216240 aatgggtctt aggtaagaat ccaggcacac agacgctgtg gtgtggtcca gatctgtgga 216300 caggtttcca gggagggcgg cktcaggctc acaccccctt ccacgcagct ggggcacctg 216360 ggttgatgtc tcagcctcca gcatctgccc tggcagcgtc gtgtggtcac cctcggcatt 216420 cccgctcctt gctgttagca gacgtacagt tcacgaggaa atgggaactc tgactggact 216480 tccccacttg acttccctgg ctcgtgtgaa aaatccaggc tacccaaagc caccccrggc 216540 cacccctgtg ggcacagact ctccgggcac ccctcttaga ccctccctcc ccagtgcctc 216600 cttgtcctgc ttcaggagtc cctggcagcg cccggcactg gggcccaagc ccccgtccct 216660 gtcatctcct ctcccaggta catctcatga tcactccgtc tgctcatgtg ctcaaagggt 216720 gttaaaagac gtcaaacgac tccatctttt atttgacaaa gtgagcacag tgtgaccgta 216780 atgtcccact ctggcgttca tggagctgcg ccaggcgccg tgtgcgattc tggggaggaa 216840 gaggtggtag gagctgagct gagatcggag gaggctggaa ccccacgccg tgctaacaca 216900 cgggctccag gagacttgca ggtgatcccc ggagaagagg gttaaggaag agtgtgaagc 216960 aaggacggcc tggggaatgc ggaggaagca ggggcagcgt ctgtgctaga aattacctgc 217020 cctgtggtgg agtcatatgt ggcgggacaa gcctagggct ccactgtggg gaaatcccac 217080 accctcctcc atggggttgt gataaacatg ttagtttgct tgggctgcca tcgcaaaata 217140 ctacaggctg ggtggcttca aacaacacgc attgtctctc agttctggag gctggaagtc 217200 taagatgggg tatcggcagc gttggtttcc cctgaggcct ctctcctggg cttgcagaca 217260 gctgccttct tcctgtgacc tcacgtggcc tttcctccat gcacacacat ccctggtatc 217320 tctgtgtgtg tccaaatgtt ctcttctcta aggataccag tcagattgga ttagggctca 217380 cccaatggca tacttttatt tgcttttatt tatttttttg aaacagtgtc tcgctctgtc 217440 acccaggatg gagtgcagta gcatgatcac agcttactgc agcctcagcc tctctggctg 217500 aagtgattct cctgcctcag cctcccaagt agctggaact acaggtgcac accacgatgc 217560 ccagcttttc tttctttttt tttttttttt tttgtagaga tggggtctcc ctatgttgcc 217620 caggatagtc tcaaactccg gggctcaagc gatcctcctg ctttggcttc ccaaagtgct 217680 gggattacag gtgtgagcca ctgcacccag ccccagtggc atcattttaa cttgtctttt 217740 tcaaggcccc atctccaaat acagtctcat cctgagttac tgagggttaa gacatcgaca 217800 tacgaatttt gggcagacac aattcagccc ataacaatga atcactctag tttcagcccc 217860 tggggccaag atccttaccc gactttagag gtacatcccc tctctctctc tcaatctctc 217920 tctctctctc ccgttctctc attctttttc tctctctttg cttccatctc cttccatgtt 217980 tcctattcag tctcctttct tagtactttt gcatgtctct aaatcctaaa cttctggctt 218040 ttctcatccg ctgctcaaca ttatccctta atagacaagt agatactgtg tttgttcaag 218100 ttacattcgt atctaactac ggacatttta caagtatctt ttacatgact gatggtcatc 218160 ctttcatata ttttagaagt gtggcaatca aaagtaattt tttactctgg tgcagagtaa 218220 ttcatctttt gcctggaaac caacttccaa aaaaaaaaaa actatgattt tagtcacagt 218280 ccaaaagcta agaggctgtt tactcttttc taaatgccaa gaatataacc ttcaaaacat 218340 cctatgttct gaaacagagg ttgttgtttt gtttttctgg agaagtgtat tatcaaaatg 218400 ccacggactg cagaacagaa ctgggcctga aagcatgtct gggccagctg acggaactgt 218460 gcacacgatt gatatccaca gtgcatatca acaggcagtc tttttggagt ttgcaaagcg 218520 tgtgccgtgc agtgcccgag cctgcctctg cactcgtgtt tccaggttgg gtggctctga 218580 cagccccttc ctgtgggtcc tgcgtccttg tgtggagtca cgcttgctcg gcagctgctc 218640 acttcctccg gttgttttgc cgctcggctc tcccgcccgt gggttttcag gaggcgaatg 218700 tctacctgct taatcctgag gcttcgatcc cgcaaagccc ttcagagttc tctgacttcc 218760 aggccctggc cacaggcccc agcctctttt tctttcctcc tgtaacttgt gtcctgtttc 218820 tgatttctca ccaattatgc catctgcctg tgcccttggt aacatctggg tattgtgtgt 218880 gctgcagacc tcacccatgt gagacaggtc ccctcactcg ccggccacca gaccccagtg 218940 tagtgggcgt ctccagcgta gtgggcgtct ccagtgtagt gggcatctcc agtgtagtag 219000 acctctccag tgtaccaggc ctctccagcc cacactctct gagatgtaag atcacgtagt 219060 tctcaagtat ttattggctt gtatttttct ctttgtgaag tgaattccaa tctagtagct 219120 gcagctatgt acgaataaag aagggtttat ttttctgtcc gtacatactt ctggcttttc 219180 tcaccctctg ctaaacatta tcctttaata gacaagtaga tttttttgta tttttctctt 219240 tgtgaattga attccaatct ggtagctgcc gctatgtaca aataaaggaa ggtttatttt 219300 tctgtccata catacacacg taaacctaca gaacacacag tccagggcat tgcgtttcct 219360 gcctcatcca ggtccaggct atttgcttat tctctaacca gaaacaaatc atatactttt 219420 tttttttttt ttctgagatg gagtctcgct gtgtcaccag gctggagtgt gcagtgatga 219480 gatctcagct cactgcaacc ttcacctcct gggttcaagt gattcttctg cctcagcctt 219540 cccagtagct ggaattacag gccccgccac catgcccagg taatttttgt atttttagta 219600 gagatgaggt ttcaccatgt tggccaggct ggtctcaaac ccccaacctc aagtgatcct 219660 cctgcctcgg cctcccaaag tgctgggatt acaggcgtga gccaccgtgc ctggccgaaa 219720 tcacctattt tctgtggaat gcatttactt catgtataaa acagagtcat agcctccacc 219780 ttgcttaccc cacatgctgg ttaaaggagg aaacacagag agcgcaaatg ccctgtggca 219840 ggcgtaggct tcttaagtgt ggcagattga cggtatccat ggatgtgtcc tcatcatccc 219900 tgccccttcg acaaagcaca ttgtgtcttt tggagacttt ttttcctccc gttcatttcc 219960 attataacaa atgcttctct ggacaatgtt tcattctcaa aatatcgcaa tattgaaaaa 220020 ctaggaatat atcaaaccat tttaaagcac caaatcgaaa aagaagttat tttgtttaaa 220080 taaattatga aaagacaata ctcaaaaaaa aatcaattaa atttattcaa actggaatat 220140 caactgcttt gtaaggtagg gtccctgagc gtcttagagt aatttgagcc gggcgtggtg 220200 gcccatgcct gttgtcttag ctacgtggga gcttggcttg agcccataag ttcaaggctg 220260 cggtgagcaa cgatcccacc actgtactcc agcctaggca acagagcaag accccatctc 220320 taaaaagaaa aaaaaaagaa tcatttttca gtgcctttat attgtttctg tatcttaaca 220380 gtcttgtttt gcagatgtcg taaactcaca gggggtggag aaccaggagt tttttagcca 220440 ctaggaacct ctctgagaag tttcttttct tttcctttct ttattattat tagtattttg 220500 tggccagagg agggaaagga aggtgggtac tgaaacgaca gctcttcccc tgggactgca 220560 gcatccgagc accacagtcc acccgccagc ctttgttcct gcacagtctg cctctcaaga 220620 ccaacaactc catatctatg acgataaaaa ttgttagtga ttattttact tgtaagaatt 220680 tctttcgacc tcagctctga ggtgaccctc agctcgcccg ccaccccagc tgccccacct 220740 tgctggcata gaacagggag tggaggtgtg aagtcactca acagggctca gtatacaaaa 220800 tgtaagccac gcctcactca cttgctccct ggagaatttc atctgcgccg cgttgcctaa 220860 taacggggtt atcggaaagg gcatgattac gttccctctt cattccctgg agtctttttt 220920 ccctgaaact gtattgtact tgggccaaga ttcttgatga atcattcaac cagaaggaga 220980 aatggggttg ttgtttggtt tttttgtttt gttttttttt tttttttgcg ttttgagaga 221040 gcacacttgt gggtggttga acatggataa aaataaacgg gaaaacaaaa atcaaattcc 221100 cggccctagg aaataaaatg ttacctttac ctgatattga taatacatat tatatttgaa 221160 agcatttgct aatggttgca ttttcccccc aacactccca tgacatataa ttcccatttt 221220 ataagtcacg aaacgaagac cctggggtct gaaggaactt ggctggggtg aggatcacaa 221280 gcccttgggt ggagctctga gccctggcgc ggtcctcaag ggtctgcgac atttgtgctg 221340 tggtcagctc tgtgcactct tccctccctg ctgctgttat cacgaaaggc tggcttggcc 221400 tttctcatag gcgtatttcc actctcaggc gcccttttat tgtctgggct ccattcaagt 221460 gataagacat acatttatgc tattgtggga acataatgta atattctcaa cagcattgcc 221520 aaacaaaaaa aaagtttagc ctctgcctga ttttcttata acttataaag aaaatttggt 221580 ttgaacatgt cccatgtcga tgttttcagg aaaaagatcc gatagcatgc aggccttctc 221640 atgctggcmt ggctcattca tcgtttcccc taatgactga ctgaccagaa aaatgcacga 221700 cgctcccatg gggccactcg ggaggcctca ggcttcgggc ttcctgattc agtagatatg 221760 tgaggcttga tcagtcaccg cagtccacat ctccattgcc tcgataagga accagtcgca 221820 gagaggggag gccatctgca gaagctgtgg agagtggcag agaggaragt gaggacgggg 221880 actgccccct tccagcccct ctcctccaag gacggcctca ttttatcccc acccaggttt 221940 ccacacccag gagctcagca accgctcaga aaatgtttgt agaattcaaa gacataattc 222000 agacaatatg aagaattatt tttcctttga gttgttctta aaacagacga aatctaccag 222060 catataaatg aatgagaact aaaactggtg ggatttggta atgtcgacat ctgagatgtt 222120 taggctttta aatatatatc tcagccaggt gcggtggccc atgcctataa tcccagcact 222180 ttaggaggcc gaggcgggtg ggtcgtttga gcccagcagc tcgagtccag cctgggcaac 222240 atggtagaat ctcgtctgta caaaaaagta caataattag cgggcatggt ggtgcaagcc 222300 tatagttgca gctacatgag aggctaaggt gggaggatca cctgagctca gggaggtcag 222360 tgctgcagtg agctgtgatc atgccattgc actccagcct gtgcgacaga gtgagaacct 222420 gtctaaaaat atatatgtgt ttatatatat atatttatat aaacattagt gggttttaaa 222480 aaaaattaac taactgctag ctcctaaaac agtattttgc cattagcttt ggaaaggttt 222540 gctcagaaaa tgaatttcta agcactccct tcattgcatt tattggtcaa actaatggtc 222600 ctggatggtt atctttgaaa cttcctaacc tgttgggtcc ccgtcgttaa acttatgcca 222660 acagaactaa actcactgga tgtgaattgc atcagagatg taaacattta aaagcgtatt 222720 aaggctgggc gcagtggctc actcccgtca tcccagcact ttgggaggcc gaagcgggcg 222780 gatcatgagg tcaggagatc gagaccatcc tggctaacac agtgaaaccc cgtctctatt 222840 aaaaatacag aaaaattagc cggtcgtggt ggcaggtgcc tgtagtccca gctactcagg 222900 aggctgaggc aggagaatgc atgaacccgg gaggcagagc ttgcagtgag ccgagatcac 222960 gccactgcac tccagcctgg gcaacagagt aagactctgt ctcaaaaaaa aaaaaaaaaa 223020 aaaaaaacat taaaagcaga ccaagaaaat cctagaatac aggagtcagc tgtctattca 223080 attcagaata agaaatattg tagacaaggc aacattttat gtgtattaga aatgtggtgg 223140 ttggtttgag aagtgaaacc agccatgtat atgctgctcc aagcattttg gttgtggcag 223200 gaaactttga agactatttt gctgtacaaa ttcacaaagc cccctgcaaa cactcccgtg 223260 cttggggtga atgcccaagt gtgtcacagc tgccttgcag ctctgaggat cagaaaggtt 223320 aatggacata aaagaaactt caaagctcaa cctcctaatg ggaagctgcc cttggtttta 223380 ggctgtcttt gcttactgac cgacttaatt catgctttgg gttatgactg taggagagat 223440 tttcctgtgt ctttggagta tgctgaactt gtgtttcttt ttgttgttgc atattagaca 223500 gtcagtgttg aaactaaagt gacctaaagt gacagagctc atgttatggg ctgaattttg 223560 tctccccaga attcataggt tgaagccttc ccagtcctta gaacatgatt gtatctggag 223620 ctagggcctt taaagacata aataaggtaa catgaggtca taagggcaag gccctaatcc 223680 aatatgactg gtgtccttat acgaagagga agaggccagg cgtggtggct tacgcctata 223740 atcccagcac tttgggaggc cagggccggc agatcacttg aggtcaggag tttgggacca 223800 gtgtgtccaa catggtgaaa ccccgtctct actaaaaatg caaaattagc tgggcatggt 223860 tgtgggcacc tgcaatccca gctacttggg aggctgaggc aggagaatcc cttgaacaca 223920 agaggcggag gctgcagtta gtcgtgatcc caccactgca ctccaacctg tgcaacagag 223980 caaaacccca tctcaaaaaa ataaaaataa aataaaggaa gacaaagaaa caccaaagat 224040 atttttgcac agagaagagt ccaagtgagg actcagggag aaggtggcca tctgcaaccc 224100 gagcagtctc ccaggaagcc tcaggagaaa ctaacccctg tgacaccttg gtcttggact 224160 tcctgccctc cagaactgtg aaaaaataca tgtctgctgt ttaagccacc caccctgtgg 224220 cattttgtta tggtagcctg agcaaactag ttcagcccaa aatgaattct gatatcacct 224280 gcagaaatct gcttttagac agcaggaaac tgagggcctc tgagtttcta ggccagagtc 224340 atgcagtgaa ttactgaaag acccagaacc ccagtcctgg cccctgattt tcagtttaga 224400 atcttccttg gtaagaagca ggatcttagg ctgggcccag caagtggaaa actctttttt 224460 atttacacag ccactgactg ttgtggtctc agactgtacc acagaacctg gtgttccaca 224520 aacttcccca gtttggagca agagaaaaaa gtagttggat gaaatgatct cattttattt 224580 tttagtcaat ttttcttaaa tgttggtgct tgaaaacaaa tggatggcag taaagtaatc 224640 ctgaagaaca caggaggaaa gaaataaaag aggcaatacc aaatgttagc aaaatggcag 224700 caaggcaaat aagaggctca gcaatagcaa aaaactgagt tctttggctg ggaaaaactt 224760 ataaatatta aaaatcctga caatgttgaa aaagaaaggc agagataggg ttccaggaga 224820 aatactaaga atgaaattgg agctgtcact gcagttatcg taaggatatt ttaaaatcat 224880 aagagagcat gatgaacaat ttaataccaa taaatttgaa aacaggtaag atggatgatt 224940 tttagaaaaa tgttaccaaa attgattcaa gaaatagaaa atctaaacaa gctcaagcgt 225000 taaaaaaatt aaataggtaa aatatgtaca tcaactgggc acagtggctc acgcctgtaa 225060 tcccaacact ttgggaggct gaagtggaca gatcacttga ggtcaggaac tagagaccag 225120 cctgaccaac acggtgaaac cctgtcttta ctaaaaatac aaaatgagcc aggcatgatg 225180 gggcatgcct gtgatcccag ctacttggga ggctgaggca ggagaatcgc ttgaacctgg 225240 gaggtggagg ttgcagtgag ccgagactgt gccattgcac tccagcctgg gcaactagag 225300 caaaactctg tcctaaaaaa aaaaaacaaa aaaaaaacaa ttatatatca acaaaaaaaa 225360 gaaaatttta aaaagtaaca atttgaaaaa gtcaaatagg caatcaaaag tattcctttc 225420 accagccact aaaaaggcac ctgtacatgg gaatggtagc aaaatgacag aagaggaaac 225480 tctaacctct catccaacac agaaaccgct aaaaccaggc agaagctgtc tgcagagatg 225540 ttgcaggtgc tctaaaaggt gctctaaaca accaccaaat gcatacagca accaggcaaa 225600 tgcctgatag aggaaagcca tcttcaagcc cgcaggaaag ttttstggca catggtggca 225660 acccagttcc cagttcccag ttcccttcct caagctgcag ggagcagacc agacatgatt 225720 tgttctagtc tagctgattc atacctgaag gattgatcct catctccatc tcacataaca 225780 tgcaaggtgg gcaagaaaaa gaggtgggca cagctcatga aagccacaga gaggcaatta 225840 aggtaaaaat agataaattg cactatatac aaattaaaga cttcagtgca tcaaaggata 225900 cagtcaacag agtgaaaagc aatctatgga ataggagaaa atatttgcaa ataacgggtt 225960 aatcttcaca atatataaag aactcctgca actcaacaac aaaaaaaaac cccagtttca 226020 aactgagcaa agaacttgaa taaacatttc ttcaaaaaag atgatataaa tgtccaatag 226080 gcaaatgaaa agatgcttaa cattactaat ccttaggaag atgcaaatca aaaccacaat 226140 gagatagcac ctcagcacct cacacccatt atgattgcta ctataaaaaa aaaaaaaaac 226200 ccagaaaata acaagtgtta gtaaggatgt ggaaaattgg aaccttgtgt ctgcctcatg 226260 taatgttggg aatgtaagat attgtagcca cgatagaaaa cagtgtggca gttcatcaaa 226320 aaatgaaaag tagaattact gtatgatcca acaattcctc ttctgggtat atgccaaaaa 226380 aattgaaagc aggatctcaa aagaataatt gtacatccac atttatagca gcattgttca 226440 caatagccaa aaggcagaag cccaagtgtt catcagtgga tgcataagaa acaaaatgtg 226500 gtctatccat acagtggaat attattcacc cttaaaaagg aaggagattc tgatacatgt 226560 aacactgtgg atgaactttg aaaacatcat gttaagtgaa ataagccaga aaccaaagga 226620 caaatatcat acgactacac ttataagagg aacttagaat agacaaagtc acagagacaa 226680 actatagttg aattaccaag ggtggagtag gcaggaaggg agtggagaat tattgtttaa 226740 tggctacaga gactcagttt tggataatga gaacattcta gaaattaata gtagtgatgg 226800 ctgcacagca ttgcgaatgt acttcatgcc actgaagtgg acacttaaaa atagctaata 226860 tggtaaattt tatgttatgt ctatcaaact tttaaaggca ccctccacag atagttttag 226920 tagtaagttt taccaaacat tataaagttt tacaggaaaa aaaaagaaat ctattcacct 226980 cattttacaa ggctacattg atcttgacct aatactggtt taaaaaactc atttgtaaac 227040 aagtacataa aaatctgagg ctgagcgcag tgactcatgc ctgtaatccc aacactttgg 227100 aaggccgagg ggggcggatc acaaggtcag gagatcgaga ccatcctggc taacacagtg 227160 aaaccccatc tctactaaaa atacaaaaaa ttagccgggc gtggtggcat gtgcctgtag 227220 tcccagctac tcgggaggct gaggcaggag aatcacttaa acctgggaga aagaggttgc 227280 agtgagccaa gagtgcgcca ttgcactcca gcctaggcaa cagagtgaga ctctgtctaa 227340 gaagaagaaa agaaaaaaaa actcagaaat aagatatttc atcaagtcaa atttggtagt 227400 gtgtttttaa aacacacaca cacataacca agtgtggttt aacctaagaa tgaaaggata 227460 aatgaatagc attaagtctt cttttttcta atccattaat tttcttagta gtgttaaaaa 227520 gcagtaggga agattcaatg ccgagtaatg atttaaaaaa aaaaaaactc ttcagaaacc 227580 aggaatagat aactttctta actatggagg ttatctataa aaaacgtaca acaaatattg 227640 aatggtgaaa accttagttt aaggcttaaa tcaggtacaa gacacacatg aatgctatta 227700 ctcttcaaca gtgttctatg attcctagtc aagggaataa aataaaaaaa attacaagaa 227760 ttatacagga agggacacat tttgtttgca tgtcatacag ttgtctacat agaaacatca 227820 aagagagtca ataaactgtt acaactcatt cagcaaaatt cctctttgta agatccactc 227880 actgaaatct ttagcatttg tatacccaat gataaacaat tataaaatgt aacagaaaac 227940 atagtaaata atagtggatt caaggctagc catgtaatac agattgaaca ttcctaattt 228000 taatctgaaa tgctccgata tcttaaactt tttgagtgcc aacctgtcaa cacaagtgga 228060 aaattccaca cctgacctca tgtgacaggg catagtcaaa gcacaggtgc acgacacagt 228120 tgatttagcg tccccaaggg aaaaaaaaga cccacccagc ccccttcaac tatagtataa 228180 cttttccacg cacacccaaa ttcccccaca caagcacgcc cacaatgtgt aataaaatgg 228240 cacgtgtgca ggctggacgc acccaacgca gattccccac gatacctcac gtggggccga 228300 gaactccatg cattactcac tgtggttttt tgcttattct ctgcagtgtc atgtaaaaat 228360 attactgaaa atgtcgaaaa ggcctgcaga tccccctatg tgtaacagtg atcagaaaaa 228420 gaggaataat ttatgtttat caatagcaca aacagtcaac ttgttggagg aactgaacag 228480 cagtataagt gtgaagcgtc ttacagaaga gtatggtgtt gggatgacca ccatacatga 228540 cctgaagaaa cagaaggata cgcttttgaa gttctatgct gaatgtgatg agcagaagtt 228600 aatgaaaaat agaaaaactc tacgtaaagc taaaaatgaa gatgtgaata gtgtattgaa 228660 aaactagatc tgaaggcatc acactgaacc cgtgccactc agtggtaggc tgatcatgaa 228720 acaagcgaag atctatcctg atgaactgaa aattgaaggg aactgtgaat attcaacagg 228780 ctggttgcag aaatttaaga aatgacatgg aattcaagtt ttaaagcatc tgcagatcac 228840 aaggcagcgt cgaaactcat tgacgagttt gccaagatta tcgctaatga aaatctgatg 228900 ccagaacaag tctgtattgc tgatgagaca tgaccatttg ggtgctactg ccccagaaag 228960 atgctgacta cagctgacgg gacagcccct acaggaatta aggatgccaa ggacagaatg 229020 actgcagtgc tgtgcaaatg cagcaggcac gcataagtgt aaacctgctc tcatgggcaa 229080 aagcttttgt ccgtgctgtt ttcaaagagt aaatttctta ccagtccatt attatgctaa 229140 caaaaaggca tagatcacca gggacatctt ttctgatcgg ttttacaaac acttcgtaca 229200 ggcctcttgt gctcgctgca gaaaagttgg accggatgat gacagcaaga ttttcttatg 229260 ccttgactac tgttctgctc atcctccagc tgaaattctc atcaaagata atattgatgc 229320 tgtgtacttt cccccaaacg tgacttcatt agttgagcct gtaaccaggg tatctttaga 229380 tcaatgraaa gtaaatwtaa aaacactgtc ttgaattgca cgctcgcagc agtgaacgga 229440 ggtgtaggtg tagaagattt tcaggagctg agcatgaagg atgccataca tgctgttgcc 229500 aacacttgca acacagtgac taaagacaca gatgtgcgtg cctggcgtga cctctggcct 229560 acgactgtgt tcagtgatga tgatgaacca ggtggtggtt tagaagaatt cagcttgtca 229620 agtgagaaga aaaggatgtc tgacctccaa aaaatatacc ttcagagttc atcagtcagc 229680 gggaagaagt acacattaat gtcattttta acattgataa tgaggctccg gttgttcatt 229740 tcattgactg ttggggaaat agccagaatg gttctgaatc aaggtgatcg tgatgatacg 229800 accatgaaga tgacgttaac actgcagaaa aagcacccgt ggacagcgtg gagctcaggt 229860 gtgatgggtt aactgaggcc cagagcagcg tgcattcaca acagaacaag caatcatgtc 229920 agcttataaa atcaaagaaa gaatcctaag acaaaaaaga aagaaaaaaa attagccggg 229980 catggtgaca cgtgactata gtcccagctg tgtgggaggc tgaggtaaga gtcttgcctg 230040 agcccaggag ttagaggctg cagtgagccg tgatcatgcc actgcacacc agcctgggaa 230100 acagcgaggc cctgtctcaa aaaaacccaa aaaactaagt aaatattttg tacatgaaac 230160 aaactttgtg tacactgaac caacagaaag cagctgtcgg ttctgagacc attgttagtg 230220 gtgcagatac cattaaaaag ccccccagca gaatgcctcc tcgtccccag aggacccact 230280 tcctgggcct gtaactgctt cttatgttcc ttctcaccta aaatgtaaaa tgccgtgtcc 230340 cgtaagcttt gaatcaaagc acagcatggt tgggagagca gaggcctgct gttgtttgtt 230400 gttgctgctg ttgttcagca gctgattgcg gtctctgctg atgccactgg ctgcttagct 230460 cccctgagca cgtaagtctt cactgtgtta atggcatgtc ttatttttta ctgtgaagta 230520 cttatgtgtg aataagtgta aggaaatgac tgcttggtag tagcatataa attcagagtc 230580 acgggcaggc acggtggctc acgcctgtaa tcccagcact ttgggaggcc aaggcgggca 230640 gatcgcttga ggccaggagt tcaacaccag cctggccaac atggcaaaac cccatctcta 230700 ctaaaaatta caaaaattag ccgggcgtga tggcacatgc atgtagtccc agctacttgg 230760 gaggctgagg caggggaatc gcttgagcct gggaggtaga gattgcagtg agccaagatt 230820 tcaccactgc actccagcct gggtgacaga gagactgtct caaaaaaaaa aaaaaaaaag 230880 tcacagtcag gaatgagggt gatgccacac aaccactgat tgtccacatg ggggtgaggg 230940 ctgagatagt gatacctctg ctttctgatg gttccatgta cacagacttt gtttcatgca 231000 caaaatttgt ttgtttattt tttgaaacag agtttggctc tgttgcccag gctggtgtac 231060 agtgctgcga tcatagctca ttgcagcctt taactcctgg cctcaagcga tcttcccacc 231120 tcagcctccg ttgtagctgg gactacagtc atgctgtcgc acctggcaat cacaccagtc 231180 tatgcacaga actatttaaa atactgtata aaattacctc taggctatgt gtataagatg 231240 cagatgaaac ataaatgaat tttggtttta gactctggtc ctatcttcaa gatctctcat 231300 tgtccattcc aaaaatgcca cccaccaccc cccaaaaaaa atctggaatt caaaacattt 231360 ctggtctcca gcattttgga taagggacac accacctgta atatcctttt acacatttcc 231420 tggatgggaa acagaagttg gtgtggtagg agtcacacat aaacggcaga ctttcttgtc 231480 tgtgacacat tcttaggatg tcctagagaa gtatcagcga tgtgaatgtc tccagtcaaa 231540 tatcagagca gaaagaatat gttgagaact gctgtattat tagactgggc tactttcttc 231600 aaacaacaca tggtatcagg tcattcattc atttacccag tagatatttc ctacacactt 231660 gtcatatgcc gagcatatcc taggcactgc aggtacagca actgacagga atatacagcc 231720 tttgcccttg tgggacttaa catttaagag agaagacagg cagcaaacaa tttctttaaa 231780 aatccttctg gtggtaaatg caatgaagaa aacagggtga gtatagagag gaggagtgag 231840 gtaggcccct tgcacgtgag tggcatttga gctgaggccc agatgatgaa gagaaggatg 231900 gactcttgta ggtctattgg actggccctt ccaggaatgg taagggctga gaggtcagga 231960 gaagcggtaa gtttagcgtg gctgaaatga agggagagaa gacaaagcaa taggaaatga 232020 agctggagaa gcaggcagct tcagacagga ccattccaga ccactgacac cttaacagac 232080 aacagcaaga agtttgggtt ctgttctaag gataaatgga agtcacagaa cgattttaag 232140 tgggaggatt aggctgcggt atatgtttgt ttactctgtt tgtgtttatt tttgttttaa 232200 tggatacaga gtctcccaat gttgcccagg ctggttttga actcctgggc tcaacggatc 232260 ctcctaactc ggcctctcaa agtgctgaca catgtttttt taatggaagc agagaaagca 232320 gtctcggacc tttgcagtgg ttcaggtgat tagtgatggg ggttaggacc agggacgtat 232380 cgatggaggt gttgtgaagt tgtcatattt taaatataca tttcagagcc aggtgcactc 232440 gctgatacat tggatgtggc atattagaga aagaagactc gaaggtggca cctagtcttg 232500 tgttctgagc ttccagaatg aggcatctag aagccaggac ccgggagaag cacggaagga 232560 gcagtggttt attcagtctg cagaagcagt gcctacagga ctgctgtgtg aaagaggaca 232620 catgtgatat gagcagatga aaatcacaca gcaggcagct ctgggctcat tatgagaaac 232680 gactctagga atatttgtaa cctgctgggc tctactgcta agggctgcct taagccatga 232740 agccgcagag gctgggtgac caccgtccca cagtgaggga gctgggcaat tccttaccag 232800 agtggagatg tggctagatc tcctagccct aacatgctta cttattttga taagcaaaga 232860 tgaagctcac atgggtcccg tgtgctcttg aacttctgta cattgtacca ttaaccacac 232920 ttggatgctg gcaatcgcag ttttagttaa ataaagtgac ttgcccacca tactataaaa 232980 aattaatttt ggtagcatgt tgattctgta tcctaaccat aagaccacac agagccatgg 233040 ctagtaaact ttagcttgtg cgtaaatgcc tgccaagacc tgctaaatac tgttgcttac 233100 atttaaaaaa aaaaaaaaaa tttttttttt aatttaaatt tcacggagct gctcaagggc 233160 agttcagctt cctattcatc tctgtctcca ccggccagga ctggcattac tctaacatct 233220 gtctacggcc acattttatg ggatgtttga ggattattcc tatgaagtga cattggaatt 233280 tggggatgtg gctatgttca gatgccaaat aaacttggat agaaatcatt tttcctgtgt 233340 gtgtttacag ttaggaacgt ggggctgtga ggggctccct ggacatgacc ctggagctgt 233400 cggcccttgt tcagtggtca gatgcgcttc agacctccca gagtgctgcc cgcacactca 233460 gtcacagccc catgcgcacc tcaacgccac tgctcagaag tccagtgtaa ttcctcaggc 233520 agcatgtcct agagcaggcc atgagaggtg taaggtacag actttgttgt gaggttacat 233580 gtaggcttct gttccatctt gtctctgttt aaagatcgat acttctggca gcctttatcc 233640 ccaccacgat aaatacgtgg atggaaggat acatgcgtgg aagggtggat gggtggatgg 233700 ttggatggat gggtagacgg gtgcatgggt agatgggtag atgggtggat ggagtgatat 233760 ttgatttcat agtcaaagaa ctcaaacagt agacaagtac acagggtcct ccagtcttac 233820 aacccttcct taactacaat aaagatagaa gtgtatcttc tagatttctt ttaaaaacat 233880 atttatgaat gtaaacatat tatggtcagg tccagtgact cacatgtata atctaacact 233940 ttgggaagcc aaggtgagtg gactgcttga tgccgggagt ttgagaccag ccttggcaac 234000 atagaaagac cgtgtcccta caaaaaaaat tttaaaagta gcctggtgtc atggcacatg 234060 cctgtagtcc tagctactca ggacgtcaag gtgggaggat cactcgagga caggaattcc 234120 aggctgcagt aagccatgat cataccactg cactccagtc tgggcaatgg atcaagatcc 234180 tgtctcttta aaaaaaaaaa aaaacatatt tacatagaaa taaatgtata taaacacaga 234240 tattgtttag ggatttgttt ttatatatat tggagaatga catgcttttt caggagcttt 234300 tatttaaccc tatgcctaga agatccttcc agcttaacac atatacagct acttcattct 234360 ttttaaccat tgggaggtac tgtaattaat ttatgtgctt tctgttattt tcattgtttt 234420 gctattgtat ttacttattt attttagaaa caagatgtca ctatgttgcc caggctggcc 234480 tcaaactctt gggctcaagc agtcctccca ccttagcctc ccaagtaggc gggactacag 234540 gcatgaaccc tgcaatacgg ctggcttctg ctattttaaa ctcgtgtgtg tgtgtgtgtg 234600 tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg cgcgcgcgtg tgtgtgtgtg tgcgtgtgtg 234660 tgtgtgtttt ctaactgaac aatctgaatt caattttaag agattttctt gagctggaat 234720 tattctagtc cgagcccagg ctcatgaaga tttctgtaaa atacattcca agcagtgaaa 234780 ttactgtgcc ctaggatatg tgtacttaaa ttctgataca caaggctgca gcaatttaca 234840 ctattactaa cggtacataa agtcctattt cctatgtcct ataaattccc atgtccagta 234900 ctggacataa cccatatttt caatattggg tgatccgatt agttaaaaaa atagatctca 234960 ttaatttcta attgcctgat tactaaatta tgaatgagtc tgaatatctt agataggaga 235020 tttatcattc gtgaattacc tgtcctgatc ccttaactgt tttgaaattg ggttatttat 235080 atttttcaca tggttttaca gcaatgttta cataatatgg acattaaact tttgttgtgt 235140 tataaaactc tgtctcttta gctgtgctta tggtgtctta agtattacca agtttttaat 235200 ttttaactat tattttttac aaaattaaac acctcttttc ctccatggca cctacccttg 235260 tggttttgct tagaaaggcc ttcctcaccc tctgagcttt aaaaataatc tcatattctc 235320 ctatttatag ttttaaaaaa tatttagacc tttaatgcat gtgcatttca cttactgtat 235380 aatgtgaggg gaccatgttg tttttaataa ctaatttatt gacactgacc tatattgccc 235440 cctgtgagtc atctcttaca ttcccacatg gtatgggtgt gtttctggtt attctcgtcc 235500 attgatctgt ttgtctattc tgtgctgacc tctattttac tgctataatt gtacagactg 235560 ttttgatatc tggtatgtca aattttttct catcatttct ctttttaaaa atcatcttcc 235620 tatgcatttt tttctttcct ataaacttta gaataaacat gtcgttttct ttttgaaaag 235680 tttgaaattt ttggattaca ttgaatttct agatgaattt ggaaagagca tcattttttc 235740 tgcatttttt tatgattttt caaaactgac acctagtcag aaaactaagt gtaaaaattg 235800 aatccataga gtttttacaa cctggaagaa aatacaaatg tggctgaatg actttaaacc 235860 ctgagtatcg gaaaaggctt ccacctacct atgactcaaa agccagatgc aataagacaa 235920 agtgttgata taatttgaat acataagaaa ttgaaactta tacatggcaa aagtttgcat 235980 aagaaaagtc aagccaggtg tggtgggtta tgtctataat cccagcattt tggaagactg 236040 aggcacagga agattgcttg agcccaggag ttcgagatca gcctgggcaa caaagtgaga 236100 cattggctct acaaaaaatc aaaacattaa ctgggtgtgg tggtgcatac ctgtagtccc 236160 ggctacctgg gaagctgagt ctggaggatc acctgagtcc aggagactga ggctgcagtg 236220 agtcatgttt gcaccaatgc agtctaacct gcgtgactga gcaagaccct atctcaaaaa 236280 aagaaaaaat atgtaaatca taataatacc tgcttcactg ttgtggagag aattaagtag 236340 tatgcctagt actaataata ttgttataat tatatacaat gtttttaact atatcatttc 236400 ttatatatat aagctatcac aaatgttagt gttcctccct tctgaaattc atctgagggt 236460 ccctcactga cccaggcctc ctgggtagaa gcacatttgt attgagaaga caacagttaa 236520 attctgggac actatcttga gctataacta agataagtca tttttttctt ccatttctaa 236580 aaatatttgt agattaaacc catttttttc ttttttgtac cataccacca ggatagcttt 236640 ccaccttcca tcactcatct gtgtgacttc ttaagttcct tcaaatgtaa ctctgtaatt 236700 ataattatat attcacacaa tcattgtgat tctttaattg caattgattt aatctacctt 236760 atcatccaat cggtgctgac agtggatttc attccttttt ttttctaaca gtaggaatag 236820 aatgcagtgc gcttgccagg actgaggaaa gagggagggg ttgtttccgc cagctgccag 236880 gatcacctgt gctgaccctt cagcagcacc tgcagcgcta tcctgggcca ggcgcaactt 236940 gtgattttca taaaatagtc gagtttcaaa cggatgggac tttagagctt ctttaatttg 237000 agctatgaag aacagagttt tagaaagtat gcttattcac ttggaattcc ataaaaaata 237060 cctatgctgg gtagatagga tagcacggcc tacctctcac cactggtgtc ataattaaaa 237120 ctcatatatg tatttactta tactctgcct tatgccaaga gtactggaag tggtgagcta 237180 agattagaaa ttcttggctc ctatgtcaca gactggcaag cttcccaccc tgcccactga 237240 gtgtcctgac acaacgggaa cgtgccctgc atctaatggg acatgtggct accaagcact 237300 tgaactggcc agtgtgactg agaactgaat gtttcattgt attgaatttc gtttcacgtt 237360 aatttaaaaa ggtatgtgtg ctctatggac gtgggggggc ctatggacaa cacagctctt 237420 ggctatttgt ttttaaatat agtttcatgt atatacaaac aggttatcac tttcctatgt 237480 ggctggctat tatgaatgct aaactgcttt tcgctctctc tctagattcc atcacccagc 237540 acaaggtctg tgccyctgaa aactacctat tgtcacaatg acagtgacct cactggcctg 237600 tggtgactgc acacagctcg caaaactgtc tttggatgtt caaatgagaa acaaaactgt 237660 gaagagaagg aactggcgta tacaagatga cttctgatat catgtttgcc atgtgttgtg 237720 gttcttaaga actcataggt gactttctga tgactgaatg tctgtttcag agacgcttcg 237780 ggccttttta tttttatttt attttttatt ttttgagacg gagtcctgcc ctgtttccca 237840 ggctggagtg caatggcaca atctcggctc actgcaacct ccacctccca ggttcaagcg 237900 attctgctgc ctcagcctcc tgagtagctg ggattacaga tgtgtgccac catgcctggc 237960 taatttttgt agttttagta gagacagggt ttcgccatgt tggccaggct ggtctcaaac 238020 gcctgagctc aggtgatctg tcaggcctct tctatagaat tccagtcttt gtgtcttagt 238080 catgatcata attgaaaggt cacagaacct ttgtcattag agcacagtac tgccaaataa 238140 agaatggaaa ttcaatgaca ttgttttatt actgagaaca actagagaac tctgcaagtt 238200 tcttggctta gactcgatct ttattaatac attatctatt aggtaggaaa gacatttgtc 238260 agctattaag gtgactttta tctagcggag attcctctct taaagtaatg aaaggagata 238320 ggtatggggg gtgttataca ggataattgg tgacatctga gtgtcttact tctgcaagcc 238380 tgctttatgg tgagcaaagc atcaccagca agtgatcaca atgtccactg gccgcttttt 238440 gcctgccgtc ctcgagatga aattggcagt tggggctgat tcacagaaac accgatttgt 238500 ggctgagcac ggtggctcac acctgtcatc ccagcccttt gggaggctga ggtggacaga 238560 tcacttgagg tcaggagttc gagaccagcc tgaccaacgc agcaaaaccc atctctacta 238620 aaaatacaaa aatcagctgg gtgtggtggc acacacctgt ggtcccagct cctcaggagt 238680 ctgaggcaga agaatcgctt gaacccaaga ggcagaggtt gcagtgagcc aaggttgcag 238740 tgaatcaaga ttgctccact gcactccagc ctgggcaaca gagtaactct ccttctcaaa 238800 taaataaata aataaataag aaacactgat gtgtctgtca ccttctaaag aaatgaaatg 238860 ctaggaagtc ctagccagag tgatcaggca agaataagcc ataaaaggca tccaaatagg 238920 aaaagaagtc aaactgtctc tcttcactgc cgatatgatt ctatacctag aaaaccctaa 238980 agactctgcc aaaaggctcc tggaaccgat aaatgactta agtaaagttt caggatagta 239040 aatccatgta caaaaatcag catttccaaa cacagtaaca ttcaagctga gcaccaaatc 239100 aagaacgcaa tcccatttcc aatagccacg gaatgaaata cctaggaaca cgtataacca 239160 aggaggcaaa ggatctctac aaggagaacc ataaacgaga tgctgagtcc cagcgaggtc 239220 ggaggtgcca ctgagccctc atcgtggtgc cgttcccgct ctgggttatt tatctgttgc 239280 tcatctcagc tgttgttcct acctcaaatt tcaagtccct caacaaatat aacagaacca 239340 cttctagaat gaacctttga gaagggaggt agcagtgcat tgtataggaa ttggcattct 239400 atagaaaacc acagaaactg gaaataatga agggttgtct cttggtttta aaataatgta 239460 tacacctaaa tcatcccctt atgatactca tcctctaaca gcaattgaac ttcaatacaa 239520 tgagtcattc ctgagttcac tcgcttcaca ttacatatgt ttctctataa ccacaagcat 239580 cctggcttgg tagtgctccc acagcaccaa aaatccctga ggaggctgac aaacattgtg 239640 ctgactcatg ctggagacaa gccacagaga acttccatcc cccaccacat cagccacgga 239700 gccagcccag cctctgccca cccaggcctc agtccccagt gttaagttct gatccctgat 239760 gctggcctgc cagtggccag tcaagattct ctttctgaaa gctagtattt tatgaggact 239820 gactgttgct agacattaca ctaagcacat tatatgttgt acttcatttt accctttcaa 239880 caatcctatt agtagcttac tgtgggtctg caaagcctta ctcaaaacat atagggctag 239940 aggttctcag gattctgaat tttaaaaaaa atttgtaaag gcttatggct ctcaccactg 240000 ttattcaacg ttgcattaaa gtttctaccc agagaaggca ataaaaggaa attaaagcta 240060 tacagattgg aagtgaagaa ataaaagtct ttattctcaa gaatacaaga cactatgtat 240120 agaaattgta aggaatgcaa aaaaaaaaaa aaaaaaaagc cctacaagaa cttataacaa 240180 gtttagcaag attgcaatat acaatcttgc aatcttccta aagattatat acaaacctaa 240240 cagaattgta tttatatata ctgtcaataa gcaattcaaa atgaaattaa gaccacgatt 240300 ccatttaaaa ttgcatctaa aaataaacaa aataggaata gacttggcaa cagttgtaac 240360 atctgtatac tgaaacctgt aaaacattgc tgaaagaagt taaagacttc tttaaataga 240420 gacatataca aagttcatag attagaagat gcaatattgt taagatgata gtcctcaaat 240480 tgacgtatag attcaatgca atccattaaa atctcagatg gctttttata gaatttgaaa 240540 agctgatgct aaatctttta tgaaaatgca aagaacctct agtagacaaa acaatttttt 240600 taagagcaaa gttggaggat ttatagaacc tgattccaaa actgtcagta aaactacaat 240660 aattacaaag tatcagccag gtgccgtggc tcacatctgt aataccagct ctctgggagg 240720 ctgaggcggg tggatcactt gaagtcggga gtttaagacc agcctggcca acttggtgaa 240780 accttgtctc tactagaaat acaaaaaatt agccaggcat gatgg 240825 2 3809 DNA Homo sapiens 5′UTR 1..57 CDS 58..2565 3′UTR 2566..3809 polyA_signal 3795..3800 allele 285 5-392-222 polymorphic base G or T 2 gcgccgccag gctcgcaagc accgcgtagg ccagctggcc ggatcccgcc gtctgtc 57 atg gcg gcc ccc atc ctg aaa gat gta gtg gcc tat gtt gaa gtg tgg 105 Met Ala Ala Pro Ile Leu Lys Asp Val Val Ala Tyr Val Glu Val Trp 1 5 10 15 tca tcc aat gga aca gaa aat tat tca aag aca ttt aca aca cag ctt 153 Ser Ser Asn Gly Thr Glu Asn Tyr Ser Lys Thr Phe Thr Thr Gln Leu 20 25 30 gtg gat atg ggg gca aag gtt tca aaa act ttt aac aaa caa gta act 201 Val Asp Met Gly Ala Lys Val Ser Lys Thr Phe Asn Lys Gln Val Thr 35 40 45 cac gtt atc ttc aaa gat ggc tac cag agc act tgg gac aaa gct cag 249 His Val Ile Phe Lys Asp Gly Tyr Gln Ser Thr Trp Asp Lys Ala Gln 50 55 60 aag aga ggc gta aag ctc gtt tcg gtg ctc tgg gtk gaa aaa tgc agg 297 Lys Arg Gly Val Lys Leu Val Ser Val Leu Trp Val Glu Lys Cys Arg 65 70 75 80 aca gct gga gca cac att gat gaa tca ttg ttc cct gca gct aat atg 345 Thr Ala Gly Ala His Ile Asp Glu Ser Leu Phe Pro Ala Ala Asn Met 85 90 95 aat gaa cac tta tca agc cta att aaa aaa aaa cgt aaa tgt atg cag 393 Asn Glu His Leu Ser Ser Leu Ile Lys Lys Lys Arg Lys Cys Met Gln 100 105 110 ccc aaa gat ttt aat ttt aaa aca cca gaa aat gat aag aga ttt cag 441 Pro Lys Asp Phe Asn Phe Lys Thr Pro Glu Asn Asp Lys Arg Phe Gln 115 120 125 aag aaa ttt gag aaa atg gct aaa gag cta caa agg caa aaa aca aat 489 Lys Lys Phe Glu Lys Met Ala Lys Glu Leu Gln Arg Gln Lys Thr Asn 130 135 140 cta gat gat gat gta cct att ctc tta ttt gaa tct aat ggt tca tta 537 Leu Asp Asp Asp Val Pro Ile Leu Leu Phe Glu Ser Asn Gly Ser Leu 145 150 155 160 ata tat act ccc aca att gaa att aat agt agt cac cac agc gca atg 585 Ile Tyr Thr Pro Thr Ile Glu Ile Asn Ser Ser His His Ser Ala Met 165 170 175 gag aag aga tta caa gag atg aag gag aaa agg gaa aat ctt tcc ccc 633 Glu Lys Arg Leu Gln Glu Met Lys Glu Lys Arg Glu Asn Leu Ser Pro 180 185 190 acc tct tcc caa atg att cag cag tct cat gat aat cca agt aac tct 681 Thr Ser Ser Gln Met Ile Gln Gln Ser His Asp Asn Pro Ser Asn Ser 195 200 205 ctg tgt gaa gca cct ttg aac att tca cgt gat act ttg tgt tca gat 729 Leu Cys Glu Ala Pro Leu Asn Ile Ser Arg Asp Thr Leu Cys Ser Asp 210 215 220 gaa tac ttt gct ggt ggc tta cac tca tct ttt gat gat ctt tgt gga 777 Glu Tyr Phe Ala Gly Gly Leu His Ser Ser Phe Asp Asp Leu Cys Gly 225 230 235 240 aac tca gga tgt gga aat cag gaa agg aag ttg gaa gga tcc att aat 825 Asn Ser Gly Cys Gly Asn Gln Glu Arg Lys Leu Glu Gly Ser Ile Asn 245 250 255 gac att aaa agt gat gtg tgt att tct tca ctt gta ttg aaa gca aat 873 Asp Ile Lys Ser Asp Val Cys Ile Ser Ser Leu Val Leu Lys Ala Asn 260 265 270 aat att cat tca tca cca tct ttc act cac ctc gat aaa tca agt cct 921 Asn Ile His Ser Ser Pro Ser Phe Thr His Leu Asp Lys Ser Ser Pro 275 280 285 cag aaa ttt ctg agt aat ctt tca aag gaa gaa ata aac ttg caa aka 969 Gln Lys Phe Leu Ser Asn Leu Ser Lys Glu Glu Ile Asn Leu Gln Xaa 290 295 300 aat att gca ggt aaa gta gtc acc cct sac caa aag cag gct gca ggt 1017 Asn Ile Ala Gly Lys Val Val Thr Pro Xaa Gln Lys Gln Ala Ala Gly 305 310 315 320 atg tct cag gag acg ttt gaa gag aag tat cgt ttg tct cct acc tta 1065 Met Ser Gln Glu Thr Phe Glu Glu Lys Tyr Arg Leu Ser Pro Thr Leu 325 330 335 tct tca aca aaa ggc cac ctt ttg ata cat tca aga ccc agg agt tcc 1113 Ser Ser Thr Lys Gly His Leu Leu Ile His Ser Arg Pro Arg Ser Ser 340 345 350 tca gta aag aga aaa aga gta tca cat ggc tcc cat tca cct ccg aag 1161 Ser Val Lys Arg Lys Arg Val Ser His Gly Ser His Ser Pro Pro Lys 355 360 365 gaa aaa tgc aag aga aag agg agc acc agg aga tct atc atg ccg agg 1209 Glu Lys Cys Lys Arg Lys Arg Ser Thr Arg Arg Ser Ile Met Pro Arg 370 375 380 ctg cag ctg tgc agg tcg gaa ggc agg ctg cag cac gtg gcg gga cct 1257 Leu Gln Leu Cys Arg Ser Glu Gly Arg Leu Gln His Val Ala Gly Pro 385 390 395 400 gcc ctg gag gct ctt agc tgt ggg gag tct tca tat gat gac tat ttt 1305 Ala Leu Glu Ala Leu Ser Cys Gly Glu Ser Ser Tyr Asp Asp Tyr Phe 405 410 415 tca cct gat aat ctt aag gaa agg tat tca gag aat ctt cct cct gaa 1353 Ser Pro Asp Asn Leu Lys Glu Arg Tyr Ser Glu Asn Leu Pro Pro Glu 420 425 430 tct cag ctg cca tca agc cct gct cag ttg agc tgc aga agt ctt tct 1401 Ser Gln Leu Pro Ser Ser Pro Ala Gln Leu Ser Cys Arg Ser Leu Ser 435 440 445 aag aag gag aga aca agc ata ttt gaa atg tct gat ttt tcc tgc gtt 1449 Lys Lys Glu Arg Thr Ser Ile Phe Glu Met Ser Asp Phe Ser Cys Val 450 455 460 ggc aaa aaa acc aga aca gtt gac att acc aat ttc aca gca aaa acc 1497 Gly Lys Lys Thr Arg Thr Val Asp Ile Thr Asn Phe Thr Ala Lys Thr 465 470 475 480 atc tcc agt cct cgg aaa act gga aat ggt gaa ggc cgt gca act tcg 1545 Ile Ser Ser Pro Arg Lys Thr Gly Asn Gly Glu Gly Arg Ala Thr Ser 485 490 495 agt tgc gtg act tct gcc cct gaa gaa gcc cta agg tgt tgt aga cag 1593 Ser Cys Val Thr Ser Ala Pro Glu Glu Ala Leu Arg Cys Cys Arg Gln 500 505 510 gct ggg aaa gaa gac gca tgc cca gag gga aat ggc ttt tct tac acc 1641 Ala Gly Lys Glu Asp Ala Cys Pro Glu Gly Asn Gly Phe Ser Tyr Thr 515 520 525 att gag gac cct gct ctt cca aaa gga cat gat gat gat tta act cct 1689 Ile Glu Asp Pro Ala Leu Pro Lys Gly His Asp Asp Asp Leu Thr Pro 530 535 540 ttg gaa gga agc ctt gaa gaa atg aaa gaa gcg gtt ggt ctg aaa agc 1737 Leu Glu Gly Ser Leu Glu Glu Met Lys Glu Ala Val Gly Leu Lys Ser 545 550 555 560 aca cag aac aaa ggt acc act tcc aaa ata tca aac tcc tct gaa ggc 1785 Thr Gln Asn Lys Gly Thr Thr Ser Lys Ile Ser Asn Ser Ser Glu Gly 565 570 575 gaa gcc cag agt gaa cat gag cca tgt ttt ata gtt gac tgt aac atg 1833 Glu Ala Gln Ser Glu His Glu Pro Cys Phe Ile Val Asp Cys Asn Met 580 585 590 gag acg tct aca gaa gag aag gaa aac tta ccc gga gga tac agt gga 1881 Glu Thr Ser Thr Glu Glu Lys Glu Asn Leu Pro Gly Gly Tyr Ser Gly 595 600 605 agt gtt aaa aat aga cca aca agg cat gat gtt tta gat gac tca tgt 1929 Ser Val Lys Asn Arg Pro Thr Arg His Asp Val Leu Asp Asp Ser Cys 610 615 620 gac ggc ttt aag gac ctc atc aaa cct cat gag gaa ttg aag aaa agt 1977 Asp Gly Phe Lys Asp Leu Ile Lys Pro His Glu Glu Leu Lys Lys Ser 625 630 635 640 ggg aga ggc aaa aag cca aca aga aca tta gtc atg aca agc atg cca 2025 Gly Arg Gly Lys Lys Pro Thr Arg Thr Leu Val Met Thr Ser Met Pro 645 650 655 tct gaa aag cag aat gtc gtc atc cag gtt gtg gat aaa ttg aaa ggc 2073 Ser Glu Lys Gln Asn Val Val Ile Gln Val Val Asp Lys Leu Lys Gly 660 665 670 ttt tca att gca cca gac gtc tgt gag amc acg act cac gtg ctt tcc 2121 Phe Ser Ile Ala Pro Asp Val Cys Glu Xaa Thr Thr His Val Leu Ser 675 680 685 ggg aag cca ctt cgc acc ctg aat gtg ctg ctg gga att gcg cgt ggc 2169 Gly Lys Pro Leu Arg Thr Leu Asn Val Leu Leu Gly Ile Ala Arg Gly 690 695 700 tgc tgg gtt ctc tct tat gat tgg gtg cta tgg tct tta gaa ttg ggt 2217 Cys Trp Val Leu Ser Tyr Asp Trp Val Leu Trp Ser Leu Glu Leu Gly 705 710 715 720 cac tgg att tct gag gag ccg ttc gaa ctg tct cac cac ttc cct gca 2265 His Trp Ile Ser Glu Glu Pro Phe Glu Leu Ser His His Phe Pro Ala 725 730 735 gct ccc ctg tgc cga agy gag tgc cac ttg tct gca ggg ccg tac cgc 2313 Ala Pro Leu Cys Arg Ser Glu Cys His Leu Ser Ala Gly Pro Tyr Arg 740 745 750 gga acc ctc ttt gcc gac cag cca gyg atg ttt gtc tcg cct gcc agc 2361 Gly Thr Leu Phe Ala Asp Gln Pro Xaa Met Phe Val Ser Pro Ala Ser 755 760 765 agc ccc cca gtg gcc aag ctc tgt gaa cta gtc cac ctg tgc gga ggc 2409 Ser Pro Pro Val Ala Lys Leu Cys Glu Leu Val His Leu Cys Gly Gly 770 775 780 cgg gtc agc caa gtc ccc cgc cag gcc agc atc gtc atc ggg ccc tac 2457 Arg Val Ser Gln Val Pro Arg Gln Ala Ser Ile Val Ile Gly Pro Tyr 785 790 795 800 agc gga aag aag aaa gcm aca gtc aag tat ctg tct gag aaa tgg gtc 2505 Ser Gly Lys Lys Lys Ala Thr Val Lys Tyr Leu Ser Glu Lys Trp Val 805 810 815 tta gat tcc atc acc cag cac aag gtc tgt gcc yct gaa aac tac cta 2553 Leu Asp Ser Ile Thr Gln His Lys Val Cys Ala Xaa Glu Asn Tyr Leu 820 825 830 ttg tca caa tga cagtgacctc actggcctgt ggtgactgca cacagctcgc 2605 Leu Ser Gln * 835 aaaactgtct ttggatgttc aaatgagaaa caaaactgtg aagagaagga actggcgtat 2665 acaagatgac ttctgatatc atgtttgcca tgtgttgtgg ttcttaagaa ctcataggtg 2725 actttctgat gactgaatgt ctgtttcaga gacgcttcgg gcctttttat ttttatttta 2785 ttttttattt tttgagacgg agtcctgccc tgtttcccag gctggagtgc aatggcacaa 2845 tctcggctca ctgcaacctc cacctcccag gttcaagcga ttctgctgcc tcagcctcct 2905 gagtagctgg gattacagat gtgtgccacc atgcctggct aatttttgta gttttagtag 2965 agacagggtt tcgccatgtt ggccaggctg gtctcaaacg cctgagctca ggtgatctgt 3025 caggcctctt ctatagaatt ccagtctttg tgtcttagtc atgatcataa ttgaaaggtc 3085 acagaacctt tgtcattaga gcacagtact gccaaataaa gaatggaaat tcaatgacat 3145 tgttttatta ctgagaacaa ctagagaact ctgcaagttt cttggcttag actcgatctt 3205 tattaataca ttatctatta ggtaggaaag acatttgtca gctattaagg tgacttttat 3265 ctagcggaga ttcctctctt aaagtaatga aaggagatag gtatgggggg tgttatacag 3325 gataattggt gacatctgag tgtcttactt ctgcaagcct gctttatggt gagcaaagca 3385 tcaccagcaa gtgatcacaa tgtccactgg ccgctttttg cctgccgtcc tcgagatgaa 3445 attggcagtt ggggctgatt cacagaaaca ccgatttgtg gctgagcacg gtggctcaca 3505 cctgtcatcc cagccctttg ggaggctgag gtggacagat cacttgaggt caggagttcg 3565 agaccagcct gaccaacgca gcaaaaccca tctctactaa aaatacaaaa atcagctggg 3625 tgtggtggca cacacctgtg gtcccagctc ctcaggagtc tgaggcagaa gaatcgcttg 3685 aacccaagag gcagaggttg cagtgagcca aggttgcagt gaatcaagat tgctccactg 3745 cactccagcc tgggcaacag agtaactctc cttctcaaat aaataaataa ataaataaga 3805 aaca 3809 3 835 PRT Homo sapiens VARIANT 304 Xaa=Arg or Ile 3 Met Ala Ala Pro Ile Leu Lys Asp Val Val Ala Tyr Val Glu Val Trp 1 5 10 15 Ser Ser Asn Gly Thr Glu Asn Tyr Ser Lys Thr Phe Thr Thr Gln Leu 20 25 30 Val Asp Met Gly Ala Lys Val Ser Lys Thr Phe Asn Lys Gln Val Thr 35 40 45 His Val Ile Phe Lys Asp Gly Tyr Gln Ser Thr Trp Asp Lys Ala Gln 50 55 60 Lys Arg Gly Val Lys Leu Val Ser Val Leu Trp Val Glu Lys Cys Arg 65 70 75 80 Thr Ala Gly Ala His Ile Asp Glu Ser Leu Phe Pro Ala Ala Asn Met 85 90 95 Asn Glu His Leu Ser Ser Leu Ile Lys Lys Lys Arg Lys Cys Met Gln 100 105 110 Pro Lys Asp Phe Asn Phe Lys Thr Pro Glu Asn Asp Lys Arg Phe Gln 115 120 125 Lys Lys Phe Glu Lys Met Ala Lys Glu Leu Gln Arg Gln Lys Thr Asn 130 135 140 Leu Asp Asp Asp Val Pro Ile Leu Leu Phe Glu Ser Asn Gly Ser Leu 145 150 155 160 Ile Tyr Thr Pro Thr Ile Glu Ile Asn Ser Ser His His Ser Ala Met 165 170 175 Glu Lys Arg Leu Gln Glu Met Lys Glu Lys Arg Glu Asn Leu Ser Pro 180 185 190 Thr Ser Ser Gln Met Ile Gln Gln Ser His Asp Asn Pro Ser Asn Ser 195 200 205 Leu Cys Glu Ala Pro Leu Asn Ile Ser Arg Asp Thr Leu Cys Ser Asp 210 215 220 Glu Tyr Phe Ala Gly Gly Leu His Ser Ser Phe Asp Asp Leu Cys Gly 225 230 235 240 Asn Ser Gly Cys Gly Asn Gln Glu Arg Lys Leu Glu Gly Ser Ile Asn 245 250 255 Asp Ile Lys Ser Asp Val Cys Ile Ser Ser Leu Val Leu Lys Ala Asn 260 265 270 Asn Ile His Ser Ser Pro Ser Phe Thr His Leu Asp Lys Ser Ser Pro 275 280 285 Gln Lys Phe Leu Ser Asn Leu Ser Lys Glu Glu Ile Asn Leu Gln Xaa 290 295 300 Asn Ile Ala Gly Lys Val Val Thr Pro Xaa Gln Lys Gln Ala Ala Gly 305 310 315 320 Met Ser Gln Glu Thr Phe Glu Glu Lys Tyr Arg Leu Ser Pro Thr Leu 325 330 335 Ser Ser Thr Lys Gly His Leu Leu Ile His Ser Arg Pro Arg Ser Ser 340 345 350 Ser Val Lys Arg Lys Arg Val Ser His Gly Ser His Ser Pro Pro Lys 355 360 365 Glu Lys Cys Lys Arg Lys Arg Ser Thr Arg Arg Ser Ile Met Pro Arg 370 375 380 Leu Gln Leu Cys Arg Ser Glu Gly Arg Leu Gln His Val Ala Gly Pro 385 390 395 400 Ala Leu Glu Ala Leu Ser Cys Gly Glu Ser Ser Tyr Asp Asp Tyr Phe 405 410 415 Ser Pro Asp Asn Leu Lys Glu Arg Tyr Ser Glu Asn Leu Pro Pro Glu 420 425 430 Ser Gln Leu Pro Ser Ser Pro Ala Gln Leu Ser Cys Arg Ser Leu Ser 435 440 445 Lys Lys Glu Arg Thr Ser Ile Phe Glu Met Ser Asp Phe Ser Cys Val 450 455 460 Gly Lys Lys Thr Arg Thr Val Asp Ile Thr Asn Phe Thr Ala Lys Thr 465 470 475 480 Ile Ser Ser Pro Arg Lys Thr Gly Asn Gly Glu Gly Arg Ala Thr Ser 485 490 495 Ser Cys Val Thr Ser Ala Pro Glu Glu Ala Leu Arg Cys Cys Arg Gln 500 505 510 Ala Gly Lys Glu Asp Ala Cys Pro Glu Gly Asn Gly Phe Ser Tyr Thr 515 520 525 Ile Glu Asp Pro Ala Leu Pro Lys Gly His Asp Asp Asp Leu Thr Pro 530 535 540 Leu Glu Gly Ser Leu Glu Glu Met Lys Glu Ala Val Gly Leu Lys Ser 545 550 555 560 Thr Gln Asn Lys Gly Thr Thr Ser Lys Ile Ser Asn Ser Ser Glu Gly 565 570 575 Glu Ala Gln Ser Glu His Glu Pro Cys Phe Ile Val Asp Cys Asn Met 580 585 590 Glu Thr Ser Thr Glu Glu Lys Glu Asn Leu Pro Gly Gly Tyr Ser Gly 595 600 605 Ser Val Lys Asn Arg Pro Thr Arg His Asp Val Leu Asp Asp Ser Cys 610 615 620 Asp Gly Phe Lys Asp Leu Ile Lys Pro His Glu Glu Leu Lys Lys Ser 625 630 635 640 Gly Arg Gly Lys Lys Pro Thr Arg Thr Leu Val Met Thr Ser Met Pro 645 650 655 Ser Glu Lys Gln Asn Val Val Ile Gln Val Val Asp Lys Leu Lys Gly 660 665 670 Phe Ser Ile Ala Pro Asp Val Cys Glu Xaa Thr Thr His Val Leu Ser 675 680 685 Gly Lys Pro Leu Arg Thr Leu Asn Val Leu Leu Gly Ile Ala Arg Gly 690 695 700 Cys Trp Val Leu Ser Tyr Asp Trp Val Leu Trp Ser Leu Glu Leu Gly 705 710 715 720 His Trp Ile Ser Glu Glu Pro Phe Glu Leu Ser His His Phe Pro Ala 725 730 735 Ala Pro Leu Cys Arg Ser Glu Cys His Leu Ser Ala Gly Pro Tyr Arg 740 745 750 Gly Thr Leu Phe Ala Asp Gln Pro Xaa Met Phe Val Ser Pro Ala Ser 755 760 765 Ser Pro Pro Val Ala Lys Leu Cys Glu Leu Val His Leu Cys Gly Gly 770 775 780 Arg Val Ser Gln Val Pro Arg Gln Ala Ser Ile Val Ile Gly Pro Tyr 785 790 795 800 Ser Gly Lys Lys Lys Ala Thr Val Lys Tyr Leu Ser Glu Lys Trp Val 805 810 815 Leu Asp Ser Ile Thr Gln His Lys Val Cys Ala Xaa Glu Asn Tyr Leu 820 825 830 Leu Ser Gln 835 4 18 DNA Artificial Sequence sequencing oligonucleotide PrimerPU 4 tgtaaaacga cggccagt 18 5 18 DNA Artificial Sequence sequencing oligonucleotide PrimerRP 5 caggaaacag ctatgacc 18 

What is claimed:
 1. A composition comprising an isolated, purified or recombinant nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of: a) a contiguous span of at least 200 nucleotides of SEQ ID No 1 or the complement thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 1-97921, 98517-103471, 103603-108222, 108390-109221, 109324-114409, 114538-115723, 115957-122102, 122225-126876, 127033-157212, 157808-240825; b) a contiguous span of at least 15 nucleotides of SEQ ID No 2 or the complement thereof; c) a contiguous span of at least 15 nucleotides of anyone of SEQ ID Nos 1 and 2 or the complements thereof, wherein said span includes a PG-3-related biallelic marker selected from the group consisting of A1 to A5 and A8 to A80, and the complements thereof; d) a polynucleotide consisting essentially of a sequence selected from the following sequences: P1 to P4 and P6 to P80, and the complementary sequences thereto; e) a polynucleotide consisting essentially of a sequence selected from the following sequences: D1 to D4, D6 to D80, E1 to E4, and E6 to E80; f) a polynucleotide consisting essentially of a sequence selected from the following sequences: B1 to B52 and C1 to C52; and g) a polynucleotide which encodes a polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID No
 3. 2. A composition comprising an isolated recombinant vector, wherein said vector comprises a polynucleotide according to claim
 1. 3. A composition comprising an isolated host cell, wherein said host cell contains either the recombinant vector of claim 2 or a PG-3 gene operably linked to a heterologous regulatory element.
 4. A non-human host animal comprising either the recombinant vector of claim 2 or a PG-3 gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to claim
 1. 5. A composition comprising an isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID No
 3. 6. A composition comprising an isolated or purified antibody capable of selectively binding to an epitope-containing fragment of the polypeptide of claim
 5. 7. A method of genotyping comprising determining the identity of a nucleotide at a PG-3-related biallelic marker or the complement thereof in a biological sample.
 8. A method of genotyping according to claim 7, wherein said biological sample is from a single individual.
 9. A method of genotyping according to claim 7, further comprising amplifying a portion of said sequence comprising said biallelic marker prior to said determining step.
 10. A method of estimating the frequency of an allele of a PG-3-related biallelic marker in a population comprising: a) genotyping individuals from said population for said biallelic marker according to the method of claim 7; and b) determining the proportional representation of said biallelic marker in said population.
 11. A method of detecting an association between a genotype and a trait, comprising the steps of: a) determining the frequency of at least one PG-3-related biallelic marker in a trait positive population according to the method of claim 10; b) determining the frequency of at least one PG-3-related biallelic marker in a control population according to the method of claim 10; and c) determining whether a statistically significant association exists between said genotype and said trait.
 12. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising: a) genotyping at least one PG-3-related biallelic marker according to claim 8 for each individual in said population; b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.
 13. A method of detecting an association between a haplotype and a trait, comprising the steps of: a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 12; b) estimating the frequency of said haplotype in a control population according to the method of claim 12; and c) determining whether a statistically significant association exists between said haplotype and said trait. 